propranolol has been researched along with Angioma in 675 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Angioma: A vascular anomaly due to proliferation of blood or lymphatic vessels that forms a tumor-like mass. Vessels in the angioma may or may not be dilated.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our primary objective was to review the current use of propranolol for treatment of infantile hemangioma (IH), specifically regarding 1) the age at initiation of therapy, 2) the method of initiation, 3) the use of other adjuvant therapy, 4) the duration of therapy and relapse rate, 5) the adverse events, and 6) the outcome." | 10.25 | Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial. ( Bauman, NM; Greene, EA; McCarter, R; Menezes, MD, 2011) |
| "The initial recommendation propranolol usage in managing infantile hemangioma was in 2008 followed by various researches assessing the dosage, efficacy, and other parameters." | 9.51 | Itraconazole versus propranolol: therapeutic and pharmacologic effect on serum angiopoietin-2 in patients with infantile hemangioma. ( Bessar, H; Kandil, AH; Khattab, F; Nasr, NM, 2022) |
| "Although propranolol has been established as the gold standard when treatment is sought for infantile hemangioma, concerns over its side effect profile have led to increasing usage of atenolol, a beta-1 selective blocker." | 9.41 | Should Propranolol Remain the Gold Standard for Treatment of Infantile Hemangioma? A Systematic Review and Meta-Analysis of Propranolol Versus Atenolol. ( Carroll, W; Chen, T; Clemmens, C; Gudipudi, R; Nguyen, SA, 2023) |
| "With the emergence of propranolol as the first choice of treatment for problematic infantile haemangioma at many centres, the number of patients with a partial or non-response to propranolol has also been growing." | 9.27 | Role of intralesional bleomycin and intralesional triamcinolone therapy in residual haemangioma following propranolol. ( Kumar, R; Pandey, V; Sharma, SP; Singh, OP; Tiwari, P, 2018) |
| "There is no consensus on optimal treatment duration for propranolol in infantile hemangioma (IH)." | 9.27 | Efficacy of Propranolol Between 6 and 12 Months of Age in High-Risk Infantile Hemangioma. ( Baselga, E; Bouroubi, A; de Lucas-Laguna, R; Delarue, A; Dembowska-Baginska, B; Esteve-Martinez, A; Gautier, S; González-Enseñat, MA; Lebbé, G; López Gutiérrez, JC; Menon, Y; Przewratil, P; Roé, E; Rychłowska-Pruszyńska, M; Torrelo, A; Voisard, JJ; Wyrzykowski, D; Zaim, M, 2018) |
| "There are limited data from randomized clinical trials comparing propranolol and steroid medication for treatment of infantile hemangioma (IH)." | 9.24 | Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial. ( Cheon, JE; Choe, YS; Choi, TH; Choi, Y; Hong, KY; Jeong, JH; Kang, HJ; Kim, DY; Kim, KH; Lee, H; Park, JB; Park, KD; Park, YW; Shin, HY, 2017) |
| "Although the efficacy of propranolol for the treatment of infantile hemangiomas (IHs) has been well documented, there is a paucity of clinical data regarding the safety and tolerance of propranolol in neonates." | 9.24 | Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study. ( Chen, S; Ji, Y; Qiu, L; Xiang, B; Yang, Y, 2017) |
| "The nonselective beta-blocker propranolol is the current criterion standard for treatment of infantile hemangiomas (IHs) and the first therapy that the U." | 9.24 | Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study. ( Bayart, CB; Golden, AB; Tamburro, JE; Vidimos, AT; Wang, L, 2017) |
| "Topical timolol and lasers are widely used for the treatment of infantile hemangioma (IH), and they can replace propranolol as the first-line treatment of IH." | 9.22 | Comparison of the efficacy and safety of lasers, topical timolol, and combination therapy for the treatment of infantile hemangioma: A meta-analysis of 10 studies. ( Cai, B; Chen, X; Huang, H; Wang, B; Yu, J, 2022) |
| "Propranolol is a valuable therapeutic alternative for treatment of ulcerated haemangiomas and effectively reduces pain." | 9.22 | Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. ( Gangopadhyay, AN; Gupta, DK; Pandey, V; Sharma, SP; Tiwari, P, 2016) |
| "The combination treatment for mix infantile hemangiomas (IHs) using oral propranolol with topical timolol maleate was not well documented in the literature." | 9.22 | Oral Propranolol With Topical Timolol Maleate Therapy for Mixed Infantile Hemangiomas in Oral and Maxillofacial Regions. ( Li, G; Sun, NN; Tong, S; Wang, XK; Xu, DP; Xue, L, 2016) |
| "Propranolol has been widely used in the treatment of infantile hemangiomas since 2008." | 9.22 | Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas. ( Chang, L; Chen, H; Hu, L; Huang, H; Jin, Y; Li, W; Lin, X; Ma, G; Qiu, Y; Xu, X; Zhou, B, 2016) |
| "The objective of the present study is to formulate and characterize propranolol hydrochloride (PPL · HCl) gel, and to evaluate the efficacy of this formulation in transdermal treatment for superficial infantile hemangioma (IH)." | 9.20 | Formulation, characterization and clinical evaluation of propranolol hydrochloride gel for transdermal treatment of superficial infantile hemangioma. ( Chen, X; Ding, J; He, S; Jian, D; Yang, Y; Zhou, W, 2015) |
| "Oral propranolol has been used to treat complicated infantile hemangiomas, although data from randomized, controlled trials to inform its use are limited." | 9.20 | A randomized, controlled trial of oral propranolol in infantile hemangioma. ( Ballona, R; Barbarot, S; Baselga, E; Benjamin, L; Bernabeu-Wittel, J; Berul, CI; Birchall, N; Boccara, O; Boralevi, F; Buckova, H; Caceres, H; Cambazard, F; Delarue, A; Febrer Bosch, MI; Foelster-Holst, R; Frieden, IJ; Friedlander, SF; Glick, S; Grantzow, R; Guibaud, L; Heritier, S; Hoeger, P; Krol, A; Léauté-Labrèze, C; Lopez Gutierrez, JC; Mancini, AJ; Maruani, A; Mazereeuw-Hautier, J; Mehta, CR; Metz, B; Morgan, CC; Perek, D; Phillips, RJ; Pope, E; Posiunas, G; Powell, J; Prey, S; Przewratil, P; Roessler, J; Souteyrand, P; Su, J; Szalai, ZZ; Torrelo, A; Vabres, P; Valencia, AM; Voisard, JJ; Wargon, O; Wyrzykowski, D, 2015) |
| "Combining propranolol with corticosteroids gives a faster response and should be considered in treating life- or function-threatening hemangiomas." | 9.20 | Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. ( Abdel Kader, HM; Aly, MM; Ghazy, MS; Hamza, AF; Ragab, IA; Saafan, HA, 2015) |
| "While propranolol is touted as superior to prednisolone for treating infantile hemangiomas (IH), a randomized clinical trial (RCT) comparing the outcome and tolerability of these medications for symptomatic, proliferating IH has not been reported." | 9.19 | Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial. ( Bauman, NM; Greene, EA; Guzzetta, PC; He, J; McCarter, RJ; Oh, AK; Preciado, DA; Puttgen, KB; Shin, JJ, 2014) |
| "Propranolol therapy is changing the treatment paradigm for infantile hemangioma." | 9.19 | Propranolol therapy for reducing the number of nasal infantile hemangioma invasive procedures. ( Chen, BS; Manning, SC; Parikh, SR; Perkins, JA; Saltzman, B, 2014) |
| "The combination of pulsed dye laser (PDL) and topical propranolol are used with variable effectiveness for the treatment of infantile hemangiomas (IH), particularly for superficial lesions." | 9.19 | Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial. ( Abdolreza, M; Arianian, Z; Balighi, K; Daklan, S; Ehsani, AH; Noormohammadpoor, P, 2014) |
| "The dramatic response of infantile hemangiomas to propranolol and few side effects suggest that early treatment of infantile hemangiomas could result in decreased disfigurement." | 9.17 | Propranolol is more effective than pulsed dye laser and cryosurgery for infantile hemangiomas. ( Aozasa, N; Araki, M; Inuzuka, R; Isomura, S; Kagami, S; Katori, T; Kuwano, Y; Masui, Y; Miyagawa, T; Miyamoto, A; Sato, S; Shibata, S; Takahashi, K; Uwajima, Y; Yamada, D; Yamamoto, M, 2013) |
| "To assess propranolol efficacy and safety in complicated infantile hemangiomas in two different age groups." | 9.17 | The use of propranolol for complicated infantile hemangiomas. ( Dalmonte, P; Occella, C; Pelegrini, M; Rimini, A; Romanini, MV; Vercellino, N, 2013) |
| "Propranolol has emerged as front-line therapy for infantile hemangiomas (IHs)." | 9.17 | Propranolol for infantile hemangioma (PINCH): an open-label trial to assess the efficacy of propranolol for treating infantile hemangiomas and for determining the decline in heart rate to predict response to propranolol. ( Patnaik, SK; Sondhi, V, 2013) |
| "The purpose of this study was to compare the efficacy of orally administered propranolol versus prednisolone versus both in the treatment of potentially disfiguring or functionally threatening infantile hemangiomas." | 9.17 | Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study. ( Malik, MA; Menon, P; Rao, KL; Samujh, R, 2013) |
| "The mechanism of therapeutic success of propranolol for severe infantile haemangioma remains unclear." | 9.16 | Urinary matrix metalloproteinases-2/9 in healthy infants and haemangioma patients prior to and during propranolol therapy. ( Hinz, U; Holland-Cunz, S; Kleber, CJ; Kleber, JB; Spiess, A; Weiss, J, 2012) |
| "To observe the therapeutic effect of propranolol with 1 064 nm Nd:YAG laser on proliferating hemangioma in body surface." | 9.16 | [The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface]. ( Duan, B; Gong, H; Tan, M; Zhou, CM, 2012) |
| "Propranolol hydrochloride is a safe and effective medication for treating infantile hemangiomas (IHs), with decreases in IH volume, color, and elevation." | 9.15 | A randomized controlled trial of propranolol for infantile hemangiomas. ( Adams, S; Hogeling, M; Wargon, O, 2011) |
| "To investigate the clinical results of the treatment of severe infantile hemangioma with high-dose propranolol in Chinese." | 9.15 | [Preliminary clinical study on the treatment of severe infantile hemangioma with high-dose propranolol in China]. ( Chen, XS; Guo, ZH; Huang, BR; Li, M; Xie, YD; Yang, YC; Zhan, MK; Zhou, YK, 2011) |
| "To prospectively assess the efficacy and safety or propranolol as a first-line treatment for problematic infantile haemangioma in China." | 9.15 | [A prospective study of propranolol as first-line treatment for problematic infantile hemangioma in China]. ( Chen, H; Chen, XD; Da, C; Hu, XJ; Jiang, CH; Jin, YB; Lin, XX; Ma, G; Ye, XX, 2011) |
| "To evaluate the short-term efficacy and safety of propranolol for problematic infantile hemangiomas." | 9.15 | [Propranolol in the treatment of problematic infantile hemangiomas]. ( Chen, J; Huang, J; Li, S; Lu, J; Qin, G; Tna, L; Xiang, Y; Yang, S; Zhao, J; Zuo, C, 2011) |
| "Propranolol has recently been introduced as a novel pharmacologic treatment for infantile hemangiomas." | 9.14 | Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. ( Buckmiller, LM; Dai, Y; Dyamenahalli, U; Munson, PD; Richter, GT, 2010) |
| "Propranolol has changed the management of infantile hemangiomas (IHs)." | 9.01 | Clinical and economic impact of surgery for treating infantile hemangiomas in the era of propranolol: overview of single-center experience from La Paz Hospital, Madrid. ( López-Gutiérrez, JC, 2019) |
| "Recently, several studies have reported their experience in using oral atenolol in patients with infantile haemangioma (IH), especially as an alternative to propranolol, but the efficacy and safety of oral atenolol has not been evaluated." | 9.01 | Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: A systematic review. ( Chen, S; Ji, Y; Wang, Q; Xiang, B, 2019) |
| "We report a case presented in deep hypoglycemic coma during his treatment with propranolol for IH." | 9.01 | Deep coma in a child treated with propranolol for infantile hemangioma. ( Bakalli, I; Celaj, E; Gjeta, I; Klironomi, D; Kola, E; Lluka, R; Sala, D; Sallabanda, S, 2019) |
| "A number of clinical trials evaluated the effect of topical timolol in the treatment of infantile hemangioma and provided inconsistent results." | 8.98 | Effect of topical timolol on response rate and adverse events in infantile hemangioma: a meta-analysis. ( Li, Y; Zheng, L, 2018) |
| "Propranolol is a well tolerated and effective treatment for infantile hemangiomas." | 8.98 | Infantile hemangiomas: what have we learned from propranolol? ( Ghareeb, E; Hagen, R; Jalali, O; Zinn, Z, 2018) |
| "Five cases of subglottic hemangioma treated with systemic propranolol are presented." | 8.98 | [Tiempo de respuesta terapéutica al propranolol sistémico en el manejo de hemangiomas subglóticos pediátricos: serie de casos y revisión de la literatura]. ( Álvarez-Neri, H; Morera-Serna, E; Penchyna-Grub, J; Teyssier-Morales, G; Torre, C; Villamor, P, 2018) |
| "Propranolol has recently become the treatment of choice for management of subglottic and airway hemangiomas." | 8.95 | Efficacy and rebound rates in propranolol-treated subglottic hemangioma: A literature review. ( Chun, RH; Faria, J; Pawar, S; Schwartz, T; Siegel, D, 2017) |
| "Propranolol has become the first-line treatment for complicated Infantile Hemangioma (IH), showing so far a good risk-benefit profile." | 8.95 | Cardiac arrest in a toddler treated with propranolol for infantile Hemangioma: a case report. ( Cutrone, M; Dalle Carbonare, M; Perilongo, G; Pettenazzo, A; Sartori, S; Tosoni, A, 2017) |
| "EBSCO host and Ovid database search for key words of infantile hemangiomas, propranolol, vascular lesion, and proliferative lesion was utilized." | 8.93 | Infantile Hemangiomas: Pathogenesis and Review of Propranolol Use. ( Laken, PA, 2016) |
| "Given the widespread use of propranolol in infantile hemangioma (IH) it was considered essential to perform a systematic review of its safety." | 8.93 | Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review. ( Boccara, O; Degrugillier-Chopinet, C; Delarue, A; Gautier, S; Lafon, M; Léaute-Labrèze, C; Lebbé, G; Mazereeuw-Hautier, J; Montagne, A; Ortis, V; Prey, S; Voisard, JJ, 2016) |
| "1) Describe the origins of the use of propranolol in the treatment of subglottic hemangiomas, 2) Perform meta-analysis of all case reports and series in which propranolol was used to treat subglottic hemangiomas." | 8.93 | The use of propranolol in the treatment of subglottic hemangiomas: A literature review and meta-analysis. ( Dodson, KM; Hardison, S; Wan, W, 2016) |
| "Currently, propranolol is the preferred treatment for problematic proliferating infantile haemangiomas (IHs)." | 8.91 | The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. ( Chen, S; Ji, Y; Li, L; Xiang, B; Xu, C, 2015) |
| "ince 2008, propranolol has become the first line therapy for infantile hemangiomas." | 8.91 | Propranolol induced hypoglycemia. ( Haim, A; Horev, A; Zvulunov, A, 2015) |
| "Propranolol may have shown excellent results as a first line therapy in infantile haemangiomas (IHs) at all sites in the body, but this conclusion remains controversial." | 8.90 | The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies. ( Cao, DS; Cao, Y; Li, HH; Lou, Y; Peng, WJ; Xie, J, 2014) |
| "The clinical efficacy and safety profile of propranolol 1% cream in treatment of superficial infantile hemangiomas (IHs) were determined in a preliminary randomized group of eight infants." | 8.90 | Topical propranolol cream in treatment of superficial infantile hemangiomas: a literature review and 4 years of clinical experience. ( Kovačević, M; Krnjević-Pezić, G; Lukinović Škudar, V; Maričić, G; Stanimirović, A, 2014) |
| "In 2008, the positive effects of propranolol on infantile hemangiomas (IH) have been discovered serendipitously by Léauté-Labrèze and her coworkers." | 8.89 | Propranolol in use for treatment of complex infant hemangiomas: literature review regarding current guidelines for preassessment and standards of care before initiation of therapy. ( Fette, A, 2013) |
| "Recent reports of propranolol for the treatment of hemangiomas have led many physicians to question the best treatment strategy for children with vision-threatening hemangiomas." | 8.89 | Hemangiomas treated with propranolol: do the rewards outweigh the risks? ( Haider, KM; Neely, DE; Plager, DA, 2013) |
| "Propranolol is a relatively recent therapy of hemangiomas with fewer side effects, a different mechanism of action, and greater efficacy than current first-line corticosteroid therapy." | 8.89 | Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis. ( Belzile, E; Izadpanah, A; Kanevsky, J; Schwarz, K, 2013) |
| "Propranolol is a beta blocker which is safely used in the management of infantile hemangiomas." | 8.89 | Novel use of propranolol for management of pain in children with vertebral hemangioma: report of two cases. ( Celkan, T; Gungor, S; Hasiloglu, Z; Ozdemir, N; Saygin, C; Uzunaslan, D, 2013) |
| "To study the effectiveness of propranolol in infantile airway haemangiomas and compare the effectiveness of propranolol vs." | 8.87 | A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. ( Athanasopoulos, I; Parpounas, K; Peridis, S; Pilgrim, G, 2011) |
| "The objective of this study is to describe the initial use of propranolol as the sole treatment for focal infantile airway hemangiomas, and to report on available literature describing the use of propranolol for airway lesions." | 8.86 | Initial experience using propranolol as the sole treatment for infantile airway hemangiomas. ( Hartnick, C; Maturo, S, 2010) |
| "Propranolol, a nonselective beta-blocker, has recently been introduced as a novel modality for the treatment of proliferating haemangiomas." | 8.86 | Propranolol therapy for infantile haemangiomas: review of the literature. ( Eivazi, B; Werner, JA; Wiegand, S; Zimmermann, AP, 2010) |
| "Propranolol was serendipitously found to induce early involution in hemangiomas even during the proliferative phase of the hemangioma cycle." | 8.85 | Propranolol treatment for infantile hemangiomas. ( Buckmiller, LM, 2009) |
| "Propranolol has emerged as a first line agent in the management of hemangiomas." | 8.31 | Bleomycin-triamcinolone sclerotherapy in the management of propranolol resistant infantile hemangioma of the maxillofacial region: A single arm prospective evaluation of clinical outcome and Doppler ultrasound parameters. ( Bera, RN; Pandey, V; Tiwari, P, 2023) |
| "The purpose of this study was to compare long-term neurocognitive functioning (working memory, processing speed, and attention) between children who had been treated with either propranolol or atenolol for infantile hemangioma during infancy." | 8.31 | Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma. ( Breugem, CC; Breur, JMPJ; de Graaf, M; de Laat, PCJ; de Wildt, SN; Hermans, MM; Langeveld, HR; Mendels, EJ; Pasmans, SGMA; Raphael, MF; Rietman, AB; Schappin, R, 2023) |
| "The introduction of propranolol as systemic therapy for infantile hemangiomas (IH) has changed the natural history of these tumors." | 8.31 | Propranolol and infantile hemangiomas: Outcome from a tricentric study. ( Benetton, C; Cimador, M; De Corti, F; Gamba, P; Midrio, P; Pace, MD, 2023) |
| "Despite its effectivity, there are reports of poor response to propranolol in the treatment of infantile hemangioma (IH)." | 8.31 | Intralesional steroid in the era of propranolol for infantile hemangioma-Do we need it? ( Pandey, A; Pant, N; Rawat, J; Singh, S; Srivastava, A, 2023) |
| "The distribution and response to propranolol of problematic facial infantile haemangiomas (IHs) has rarely been described in the literature." | 8.31 | Distribution of problematic localized facial infantile haemangiomas and their response to propranolol: a retrospective cohort study. ( Chang, L; Chang, SJ; Chen, J; Chen, Q; Gao, W; Li, H; Lin, X; Qiu, Y; Yu, Z; Zhou, L, 2023) |
| "We studied 95 patients with infantile hemangioma (IH) treated with propranolol at the Department of Dermatology, Kumamoto University Hospital, from November 2016 to January 2022, based on sex, site, clinical classification, duration of treatment, and residual lesions after treatment." | 8.31 | A study of 95 infantile hemangiomas treated with propranolol: A potentially efficacious combination with laser therapy. ( Amano, F; Aoi, J; Fukushima, S; Kajihara, I; Makino, K; Masuguchi, S; Nakayama, W; Nishimura, Y; Sawamura, S; Shimada, S; Yamada-Kanazawa, S, 2023) |
| "Although the efficacy of propranolol in the treatment of infantile hemangioma (IH) has been well established, clinical data on the safety and tolerability of propranolol in neonates are still lacking." | 8.31 | Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population. ( Bai, H; Cheng, J; Fu, R; Huan, X; Huang, M; Jin, P; Wu, Z; Yuan, H; Zou, Y, 2023) |
| "Between January 2016 and February 2019, dermatologists experienced hemangioma treatment and recommended propranolol treatment for 232 IHs." | 8.31 | Our experience with propranolol for infantile hemangioma. ( Dai, T; Lu, W; Song, W; Wang, L; Wu, Y; Zhao, P, 2023) |
| "Propranolol, a nonselective beta-blocker used in the medical treatment of infantile Hemangioma (IH), has been shown to decrease the levels of vascular endothelial growth factor and reduce angiogenesis with its antiproliferative and antiangiogenetic effects." | 8.31 | Can Propranolol Affect Platelet Indices in Infantile Hemangioma? ( Eker, I; Eroglu, N; Kar, YD; Pektas, A; Sen, HS, 2023) |
| "Propranolol is the first-line treatment for infantile hemangiomas (IH)." | 8.31 | Predictors of poor response to oral propranolol in infantile hemangiomas. ( Berrami, H; Chiheb, S; Hali, F; Moubine, I; Othmani, MB; Serhier, Z, 2023) |
| "Propranolol, a non-selective blocker of the β-adrenoceptor (AR), is a first-line treatment for infantile hemangioma (IH)." | 8.12 | Propranolol inhibits the angiogenic capacity of hemangioma endothelia via blocking β-adrenoceptor in mast cell. ( Dong, C; Dong, K; Dou, L; Gao, W; He, L; Li, J; Li, K; Lu, W; Song, W; Wang, L; Xia, C; Ye, Y; Zhong, H, 2022) |
| "Propranolol and atenolol, current therapies for problematic infantile hemangioma (IH), are composed of R(+) and S(-) enantiomers: the R(+) enantiomer is largely devoid of beta blocker activity." | 8.12 | Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma. ( Bischoff, J; Fontaine, F; Francois, M; Graus, MS; Huang, L; Karnezis, T; McCann, A; Meunier, F; Mulliken, JB; Seebauer, CT; Staffa, SJ; Wylie-Sears, J; Zurakowski, D, 2022) |
| "To evaluate the safety of initiating and maintaining propranolol therapy for infantile hemangioma (IH) and the safety of different doses." | 8.12 | Safety assessment of propranolol for infantile hemangioma: a study in an Asian population. ( Han, X; He, R; Li, L; Liu, Y; Ma, L; Qiu, L; Sun, Y; Wang, C; Wei, L; Xiu, B; Xu, Z; Yu, L; Zhang, B, 2022) |
| "The long-term evolution of children with segmental facial infantile haemangioma (SFIH) treated with propranolol remains unstudied." | 8.12 | Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age. ( Boccara, O; Boralevi, F; Léauté-Labrèze, C; Letertre, O; Pedespan, JM; Prey, S, 2022) |
| "Propranolol is a nonselective β-adrenergic receptor (AR) blocker that has been the first-line therapy for problematic infantile hemangioma (IH), the most frequent childhood vascular tumor." | 8.12 | A transcription factor is the target of propranolol treatment in infantile hemangioma. ( Boscolo, E; Schrenk, S, 2022) |
| "For infantile hemangiomas (IH) requiring treatment, including those in high-risk locations or in the setting of ulceration, oral propranolol is first-line therapy." | 8.12 | Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol. ( Boull, C; Maguiness, S; Meyer-Mueller, C; Nicholson, C; Polcari, I, 2022) |
| "We report three infants with infantile hemangioma who experienced severe agitation and diarrhea following propranolol administration." | 8.12 | Propranolol therapy for hemangiomas in infants with neonatal abstinence syndrome may produce intolerable side effects. ( Chen, A; Poffenberger, P; Twist, J; Zinn, Z, 2022) |
| "Propranolol has evolved as a first line management of infantile haemangiomas." | 8.12 | Sandwich therapy in the management of propranolol resistant infantile hemangioma of the lip. ( Bera, RN; Mishra, A; Pandey, V; Sharma, SP; Tiwari, P; Tiwary, N, 2022) |
| "Propranolol is used to treat problematic infantile hemangiomas (IHs), but its safety in infants <5 weeks corrected age has not been established." | 8.12 | Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age. ( Check, JF; Gatts, JE; McLean, TW; Rush, MC; Samelak, DM, 2022) |
| "Propranolol is used as the first-line treatment for infantile hemangiomas (IHs)." | 8.12 | Topical Formulations of Propranolol for Infantile Hemangiomas: Characteristics of Formulations and Three Cases of Infants Administered Topical Propranolol Cream. ( Endoh, A; Hakamata, A; Inui, N; Kashiwagura, Y; Namiki, N; Shirai, M; Tanaka, S; Uchida, S; Watanabe, H, 2022) |
| "Infantile haemangiomas are common benign tumours of infancy, which can be treated effectively with beta-blockers such as propranolol and atenolol." | 8.12 | Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma. ( Breugem, CC; Breur, JMPJ; De Graaf, M; De Laat, PCJ; De Wildt, SN; Hermans, MM; Jonge Poerink, E; Langeveld, HR; Mendels, EJ; Pasmans, SGMA; Ragamin, A; Raphael, MF; Rietman, AB; Schappin, R, 2022) |
| "Oral propranolol is recommended as the first-line agent for infantile hemangioma requiring systemic treatment." | 8.12 | Efficacy of intravenous propranolol for life-threatening diffuse neonatal hemangiomatosis. ( Ishikawa, T; Seki, K; Uchiyama, H, 2022) |
| "To assess the efficacy of transcatheter arterial embolization (TAE) plus propranolol treatment for infantile hepatic hemangioma (IHH)." | 8.12 | Clinical evaluation of transcatheter arterial embolization combined with propranolol orally treatment of infantile hepatic hemangioma. ( Guo, L; Li, J; Song, D; Wang, L, 2022) |
| "To analyze the therapeutic effect of oral propranolol combined with sclerotherapy of lauromacrogol and triamcinolone acetonide in the treatment of lip infantile hemangiomas (IHs)." | 8.12 | A Retrospective Study of Lip Hemangiomas: Curative Effect of Oral Propranolol Combined with Topical Sclerotherapy. ( Huo, R; Ling, J; Yang, K; Zhang, D, 2022) |
| "Propranolol is a first-line clinical drug for infantile haemangiomas (IH) therapy." | 8.12 | Circular RNA hsa_circ_0000915 promotes propranolol resistance of hemangioma stem cells in infantile haemangiomas. ( Chen, H; Li, Y, 2022) |
| "To investigate the effect of propranolol on urine bFGF, MMP-2, MMP-9 expression of children with proliferative infantile hemangioma(IH), so as to clarify the mechanism of propranolol in treating IH." | 8.12 | [Effects of oral propranolol on urine bFGF, MMP-2, MMP-9 expression in children with proliferative infantile hemangioma]. ( Wang, XK; Yuan, WL, 2022) |
| "To assess the adverse effects of propranolol therapy in infantile hemangioma." | 8.02 | Adverse Drug Reactions Following Propranolol in Infantile Hemangioma. ( Imran, M; Kumar, D; Mishra, A; Pandey, V; Sharma, SP; Tiwari, P, 2021) |
| "Propranolol is the first-line drug for infantile hemangioma (IH) therapy, whereas propranolol resistance is clinically observed." | 8.02 | Exosomal miR-27a-3p derived from tumor-associated macrophage suppresses propranolol sensitivity in infantile hemangioma. ( Fan, X; Guo, S; Liu, C; Zhang, L; Zhao, Z; Zheng, J, 2021) |
| "Oral propranolol accelerates the involution of infantile haemangiomas (IHs)." | 8.02 | Sequelae following infantile haemangiomas treated with propranolol. ( Baselga, E; Bassi, A; Bernabeu-Wittel, J; Carnevale, C; Diociaiuti, A; Downey, C; El Hachem, M; Gich, I; Gonzalez-Enseñat, MA; Knopfel, N; Leuzzi, M; Manunza, F; Mascaro, P; Monserrat-García, MT; Neri, I; Oranges, T; Ortiz-Prieto, A; Puig, L; Roe, E; Torrelo, A; Vercellino, N; Vicente, A, 2021) |
| "Oral propranolol is the treatment of choice for infantile hemangiomas." | 8.02 | Recurrence rate of infantile hemangioma after oral propranolol therapy. ( Byeon, JO; Frongia, G; Günther, P; Mehrabi, A, 2021) |
| "To report the effectiveness and safety of transcatheter arterial sclerosing embolization (TASE) for the treatment of parotid infantile hemangiomas that did not respond appreciably to propranolol." | 8.02 | Transcatheter Arterial Sclerosing Embolization for the Treatment of Giant Propranolol-Resistant Infantile Hemangiomas in the Parotid Region. ( Guo, L; Li, J; Song, D; Sun, J; Wang, L; Wu, C; Zhang, Y, 2021) |
| "To assess propranolol's impact on sleep when used in infants and toddlers with infantile hemangioma (80% under 6 months old)." | 8.02 | Propranolol's effects on the sleep of infants with hemangiomas: A prospective pilot study. ( Adams, S; Frost, S; Mallitt, KA; Saddi, V; Teng, A; Wargon, O; Williamson, B, 2021) |
| "Since 2008, oral propranolol has evolved as the first-line therapy for infantile hemangiomas (IHs)." | 8.02 | A survey on the application of oral propranolol and atenolol for the management of infantile hemangiomas in mainland China: Survey on propranolol atenolol hemangiomas. ( Liu, C; Shao, L; Wang, QZ; Wu, HW; Zhang, WB; Zhao, ZL; Zheng, JW, 2021) |
| "The outcomes of propranolol treatment remain controversial for parotid hemangiomas, which may be inferior to outcomes for infantile hemangiomas (IHs) at other sites." | 8.02 | Oral propranolol therapy in parotid hemangiomas: A retrospective comparison with other infantile hemangiomas. ( Bi, J; Gao, Q; Huo, R; Li, S; Li, X; Lv, R; Wang, L; Xu, G, 2021) |
| "Propranolol can inhibit the proliferation, migration, invasion, adhesion, and tube formation of hemangioma endothelial cells; block VEGF-mediated angiogenesis signaling pathway; suppress the expressions of downstream angiogenesis-related signaling molecules; and ultimately achieve the effect of treatment of IHs." | 8.02 | Propranolol Participates in the Treatment of Infantile Hemangioma by Inhibiting HUVECs Proliferation, Migration, Invasion, and Tube Formation. ( Wang, X; Yuan, W, 2021) |
| "To evaluate the prognostic value of ultrasound and MRI findings in patients with infantile hemangioma undergoing propranolol therapy." | 8.02 | Ultrasound and MRI findings as predictors of propranolol therapy response in patients with infantile hemangioma. ( Jung, HL; Lee, SY; Park, HJ; Rho, MH, 2021) |
| "Propranolol emerged as the first-line therapy for infantile hemangioma (IH)." | 8.02 | Propranolol for infantile hemangioma: Evaluating efficacy and predictors of response and rebound growth. ( Khamaysi, Z; Kridin, K; Pam, N, 2021) |
| "The beta-blocker propranolol is the standard medical therapy for subglottic hemangioma (SGH), but side effects and incomplete response rates require close monitoring." | 8.02 | Propranolol versus nadolol for treatment of pediatric subglottic hemangioma. ( Cushing, SL; Pope, E; Propst, EJ; Wolter, JK; Wolter, NE; Yang, W, 2021) |
| "Sleep problems are frequently reported in infants treated with propranolol for infantile hemangiomas, possibly serving as a marker for a negative impact on central nervous system function." | 8.02 | Sleep behavior of infants with infantile hemangioma treated with propranolol-a cohort study. ( Gnannt, R; Kernland-Lang, K; Knöpfel, N; Kohler, M; Kurth, S; Luchsinger, I; Neuhaus, K; Schoch, SF; Schwieger-Briel, A; Smith, A; Theiler, M; von der Heydt, S; Waelchli, R; Weibel, L, 2021) |
| "We presented the case of a child with infantile hemangioma of the lumbo-sacral region, treated with combination therapy with systemic propranolol and topical timolol, with satisfactory effect in the end." | 8.02 | Infantile Sacral Region Hemangioma and Combination Treatment with Propranolol and Topical Timolol: Case Review and Reference Review. ( Dinarevic, SM; Kardasevic, M, 2021) |
| "We present a case of a one-month-old female patient with severe hypertriglyceridaemia as a side effect of treating an ulcerating infantile hemangioma with systemic propranolol." | 8.02 | Transient hypertriglyceridaemia associated with propranolol for treatment of infantile hemangioma. ( Farshchian, M; Potts, GA, 2021) |
| "Oral propranolol has been widely used for problematic infantile hemangiomas (IHs)." | 7.96 | Lip Infantile Hemangiomas Involving the Vermillion Border Have Worse Outcomes and Prognosis to Oral Propranolol Than Lesions Confined to One Side of the Vermillion. ( Huang, H; Li, W; Xu, P; Yu, Q; Zhang, W, 2020) |
| "The highest efficacy of oral propranolol is for infantile hemangioma (IH) in the proliferative phase." | 7.96 | Oral propranolol administration is effective for infantile hemangioma in late infancy: A retrospective cohort study. ( Bergman, R; Khamaysi, Z; Kridin, K; Pam, N, 2020) |
| "The aim of this study is to evaluate the association of genetic polymorphisms in Cytochrome P450 2D6(CYP2D6) and the change in VEGF levels with the response to propranolol in patients with Infantile hemangiomas (IH)." | 7.96 | Influence of Cytochrome P450 2D6 Polymorphisms on the Efficacy of Oral Propranolol in Treating Infantile Hemangioma. ( Li, X; Wang, L; Wang, Y; Xu, Q; Zheng, K, 2020) |
| "Oral propranolol has become first-line treatment for infantile hemangiomas (IHs)." | 7.96 | Serum cytokine profiles in infants with infantile hemangiomas on oral propranolol treatment: VEGF and bFGF, potential biomarkers predicting clinical outcomes. ( Cheuh, HW; Choi, YB; Jung, HL; Kim, HS; Lee, JH; Lee, JM; Lee, MJ; Lim, YJ; Park, ES; Park, M; Park, SK; Shim, YJ; Yoon, HS, 2020) |
| "To study the clinical effect of oral propranolol in the treatment of respiratory hemangioma in infants and young children." | 7.96 | [Clinical effect of propranolol in the treatment of respiratory hemangioma in infants and young children]. ( Chen, YQ; Ding, XF; Zhong, LL, 2020) |
| "Infantile hemangiomas can be successfully treated by both systemic propranolol and neodymium:YAG (Nd:YAG)-dye laser combination therapy." | 7.96 | Combination therapy of oral propranolol and combined Nd:YAG/pulsed dye laser therapy in infantile hemangiomas: a retrospective analysis of 48 treated hemangiomas in 30 children. ( Hartmann, F; Hensen, J; Himpel, O; Kühnle, I; Lockmann, A; Schön, MP; Thoms, KM, 2020) |
| "Oral propranolol (OP) demonstrated high efficacy and safety profile for treatment of critical infantile hemangiomas (IHs)." | 7.96 | A new clinical and dermoscopic monitoring of infantile hemangiomas treated with oral propranolol. ( Caini, M; Cartocci, A; Cevenini, G; Cinotti, E; de Quattro, M; Fiorani, D; Ierardi, F; Oranges, T; Pianigiani, E; Rubegni, P; Tognetti, L, 2020) |
| "We describe a case of a 6-month-old female patient with a segmental, superficial, infantile hemangioma (IH) on the forehead being treated with propranolol 2 mg/kg/d for 5 months, who developed a symplastic hemangioma (SH) over the preexisting lesion, highlighting the need to consider SH in the differential diagnosis of vascular lesions arising over preexisting vascular anomalies in children." | 7.91 | Symplastic hemangioma developing over an infantile hemangioma during propranolol treatment. ( Cervilla, K; Downey, C; González, S; Kramer, D; Pino, G; Zambrano, MJ, 2019) |
| "There has been a paradigm shift from corticosteroid to propranolol treatment for infantile hemangiomas (IHs), with surgical resection reserved for complicated or persistent IHs." | 7.91 | Surgical resection of infantile hemangiomas following medical treatment with propranolol versus corticosteroids. ( Alvarez-Allende, CR; Crafton, T; Dasgupta, R; Hammill, AM; Jenkins, TM; Polites, SF; Watanabe, M, 2019) |
| "Concerns have been raised that propranolol treatment of infantile hemangioma (IH) may be associated with increased risks of adverse effects and growth impairment in preterm infants due to their immature development." | 7.91 | No Increased Risks Associated with Propranolol Treatment for Infantile Hemangioma in Preterm Infants were Identified at 3 Years of Age. ( Li, L; Ma, L; Wei, L; Xu, ZG, 2019) |
| "Propranolol is an effective method of treatment for infantile hemangiomas (IH)." | 7.91 | Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas. ( Babiak-Choroszczak, L; Bagłaj, M; Dawid, G; Gawrych, E; Giżewska-Kacprzak, K, 2019) |
| "Propranolol is the mainstay of treatment for infantile hemangiomas (IHs) benefited from its low complication in the present study." | 7.91 | Associations between short-term efficacy and clinical characteristics of infantile hemangioma treated by propranolol. ( Guo, L; Li, J; Song, D; Wang, C; Wang, L; Wu, C, 2019) |
| "We previously developed propranolol-encapsulated liposomes-in-microspheres (PLIM) to realize the sustained propranolol release for the treatment of hemangiomas." | 7.91 | The sustained and targeted treatment of hemangiomas by propranolol-loaded CD133 aptamers conjugated liposomes-in-microspheres. ( Dong, C; Guo, X; Liu, Q; Zhang, H; Zhu, X; Zuo, S, 2019) |
| "First-line therapy for infantile hemangiomas (IH) is oral propranolol, a systemic beta-blocker with the risk of rare but serious adverse effects." | 7.91 | Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas. ( Huang, AH; Lie, E; Mannschreck, DB; Psoter, K; Puttgen, K, 2019) |
| "Propranolol could repress infantile hemangioma cell growth and induce apoptosis." | 7.91 | Propranolol suppresses infantile hemangioma cell proliferation and promotes apoptosis by upregulating miR-125b expression. ( Huang, J; Jiang, D; Wang, A; Zhao, S, 2019) |
| "The use of propranolol for the treatment of subglottic haemangioma has become hugely popular due to its effectiveness and safety profile." | 7.91 | Treatment failure with propranolol for subglottic haemangioma. ( Jackson, C; Liu, Z; Trimble, K; Yeo, YH, 2019) |
| "To present the outcomes of fixed doses of propranolol tablets for the treatment of hemangiomas." | 7.91 | EFFECTIVENESS OF FIXED DOSES OF PROPRANOLOL IN THE TREATMENT OF HEMANGIOMAS REGARDLESS OF CHILD'S WEIGHT GAIN: A CASE REPORT. ( Anger, J; Gabel, J; Oliveira, EM, 2019) |
| "This was a retrospective study to analyze the clinical therapeutic efficacy of propranolol in patients with infantile hemangioma (IH)." | 7.91 | Therapeutic efficacy of propranolol for infantile hemangiomas. ( Chen, Y; Gao, Z; Hao, J; Li, F; Wang, H; Wu, W, 2019) |
| "The efficacy of lauromacrogol injection therapy and intralesional triamcinolone for infantile hemangiomas (IH) has been well documented recently, but with an increase in serious or rare adverse reactions." | 7.91 | Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas. ( Bi, J; Chai, Y; Huo, R; Li, X; Li, Z; Lv, R; Song, J; Xu, G; Zhou, Z, 2019) |
| "A prospective study was conducted on 25 patients with infantile hemangioma, who were treated with gradually increasing dose of propranolol starting from a lower dose of 1mg/kg/day." | 7.91 | Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study. ( Kumar, B; Kumari, M; Prasad, A; Sinha, AK, 2019) |
| "Propranolol is an approved non-selective β-adrenergic blocker that is first line therapy for infantile hemangioma." | 7.91 | R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma. ( Andelfinger, G; Bischoff, J; Chiang, IK; Fontaine, F; Francois, M; Gambin, Y; Hamdan, M; Huang, L; Khosrotehrani, K; Lesieur, E; Meurer, M; Moustaqil, M; Overman, J; Pasquier, E; Patel, J; Sierecki, E; Wylie-Sears, J; Zuegg, J, 2019) |
| "BackgroundPropranolol is the first-choice treatment for severe infantile hemangioma (IH)." | 7.88 | Infantile hemangioma: factors causing recurrence after propranolol treatment. ( Chang, L; Chen, H; Gu, Y; Jin, Y; Lin, X; Lv, D; Ma, G; Qiu, Y; Ying, H; Yu, Z, 2018) |
| "The aim of this study was to examine whether oral propranolol has any effect on neurodevelopment outcomes in young children with problematic infantile hemangiomas (IHs)." | 7.88 | Effects of Propranolol on Neurodevelopmental Outcomes in Patients with Infantile Hemangioma: A Case-Control Study. ( Chen, S; Ji, Y; Wang, C; Wang, Q; Xiang, B; Xiong, F, 2018) |
| "Screening electrocardiography (ECG) before initiation of propranolol for treatment of infantile hemangiomas (IH) is controversial." | 7.88 | Utility of routine electrocardiographic screening before initiation of propranolol for infantile hemangiomas. ( Chamlin, SL; Lund, EB; Mancini, AJ, 2018) |
| "Infantile hemangiomas (IHs) are the most common benign vascular neoplasms of infancy, characterized by a rapid growth phase followed by a spontaneous involution, or triggered by propranolol treatment by poorly understood mechanisms." | 7.88 | Modulation of LIN28B/Let-7 Signaling by Propranolol Contributes to Infantile Hemangioma Involution. ( Akat, KM; Canfield, J; Lockhart, J; Matar, A; Mong, EF; Totary-Jain, H; Tsibris, JCM; Tuschl, T; VanWye, J; Wu, JK, 2018) |
| "The use of propranolol for the treatment of infantile hemangioma (IH) has been widely investigated in recent years." | 7.88 | Propranolol induces hemangioma endothelial cell apoptosis via a p53‑BAX mediated pathway. ( Du, JT; Ge, SM; Gu, XW; Li, QY; Pataer, P; Regmi, KP; Tu, JB; Yao, TH, 2018) |
| "Propranolol has become the treatment of choice for infantile hemangiomas (IH)." | 7.88 | Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas? ( Babiak-Choroszczak, L; Bagłaj, M; Fischer, K; Gawrych, E; Giżewska-Kacprzak, K; Puchalska-Niedbał, L; Rajewska-Majchrzak, J; Walecka, A, 2018) |
| "The safety of oral propranolol for infantile hemangioma has not yet been studied at population level since the pediatric use marketing authorization was obtained in Europe." | 7.88 | Safety of Oral Propranolol for Infantile Hemangioma. ( Botrel, MA; Droitcourt, C; Dupuy, A; Garlantezec, R; Guillot, B; Happe, A; Kerbrat, S; Oger, E; Rault, C; Schleich, JM, 2018) |
| "We aimed to evaluate the effects of oral propranolol for circumscribed choroidal hemangioma." | 7.88 | Effects of oral propranolol for circumscribed choroidal hemangioma. ( Gonçalves Júnior, I; Maia, M; Mattos Neto, RB; Morales, MC; Sancho, KFCB; Zett, C, 2018) |
| "There has been a paradigm shift from steroids to propranolol for the pharmacologic treatment of infantile hemangiomas (IH); however, the outcomes for ulcerated IH are not well studied." | 7.88 | Propranolol versus steroids for the treatment of ulcerated infantile hemangiomas. ( Chute, C; Dasgupta, R; Hammill, A; Polites, SF; Rodrigue, BB, 2018) |
| "Hemangioma is the most common vascular tumor in infantile period, and propranolol is the first choice, but there are still a few patients with poor curative effect." | 7.88 | [Effect of treatment of infant parotid hemangioma with no response to oral propranolol]. ( Guo, XS; Nan, J; Shen, G; Tian, Y; Wang, XL, 2018) |
| "Treating infantile haemangioma with propranolol is more cost-effective when initiated on an outpatient basis." | 7.88 | Cost-effectiveness of treating infantile haemangioma with propranolol in an outpatient setting. ( Chaturvedi, K; Snyder, CS; Steinberg, JS, 2018) |
| "We sought to evaluate effect of propranolol in the treatment of infantile hemangiomas by quantifying the amount of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and hypoxia-inducible factor-1α (HIF-1α)." | 7.88 | Propranolol inhibits the activity of PI3K, AKT, and HIF-1α in infantile hemangiomas. ( Huang, G; Lin, H; Lin, Z; Wang, L; Wang, W, 2018) |
| "Propranolol is the treatment of choicefor complicated infantile hemangiomas (IH)." | 7.85 | Propranolol for infantile hemangiomas in developing countries. ( Lawley, LP; McMichael, J, 2017) |
| "There have been reports of the use of levothyroxine or levothyroxine plus liothyronine for consumptive hypothyroidism caused by hepatic hemangiomas." | 7.85 | Use of liothyronine without levothyroxine in the treatment of mild consumptive hypothyroidism caused by hepatic hemangiomas. ( Hasegawa, Y; Higuchi, S; Takagi, M, 2017) |
| "Despite not being licensed for the treatment of infantile hemangiomas (IH) in infants younger than 5 weeks or older than 5 months, propranolol is often used in these age groups to prevent or to treat potentially severe complications." | 7.85 | Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experience. ( Berti, I; Boccaletti, V; Carnevale, C; Cutrone, M; Dalmonte, P; Diociaiuti, A; El Hachem, M; Gesualdo, F; Greco, A; Neri, I; Oranges, T; Porcedda, G; Vercellino, N, 2017) |
| "Oral propranolol is considered the first choice for the treatment of infantile hemangiomas (IHs)." | 7.85 | Study of Cognitive Function in Children Treated with Propranolol for Infantile Hemangioma. ( Del Olmo-Benito, I; Descalzo, MA; García-Doval, I; González-Llorente, N; Muñoz-Ollero, N; Torrelo, A, 2017) |
| " A cavernous hemangioma was suspected and treated with high doses of propranolol and prednisolone." | 7.85 | Unexpected Effect of Propranolol and Prednisolone on Infantile Facial Rhabdomyosarcoma. ( Bhandari, SB; Lemperle, G; Mentzel, T; Shakya, J; Shilpakar, R, 2017) |
| "To develop propranolol-loaded poly(lactic-co-glycolic acid) nanoparticle with CD133 aptamers (PPN-CD133) to treat infantile hemangioma." | 7.85 | PLGA nanoparticles with CD133 aptamers for targeted delivery and sustained release of propranolol to hemangioma. ( Dong, C; Gao, J; Guo, X; Jin, X; Liu, D; Zhu, X, 2017) |
| "The aim of this study was to investigate the mechanism of propranolol on the regression of hemangiomas." | 7.85 | Propranolol inhibits the proliferation, migration and tube formation of hemangioma cells through HIF-1α dependent mechanisms. ( Bai, N; Bi, JH; Chen, YZ; Huo, R; Li, XQ; Liu, XW; Xu, GQ; Zhang, LF, 2017) |
| "Propranolol hydrochloride has become the primary medical treatment for problematic infantile hemangioma; however, the expression of propranolol's target receptors during growth, involution, and treatment of hemangioma remains unclear." | 7.85 | Expression of β-Adrenergic Receptor Subtypes in Proliferative, Involuted, and Propranolol-Responsive Infantile Hemangiomas. ( Phillips, JD; Richter, GT; Wei, T; Zhang, H, 2017) |
| "Propranolol is becoming the treatment of choice for complicated infantile hemangioma." | 7.85 | Cardiovascular Profile of Propranolol after Multiple Dosing in Infantile Hemangioma. ( Cavalli, R; Giavarini, A; Giovanni Bianchetti, M; Gondoni, E; Lombardi, F; Maria Colli, A; Salice, P, 2017) |
| "Oral propranolol has been recently approved for infantile hemangiomas (IHs), but potential side effects stay a challenge." | 7.85 | Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment. ( Parezanović, V; Petrovic, J; Topalovic, M; Trajkovic, G; Trifunovic, B; Vukomanovic, G, 2017) |
| "Concern has been raised about the potential long-term effects of propranolol treatment for infantile hemangioma (IH)." | 7.85 | Propranolol treatment of infantile hemangioma is not associated with psychological problems at 7 years of age. ( Moyakine, AV; Spillekom-van Koulil, S; van der Vleuten, CJM, 2017) |
| "There is no definitive conclusion regarding the optimal timing for terminating propranolol treatment for infantile hemangioma (IH)." | 7.85 | When to stop propranolol for infantile hemangioma. ( Chang, L; Chen, H; Gu, Y; Jin, Y; Lin, X; Ma, G; Qiu, Y; Ying, H; Yu, Z, 2017) |
| "Propranolol is the treatment of choice for infantile hemangiomas requiring medical intervention." | 7.85 | Propranolol treatment for infantile hemangioma does not increase risk of childhood wheezing. ( Amitai, DB; Blau, H; Hoshen, M; Lapidoth, M; Mei-Zahav, M; Mussaffi, H; Prais, D; Stafler, P; Steuer, G; Zvulunov, A, 2017) |
| "Propranolol was first used in 2008 to treat hemangioma; its efficacy and safety have since changed the classical treatment indications." | 7.85 | A New Perspective for Infantile Hepatic Hemangioma in the Age of Propranolol: Experience at Baskent University. ( Boyvat, F; Demir, Ş; Erbay, A; Özçay, F; Sarıalioğlu, F; Uslu, N; Yazıcı, N, 2017) |
| "The purpose of the present study is to evaluate the efficacy and safety of propranolol for problematic infantile hemangiomas (IH), showing our experience on 24 children, with special focus on premature infants." | 7.83 | Efficacy of propranolol for cutaneous hemangiomas in premature children. ( Barruscotti, S; Borroni, G; Brazzelli, V; Codazzi, CA; Giorgini, C; Mannarino, S; Marseglia, GL; Stronati, M; Tzialla, C, 2016) |
| "A retrospective observational study was conducted on patients with ulcerated infantile haemangioma treated with pulsed dye laser in association with propranolol." | 7.83 | [Combination of pulsed dye laser and propranolol in the treatment of ulcerated infantile haemangioma]. ( del Pozo Losada, J; Rodríguez-Ruiz, M; Tellado, MG, 2016) |
| "To describe a case of diffuse choroidal hemangioma with exudative retinal detachment treated successfully with oral propranolol." | 7.83 | DIFFUSE CHOROIDAL HEMANGIOMA MASQUERADING AS CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH ORAL PROPRANOLOL. ( Dave, T; Dave, VP; Pappuru, RR; Shah, G, 2016) |
| "We review the presentation, course, management and outcomes of all cases of genital infantile hemangiomas managed by propranolol administration at a single institution from April 2010 to July 2014." | 7.83 | Propranolol for Treatment of Genital Infantile Hemangioma. ( Golden, A; Rhee, A; Tamburro, J; Tran, C, 2016) |
| "Oral propranolol is widely prescribed as first-line treatment for infantile haemangiomas (IHs)." | 7.83 | Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. ( Audrain, H; Baryschpolec, S; Baselga, E; Beattie, PE; Bhate, K; Bjerre, JV; Brown, SJ; Burrows, NP; Clayton, TH; Darne, S; Durack, A; Dvorakova, V; Flohr, C; Foelster-Holst, R; Gach, J; Glover, M; Goldstraw, N; Goodyear, H; Grabczynska, S; Greenblatt, D; Halpern, J; Hearn, RM; Hedelund, L; Hernandez-Martin, A; Hoeger, PH; Hoey, S; Hughes, B; Irvine, AD; Janmohamed, SR; Jayaraj, R; Johansson, EK; Laguda, B; Lam, M; Leech, S; McPherson, T; Morrison, D; Neri, I; O'Regan, GM; Oranje, AP; Patrizi, A; Porter, W; Ramesh, R; Ravenscroft, JC; Schill, T; Shahidullah, H; Shaw, L; Solman, L; Svensson, A; Taylor, AE; Taylor, R; Thomson, J; Tiffin, P; Tsakok, M; Wahlgren, CF; Wedgeworth, E, 2016) |
| "The present study investigated the action of propranolol in infantile hemangiomas (IHs)." | 7.83 | Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation. ( Edwards, AK; England, RW; Kitajewski, AA; Kitajewski, JK; Kung, JE; Munabi, NC; Shawber, CJ; Tan, QK; Weinstein, A; Wilcox, M; Wu, JK, 2016) |
| "Despite the increasing popularity of propranolol for treatment of infantile hemangioma (IH), there is need for further evidence of efficacy and safety." | 7.83 | Treatment for Infantile Hemangiomas: Selection Criteria, Safety, and Outcomes Using Oral Propranolol During the Early Phase of Propranolol Use for Hemangiomas. ( Gehris, R; Geisler, S; Grunwaldt, LJ; MacIsaac, ZM; Mehta, D; Nayar, HS, 2016) |
| "Few specific reports have addressed propranolol as a treatment for parotid hemangioma, and its mechanism remains unclear." | 7.83 | Use of propranolol for parotid hemangioma. ( Chang, L; Chen, H; Jin, Y; Lin, X; Lv, D; Ma, G; Qiu, Y; Wang, T; Yang, X; Ying, H; Yu, W, 2016) |
| "The aim of this study was to explore the efficacy and safety of propranolol in treating infantile haemangiomas, the most common benign vascular tumours in children." | 7.83 | Propranolol was effective in treating cutaneous infantile haemangiomas in Thai children. ( Jetsrisuparb, C; Komwilaisak, P; Panombualert, S; Techasatian, L; Uppala, R, 2016) |
| "Propranolol is first-line therapy for problematic infantile hemangiomas (IHs)." | 7.83 | Rebound Growth of Infantile Hemangiomas After Propranolol Therapy. ( Adams, D; Baselga, E; Boon, LM; Chute, C; Coulie, J; Drolet, BA; Frieden, IJ; García-Romero, MT; Garzon, MC; Grimes, B; Haggstrom, AN; McCuaig, C; Newell, BD; Pope, E; Powell, J; Roe, E; Shah, SD; Siegel, DH, 2016) |
| "From October 2010 to June 2014, 31 infantile hemangioma patients admitted to our hospital, were administered propranolol combined with betamethasone injection treatment of lesions." | 7.83 | Treatment of infantile hemangioma by intralesional injection of propranolol combined with compound betamethasone. ( Li, J; Shao, RZ; Zhao, DH, 2016) |
| "Propranolol has recently been shown to be highly effective for infantile hemangioma (IH), but the mechanism of action of propranolol and the usefulness of measurement of vascular endothelial growth factor (VEGF) remain poorly understood." | 7.83 | Propranolol for infantile hemangioma: Effect on plasma vascular endothelial growth factor. ( Fukao, T; Hori, T; Kanda, K; Kawamoto, N; Kimura, T; Nozawa, A; Ozeki, M, 2016) |
| " The 31 patients had 32 hemangiomas (1 female patient had 2 lesions) and were treated with systemic propranolol at a high dose of 2 mg/kg per day." | 7.83 | Oral Propranolol for the Treatment of Infantile Hemangiomas in the Post-Proliferative Phase: A-Single Center Retrospective Study of 31 Cases. ( Liu, ZM; Tian, Y; Tong, S; Wang, XK; Xi, SL; Xu, DP, 2016) |
| "To investigate the effects of oral administration of low-dose propranolol on heart rate variability (HRV), acceleration capacity (AC), deceleration capacity (DC), and cardiac conduction in the treatment of infantile hemangioma." | 7.83 | [Changes in ambulatory electrocardiographic findings after oral administration of low-dose propranolol in infants with hemangioma]. ( Cao, XX; Huang, S; Qiu, M; Wen, HX; Yi, LF; Zhang, JY, 2016) |
| "In the last few years propranolol has revolutionized infantile hemangioma therapy." | 7.83 | Serum and tissue profile of VEGF and its receptors VGFR1/R2 in children with infantile hemangiomas on systemic propranolol treatment. ( Andrzejewska, E; Chrzanowska, B; Kobos, J; Przewratil, P; Szemraj, J; Taran, K; Wnęk, A; Wyrzykowski, D, 2016) |
| " The medical records of infants with periorbital hemangiomas who were treated with systemic propranolol at a dose of 1." | 7.83 | Clinical Outcomes of Infants With Periorbital Hemangiomas Treated With Oral Propranolol. ( Liu, ZM; Sun, C; Wang, XK; Xu, DP; Xue, L, 2016) |
| "To determine the efficacy of oral propranolol for the treatment of infantile subglottic hemangioma." | 7.83 | Role of oral propranolol in the treatment of infantile subglottic hemangioma. ( Chen, JR; Jin, L; Li, XY; Wang, Y, 2016) |
| "Propranolol, 2 mg/kg/day, is effective in the treatment of infantile hemangioma." | 7.83 | Response to propranolol in infantile hemangioma. ( Chunharas, A; Kadegasem, P; Lekanan, W; Sirachainan, N; Thammagasorn, Y; Wanitkun, S, 2016) |
| "An open observational prospective study was performed over 25 months in a group of pediatric patients diagnosed with infantile hemangioma treated with propranolol." | 7.83 | The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol. ( Castaneda, S; De la Cruz, H; Garcia, E; Melendez-Lopez, S; Sanchez-Palacio, J, 2016) |
| "There has been a dramatic increase in the off-label use of ophthalmic timolol maleate, a β-blocker used for infantile hemangioma (IH) treatment as a topical counterpart to oral propranolol." | 7.83 | Topical Timolol Maleate Treatment of Infantile Hemangiomas. ( Adams, D; Baselga, E; Drolet, B; Feigenbaum, D; Frieden, I; Garzon, MC; Holland, K; Horii, K; Lauren, C; Lucky, A; Mathes, E; McCuaig, C; Morel, KD; Newell, B; Nopper, A; Pope, E; Powell, J; Püttgen, K; Savva, Y; Siegel, D; Song, W, 2016) |
| "In recent years propranolol has become the treatment of choice for infantile hemangiomas (IHs)." | 7.83 | Is Routine Electrocardiography Necessary Before Initiation of Propranolol for Treatment of Infantile Hemangiomas? ( Krol, AL; Leitenberger, SL; MacArthur, CJ; Mann, JA; Tollefson, MM; Yarbrough, KB, 2016) |
| "Non-selective β-blocker propranolol has been proved by FDA as the first-line agent for infantile hemangioma (IH) with dramatic response." | 7.83 | [Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas]. ( Fan, XD; Huo, R; Jiang, CH; Lei, SR; Liu, SH; Qin, ZP; Wang, XK; Wang, XY; Yang, YW; Zhao, JH; Zheng, JW; Zhou, DK, 2016) |
| "Although propranolol has been accepted as a first-line drug for infantile haemangioma (IH), no study has systematically characterized changes in heart rates during long-term propranolol treatment." | 7.81 | Safety profile of a divided dose of propranolol for heart rate in children with infantile haemangioma during 16 weeks of treatment. ( Chen, W; Shi, H; Song, H; Wang, J; Yu, Y; Zhang, X; Zhou, H, 2015) |
| "Propranolol is a valid treatment for large cranial hemangiomas, avoiding the risks involved in surgeries." | 7.81 | Giant cranial and cerebellar hemangioma treated with propranolol. ( Ben-Sira, L; Benvenisti, H; Constantini, S; Roth, J, 2015) |
| "The aim of this study was to investigate the therapeutic results and effects of propranolol on cardiovascular parameters in infants receiving systemic propranolol for complicated infantile hemangiomas (IHs), as well as to evaluate the adverse effects of propranolol throughout the course of treatment." | 7.81 | Treatment of severe infantile hemangiomas with propranolol: an evaluation of the efficacy and effects of cardiovascular parameters in 25 consecutive patients. ( Cao, RY; Sun, NN; Tong, S; Wang, XK; Xu, DP; Xue, L, 2015) |
| "The aim of our study was to assess the efficacy and safety of oral propranolol for the treatment of parotid infantile hemangiomas." | 7.81 | Oral propranolol for parotid infantile hemangiomas. ( Cheng, C; Li, G; Liu, ZM; Sun, HL; Wang, XK; Xi, SL; Xu, DP, 2015) |
| "The current study demonstrated the antiangiogenic properties of propranolol in vitro and that the drug was able to induce the regression of hemangioma cells via the inhibition of cell cycle progression, invasion, and tube formation, concomitantly with decreased NO and VEGF levels through the down-regulation of the PI3K/Akt/eNOS/VEGF pathway." | 7.81 | Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway. ( Gao, Y; Guo, ZT; Huang, Q; Li, P; Pan, WK, 2015) |
| "Propranolol has been recently approved by health authorities to treat infantile haemangiomas (IH)." | 7.81 | [Propranolol in infantile hemangiomas]. ( Léauté-Labrèze, C, 2015) |
| "Topical propranolol has been used for the therapy of superficial infantile hemangiomas (IH)." | 7.81 | A novel topical nano-propranolol for treatment of infantile hemangiomas. ( Chen, ZG; Yuan, ML; Yuan, WE; Zhang, L; Zheng, JW, 2015) |
| "Propranolol, as a non-selective blocker of the β-adrenergic receptor (AR), is utilised as the first-line treatment for infantile hemangiomas." | 7.81 | Propranolol represses infantile hemangioma cell growth through the β2-adrenergic receptor in a HIF-1α-dependent manner. ( Gao, Y; Guo, Z; Li, P; Pan, W, 2015) |
| "With the emergence of propranolol as the primary treatment for hemangiomas the indications for surgical intervention have been greatly reduced." | 7.81 | Open airway surgery for subglottic hemangioma in the era of propranolol: Is it still indicated? ( Mehta, D; Siegel, B, 2015) |
| "To evaluate the effectiveness of systemic propranolol in airway infantile hemangioma (AIH) treatment." | 7.81 | Multicenter Evaluation of the Effectiveness of Systemic Propranolol in the Treatment of Airway Hemangiomas. ( Darrow, DH; Elluru, RG; Friess, MR; Grimmer, JF; Perkins, JA; Richter, GT; Shin, JJ, 2015) |
| " Infantile hemangiomas which have numerous similarities with chorioangiomas are now usually treated with propranolol." | 7.81 | Propranolol during pregnancy for large chorioangioma. ( D'Hervé, D; Fouque, L; Le Duff, M; Padys, P; Poulain, P, 2015) |
| "I was asked to provide a commentary for "Shouldn't Propranolol be Used to Treat All Hemangiomas?" by Moodley et al." | 7.81 | Commentary on Moodley S et al. "Shouldn't Propranolol be Used to Treat All Hemangiomas?". ( Blei, F, 2015) |
| "This study suggests that propranolol become the first-line treatment of choice for all haemangiomas." | 7.81 | Shouldn't Propranolol Be Used to Treat All Haemangiomas? ( Adams, KG; Adams, S; Hudson, DA; Moodley, ST, 2015) |
| "Our aim was to compare in a prospective study the clinical effects and safety of propranolol given orally, timolol maleate applied locally, and the combination of the two, in the management of superficial infantile haemangiomas." | 7.81 | Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. ( Cheng, C; Gong, H; Li, G; Li, YX; Wang, XK; Xu, DP, 2015) |
| "To investigate the effect of topical propranolol gel on the levels of plasma vascular endothelial growth factor (VEGF), basic fibroblastic growth factor (bFGF) and matrix metalloproteinases-9 (MMP-9) in proliferating infantile hemangiomas (IHs) of superficial type." | 7.81 | [Effect of propranolol gel on plasma VEGF, bFGF and MMP-9 in proliferating infantile hemangiomas of superficial type]. ( Guoliang, H; Lie, W; Shaoquan, C; Shuming, C; Yujuan, T; Zaizhong, Z, 2015) |
| "To explore the effect and safety of topical propranolol hydrochloride gel for treatment of infantile hemangioma." | 7.81 | [Effects of topical propranolol hydrochloride gel for treatment of infantile hemangioma in nude mice]. ( Chen, L; Chengjin, L; Lie, W; Qingjin, H; Shaoquan, C; Shuming, C; Yin, X; Zaizhong, Z, 2015) |
| "To summarize the subsequent therapy experiences for infantile hemangiomas after discontinuation of oral propranolol treatment, and explore the relationships between clinical interventions and types of infantile hemangioma." | 7.81 | [Subsequent therapy for infantile hemangiomas after discontinuation of oral propranolol]. ( Chen, T; Ge, CX; Li, KL; Liu, XJ; Qin, ZP; Tai, MZ, 2015) |
| "Propranolol is emerging as the treatment of choice for high-risk infantile haemangiomas." | 7.80 | Propranolol therapy for cutaneous infantile haemangiomas initiated safely as a day-case procedure. ( McSwiney, E; Murphy, M; Murray, D, 2014) |
| "Propranolol is an effective, safe treatment for complicated infantile haemangiomas (IH)." | 7.80 | Propranolol for the treatment of infantile haemangiomas: our experience with 44 patients. ( Lenane, P; Lynch, M; O'Donnell, BF, 2014) |
| "This study proved high efficiency of propranolol in treatment of infantile hemangioma, as assessed with the objective measures for the first time." | 7.80 | Treatment of infantile hemangiomas with propranolol: clinical guidelines. ( Anderson, W; Stewart, K; Szychta, P, 2014) |
| "Oral propranolol (PRN) has recently been shown to be highly effective for infantile hemangiomas (IHs), and is currently recommended as the first-line treatment of complicated IHs." | 7.80 | Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell. ( Li, KL; Mai, HM; Qin, ZP; Wang, YA; Zhang, L; Zheng, J; Zheng, JW, 2014) |
| "Propranolol seemed to be effective for treatment of hemangiomas in children and adolescents, and not just in the proliferative stage, with responses in almost all the patients." | 7.80 | Treatment of children and adolescents with hemangioma using propranolol: preliminary results from a retrospective study. ( Albuquerque, JC; Bastos, MV; Felix, FH; Félix, JA; Fontenele, JB; Magalhães, RA; Trompieri, NM, 2014) |
| "Propranolol is highly effective in the treatment of infantile hemangioma (IH), but important clinical and pharmacological data are lacking." | 7.80 | Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases. ( Ben Amitai, D; Lapidoth, M; Sagi, L; Zvulunov, A, 2014) |
| "To highlight the importance of Magnetic Resonance Imaging (MRI) and the use of propranolol as both a final diagnostic tool and adequate treatment for orbital Infantile Haemangiomas (IHs)." | 7.80 | Propranolol as first-line treatment in orbital infantile haemangiomas: a case series. ( Coumou, AD; Freling, NJ; Groeneveld, L; Levitt, M; Saeed, P; van der Horst, CM, 2014) |
| "Propranolol, a β-adrenergic receptor (AR) antagonist, is an effective treatment for endangering infantile haemangioma (IH)." | 7.80 | Propranolol targets the contractility of infantile haemangioma-derived pericytes. ( Bischoff, J; Boscolo, E; Durham, JT; Herman, IM; Lee, D; Mulliken, JB, 2014) |
| "A small percentage of complicated infantile haemangiomas need early, safe and effective treatment, and the option of off-label systemic propranolol treatment has been in existence since 2008." | 7.80 | A retrospective analysis of systemic propranolol for the treatment of complicated infantile haemangiomas. ( Cremer, HJ; Ruef, P; Schneider, M, 2014) |
| "To prospectively assess the efficacy and safety of propranolol in children with infantile hemangioma." | 7.80 | The role of propranolol in the treatment of infantile hemangioma. ( Costa, G; Freitas, I; Laranjo, S; Martins, JD; Paramés, F; Pinto, FF; Trigo, C, 2014) |
| "Hemangioma stem cells (HemSCs) isolated from resected IH specimens were treated with adipogenic medium for 1 or 4 days in either propranolol or vehicle." | 7.80 | Propranolol promotes accelerated and dysregulated adipogenesis in hemangioma stem cells. ( England, RW; Hardy, KL; Kitajewski, AM; Kitajewski, JK; Shawber, CJ; Wong, A; Wu, JK, 2014) |
| "Propranolol has been widely used in treating infantile hemangiomas (IHs)." | 7.80 | Propranolol enhanced adipogenesis instead of induction of apoptosis of hemangiomas stem cells. ( Chang, M; Ma, X; Ma, Y; Ouyang, T; Xin, S; Zhao, T, 2014) |
| "To assess the safety and efficacy of systemic propranolol for the treatment of complicated infantile haemangiomas." | 7.80 | Propranolol for infantile haemangiomas: single centre experience of 250 cases and proposed therapeutic protocol. ( Glover, M; Gnarra, M; Harper, JI; Murabit, A; Solman, L; Syed, SB, 2014) |
| "To explore the indications of hemangiomas of different types by observing the clinical efficacy of oral propranolol." | 7.80 | [Clinical analysis for treatment of 1 080 cases of infantile hemangiomas with oral propranolol]. ( Ge, C; Li, K; Liu, X; Qin, Z; Tai, M, 2014) |
| "Propranolol is increasingly used to treat problematic infantile haemangioma (IH), although its molecular mechanisms remain unclear." | 7.80 | Increased apoptosis and secretion of tryptase by mast cells in infantile haemangioma treated with propranolol. ( Day, D; Steel, R, 2014) |
| "This study was aimed at assessing the efficacy of propranolol treatment in infantile hemangiomas (IHs) by ultrasound." | 7.80 | Ultrasound in assessing the efficacy of propranolol therapy for infantile hemangiomas. ( Shang, Y; Shi, H; Song, H; Wang, J; Xia, L; Yang, J; Zhou, H, 2014) |
| "To develop a tool for assessing amblyopic risk and monitoring the treatment effect of propranolol in periocular haemangioma management." | 7.80 | Monitoring propranolol treatment in periocular infantile haemangioma. ( Burne, R; Taylor, R, 2014) |
| "This study aims to investigate the expression levels of serum and urinary vascular endothelial growth factor-A (VEGF-A) and epidermal growth factor-like domain 7 (EGFL7) in proliferating infantile hemangioma patients under propranolol treatment." | 7.80 | [Expression of serum and urinary vascular endothelial growth factor-A and epidermal growth factor-like domain 7 in proliferating hemangioma treated with propranolol]. ( Bin, L; Jie, L; Manli, C; Xiaopeng, Y; Zhaoquan, L; Zhongcheng, G, 2014) |
| "Systemic treatment with propranolol is proven to be effective for patients with hemangiomas with less side-effect." | 7.80 | Topical treatment with propranolol gel as a supplement to the existing treatment of hemangiomas. ( Cremer, H; Reimer, A; Ruef, P; Schneider, M, 2014) |
| "To explore the new mechanism of propranolol for treatment of hemangioma and the effects of propranolol on proliferation of hemangioma-derived mesenchymal stem cells ( Hem- MSCs)." | 7.80 | [Effects of propranolol on proliferation of hemangioma-derived mesenchymal stem cells ]. ( Huiping, C; Tianxiang, O; Tinghui, Z; Xiaorong, M; Yan, X; Yingying, H, 2014) |
| "Clinical observation of conservative treatment of the left hemi-liver haemangioma by propranolol in the full-term newborn with initial symptoms of cardiac failure is presented." | 7.80 | [Clinical case of treatment of hepatic haemangioma by propranolol in the newborn]. ( Getman, AN; Ivleva, SA; Kucherov, IuI; Rekhviashvili, MG; Zhirkova, IuV, 2014) |
| "The β-blocker propranolol was discovered to be highly effective for the treatment of infantile hemangiomas (IHs), since 2008." | 7.80 | Adverse effects of propranolol treatment for infantile hemangiomas in China. ( Babajee, K; Chen, X; Hu, X; Jian, D; Li, J; Su, J; Xie, H, 2014) |
| "Propranolol has recently become a successful first-line therapy in the treatment of infantile hemangiomas (IHs)." | 7.80 | Effect of propranolol on the treatment of infantile hemangiomas: a single tertiary center 3-year experience. ( Choi, JW; Kim, DY; Kim, KH; Park, YW; Shin, H; Yeom, KB, 2014) |
| "This study provides multi-institutional practice guidelines for the initiation of propranolol hydrochloride treatment of routine infantile hemangiomas." | 7.79 | Propranolol use for infantile hemangiomas: American Society of Pediatric Otolaryngology Vascular Anomalies Task Force practice patterns. ( Darrow, DH; Grimmer, JF; Manning, SC; Parikh, SR; Perkins, JA; Richter, GT, 2013) |
| "Infantile hemangioma (IH) clearance may be slow or incomplete in response to pulsed dye laser (PDL) or propranolol alone." | 7.79 | Retrospective study of the treatment of infantile hemangiomas using a combination of propranolol and pulsed dye laser. ( Anolik, R; Bernstein, L; Blei, F; Brauer, JA; Brightman, L; Geronemus, RG; Hale, E; Karen, J; Reddy, KK; Waner, M; Weiss, E, 2013) |
| "Propranolol has been used successfully in a limited number of children with infantile hemangiomas (IHs)." | 7.79 | Use of propranolol for the treatment infantile hemangiomas in the maxillofacial region. ( Kasimova, KR; Metellmann, HR; Podmelle, F; Sadykov, RA; Sadykov, RR, 2013) |
| "Propranolol is now widely used to treat severe infantile haemangiomas (IHs)." | 7.79 | Propranolol-resistant infantile haemangiomas. ( Aubert, H; Barbarot, S; Boccara, O; Bursztejn, AC; Caussé, S; Chiaverini, C; Dreyfus, I; Eschard, C; Hadj-Rabia, S; Mahé, E; Maruani, A; Mazereeuw-Hautier, J; Miquel, J; Puzenat, E; Saint-Jean, M; Stalder, JF, 2013) |
| "Although propranolol has become the first-line therapy for infantile haemangiomas (IHs), no study has yet investigated factors associated with the risk of relapse in children with IH treated with propranolol after cessation of treatment." | 7.79 | Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol. ( Ahogo, CK; Boralevi, F; Colona, V; Diallo, A; Ezzedine, K; Léauté-Labrèze, C; Prey, S; Taïeb, A, 2013) |
| "Although propranolol can be an effective primary medical therapy for infantile hemangiomas of the head and neck, the duration of treatment and time to discontinue propranolol is unclear." | 7.79 | Successful discontinuation of propranolol for infantile hemangiomas of the head and neck at 12 months of age. ( Chiu, ES; Hong, P; Kluka, EA; Poole, JC; Simon, LM; Tammareddi, N; Walvekar, R, 2013) |
| "To evaluate the efficacy and safety of 1% propranolol ointment in the treatment of superficial infantile hemangiomas (IHs)." | 7.79 | [Treatment of superficial infantile hemangiomas with topical propranolol]. ( Huo, R; Lü, RR; Niu, JN; Xu, GQ, 2013) |
| "This case of a four and a half-month-old girl describes periocular infantile haemangioma which was treated successfully with propranolol." | 7.79 | Periocular infantile haemangioma and the role of propranolol. ( Ahmad, K; Chaudhry, TA; Kamal, M, 2013) |
| "Propranolol, a lipophilic non-selective beta-blocker, has proven to be effective in the treatment of infantile haemangioma (IH)." | 7.79 | Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group. ( Breugem, CC; Breur, JM; Bruijnzeel-Koomen, CA; de Graaf, M; Knol, MJ; Kon, M; Pasmans, SG; Raphael, MF, 2013) |
| "Oral propranolol hydrochloride treatment has been proven effective for infantile hemangiomas." | 7.79 | Effects of oral propranolol on circumscribed choroidal hemangioma: a pilot study. ( Hirose, H; Kitano, T; Sahashi, K; Saito, AM; Tanabe, H; Tomita, Y, 2013) |
| "We sought to determine the effect of propranolol on cardiovascular and blood glucose parameters in infants with symptomatic infantile hemangiomas who were hospitalized for initiation of treatment, and to analyze adverse effects of propranolol throughout the course of inpatient and outpatient treatment." | 7.79 | Cardiovascular and blood glucose parameters in infants during propranolol initiation for treatment of symptomatic infantile hemangiomas. ( Bauman, NM; Boss, EF; Cohen, BA; Puttgen, KB; Schneider, J; Summerer, B, 2013) |
| "Propranolol had a rapid stabilizing effect leading to early regression of hemangiomas when administered orally at a dose of 3 mg/kg/day with good quality safety profile." | 7.79 | Propranolol for hemangiomas. ( Hasan, M; Hoque, S; Khondker, L; Rahman, M; Zahid Hossain, AK, 2013) |
| "We investigated the clinical efficacy of propranolol in treating proliferating infantile haemangiomas, and the serological changes in vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS) during treatment." | 7.79 | Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patients. ( Jin, ZL; Liu, ZY; Wang, XK; Wei, JJ; Xue, L; Yuan, WL, 2013) |
| "We aimed to assess the efficacy and safety of low-dose propranolol for treatment of infantile hemangiomas (IHs) in China." | 7.79 | Preliminary experience on treatment of infantile hemangioma with low-dose propranolol in China. ( Chen, H; Huang, Y; Lin, J; Liu, J; Ma, X; Ouyang, T; Xiao, Y; Yu, J; Zhao, T, 2013) |
| "Treatment options for large subglottic haemangioma include steroids, laser ablation, open excision, tracheostomy and, more recently, propranolol." | 7.79 | Great Ormond Street Hospital treatment guidelines for use of propranolol in infantile isolated subglottic haemangioma. ( Albert, DM; Bajaj, Y; Harper, JI; Hartley, BE; Ifeacho, S; Jephson, CG; Kapoor, K, 2013) |
| "To evaluate the response of nasal tip hemangiomas to systemic propranolol." | 7.78 | Hemangiomas of the nasal tip treated with propranolol. ( Ben-Amitai, D; Halachmi, S; Kalish, E; Lapidoth, M; Raveh, E; Zvulunov, A, 2012) |
| "Propranolol was recently discovered to be an effective treatment for infantile haemangiomas, and varying doses and monitoring regimens have been proposed." | 7.78 | Propranolol for infantile haemangiomas: initiating treatment on an outpatient basis. ( Dyme, JL; Han, EJ; Kotb, ME; Nyirenda, TL; Shin, HT; Thampan, A, 2012) |
| "Thirty-seven infants with propranolol-treated problematic head and neck hemangiomas were included and all patients had a good response." | 7.78 | Propranolol for problematic head and neck hemangiomas: an analysis of 37 consecutive patients. ( Fan, XD; Lv, MM; Su, LX, 2012) |
| "To examine the location and degree of endothelial nitric oxide synthase (eNOS) protein expression in hemangioma growth, involution, and during propranolol therapy." | 7.78 | Decreased eNOS protein expression in involuting and propranolol-treated hemangiomas. ( Buckmiller, L; Dai, Y; Fan, CY; Hou, F; Richter, GT; Saad, A; Suen, J, 2012) |
| "Propranolol may be a promising therapeutic modality for infantile hemangioma." | 7.78 | Treatment with propranolol for infantile hemangioma in 13 Taiwanese newborns and young infants. ( Chang, TK; Chen, CH; Chou, CM; Hsu, TC; Lin, HK; Wang, JD; Wang, TM, 2012) |
| "To investigate the mechanism of propranolol on regression of infantile hemangiomas." | 7.78 | Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A. ( Armijo, BS; Chim, H; Gliniak, C; Gosain, AK; Miller, E; Serret, MA, 2012) |
| "Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP)." | 7.78 | Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. ( Blei, F; Carcao, M; Chiu, YE; Drolet, BA; Fangusaro, J; Kelly, ME; Krol, A; Lofgren, S; Mancini, AJ; Metry, DW; Pope, E; Recht, M; Silverman, RA; Tom, WL, 2012) |
| "To evaluate changes in infantile hemangioma tissue before and after propranolol therapy, using gray-scale and color Doppler ultrasound imaging." | 7.78 | Propranolol reduces infantile hemangioma volume and vessel density. ( Bingham, MM; Perkins, JA; Saltzman, B; Vo, NJ, 2012) |
| "Sixty-seven infantile hemangioma patients were included in propranolol protocol in two institutions from 2009 to 2011." | 7.78 | Propranolol as the first-line therapy for infantile hemangiomas: preliminary results of two centers. ( Celik, A; Ergun, O; Kismali, E; Levent, E; Musayev, A; Tiryaki, S, 2012) |
| " To evaluate the effectiveness, safety and tolerability of propranolol as single-agent treatment in patients with problematic, proliferative-phase, infantile hemangiomas (IHs)." | 7.78 | Propranolol treatment for severe infantile hemangiomas: a single-centre 3-year experience. ( Georgountzou, A; Kakourou, T; Karavitakis, E; Klimentopoulou, A; Xaidara, A, 2012) |
| "Propranolol has recently emerged as an effective drug treatment for infantile haemangiomas." | 7.78 | Use of propranolol for treatment of infantile haemangiomas in an outpatient setting. ( Bekhor, PS; Crock, CM; Penington, AJ; Phillips, RJ, 2012) |
| "Discuss effect and dynamics of propranolol (PR) treatment in infantile haemangioma (IH) of head and neck in children during follow-up." | 7.78 | Propranolol for infantile haemangioma: striking effect in the first weeks. ( Csákányi, Z; Gács, E; Gerlinger, I; Katona, G; Ráth, G; Szalai, Z, 2012) |
| "Propranolol increased apoptosis of hemangioma endothelial cells, but not stem cells, and accelerated adipogenesis of hemangioma stem cells." | 7.78 | Propranolol accelerates adipogenesis in hemangioma stem cells and causes apoptosis of hemangioma endothelial cells. ( Hardy, KL; Kitajewski, AM; Kitajewski, JK; Shawber, CJ; Wong, A; Wu, JK, 2012) |
| "To observe the efficacy of oral Propranolol in the treatment of infantile subglottic hemangioma." | 7.78 | [Treatment of infantile subglottic hemangioma with oral propranolol]. ( Tang, LX; Wang, GX; Zhang, YM, 2012) |
| "Propranolol, a non-selective beta-blocker, has recently been introduced as a novel treatment modality for proliferating hemangiomas." | 7.78 | Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells. ( Chen, S; Ji, Y; Li, K; Xiao, X; Xu, T; Zheng, S, 2012) |
| "The clinical efficacy and safety of topical propranolol hydrochloride gel in the treatment of superficial infantile hemangiomas (IHs) were assessed." | 7.78 | Topical propranolol hydrochloride gel for superficial infantile hemangiomas. ( Li, C; Li, Y; Wang, L; Xia, Y; Zhai, Y, 2012) |
| "In 2008, propranolol was serendipitously observed to cause accelerated involution of infantile haemangioma." | 7.77 | Low-dose propranolol for infantile haemangioma. ( Itinteang, T; Leadbitter, P; Tan, ST, 2011) |
| "We report here the case of an infant with multiple hepatic and cutaneous infantile hemangiomas (IHs) associated with deranged liver function who was treated successfully with low-dose propranolol." | 7.77 | Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function. ( Itinteang, T; Leadbitter, P; Tan, ST, 2011) |
| "I see many children with infantile hemangiomas and have read about new therapeutic options such as propranolol." | 7.77 | Use of propranolol in treating hemangiomas. ( Goldman, RD; Prendiville, JS; Shayan, YR, 2011) |
| "To outline a safe, standardized protocol for outpatient initiation of propranolol therapy for infantile hemangiomas." | 7.77 | Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas. ( Boucek, RJ; Cushing, SL; Manning, SC; Perkins, JA; Sidbury, R, 2011) |
| "Recent reports have described the successful use of propranolol to treat severe hemangiomas of infancy." | 7.77 | [Propranolol for the treatment of severe hemangiomas of infancy: results from a series of 28 patients]. ( Bernabeu-Wittel, J; Conejo-Mir, J; de Agustín, JC; Fernández-Pineda, I; Mantrana-Bermejo, ME; Pereyra-Rodríguez, JJ, 2011) |
| "To report the efficacy of propranolol as first-line treatment of head and neck hemangiomas in children and to present an optimized protocol for treating hemangiomas." | 7.77 | Propranolol as first-line treatment of head and neck hemangiomas. ( Ayari-Khalfallah, S; Froehlich, P; Fuchsmann, C; Giguere, C; Guibaud, L; McCone, C; Powell, J; Quintal, MC, 2011) |
| "A brief comment on efficacy and safety of propranolol in the treatment of parotid hemangioma is presented, with illustration of a typical case." | 7.77 | Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma. ( Zheng, JW, 2011) |
| "To observe the efficacy and safety of oral propranolol in the treatment of periorbital proliferating phase infantile hemangioma." | 7.77 | [Oral propranolol in the management of periorbital proliferating phase infantile hemangioma]. ( Fu, HB; Guo, X; Huo, R; Lin, LL; Lü, RR; Wui, JC; Xu, GQ; Zhang, J; Zhao, ZF, 2011) |
| "To determine whether propranolol therapy is safe and effective and superior to oral corticosteroids for treating infantile hemangiomas (IHs)." | 7.77 | Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. ( Baum, B; Connelly, EA; Duarte, AM; Lattouf, C; McLeod, M; Price, CJ; Schachner, LA, 2011) |
| "Four children with haemangiomas of the head and neck were treated with propranolol at a tertiary referral centre." | 7.77 | Failure of propranolol in the treatment of childhood haemangiomas of the head and neck. ( Bruce, IA; Goswamy, J; Rothera, MP, 2011) |
| "There has been a dramatic evolution in the treatment of laryngotracheal hemangiomas during the past decade and recent accounts and case reports of propranolol treatment have been encouraging." | 7.77 | Evolving treatments in the management of laryngotracheal hemangiomas: will propranolol supplant steroids and surgery? ( Jacobs, IN; Javia, LR; Zur, KB, 2011) |
| "To study the level of serum vascular endothelial growth factor, matrix metalloproteinases-9 in the proliferative hemangioma before and after propranolol treatment." | 7.77 | [The change of serum vascular endothelial growth factor and matrix metalloproteinases-9 in proliferative hemangioma treated with propranolol]. ( Fu, HB; Huo, R; Lü, RR; Xu, GQ; Zhao, ZF, 2011) |
| "Four patients with ulcerated hemangioma aged 2, 4, 5 months and 5 weeks were treated with 2 mg/kg KG propranolol." | 7.76 | Successful treatment of ulcerated haemangioma with propranolol. ( Bross, F; Lorette, G; Maruani, A; Naouri, M; Rossler, J; Schill, T, 2010) |
| "To report our experience of using propranolol to treat an infantile airway haemangioma." | 7.76 | Use of propranolol to treat multicentric airway haemangioma. ( Mistry, N; Tzifa, K, 2010) |
| "We report the rapid and dramatic efficacy of propranolol in 8 infants with infantile hepatic hemangiomas." | 7.76 | Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. ( Ammour, A; Benlahrech, S; Bodemer, C; Broue, P; Hoeger, PH; Labenne, M; Léauté-Labrèze, C; Mazereeuw-Hautier, J; Ohanessian, G; Rössler, J; Vabres, P; Vial, J, 2010) |
| "Propranolol is a novel therapeutic agent in the treatment of cutaneous infantile haemangiomas." | 7.76 | Successful treatment of infantile haemangiomas of the orbit with propranolol. ( Li, YC; Martin, FJ; Martin, PA; McCahon, E; Rowe, NA; Wilcsek, GA, 2010) |
| " Our main outcome measures were colour and size of infantile haemangioma before and after treatment, the change in astigmatism of our patients and the incidence of complications from propranolol." | 7.76 | Propranolol in the management of periorbital infantile haemangioma. ( Cheng, JF; Gole, GA; Sullivan, TJ, 2010) |
| "The successful management of subglottic hemangioma with propranolol has been reported." | 7.76 | Management of infantile subglottic hemangioma: acebutolol or propranolol? ( Amedro, P; Bigorre, M; Blanchet, C; Mondain, M; Nicollas, R, 2010) |
| "Propranolol has recently been reported to be useful in the treatment of infantile hemangiomas." | 7.76 | Outpatient treatment of periocular infantile hemangiomas with oral propranolol. ( Eikenberry, J; Haggstrom, A; Haider, KM; Neely, DE; Plager, DA, 2010) |
| "Propranolol hydrochloride has been prescribed for decades in the pediatric population for a variety of disorders, but its effectiveness in the treatment of infantile hemangiomas (IHs) was only recently discovered." | 7.76 | Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. ( Drolet, BA; Frieden, IJ; Frommelt, PC; Holland, KE; Mancini, AJ; Wyatt, D, 2010) |
| " She was given propranolol after her tracheotomy and had a significant reduction in her subglottic airway obstruction." | 7.76 | Propranolol in the management of airway infantile hemangiomas. ( Frieden, IJ; Maguiness, SM; Meyer, AK; Rosbe, KW; Suh, KY, 2010) |
| "To evaluate the short-term results and safety of propranolol for the treatment of infantile parotid hemangioma." | 7.76 | [Treatment of infantile parotid hemangioma with propranolol]. ( Ge, CX; Li, KL; Liu, XJ; Qin, ZP; Tai, MZ, 2010) |
| "Seven patients presenting with airway obstruction were treated with propranolol." | 7.76 | Propranolol for the treatment of airway hemangiomas: a case series and treatment algorithm. ( Chang, KW; Messner, AH; Perkins, JA; Truong, MT, 2010) |
| " Mean percentage of airway obstruction was 68% (15-90) before propranolol introduction." | 7.76 | Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience. ( Ayari, S; Carrabin, L; Couloigner, V; Cox, A; Denoyelle, F; Fayoux, P; Froehlich, P; Garabédian, EN; Leboulanger, N; Lescanne, E; Marianowski, R; Marie, JP; Mom, T; Mondain, M; Nicollas, R; Roger, G; Teissier, N; Triglia, JM; Van Den Abbeele, T, 2010) |
| "To describe the use of propranolol as first-line treatment or as single therapy to control the proliferating phase of infantile haemangioma in Chinese children." | 7.76 | Use of propranolol in infantile haemangioma among Chinese children. ( Chan, HB; Chik, KK; Luk, CK; Tan, HY, 2010) |
| "Propranolol treatment was recently reported to be successful for the management of severe infantile hemangioma." | 7.76 | Hyperkalemia complicating propranolol treatment of an infantile hemangioma. ( Kietz, S; Lakomek, M; Lauerer, P; Pavlakovic, H; Zutt, M, 2010) |
| "There are recent reports of effective treatment of cutaneous hemangiomas with Propranolol." | 7.75 | Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. ( Denoyelle, F; Enjolras, O; Garabedian, EN; Harris, R; Leboulanger, N; Roger, G, 2009) |
| "To evaluate the short-term efficacy and safety of propranolol in the treatment of infantile hemangiomas." | 7.75 | [Treatment of infantile hemangiomas with low-dose propranolol: evaluation of short-term efficacy and safety]. ( Li, KL; Liu, XJ; Qin, ZP; Yang, XJ; Zheng, JW; Zhou, Q, 2009) |
| "Infantile hemangioma is a benign cutaneous tumor, which sometimes rapidly enlarges, causes cosmetic problem, destroys normal tissue, and possibly threatens life." | 6.94 | Change of serum cytokine profiles by propranolol treatment in patients with infantile hemangioma. ( Inaba, Y; Jinnin, M; Kakimoto, N; Kaminaka, C; Kanazawa, N; Kunimoto, K; Mikita, N; Suenaga, T; Suzuki, H; Takeuchi, T; Tani, S; Yamamoto, Y, 2020) |
| " Our study suggested that oral propranolol combined with topical timolol treatment is very effective and well-tolerated for compound IHs, which can be used as a first line treatment." | 6.82 | Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study. ( Ge, J; Yuan, W; Zhang, L; Zhao, H; Zheng, J, 2016) |
| "Propranolol treatment decreases urinary excretion of MMP-9 in patients with IH." | 6.78 | Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. ( Bauman, N; Brown, KJ; Movius, E; Preciado, D; Saieg, A; Thaivalappil, S, 2013) |
| "Infantile haemangioma is the commonest childhood tumour and approximately 10% requires treatment." | 6.76 | Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. ( Gorst, C; Holmes, WJ; Liew, SH; Mishra, A, 2011) |
| "Infantile hemangioma is one of the most common benign tumors of infancy." | 6.72 | Propranolol treatment of infantile subglottic hemangioma: a report of two cases and a literature review. ( Ganeva, K; Nikiforova, L; Sapundzhiev, N; Shivachev, P, 2021) |
| "Infantile haemangiomas are the most common tumour of infancy." | 6.58 | Topical propranolol for infantile haemangiomas: a systematic review. ( Birchall, JC; Elhassan, HA; Mcleod, RWJ; Price, A; Rai, S, 2018) |
| " The dosage was increased up to a maximum of 2 mg/kg/d and was maintained until the lesion had involuted or showed good result." | 6.53 | Treatment of rapidly proliferating haemangiomas in newborns with propranolol and review of the literature. ( Debek, W; Dzienis-Koronkiewicz, E; Hermanowicz, A; Matuszczak, E; Oksiuta, M, 2016) |
| "Propranolol was found to be a more effective modality in treating IHs (ORs = 0." | 6.52 | Effectiveness and Safety of Oral Propranolol versus Other Treatments for Infantile Hemangiomas: A Meta-Analysis. ( Liu, X; Qu, X; Zhang, L; Zheng, J, 2015) |
| "Infantile hepatic hemangioma is the most common benign liver tumor during infancy." | 6.48 | Multifocal infantile hepatic hemangiomas--imaging strategy and response to treatment after propranolol and steroids including review of the literature. ( Bosemani, T; Huisman, TA; Puttgen, KB; Tekes, A, 2012) |
| "Infantile haemangiomas are the most common benign tumour of infancy." | 6.47 | Propranolol for infantile haemangiomas: a review. ( Shahidullah, H; Starkey, E, 2011) |
| " Data from the literature and from our own patient cohort (n = 132) confirm the remarkable efficacy of propranolol in complicated IH, without significant adverse effects." | 6.47 | [Treatment of haemangiomas of infancy with propranolol; good results, few side effects]. ( Hermans, DJ; Ottenhof, MJ; van Beynum, IM; van der Horst, CM; van der Vleuten, CJ; Wijnen, MH, 2011) |
| "Oral propranolol is a very recent therapeutic option for complicated IH with impressive efficacy and generally good tolerance." | 6.46 | Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. ( Hoeger, PH; Storch, CH, 2010) |
| "Our primary objective was to review the current use of propranolol for treatment of infantile hemangioma (IH), specifically regarding 1) the age at initiation of therapy, 2) the method of initiation, 3) the use of other adjuvant therapy, 4) the duration of therapy and relapse rate, 5) the adverse events, and 6) the outcome." | 6.25 | Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial. ( Bauman, NM; Greene, EA; McCarter, R; Menezes, MD, 2011) |
| "Propranolol treatment mostly leads to regression of hemangiomas with satisfactory aesthetic results, but unfortunately not in all cases." | 5.91 | Nd:YAG 1064-nm laser for residual infantile hemangioma after propranolol treatment. ( Avitan-Hersh, E; Khamaysi, Z; Pam, N; Zaaroura, H, 2023) |
| " To evaluate the correlation of clinical features between cutaneous IH and IHH, as well as efficacy of systemic propranolol in the treatment of cutaneous IH combined with IHH." | 5.91 | Clinical features of cutaneous infantile hemangioma combined with asymptomatic infantile hepatic hemangioma and efficacy of propranolol treatment. ( Han, X; Li, L; Ma, L; Sun, Y; Wei, L; Xu, Z; Yu, L; Zhang, B, 2023) |
| "Oral propranolol has not been shown to impact physical development, such as weight and height." | 5.91 | The impact of propranolol on the growth and development of children with proliferative infantile hemangioma during treatment. ( Chen, S; Chen, X; Deng, L; Gao, J; Huang, L; Lin, X; Liu, C; Wang, Q; Wang, T, 2023) |
| "Propranolol was successfully tapered over 3 weeks by reducing the dose by 50% weekly until it reached the therapeutic dose." | 5.91 | Excessively High Chronic Propranolol Overdose in Infantile Hemangioma: A Case Report. ( Alessa, A; Alghanem, A; Alhammad, AM; Alshammari, H; Elsharawy, Y, 2023) |
| " Adverse event and drug-related adverse event rates were 87." | 5.72 | Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study. ( Hakamata, A; Hayano, S; Inui, N; Iwashima, S; Kashiwagura, Y; Nagata, E; Nishida, M; Odagiri, K; Okada, E; Sano, S; Tanaka, S; Uchida, S; Umemura, K; Watanabe, H, 2022) |
| "Propranolol is a safe, effective and well-tolerated treatment in Australian children with IH." | 5.72 | Immediate possible adverse event rates in infants treated with oral propranolol for infantile haemangiomas at an Australian urban tertiary hospital between 2016 and 2019. ( Adams, L; Ryan, E, 2022) |
| "Severe hypoglycemia was common in infants aged >1 year, when PPL was used for ≥6 months." | 5.72 | Severe hypoglycemia in propranolol treatment for infantile hemangiomas. ( Baba, N; Kaneko, T; Kuwano, Y; Morimoto, A; Ozeki, M; Sasaki, S, 2022) |
| "Hepatic hemangioma is the most common benign liver tumor." | 5.62 | [Propranolol treatment in Kasabach-Merritt Syndrome secondary to congenital hepatic hemangioma. Clinical case]. ( Malla, I; Selzer Soria, EM, 2021) |
| "Oral propranolol has been well established as the first-line treatment of complicated hemangiomas; however, variability in the administration protocol remains." | 5.62 | Is prolonged monitoring necessary? An updated approach to infantile hemangioma treatment with oral propranolol. ( Johansen, ML; Lawley, LP; Mahendran, G, 2021) |
| "Hemangioma is one of the commonest benign vascular tumors among children." | 5.56 | Propranolol inhibits proliferation and induces apoptosis of hemangioma-derived endothelial cells via Akt pathway by down-regulating Ang-2 expression. ( Dong, C; Gong, Y; Lei, H; Li, M; Sun, B; Sun, L; Zhang, H; Zhang, Y, 2020) |
| "Infantile hemangioma is one of the most common vascular tumors, which might result in morbidity and mortality without timely intervention." | 5.56 | Enhanced efficacy of propranolol therapy for infantile hemangiomas based on a mesoporous silica nanoplatform through mediating autophagy dysfunction. ( Huang, S; Liang, H; Wang, X; Wu, H; Zhang, D; Zheng, J, 2020) |
| "Infantile hemangiomas are the most common benign vascular tumors in childhood." | 5.56 | Propranolol-resistant infantile hemangioma successfully treated with sirolimus. ( Baselga, E; Dávila-Osorio, VL; Iznardo, H; Puig, L; Roé, E, 2020) |
| " Although oral propranolol is currently first-line therapy, optimal dosing for treatment of IH remains debated." | 5.56 | Retrospective case series of increased oral propranolol dosage for infantile hemangiomas. ( Aggarwal, P; Cohen, BA; Huang, AH; Mahon, M; Mannschreck, D, 2020) |
| "The initial recommendation propranolol usage in managing infantile hemangioma was in 2008 followed by various researches assessing the dosage, efficacy, and other parameters." | 5.51 | Itraconazole versus propranolol: therapeutic and pharmacologic effect on serum angiopoietin-2 in patients with infantile hemangioma. ( Bessar, H; Kandil, AH; Khattab, F; Nasr, NM, 2022) |
| "Propranolol was started at the age of 3 months and 7 days old with an initial dosage of 1." | 5.51 | Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report. ( Liu, HC; Tsai, MC; Yeung, CY, 2019) |
| "Propranolol is a well-documented medical therapy for cutaneous lesions, but surgical treatment dominates the literature on bladder haemangiomas." | 5.51 | Propranolol as an effective therapy for infantile haemangioma of the urinary bladder. ( Anwar, T; Malm-Buatsi, E, 2019) |
| "Infantile hemangioma is the most common soft tissue tumors in childhood." | 5.51 | MiR-187-3p Enhances Propranolol Sensitivity of Hemangioma Stem Cells. ( Ji, Z; Jiang, Y; Liu, C; Zhao, Z; Zheng, J, 2019) |
| "Infantile hemangiomas are the most common tumor of childhood and undergo rapid growth during early infancy followed by gradual involution." | 5.48 | Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment. ( Kagami, S; Kaneko, M; Katori, T; Kishi, A, 2018) |
| "The propranolol treatment for the patient with suspected of bronchial asthma was suspended for 4 months." | 5.48 | Oral propranolol for infantile hemangiomas beyond the proliferative phase. ( Kagami, S; Katori, T, 2018) |
| "Propranolol has been recently introduced for the treatment of IH." | 5.48 | Propranolol inhibits proliferation and invasion of hemangioma-derived endothelial cells by suppressing the DLL4/Notch1/Akt pathway. ( Dong, C; Gong, Y; Lei, H; Li, M; Sun, B; Sun, L; Zhang, H; Zhang, Y, 2018) |
| "Treatment with propranolol in this group of Moroccan pediatric patients proved to be safe and effective at a dose of 2 mg/kg/day, reducing the size and coloration of the hemangioma." | 5.48 | Effects of propranolol therapy in Moroccan children with infantile hemangioma. ( Baline, K; Chiheb, S; Fatoiki, FZE; Hali, F; Khadir, K; Lahrichi, A, 2018) |
| "Propranolol has been demonstrated to be effective for IHs; however, the factors affecting its therapeutic effect remain unknown." | 5.46 | Analysis of factors affecting the therapeutic effect of propranolol for infantile haemangioma of the head and neck. ( Dong, JY; Huang, YY; Li, K; Li, RH; Liu, C; Liu, SH; Ning, JX; Wang, XX; Yue, LL, 2017) |
| " The dosage of propranolol was increased from 0." | 5.46 | Successful Treatment of Infantile Hemangiomas With Propranolol in Low-Birth-Weight Infants. ( Hayashi, A; Kado, M; Matsumura, T; Mizuno, H; Mochizuki, M; Shimizu, A, 2017) |
| " During the involution phase, tapering propranolol dosage can be done to minimize side effects before discontinuing treatment." | 5.46 | Propranolol therapy for infantile hemangioma: our experience. ( Wu, HW; Yuan, W; Zhang, L; Zheng, JW, 2017) |
| "Diffuse hepatic hemangiomas are a challenging disease that can be life threatening." | 5.46 | Diffuse Hepatic Hemangiomas Successfully Treated Using Sirolimus and High-Dose Propranolol. ( Diaz, L; Levy, M; Warren, D, 2017) |
| "Infantile hemangiomas are the most common tumors affecting children." | 5.46 | Promotion of Propranolol Delivery to Hemangiomas by Using Anti-VEGFR Antibody-Conjugated Poly(lactic-co-glycolic acid) Nanoparticles. ( Dong, C; Gong, Y; Guo, X; Liu, D; Sun, J; Zhu, X, 2017) |
| "Hemangiomas are common skin lesion, affecting 10-12% of children <1year of age." | 5.43 | The treatment of problematic hemangiomas in children with propranolol and 940nm diode laser. ( Dementieva, N; Jones, S, 2016) |
| "Oral propranolol was successful in 95." | 5.43 | Propranolol treatment for infantile hemangioma: a case series of sixty-two patients. ( Barbato, G; Boccaletti, V; Carano, N; Cerasoli, G; Gritti, A; Lombardi, AA; Marchesi, M; Stringari, G; Tchana, B; Zanzucchi, M, 2016) |
| "Propranolol is the only treatment that the U." | 5.43 | Use of Propranolol for Treating Hemangiomas in Infants with Previously Diagnosed Hypoglycemic Conditions. ( De Léon, DD; McMahon, P; Treat, JR; Yang, TB, 2016) |
| " However, the appropriate drug dosage, dosing regimen, time for initiation, optimal duration, monitoring for side effects remains controversial." | 5.43 | [Chinese experts consensus on the use of oral propranolol for treatment of infantile hemangiomas]. ( Fan, XD; Huo, R; Li, K; Liu, SH; Qin, ZP; Wang, XK; Wang, XY; Yang, YW; Zhao, JH; Zheng, JW; Zhou, DK, 2016) |
| "Prior to propranolol the systemic treatment for haemangiomas was prednisolone and then the concern was the opposite, namely hypertension." | 5.42 | Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome. ( Batul Syed, S; Gnarra, M; Harper, J; Solman, L, 2015) |
| "Infantile hemangiomas are the most common vascular tumors in childhood." | 5.42 | Delayed-onset of multiple cutaneous infantile hemangiomas due to propranolol: a case report. ( del Boz González, J; Navarro Morón, J; Porcel Chacón, R, 2015) |
| " The dosage of Propranolol was increased over the course of treatment, which initiated three days." | 5.42 | Large Doses of Propranolol for the Treatment of Infantile Cephalic and Facial Hemangiomas: A Clinical Report of 38 Cases. ( Jianguo, K; Mingkun, Z; Qiaoling, C; Wenjin, L; Xichun, W, 2015) |
| "Haemangiomas are benign vascular tumours that generally arise in the skin during the first days of life." | 5.42 | Propranolol (Hemangiol) and severe infantile haemangiomas. The drug of first choice. ( , 2015) |
| "Although propranolol has been established as the gold standard when treatment is sought for infantile hemangioma, concerns over its side effect profile have led to increasing usage of atenolol, a beta-1 selective blocker." | 5.41 | Should Propranolol Remain the Gold Standard for Treatment of Infantile Hemangioma? A Systematic Review and Meta-Analysis of Propranolol Versus Atenolol. ( Carroll, W; Chen, T; Clemmens, C; Gudipudi, R; Nguyen, SA, 2023) |
| "Pulmonary hemangioma is a rare benign tumor of the lungs." | 5.40 | Successful treatment of pulmonary hemangioma with propranolol. ( Akyüz, C; Emiralioğlu, N; Ersöz, DD; Kiper, N; Oğuz, B; Özçelik, U; Yalçın, B; Yalçın, E, 2014) |
| " The most important adverse effects were hypotension (3·4%), wheezing (9·2%), nocturnal restlessness (22·4%) and cold extremities (36·2%)." | 5.39 | Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions. ( Bauland, CG; Hermans, DJ; van Beynum, IM; van der Vleuten, CJ; Zweegers, J, 2013) |
| "Infantile hemangioma is a common benign pediatric tumor which shares many features with epulis, such as rich vascularity, high incidence of female patients, high hormone level and similar treatments." | 5.38 | New treatment strategy for granulomatous epulis: intralesional injection of propranolol. ( Fan, ZN; Li, KL; Liu, C; Liu, SH; Qin, ZP; Wang, YM; Wei, FC; Zhao, WJ, 2012) |
| "Propranolol has been recently discovered to shrink these lesions effectively." | 5.37 | Propranolol, infantile haemangiomas, and serendipity: new use for an old drug. ( Grech, V; Scerri, C, 2011) |
| "Infantile haemangioma is a benign tumour of the microvasculature characterised by excessive proliferation of immature endothelial cells." | 5.37 | Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. ( Brasch, HD; Day, DJ; Itinteang, T; Tan, ST, 2011) |
| "Propranolol was given to 20 patients with IH, who suffered from ulceration at the start of treatment (mean age at onset of treatment, 3." | 5.37 | Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. ( Hermans, DJ; Schultze Kool, LJ; van Beynum, IM; van de Kerkhof, PC; van der Vleuten, CJ; Wijnen, MH, 2011) |
| "Propranolol appears to be an effective and well-tolerated treatment for ulcerated IH." | 5.37 | Propranolol for treatment of ulcerated infantile hemangiomas. ( Barbarot, S; Bodak, N; Hadj-Rabia, S; Hamel-Teillac, D; Kupfer-Bessaguet, I; Lacour, JP; Léauté-Labrèze, C; Mazereeuw-Hautier, J; Naouri, M; Nguyen, JM; Saint-Jean, M; Stalder, JF; Vabres, P, 2011) |
| "Propranolol appears to be an effective treatment option for IH even in the nonproliferative phase and after the first year of life." | 5.37 | Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. ( Breugem, CC; Breur, JMPJ; de Graaf, M; Pasmans, SGMA; Raphaël, MF; Vos, M, 2011) |
| "PHACE syndrome is a neurocutaneous disorder with large facial segmental hemangionas associated with anomalies of the brain, eye, heart and aorta." | 5.37 | Use of propranolol for treatment of hemangiomas in PHACE syndrome. ( Deming, D; Hopper, A; Merritt, TA; Ninnis, J; Solomon, T, 2011) |
| "Oral propranolol was given for a period of 6 months with monthly follow up." | 5.37 | Initial experiences with propranolol treatment of infantile hemangiomas: report of three cases. ( Halilbasic, A; Halilbasic, M; Hotic, N; Husaric, E; Husaric, S; Rahmanovic, E, 2011) |
| "Hemangiomas are the most common vascular tumors in children." | 5.36 | Successful treatment of a large hemangioma with propranolol. ( Haas, E; Kues, K; Lauerer, P; Mousa, W; Pavlakovic, H; Schön, MP; Zutt, M, 2010) |
| "Haemangiomas are the most common soft tissue tumours in infancy, occurring in approximately 5-10% of 1-year-old children." | 5.36 | Propranolol as a novel treatment for congenital visceral haemangioma. ( Cornette, L; Decaluwe, W; Van Geet, C; Vandelanotte, M; Vanlander, A, 2010) |
| "Propranolol was given to 32 children (21 girls; mean age at onset of treatment: 4." | 5.35 | Propranolol for severe infantile hemangiomas: follow-up report. ( Berge, J; Boralevi, F; de la Roque, ED; Dupuis, E; Ezzedine, K; Grenier, N; Léauté-Labrèze, C; Lipsker, D; Mazereeuw-Hautier, J; Sans, V; Taïeb, A; Vergnes, P, 2009) |
| "Subglottic haemangioma is a rare but potentially life threatening condition which requires intervention." | 5.35 | Successful treatment of isolated subglottic haemangioma with propranolol alone. ( Harper, J; Hartley, BE; Jephson, CG; Manunza, F; Mills, NA; Syed, S, 2009) |
| "Hemangioma is the most common tumor of infancy." | 5.35 | [Response to oral propranolol therapy for ulcerated hemangiomas in infancy]. ( Michel, JL; Patural, H, 2009) |
| "With the emergence of propranolol as the first choice of treatment for problematic infantile haemangioma at many centres, the number of patients with a partial or non-response to propranolol has also been growing." | 5.27 | Role of intralesional bleomycin and intralesional triamcinolone therapy in residual haemangioma following propranolol. ( Kumar, R; Pandey, V; Sharma, SP; Singh, OP; Tiwari, P, 2018) |
| "There are limited data from randomized clinical trials comparing propranolol and steroid medication for treatment of infantile hemangioma (IH)." | 5.24 | Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial. ( Cheon, JE; Choe, YS; Choi, TH; Choi, Y; Hong, KY; Jeong, JH; Kang, HJ; Kim, DY; Kim, KH; Lee, H; Park, JB; Park, KD; Park, YW; Shin, HY, 2017) |
| "Topical timolol and lasers are widely used for the treatment of infantile hemangioma (IH), and they can replace propranolol as the first-line treatment of IH." | 5.22 | Comparison of the efficacy and safety of lasers, topical timolol, and combination therapy for the treatment of infantile hemangioma: A meta-analysis of 10 studies. ( Cai, B; Chen, X; Huang, H; Wang, B; Yu, J, 2022) |
| "Propranolol is a valuable therapeutic alternative for treatment of ulcerated haemangiomas and effectively reduces pain." | 5.22 | Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. ( Gangopadhyay, AN; Gupta, DK; Pandey, V; Sharma, SP; Tiwari, P, 2016) |
| "The combination treatment for mix infantile hemangiomas (IHs) using oral propranolol with topical timolol maleate was not well documented in the literature." | 5.22 | Oral Propranolol With Topical Timolol Maleate Therapy for Mixed Infantile Hemangiomas in Oral and Maxillofacial Regions. ( Li, G; Sun, NN; Tong, S; Wang, XK; Xu, DP; Xue, L, 2016) |
| "Propranolol has been widely used in the treatment of infantile hemangiomas since 2008." | 5.22 | Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas. ( Chang, L; Chen, H; Hu, L; Huang, H; Jin, Y; Li, W; Lin, X; Ma, G; Qiu, Y; Xu, X; Zhou, B, 2016) |
| "Oral propranolol has been used to treat complicated infantile hemangiomas, although data from randomized, controlled trials to inform its use are limited." | 5.20 | A randomized, controlled trial of oral propranolol in infantile hemangioma. ( Ballona, R; Barbarot, S; Baselga, E; Benjamin, L; Bernabeu-Wittel, J; Berul, CI; Birchall, N; Boccara, O; Boralevi, F; Buckova, H; Caceres, H; Cambazard, F; Delarue, A; Febrer Bosch, MI; Foelster-Holst, R; Frieden, IJ; Friedlander, SF; Glick, S; Grantzow, R; Guibaud, L; Heritier, S; Hoeger, P; Krol, A; Léauté-Labrèze, C; Lopez Gutierrez, JC; Mancini, AJ; Maruani, A; Mazereeuw-Hautier, J; Mehta, CR; Metz, B; Morgan, CC; Perek, D; Phillips, RJ; Pope, E; Posiunas, G; Powell, J; Prey, S; Przewratil, P; Roessler, J; Souteyrand, P; Su, J; Szalai, ZZ; Torrelo, A; Vabres, P; Valencia, AM; Voisard, JJ; Wargon, O; Wyrzykowski, D, 2015) |
| "Combining propranolol with corticosteroids gives a faster response and should be considered in treating life- or function-threatening hemangiomas." | 5.20 | Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. ( Abdel Kader, HM; Aly, MM; Ghazy, MS; Hamza, AF; Ragab, IA; Saafan, HA, 2015) |
| "Propranolol therapy is changing the treatment paradigm for infantile hemangioma." | 5.19 | Propranolol therapy for reducing the number of nasal infantile hemangioma invasive procedures. ( Chen, BS; Manning, SC; Parikh, SR; Perkins, JA; Saltzman, B, 2014) |
| "The dramatic response of infantile hemangiomas to propranolol and few side effects suggest that early treatment of infantile hemangiomas could result in decreased disfigurement." | 5.17 | Propranolol is more effective than pulsed dye laser and cryosurgery for infantile hemangiomas. ( Aozasa, N; Araki, M; Inuzuka, R; Isomura, S; Kagami, S; Katori, T; Kuwano, Y; Masui, Y; Miyagawa, T; Miyamoto, A; Sato, S; Shibata, S; Takahashi, K; Uwajima, Y; Yamada, D; Yamamoto, M, 2013) |
| "To assess propranolol efficacy and safety in complicated infantile hemangiomas in two different age groups." | 5.17 | The use of propranolol for complicated infantile hemangiomas. ( Dalmonte, P; Occella, C; Pelegrini, M; Rimini, A; Romanini, MV; Vercellino, N, 2013) |
| "The purpose of this study was to compare the efficacy of orally administered propranolol versus prednisolone versus both in the treatment of potentially disfiguring or functionally threatening infantile hemangiomas." | 5.17 | Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study. ( Malik, MA; Menon, P; Rao, KL; Samujh, R, 2013) |
| "The mechanism of therapeutic success of propranolol for severe infantile haemangioma remains unclear." | 5.16 | Urinary matrix metalloproteinases-2/9 in healthy infants and haemangioma patients prior to and during propranolol therapy. ( Hinz, U; Holland-Cunz, S; Kleber, CJ; Kleber, JB; Spiess, A; Weiss, J, 2012) |
| "To observe the therapeutic effect of propranolol with 1 064 nm Nd:YAG laser on proliferating hemangioma in body surface." | 5.16 | [The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface]. ( Duan, B; Gong, H; Tan, M; Zhou, CM, 2012) |
| "Propranolol hydrochloride is a safe and effective medication for treating infantile hemangiomas (IHs), with decreases in IH volume, color, and elevation." | 5.15 | A randomized controlled trial of propranolol for infantile hemangiomas. ( Adams, S; Hogeling, M; Wargon, O, 2011) |
| "To evaluate the short-term efficacy and safety of propranolol for problematic infantile hemangiomas." | 5.15 | [Propranolol in the treatment of problematic infantile hemangiomas]. ( Chen, J; Huang, J; Li, S; Lu, J; Qin, G; Tna, L; Xiang, Y; Yang, S; Zhao, J; Zuo, C, 2011) |
| "Propranolol has recently been introduced as a novel pharmacologic treatment for infantile hemangiomas." | 5.14 | Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. ( Buckmiller, LM; Dai, Y; Dyamenahalli, U; Munson, PD; Richter, GT, 2010) |
| "Propranolol has changed the management of infantile hemangiomas (IHs)." | 5.01 | Clinical and economic impact of surgery for treating infantile hemangiomas in the era of propranolol: overview of single-center experience from La Paz Hospital, Madrid. ( López-Gutiérrez, JC, 2019) |
| "Recently, several studies have reported their experience in using oral atenolol in patients with infantile haemangioma (IH), especially as an alternative to propranolol, but the efficacy and safety of oral atenolol has not been evaluated." | 5.01 | Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: A systematic review. ( Chen, S; Ji, Y; Wang, Q; Xiang, B, 2019) |
| "We report a case presented in deep hypoglycemic coma during his treatment with propranolol for IH." | 5.01 | Deep coma in a child treated with propranolol for infantile hemangioma. ( Bakalli, I; Celaj, E; Gjeta, I; Klironomi, D; Kola, E; Lluka, R; Sala, D; Sallabanda, S, 2019) |
| "A number of clinical trials evaluated the effect of topical timolol in the treatment of infantile hemangioma and provided inconsistent results." | 4.98 | Effect of topical timolol on response rate and adverse events in infantile hemangioma: a meta-analysis. ( Li, Y; Zheng, L, 2018) |
| "Propranolol is a well tolerated and effective treatment for infantile hemangiomas." | 4.98 | Infantile hemangiomas: what have we learned from propranolol? ( Ghareeb, E; Hagen, R; Jalali, O; Zinn, Z, 2018) |
| "Five cases of subglottic hemangioma treated with systemic propranolol are presented." | 4.98 | [Tiempo de respuesta terapéutica al propranolol sistémico en el manejo de hemangiomas subglóticos pediátricos: serie de casos y revisión de la literatura]. ( Álvarez-Neri, H; Morera-Serna, E; Penchyna-Grub, J; Teyssier-Morales, G; Torre, C; Villamor, P, 2018) |
| "Propranolol has recently become the treatment of choice for management of subglottic and airway hemangiomas." | 4.95 | Efficacy and rebound rates in propranolol-treated subglottic hemangioma: A literature review. ( Chun, RH; Faria, J; Pawar, S; Schwartz, T; Siegel, D, 2017) |
| "Propranolol has become the first-line treatment for complicated Infantile Hemangioma (IH), showing so far a good risk-benefit profile." | 4.95 | Cardiac arrest in a toddler treated with propranolol for infantile Hemangioma: a case report. ( Cutrone, M; Dalle Carbonare, M; Perilongo, G; Pettenazzo, A; Sartori, S; Tosoni, A, 2017) |
| "We present a one-month old boy with an intracranial infantile hemangioma treated with propranolol." | 4.93 | Beta Blockade as Treatment for Intracranial Infantile Hemangioma: Case Report and Literature Review. ( Friedman, N; Golden, A; Kang, E; Mamoun, I; Tamburro, J, 2016) |
| "1) Describe the origins of the use of propranolol in the treatment of subglottic hemangiomas, 2) Perform meta-analysis of all case reports and series in which propranolol was used to treat subglottic hemangiomas." | 4.93 | The use of propranolol in the treatment of subglottic hemangiomas: A literature review and meta-analysis. ( Dodson, KM; Hardison, S; Wan, W, 2016) |
| "Currently, propranolol is the preferred treatment for problematic proliferating infantile haemangiomas (IHs)." | 4.91 | The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. ( Chen, S; Ji, Y; Li, L; Xiang, B; Xu, C, 2015) |
| "The serendipitous demonstration that the nonselective β-adrenergic receptor (β-AR) antagonist propranolol promotes the regression of infantile hemangiomas (IHs) aroused interest around the involvement of the β-adrenergic system in angiogenic processes." | 4.91 | Infantile hemangiomas, retinopathy of prematurity and cancer: a common pathogenetic role of the β-adrenergic system. ( Bagnoli, P; Casini, G; Dal Monte, M; Daniotti, M; Filippi, L; Sereni, F, 2015) |
| "ince 2008, propranolol has become the first line therapy for infantile hemangiomas." | 4.91 | Propranolol induced hypoglycemia. ( Haim, A; Horev, A; Zvulunov, A, 2015) |
| "Propranolol has been recently adopted as the first-line medical treatment for complicated infantile hemangiomas." | 4.91 | Current trends in medical management of infantile hemangioma. ( Ames, JA; Sykes, JM, 2015) |
| "Propranolol may have shown excellent results as a first line therapy in infantile haemangiomas (IHs) at all sites in the body, but this conclusion remains controversial." | 4.90 | The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies. ( Cao, DS; Cao, Y; Li, HH; Lou, Y; Peng, WJ; Xie, J, 2014) |
| "Propranolol has replaced corticosteroids as preferred first-line therapy for the management of infantile hemangiomas (IH)." | 4.90 | Diagnosis and management of infantile hemangiomas. ( Püttgen, KB, 2014) |
| " The benefits with bedaquiline or Sirturo® are its ability to likely provide clinically relevant activity as part of multi-drug regimens against tuberculosis (TB) based on clinical data in multi-drug resistant tuberculosis (MDR TB) patients, who were defined as being at least resistant against the two major tuberculostatic medicines (isaoniazide and rifampicine)." | 4.90 | [Two news drugs (ivacaftor & bedaquiline), one biomarker (florbetapir) and a re-positioned drug (propranolol) on the market]. ( Monneret, C, 2014) |
| "Recent reports of propranolol for the treatment of hemangiomas have led many physicians to question the best treatment strategy for children with vision-threatening hemangiomas." | 4.89 | Hemangiomas treated with propranolol: do the rewards outweigh the risks? ( Haider, KM; Neely, DE; Plager, DA, 2013) |
| "Propranolol is a beta blocker which is safely used in the management of infantile hemangiomas." | 4.89 | Novel use of propranolol for management of pain in children with vertebral hemangioma: report of two cases. ( Celkan, T; Gungor, S; Hasiloglu, Z; Ozdemir, N; Saygin, C; Uzunaslan, D, 2013) |
| "To study the effectiveness of propranolol in infantile airway haemangiomas and compare the effectiveness of propranolol vs." | 4.87 | A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. ( Athanasopoulos, I; Parpounas, K; Peridis, S; Pilgrim, G, 2011) |
| "The objective of this study is to describe the initial use of propranolol as the sole treatment for focal infantile airway hemangiomas, and to report on available literature describing the use of propranolol for airway lesions." | 4.86 | Initial experience using propranolol as the sole treatment for infantile airway hemangiomas. ( Hartnick, C; Maturo, S, 2010) |
| "Propranolol, a nonselective beta-blocker, has recently been introduced as a novel modality for the treatment of proliferating haemangiomas." | 4.86 | Propranolol therapy for infantile haemangiomas: review of the literature. ( Eivazi, B; Werner, JA; Wiegand, S; Zimmermann, AP, 2010) |
| "Propranolol was serendipitously found to induce early involution in hemangiomas even during the proliferative phase of the hemangioma cycle." | 4.85 | Propranolol treatment for infantile hemangiomas. ( Buckmiller, LM, 2009) |
| " The present report describes a case of multifocal IHH associated with subcutaneous and lingual hemangiomas, complicated by consumptive hypothyroidism and successfully managed with oral propranolol and thyroid replacement therapy, without documented adverse effects." | 4.31 | Multifocal Infantile Hepatic Hemangiomas Complicated by Consumptive Hypothyroidism: The Benefits of Early Diagnosis and Treatment. ( Alves, I; Coelho, J; Do Bom-Sucesso, M; Morais, CG; Vilares, AT, 2023) |
| "Infantile hemangioma (IH), the most common benign tumor in infancy, is generally sensitive to propranolol treatment." | 4.31 | Apelin Receptor Can Act as a Specific Marker and Promising Therapeutic Target for Infantile Hemangioma. ( Chang, L; Chang, SJ; Chen, J; Chen, Q; Chen, Z; Lin, X; Qiu, Y; Ying, H; Yu, Z, 2023) |
| "Propranolol has emerged as a first line agent in the management of hemangiomas." | 4.31 | Bleomycin-triamcinolone sclerotherapy in the management of propranolol resistant infantile hemangioma of the maxillofacial region: A single arm prospective evaluation of clinical outcome and Doppler ultrasound parameters. ( Bera, RN; Pandey, V; Tiwari, P, 2023) |
| "The purpose of this study was to compare long-term neurocognitive functioning (working memory, processing speed, and attention) between children who had been treated with either propranolol or atenolol for infantile hemangioma during infancy." | 4.31 | Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma. ( Breugem, CC; Breur, JMPJ; de Graaf, M; de Laat, PCJ; de Wildt, SN; Hermans, MM; Langeveld, HR; Mendels, EJ; Pasmans, SGMA; Raphael, MF; Rietman, AB; Schappin, R, 2023) |
| "The introduction of propranolol as systemic therapy for infantile hemangiomas (IH) has changed the natural history of these tumors." | 4.31 | Propranolol and infantile hemangiomas: Outcome from a tricentric study. ( Benetton, C; Cimador, M; De Corti, F; Gamba, P; Midrio, P; Pace, MD, 2023) |
| "Despite its effectivity, there are reports of poor response to propranolol in the treatment of infantile hemangioma (IH)." | 4.31 | Intralesional steroid in the era of propranolol for infantile hemangioma-Do we need it? ( Pandey, A; Pant, N; Rawat, J; Singh, S; Srivastava, A, 2023) |
| "The distribution and response to propranolol of problematic facial infantile haemangiomas (IHs) has rarely been described in the literature." | 4.31 | Distribution of problematic localized facial infantile haemangiomas and their response to propranolol: a retrospective cohort study. ( Chang, L; Chang, SJ; Chen, J; Chen, Q; Gao, W; Li, H; Lin, X; Qiu, Y; Yu, Z; Zhou, L, 2023) |
| "We studied 95 patients with infantile hemangioma (IH) treated with propranolol at the Department of Dermatology, Kumamoto University Hospital, from November 2016 to January 2022, based on sex, site, clinical classification, duration of treatment, and residual lesions after treatment." | 4.31 | A study of 95 infantile hemangiomas treated with propranolol: A potentially efficacious combination with laser therapy. ( Amano, F; Aoi, J; Fukushima, S; Kajihara, I; Makino, K; Masuguchi, S; Nakayama, W; Nishimura, Y; Sawamura, S; Shimada, S; Yamada-Kanazawa, S, 2023) |
| "This study aims to review how the introduction of propranolol as the primary treatment option for children with infantile hemangiomas (IHs) has affected the use of other treatment options at our institution and to determine the indications for surgical treatment of children with IHs in the propranolol era." | 4.31 | Indications for surgical resection of complicated infantile hemangiomas in the β-blocker's era: a single-institution experience from a retrospective cohort study. ( Beqo, BP; Flucher, C; Gasparella, P; Haxhija, EQ; Quehenberger, F; Spendel, S, 2023) |
| "Although the efficacy of propranolol in the treatment of infantile hemangioma (IH) has been well established, clinical data on the safety and tolerability of propranolol in neonates are still lacking." | 4.31 | Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population. ( Bai, H; Cheng, J; Fu, R; Huan, X; Huang, M; Jin, P; Wu, Z; Yuan, H; Zou, Y, 2023) |
| "Between January 2016 and February 2019, dermatologists experienced hemangioma treatment and recommended propranolol treatment for 232 IHs." | 4.31 | Our experience with propranolol for infantile hemangioma. ( Dai, T; Lu, W; Song, W; Wang, L; Wu, Y; Zhao, P, 2023) |
| "Propranolol is the first-line treatment for infantile hemangiomas (IH)." | 4.31 | Predictors of poor response to oral propranolol in infantile hemangiomas. ( Berrami, H; Chiheb, S; Hali, F; Moubine, I; Othmani, MB; Serhier, Z, 2023) |
| "Propranolol is the first choice for treating infantile hemangioma (IH)." | 4.31 | The effects of propranolol on the biology and Notch signaling pathway of human umbilical vein endothelial cells. ( Chen, J; Chen, S; Huang, J; Lin, C; Lin, N; Wang, L; Xu, Q; Zhang, Z; Zhao, X, 2023) |
| "Propranolol, a non-selective blocker of the β-adrenoceptor (AR), is a first-line treatment for infantile hemangioma (IH)." | 4.12 | Propranolol inhibits the angiogenic capacity of hemangioma endothelia via blocking β-adrenoceptor in mast cell. ( Dong, C; Dong, K; Dou, L; Gao, W; He, L; Li, J; Li, K; Lu, W; Song, W; Wang, L; Xia, C; Ye, Y; Zhong, H, 2022) |
| "Propranolol and atenolol, current therapies for problematic infantile hemangioma (IH), are composed of R(+) and S(-) enantiomers: the R(+) enantiomer is largely devoid of beta blocker activity." | 4.12 | Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma. ( Bischoff, J; Fontaine, F; Francois, M; Graus, MS; Huang, L; Karnezis, T; McCann, A; Meunier, F; Mulliken, JB; Seebauer, CT; Staffa, SJ; Wylie-Sears, J; Zurakowski, D, 2022) |
| "To evaluate the safety of initiating and maintaining propranolol therapy for infantile hemangioma (IH) and the safety of different doses." | 4.12 | Safety assessment of propranolol for infantile hemangioma: a study in an Asian population. ( Han, X; He, R; Li, L; Liu, Y; Ma, L; Qiu, L; Sun, Y; Wang, C; Wei, L; Xiu, B; Xu, Z; Yu, L; Zhang, B, 2022) |
| "The long-term evolution of children with segmental facial infantile haemangioma (SFIH) treated with propranolol remains unstudied." | 4.12 | Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age. ( Boccara, O; Boralevi, F; Léauté-Labrèze, C; Letertre, O; Pedespan, JM; Prey, S, 2022) |
| "Propranolol is a nonselective β-adrenergic receptor (AR) blocker that has been the first-line therapy for problematic infantile hemangioma (IH), the most frequent childhood vascular tumor." | 4.12 | A transcription factor is the target of propranolol treatment in infantile hemangioma. ( Boscolo, E; Schrenk, S, 2022) |
| "For infantile hemangiomas (IH) requiring treatment, including those in high-risk locations or in the setting of ulceration, oral propranolol is first-line therapy." | 4.12 | Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol. ( Boull, C; Maguiness, S; Meyer-Mueller, C; Nicholson, C; Polcari, I, 2022) |
| "We report three infants with infantile hemangioma who experienced severe agitation and diarrhea following propranolol administration." | 4.12 | Propranolol therapy for hemangiomas in infants with neonatal abstinence syndrome may produce intolerable side effects. ( Chen, A; Poffenberger, P; Twist, J; Zinn, Z, 2022) |
| "Propranolol has evolved as a first line management of infantile haemangiomas." | 4.12 | Sandwich therapy in the management of propranolol resistant infantile hemangioma of the lip. ( Bera, RN; Mishra, A; Pandey, V; Sharma, SP; Tiwari, P; Tiwary, N, 2022) |
| "Propranolol is used to treat problematic infantile hemangiomas (IHs), but its safety in infants <5 weeks corrected age has not been established." | 4.12 | Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age. ( Check, JF; Gatts, JE; McLean, TW; Rush, MC; Samelak, DM, 2022) |
| "Propranolol is used as the first-line treatment for infantile hemangiomas (IHs)." | 4.12 | Topical Formulations of Propranolol for Infantile Hemangiomas: Characteristics of Formulations and Three Cases of Infants Administered Topical Propranolol Cream. ( Endoh, A; Hakamata, A; Inui, N; Kashiwagura, Y; Namiki, N; Shirai, M; Tanaka, S; Uchida, S; Watanabe, H, 2022) |
| "Infantile haemangiomas are common benign tumours of infancy, which can be treated effectively with beta-blockers such as propranolol and atenolol." | 4.12 | Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma. ( Breugem, CC; Breur, JMPJ; De Graaf, M; De Laat, PCJ; De Wildt, SN; Hermans, MM; Jonge Poerink, E; Langeveld, HR; Mendels, EJ; Pasmans, SGMA; Ragamin, A; Raphael, MF; Rietman, AB; Schappin, R, 2022) |
| "Oral propranolol is recommended as the first-line agent for infantile hemangioma requiring systemic treatment." | 4.12 | Efficacy of intravenous propranolol for life-threatening diffuse neonatal hemangiomatosis. ( Ishikawa, T; Seki, K; Uchiyama, H, 2022) |
| "To assess the efficacy of transcatheter arterial embolization (TAE) plus propranolol treatment for infantile hepatic hemangioma (IHH)." | 4.12 | Clinical evaluation of transcatheter arterial embolization combined with propranolol orally treatment of infantile hepatic hemangioma. ( Guo, L; Li, J; Song, D; Wang, L, 2022) |
| "To analyze the therapeutic effect of oral propranolol combined with sclerotherapy of lauromacrogol and triamcinolone acetonide in the treatment of lip infantile hemangiomas (IHs)." | 4.12 | A Retrospective Study of Lip Hemangiomas: Curative Effect of Oral Propranolol Combined with Topical Sclerotherapy. ( Huo, R; Ling, J; Yang, K; Zhang, D, 2022) |
| "The mechanisms underlying the success of propranolol in the treatment of infantile hemangioma (IH) remain elusive and do not fully explain the rapid regression of hemangiomatous lesions following drug administration." | 4.12 | Β-blockers activate autophagy on infantile hemangioma-derived endothelial cells in vitro. ( Caputi, M; Cerasoli, G; Cerretani, E; Corradini, E; Falco, A; Frati, C; Gherli, A; Gnetti, L; Graiani, G; Lagrasta, C; Lorusso, B; Madeddu, D; Nogara, A; Pilato, FP; Quaini, F; Roti, G, 2022) |
| "Propranolol is a first-line clinical drug for infantile haemangiomas (IH) therapy." | 4.12 | Circular RNA hsa_circ_0000915 promotes propranolol resistance of hemangioma stem cells in infantile haemangiomas. ( Chen, H; Li, Y, 2022) |
| "To assess the adverse effects of propranolol therapy in infantile hemangioma." | 4.02 | Adverse Drug Reactions Following Propranolol in Infantile Hemangioma. ( Imran, M; Kumar, D; Mishra, A; Pandey, V; Sharma, SP; Tiwari, P, 2021) |
| "Propranolol has been used in the first-line therapy of infantile hemangioma (IH) for a number of years; however, the mechanisms through which propranolol regulates IH are not yet fully understood." | 4.02 | Propranolol Suppresses Proliferation and Migration of HUVECs through Regulation of the miR-206/VEGFA Axis. ( Hu, C; Li, W; Lu, H; Qian, H; Qian, Y; Wu, Y; Yuan, C; Zhang, T, 2021) |
| "Oral propranolol accelerates the involution of infantile haemangiomas (IHs)." | 4.02 | Sequelae following infantile haemangiomas treated with propranolol. ( Baselga, E; Bassi, A; Bernabeu-Wittel, J; Carnevale, C; Diociaiuti, A; Downey, C; El Hachem, M; Gich, I; Gonzalez-Enseñat, MA; Knopfel, N; Leuzzi, M; Manunza, F; Mascaro, P; Monserrat-García, MT; Neri, I; Oranges, T; Ortiz-Prieto, A; Puig, L; Roe, E; Torrelo, A; Vercellino, N; Vicente, A, 2021) |
| "Teledermatology can solve diagnostic and therapeutic problems in paediatrics, for example in infantile haemangiomas (IHs) requiring early treatment with propranolol." | 4.02 | Teledermatology in paediatrics: Health-care impact on the early treatment of infantile haemangiomas. ( Berbegal-DeGracia, L; Betlloch-Mas, I; Martínez-Miravete, MT; Sánchez-Payá, J; Sánchez-Vázquez, L, 2021) |
| " Of these, 14 were proliferating hemangiomas, 14 were stationary, 14 were involuted, and 13 had been treated with propranolol." | 4.02 | NOTCH pathway activation in infantile hemangiomas. ( Johnson, A; Richter, G; Strub, GM; Sun, R; Wei, T; Zhang, H, 2021) |
| "Oral propranolol is the treatment of choice for infantile hemangiomas." | 4.02 | Recurrence rate of infantile hemangioma after oral propranolol therapy. ( Byeon, JO; Frongia, G; Günther, P; Mehrabi, A, 2021) |
| "To report the effectiveness and safety of transcatheter arterial sclerosing embolization (TASE) for the treatment of parotid infantile hemangiomas that did not respond appreciably to propranolol." | 4.02 | Transcatheter Arterial Sclerosing Embolization for the Treatment of Giant Propranolol-Resistant Infantile Hemangiomas in the Parotid Region. ( Guo, L; Li, J; Song, D; Sun, J; Wang, L; Wu, C; Zhang, Y, 2021) |
| "The outcomes of propranolol treatment remain controversial for parotid hemangiomas, which may be inferior to outcomes for infantile hemangiomas (IHs) at other sites." | 4.02 | Oral propranolol therapy in parotid hemangiomas: A retrospective comparison with other infantile hemangiomas. ( Bi, J; Gao, Q; Huo, R; Li, S; Li, X; Lv, R; Wang, L; Xu, G, 2021) |
| "Propranolol emerged as the first-line therapy for infantile hemangioma (IH)." | 4.02 | Propranolol for infantile hemangioma: Evaluating efficacy and predictors of response and rebound growth. ( Khamaysi, Z; Kridin, K; Pam, N, 2021) |
| "Serum GLUT1, IGF-2, and VEGF-A levels were positively correlated with disease severity in patients with hemangioma, for example, in complicated hemangioma and hemangioma requiring propranolol treatment." | 4.02 | Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma. ( Aydin Köker, S; Köker, A; Köksoy, AY; Kömüroğlu, AU; Şiraz, ÜG; Tekin, E, 2021) |
| "The beta-blocker propranolol is the standard medical therapy for subglottic hemangioma (SGH), but side effects and incomplete response rates require close monitoring." | 4.02 | Propranolol versus nadolol for treatment of pediatric subglottic hemangioma. ( Cushing, SL; Pope, E; Propst, EJ; Wolter, JK; Wolter, NE; Yang, W, 2021) |
| "Sleep problems are frequently reported in infants treated with propranolol for infantile hemangiomas, possibly serving as a marker for a negative impact on central nervous system function." | 4.02 | Sleep behavior of infants with infantile hemangioma treated with propranolol-a cohort study. ( Gnannt, R; Kernland-Lang, K; Knöpfel, N; Kohler, M; Kurth, S; Luchsinger, I; Neuhaus, K; Schoch, SF; Schwieger-Briel, A; Smith, A; Theiler, M; von der Heydt, S; Waelchli, R; Weibel, L, 2021) |
| "We present a case of a one-month-old female patient with severe hypertriglyceridaemia as a side effect of treating an ulcerating infantile hemangioma with systemic propranolol." | 4.02 | Transient hypertriglyceridaemia associated with propranolol for treatment of infantile hemangioma. ( Farshchian, M; Potts, GA, 2021) |
| "Oral propranolol has been widely used for problematic infantile hemangiomas (IHs)." | 3.96 | Lip Infantile Hemangiomas Involving the Vermillion Border Have Worse Outcomes and Prognosis to Oral Propranolol Than Lesions Confined to One Side of the Vermillion. ( Huang, H; Li, W; Xu, P; Yu, Q; Zhang, W, 2020) |
| "Oral propranolol is widely considered to be first-line therapy for complicated infantile hemangioma, but its use in patients with PHACE (posterior fossa malformations, hemangioma, arterial anomalies, cardiac defects, eye anomalies) syndrome has been debated owing to concerns that the cardiovascular effects of the drug may increase the risk for arterial ischemic stroke." | 3.96 | Evaluating the Safety of Oral Propranolol Therapy in Patients With PHACE Syndrome. ( Adams, D; Baselga, E; Chamlin, S; Drolet, BA; Frieden, IJ; Frommelt, P; Garzon, MC; Gupta, D; Hansen, LM; Horii, K; Klajn, J; Lauren, C; Maheshwari, M; Mancini, AJ; Mathes, E; McCuaig, CC; Newell, B; Nguyen, HL; Nopper, A; Olsen, GM; Powell, J; Puttgen, KB; Siegel, DH; Stefanko, NS; Tollefson, MM, 2020) |
| "Since the discovery of propranolol in the treatment of infantile hemangioma (IH), there has been emergent investigation of β-adrenergic receptor (β-AR) signaling in IH and the mechanisms of action for which β-AR blockers regulate hemangioma cell proliferation." | 3.96 | Rebound of Involuted Infantile Hemangioma After Administration of Salbutamol. ( Knöpfel, N; Oesch, V; Szello, P; Theiler, M; Weibel, L, 2020) |
| "Propranolol is approved for treatment of infantile hemangiomas (IH)." | 3.96 | Special management considerations for propranolol use in breastfed infants of mothers taking antihypertensives. ( Aizman, L; Kirkorian, AY; Krishnan, A; Tender, J; Van Den Anker, J, 2020) |
| "The highest efficacy of oral propranolol is for infantile hemangioma (IH) in the proliferative phase." | 3.96 | Oral propranolol administration is effective for infantile hemangioma in late infancy: A retrospective cohort study. ( Bergman, R; Khamaysi, Z; Kridin, K; Pam, N, 2020) |
| "To study the clinical effect of oral propranolol in the treatment of respiratory hemangioma in infants and young children." | 3.96 | [Clinical effect of propranolol in the treatment of respiratory hemangioma in infants and young children]. ( Chen, YQ; Ding, XF; Zhong, LL, 2020) |
| "Oral propranolol (OP) demonstrated high efficacy and safety profile for treatment of critical infantile hemangiomas (IHs)." | 3.96 | A new clinical and dermoscopic monitoring of infantile hemangiomas treated with oral propranolol. ( Caini, M; Cartocci, A; Cevenini, G; Cinotti, E; de Quattro, M; Fiorani, D; Ierardi, F; Oranges, T; Pianigiani, E; Rubegni, P; Tognetti, L, 2020) |
| "We describe a case of a 6-month-old female patient with a segmental, superficial, infantile hemangioma (IH) on the forehead being treated with propranolol 2 mg/kg/d for 5 months, who developed a symplastic hemangioma (SH) over the preexisting lesion, highlighting the need to consider SH in the differential diagnosis of vascular lesions arising over preexisting vascular anomalies in children." | 3.91 | Symplastic hemangioma developing over an infantile hemangioma during propranolol treatment. ( Cervilla, K; Downey, C; González, S; Kramer, D; Pino, G; Zambrano, MJ, 2019) |
| "Propranolol is an effective method of treatment for infantile hemangiomas (IH)." | 3.91 | Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas. ( Babiak-Choroszczak, L; Bagłaj, M; Dawid, G; Gawrych, E; Giżewska-Kacprzak, K, 2019) |
| "Propranolol is the mainstay of treatment for infantile hemangiomas (IHs) benefited from its low complication in the present study." | 3.91 | Associations between short-term efficacy and clinical characteristics of infantile hemangioma treated by propranolol. ( Guo, L; Li, J; Song, D; Wang, C; Wang, L; Wu, C, 2019) |
| "The main purpose of this study was to describe a unique case of retro-orbital infantile hemangioma (IH) simulating a congenital glaucoma requiring prompt management with systemic propranolol." | 3.91 | Secondary Congenital Glaucoma Associated With Retro-orbital Infantile Hemangioma: A Masquerade Syndrome. ( Beylerian, M; Dambricourt, L; Denis, D; Matonti, F; Ramtohul, P, 2019) |
| "The use of propranolol for the treatment of subglottic haemangioma has become hugely popular due to its effectiveness and safety profile." | 3.91 | Treatment failure with propranolol for subglottic haemangioma. ( Jackson, C; Liu, Z; Trimble, K; Yeo, YH, 2019) |
| "To present the outcomes of fixed doses of propranolol tablets for the treatment of hemangiomas." | 3.91 | EFFECTIVENESS OF FIXED DOSES OF PROPRANOLOL IN THE TREATMENT OF HEMANGIOMAS REGARDLESS OF CHILD'S WEIGHT GAIN: A CASE REPORT. ( Anger, J; Gabel, J; Oliveira, EM, 2019) |
| "This was a retrospective study to analyze the clinical therapeutic efficacy of propranolol in patients with infantile hemangioma (IH)." | 3.91 | Therapeutic efficacy of propranolol for infantile hemangiomas. ( Chen, Y; Gao, Z; Hao, J; Li, F; Wang, H; Wu, W, 2019) |
| "The efficacy of lauromacrogol injection therapy and intralesional triamcinolone for infantile hemangiomas (IH) has been well documented recently, but with an increase in serious or rare adverse reactions." | 3.91 | Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas. ( Bi, J; Chai, Y; Huo, R; Li, X; Li, Z; Lv, R; Song, J; Xu, G; Zhou, Z, 2019) |
| "Propranolol is an approved non-selective β-adrenergic blocker that is first line therapy for infantile hemangioma." | 3.91 | R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma. ( Andelfinger, G; Bischoff, J; Chiang, IK; Fontaine, F; Francois, M; Gambin, Y; Hamdan, M; Huang, L; Khosrotehrani, K; Lesieur, E; Meurer, M; Moustaqil, M; Overman, J; Pasquier, E; Patel, J; Sierecki, E; Wylie-Sears, J; Zuegg, J, 2019) |
| "BackgroundPropranolol is the first-choice treatment for severe infantile hemangioma (IH)." | 3.88 | Infantile hemangioma: factors causing recurrence after propranolol treatment. ( Chang, L; Chen, H; Gu, Y; Jin, Y; Lin, X; Lv, D; Ma, G; Qiu, Y; Ying, H; Yu, Z, 2018) |
| "The primary management of infantile hemangioma (IH) has changed since 2008, with the initiation of propranolol." | 3.88 | Management trends of infantile hemangioma: A national perspective. ( Chun, RH; Espahbodi, M; McCormick, ME; Yan, K, 2018) |
| " The most common vascular tumor is infantile hemangioma, which treatment, when necessary, is propranolol." | 3.88 | [Benign aggressive vascular anomalies in children]. ( Boccara, O; Léauté-Labrèze, C; Maruani, A, 2018) |
| " Recently, the repurposing of the wide spectrum betablocker propranolol revolutionized the infantile hemangioma management." | 3.88 | [Repurposing of betablockers in dermatology]. ( Boehncke, WH; Le Gal, FA; Wrobel, LJ, 2018) |
| "Propranolol has become the treatment of choice for infantile hemangiomas (IH)." | 3.88 | Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas? ( Babiak-Choroszczak, L; Bagłaj, M; Fischer, K; Gawrych, E; Giżewska-Kacprzak, K; Puchalska-Niedbał, L; Rajewska-Majchrzak, J; Walecka, A, 2018) |
| "The safety of oral propranolol for infantile hemangioma has not yet been studied at population level since the pediatric use marketing authorization was obtained in Europe." | 3.88 | Safety of Oral Propranolol for Infantile Hemangioma. ( Botrel, MA; Droitcourt, C; Dupuy, A; Garlantezec, R; Guillot, B; Happe, A; Kerbrat, S; Oger, E; Rault, C; Schleich, JM, 2018) |
| "We aimed to evaluate the effects of oral propranolol for circumscribed choroidal hemangioma." | 3.88 | Effects of oral propranolol for circumscribed choroidal hemangioma. ( Gonçalves Júnior, I; Maia, M; Mattos Neto, RB; Morales, MC; Sancho, KFCB; Zett, C, 2018) |
| "There has been a paradigm shift from steroids to propranolol for the pharmacologic treatment of infantile hemangiomas (IH); however, the outcomes for ulcerated IH are not well studied." | 3.88 | Propranolol versus steroids for the treatment of ulcerated infantile hemangiomas. ( Chute, C; Dasgupta, R; Hammill, A; Polites, SF; Rodrigue, BB, 2018) |
| "Hemangioma is the most common vascular tumor in infantile period, and propranolol is the first choice, but there are still a few patients with poor curative effect." | 3.88 | [Effect of treatment of infant parotid hemangioma with no response to oral propranolol]. ( Guo, XS; Nan, J; Shen, G; Tian, Y; Wang, XL, 2018) |
| "Treating infantile haemangioma with propranolol is more cost-effective when initiated on an outpatient basis." | 3.88 | Cost-effectiveness of treating infantile haemangioma with propranolol in an outpatient setting. ( Chaturvedi, K; Snyder, CS; Steinberg, JS, 2018) |
| "Propranolol is the first-line drug for treatment of infantile hemangioma." | 3.88 | Role of Thrombospondin-1 and Nuclear Factor-κB Signaling Pathways in Antiangiogenesis of Infantile Hemangioma. ( An, W; Li, S; Sun, C; Wang, W; Xu, W; Yang, X; Yu, F; Zhang, Y, 2018) |
| "We sought to evaluate effect of propranolol in the treatment of infantile hemangiomas by quantifying the amount of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and hypoxia-inducible factor-1α (HIF-1α)." | 3.88 | Propranolol inhibits the activity of PI3K, AKT, and HIF-1α in infantile hemangiomas. ( Huang, G; Lin, H; Lin, Z; Wang, L; Wang, W, 2018) |
| "Propranolol is the treatment of choicefor complicated infantile hemangiomas (IH)." | 3.85 | Propranolol for infantile hemangiomas in developing countries. ( Lawley, LP; McMichael, J, 2017) |
| "There have been reports of the use of levothyroxine or levothyroxine plus liothyronine for consumptive hypothyroidism caused by hepatic hemangiomas." | 3.85 | Use of liothyronine without levothyroxine in the treatment of mild consumptive hypothyroidism caused by hepatic hemangiomas. ( Hasegawa, Y; Higuchi, S; Takagi, M, 2017) |
| "Despite not being licensed for the treatment of infantile hemangiomas (IH) in infants younger than 5 weeks or older than 5 months, propranolol is often used in these age groups to prevent or to treat potentially severe complications." | 3.85 | Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experience. ( Berti, I; Boccaletti, V; Carnevale, C; Cutrone, M; Dalmonte, P; Diociaiuti, A; El Hachem, M; Gesualdo, F; Greco, A; Neri, I; Oranges, T; Porcedda, G; Vercellino, N, 2017) |
| "Propranolol is a widely-known beta-blocker approved for treating infantile hemangiomas (IH)." | 3.85 | Tissue and serum mRNA profile of MMPs-2/9 as a potential novel biomarker for the most individual approach in infantile hemangiomas and cancer disease. ( Andrzejewska, E; Kobos, J; Przewratil, P; Taran, K; Wnęk, A, 2017) |
| " A cavernous hemangioma was suspected and treated with high doses of propranolol and prednisolone." | 3.85 | Unexpected Effect of Propranolol and Prednisolone on Infantile Facial Rhabdomyosarcoma. ( Bhandari, SB; Lemperle, G; Mentzel, T; Shakya, J; Shilpakar, R, 2017) |
| "Systemic propranolol is currently the first-line treatment modality for complicated infantile haemangiomas." | 3.85 | [Infantile haemangioma: clinical and demographic characteristics, experiences in the treatment]. ( Ábrahám, R; Csoma, ZR; Dalmády, S; Kemény, L; Rácz, K; Rózsa, T, 2017) |
| "Propranolol hydrochloride has become the primary medical treatment for problematic infantile hemangioma; however, the expression of propranolol's target receptors during growth, involution, and treatment of hemangioma remains unclear." | 3.85 | Expression of β-Adrenergic Receptor Subtypes in Proliferative, Involuted, and Propranolol-Responsive Infantile Hemangiomas. ( Phillips, JD; Richter, GT; Wei, T; Zhang, H, 2017) |
| "Oral propranolol has been recently approved for infantile hemangiomas (IHs), but potential side effects stay a challenge." | 3.85 | Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment. ( Parezanović, V; Petrovic, J; Topalovic, M; Trajkovic, G; Trifunovic, B; Vukomanovic, G, 2017) |
| "Concern has been raised about the potential long-term effects of propranolol treatment for infantile hemangioma (IH)." | 3.85 | Propranolol treatment of infantile hemangioma is not associated with psychological problems at 7 years of age. ( Moyakine, AV; Spillekom-van Koulil, S; van der Vleuten, CJM, 2017) |
| "There is no definitive conclusion regarding the optimal timing for terminating propranolol treatment for infantile hemangioma (IH)." | 3.85 | When to stop propranolol for infantile hemangioma. ( Chang, L; Chen, H; Gu, Y; Jin, Y; Lin, X; Ma, G; Qiu, Y; Ying, H; Yu, Z, 2017) |
| "Propranolol is the treatment of choice for infantile hemangiomas requiring medical intervention." | 3.85 | Propranolol treatment for infantile hemangioma does not increase risk of childhood wheezing. ( Amitai, DB; Blau, H; Hoshen, M; Lapidoth, M; Mei-Zahav, M; Mussaffi, H; Prais, D; Stafler, P; Steuer, G; Zvulunov, A, 2017) |
| "Propranolol was first used in 2008 to treat hemangioma; its efficacy and safety have since changed the classical treatment indications." | 3.85 | A New Perspective for Infantile Hepatic Hemangioma in the Age of Propranolol: Experience at Baskent University. ( Boyvat, F; Demir, Ş; Erbay, A; Özçay, F; Sarıalioğlu, F; Uslu, N; Yazıcı, N, 2017) |
| "The purpose of the present study is to evaluate the efficacy and safety of propranolol for problematic infantile hemangiomas (IH), showing our experience on 24 children, with special focus on premature infants." | 3.83 | Efficacy of propranolol for cutaneous hemangiomas in premature children. ( Barruscotti, S; Borroni, G; Brazzelli, V; Codazzi, CA; Giorgini, C; Mannarino, S; Marseglia, GL; Stronati, M; Tzialla, C, 2016) |
| "A retrospective observational study was conducted on patients with ulcerated infantile haemangioma treated with pulsed dye laser in association with propranolol." | 3.83 | [Combination of pulsed dye laser and propranolol in the treatment of ulcerated infantile haemangioma]. ( del Pozo Losada, J; Rodríguez-Ruiz, M; Tellado, MG, 2016) |
| "To describe a case of diffuse choroidal hemangioma with exudative retinal detachment treated successfully with oral propranolol." | 3.83 | DIFFUSE CHOROIDAL HEMANGIOMA MASQUERADING AS CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH ORAL PROPRANOLOL. ( Dave, T; Dave, VP; Pappuru, RR; Shah, G, 2016) |
| "We review the presentation, course, management and outcomes of all cases of genital infantile hemangiomas managed by propranolol administration at a single institution from April 2010 to July 2014." | 3.83 | Propranolol for Treatment of Genital Infantile Hemangioma. ( Golden, A; Rhee, A; Tamburro, J; Tran, C, 2016) |
| "Oral propranolol is widely prescribed as first-line treatment for infantile haemangiomas (IHs)." | 3.83 | Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. ( Audrain, H; Baryschpolec, S; Baselga, E; Beattie, PE; Bhate, K; Bjerre, JV; Brown, SJ; Burrows, NP; Clayton, TH; Darne, S; Durack, A; Dvorakova, V; Flohr, C; Foelster-Holst, R; Gach, J; Glover, M; Goldstraw, N; Goodyear, H; Grabczynska, S; Greenblatt, D; Halpern, J; Hearn, RM; Hedelund, L; Hernandez-Martin, A; Hoeger, PH; Hoey, S; Hughes, B; Irvine, AD; Janmohamed, SR; Jayaraj, R; Johansson, EK; Laguda, B; Lam, M; Leech, S; McPherson, T; Morrison, D; Neri, I; O'Regan, GM; Oranje, AP; Patrizi, A; Porter, W; Ramesh, R; Ravenscroft, JC; Schill, T; Shahidullah, H; Shaw, L; Solman, L; Svensson, A; Taylor, AE; Taylor, R; Thomson, J; Tiffin, P; Tsakok, M; Wahlgren, CF; Wedgeworth, E, 2016) |
| "Despite the increasing popularity of propranolol for treatment of infantile hemangioma (IH), there is need for further evidence of efficacy and safety." | 3.83 | Treatment for Infantile Hemangiomas: Selection Criteria, Safety, and Outcomes Using Oral Propranolol During the Early Phase of Propranolol Use for Hemangiomas. ( Gehris, R; Geisler, S; Grunwaldt, LJ; MacIsaac, ZM; Mehta, D; Nayar, HS, 2016) |
| "Few specific reports have addressed propranolol as a treatment for parotid hemangioma, and its mechanism remains unclear." | 3.83 | Use of propranolol for parotid hemangioma. ( Chang, L; Chen, H; Jin, Y; Lin, X; Lv, D; Ma, G; Qiu, Y; Wang, T; Yang, X; Ying, H; Yu, W, 2016) |
| "Propranolol-induced involution is a unique biological feature of some pediatric vascular tumors, for instance infantile hemangioma (IH), cerebral cavernoma or chorioangioma." | 3.83 | The embryo-placental CD15-positive "vasculogenic zones" as a source of propranolol-sensitive pediatric vascular tumors. ( Anspach, L; Roth, W; Seidmann, L, 2016) |
| "The aim of this study was to explore the efficacy and safety of propranolol in treating infantile haemangiomas, the most common benign vascular tumours in children." | 3.83 | Propranolol was effective in treating cutaneous infantile haemangiomas in Thai children. ( Jetsrisuparb, C; Komwilaisak, P; Panombualert, S; Techasatian, L; Uppala, R, 2016) |
| "From October 2010 to June 2014, 31 infantile hemangioma patients admitted to our hospital, were administered propranolol combined with betamethasone injection treatment of lesions." | 3.83 | Treatment of infantile hemangioma by intralesional injection of propranolol combined with compound betamethasone. ( Li, J; Shao, RZ; Zhao, DH, 2016) |
| " The 31 patients had 32 hemangiomas (1 female patient had 2 lesions) and were treated with systemic propranolol at a high dose of 2 mg/kg per day." | 3.83 | Oral Propranolol for the Treatment of Infantile Hemangiomas in the Post-Proliferative Phase: A-Single Center Retrospective Study of 31 Cases. ( Liu, ZM; Tian, Y; Tong, S; Wang, XK; Xi, SL; Xu, DP, 2016) |
| "In the last few years propranolol has revolutionized infantile hemangioma therapy." | 3.83 | Serum and tissue profile of VEGF and its receptors VGFR1/R2 in children with infantile hemangiomas on systemic propranolol treatment. ( Andrzejewska, E; Chrzanowska, B; Kobos, J; Przewratil, P; Szemraj, J; Taran, K; Wnęk, A; Wyrzykowski, D, 2016) |
| "Thirteen children with infantile haemangiomas presenting to the Vascular Anomalies Clinic, Royal Children's Hospital/Lady Cilento Children's Hospital treated with propranolol were included in the study." | 3.83 | 3D photography is a reliable method of measuring infantile haemangioma volume over time. ( Gee Kee, EL; Kimble, RM; Robertson, SA; Stockton, KA; Storey, KJ, 2016) |
| " The medical records of infants with periorbital hemangiomas who were treated with systemic propranolol at a dose of 1." | 3.83 | Clinical Outcomes of Infants With Periorbital Hemangiomas Treated With Oral Propranolol. ( Liu, ZM; Sun, C; Wang, XK; Xu, DP; Xue, L, 2016) |
| "To determine the efficacy of oral propranolol for the treatment of infantile subglottic hemangioma." | 3.83 | Role of oral propranolol in the treatment of infantile subglottic hemangioma. ( Chen, JR; Jin, L; Li, XY; Wang, Y, 2016) |
| "Propranolol, 2 mg/kg/day, is effective in the treatment of infantile hemangioma." | 3.83 | Response to propranolol in infantile hemangioma. ( Chunharas, A; Kadegasem, P; Lekanan, W; Sirachainan, N; Thammagasorn, Y; Wanitkun, S, 2016) |
| "An open observational prospective study was performed over 25 months in a group of pediatric patients diagnosed with infantile hemangioma treated with propranolol." | 3.83 | The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol. ( Castaneda, S; De la Cruz, H; Garcia, E; Melendez-Lopez, S; Sanchez-Palacio, J, 2016) |
| "There has been a dramatic increase in the off-label use of ophthalmic timolol maleate, a β-blocker used for infantile hemangioma (IH) treatment as a topical counterpart to oral propranolol." | 3.83 | Topical Timolol Maleate Treatment of Infantile Hemangiomas. ( Adams, D; Baselga, E; Drolet, B; Feigenbaum, D; Frieden, I; Garzon, MC; Holland, K; Horii, K; Lauren, C; Lucky, A; Mathes, E; McCuaig, C; Morel, KD; Newell, B; Nopper, A; Pope, E; Powell, J; Püttgen, K; Savva, Y; Siegel, D; Song, W, 2016) |
| "In recent years propranolol has become the treatment of choice for infantile hemangiomas (IHs)." | 3.83 | Is Routine Electrocardiography Necessary Before Initiation of Propranolol for Treatment of Infantile Hemangiomas? ( Krol, AL; Leitenberger, SL; MacArthur, CJ; Mann, JA; Tollefson, MM; Yarbrough, KB, 2016) |
| "Hemangiomas are tumors most commonly encountered in pediatric patients, and are frequently treated with propranolol." | 3.83 | Cardiac evaluation in children with hemangiomas. ( Erdoğan, İ; Sarıalioğlu, F, 2016) |
| "Non-selective β-blocker propranolol has been proved by FDA as the first-line agent for infantile hemangioma (IH) with dramatic response." | 3.83 | [Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas]. ( Fan, XD; Huo, R; Jiang, CH; Lei, SR; Liu, SH; Qin, ZP; Wang, XK; Wang, XY; Yang, YW; Zhao, JH; Zheng, JW; Zhou, DK, 2016) |
| "Although propranolol has been accepted as a first-line drug for infantile haemangioma (IH), no study has systematically characterized changes in heart rates during long-term propranolol treatment." | 3.81 | Safety profile of a divided dose of propranolol for heart rate in children with infantile haemangioma during 16 weeks of treatment. ( Chen, W; Shi, H; Song, H; Wang, J; Yu, Y; Zhang, X; Zhou, H, 2015) |
| "Propranolol is a valid treatment for large cranial hemangiomas, avoiding the risks involved in surgeries." | 3.81 | Giant cranial and cerebellar hemangioma treated with propranolol. ( Ben-Sira, L; Benvenisti, H; Constantini, S; Roth, J, 2015) |
| "The successful use of nadolol as an alternative to propranolol therapy in three cases of infantile hemangioma is reported." | 3.81 | Nadolol for the treatment of infantile hemangioma. ( Bautista-Paloma, FJ; Cotrina-Luque, J; Del Vayo-Benito, CA; Flores-Moreno, S; Villalba-Moreno, AM, 2015) |
| "The aim of this study was to investigate the therapeutic results and effects of propranolol on cardiovascular parameters in infants receiving systemic propranolol for complicated infantile hemangiomas (IHs), as well as to evaluate the adverse effects of propranolol throughout the course of treatment." | 3.81 | Treatment of severe infantile hemangiomas with propranolol: an evaluation of the efficacy and effects of cardiovascular parameters in 25 consecutive patients. ( Cao, RY; Sun, NN; Tong, S; Wang, XK; Xu, DP; Xue, L, 2015) |
| "Although consensus guidelines for pretreatment evaluation and monitoring of propranolol therapy in patients with infantile hemangiomas (IH) have been formulated, little is known about the cardiovascular side effects." | 3.81 | Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas?: A cohort study. ( Breugem, CC; Breur, JM; de Graaf, M; Pasmans, SG; Raphael, MF; Slieker, MG; Vlasveld, FA, 2015) |
| "Intralesional compound betamethasone preparation is a feasible choice for the small-size hemangioma." | 3.81 | Intralesional injection of diprospan is effective for infantile hemangioma. ( Cui, L; Guo, Y; Hong, ZJ; Jiang, HQ; Yuan, SM; Zhang, M, 2015) |
| "The aim of our study was to assess the efficacy and safety of oral propranolol for the treatment of parotid infantile hemangiomas." | 3.81 | Oral propranolol for parotid infantile hemangiomas. ( Cheng, C; Li, G; Liu, ZM; Sun, HL; Wang, XK; Xi, SL; Xu, DP, 2015) |
| "The current study demonstrated the antiangiogenic properties of propranolol in vitro and that the drug was able to induce the regression of hemangioma cells via the inhibition of cell cycle progression, invasion, and tube formation, concomitantly with decreased NO and VEGF levels through the down-regulation of the PI3K/Akt/eNOS/VEGF pathway." | 3.81 | Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway. ( Gao, Y; Guo, ZT; Huang, Q; Li, P; Pan, WK, 2015) |
| "Propranolol has been recently approved by health authorities to treat infantile haemangiomas (IH)." | 3.81 | [Propranolol in infantile hemangiomas]. ( Léauté-Labrèze, C, 2015) |
| "Topical propranolol has been used for the therapy of superficial infantile hemangiomas (IH)." | 3.81 | A novel topical nano-propranolol for treatment of infantile hemangiomas. ( Chen, ZG; Yuan, ML; Yuan, WE; Zhang, L; Zheng, JW, 2015) |
| "With the emergence of propranolol as the primary treatment for hemangiomas the indications for surgical intervention have been greatly reduced." | 3.81 | Open airway surgery for subglottic hemangioma in the era of propranolol: Is it still indicated? ( Mehta, D; Siegel, B, 2015) |
| "To evaluate the effectiveness of systemic propranolol in airway infantile hemangioma (AIH) treatment." | 3.81 | Multicenter Evaluation of the Effectiveness of Systemic Propranolol in the Treatment of Airway Hemangiomas. ( Darrow, DH; Elluru, RG; Friess, MR; Grimmer, JF; Perkins, JA; Richter, GT; Shin, JJ, 2015) |
| " Infantile hemangiomas which have numerous similarities with chorioangiomas are now usually treated with propranolol." | 3.81 | Propranolol during pregnancy for large chorioangioma. ( D'Hervé, D; Fouque, L; Le Duff, M; Padys, P; Poulain, P, 2015) |
| "I was asked to provide a commentary for "Shouldn't Propranolol be Used to Treat All Hemangiomas?" by Moodley et al." | 3.81 | Commentary on Moodley S et al. "Shouldn't Propranolol be Used to Treat All Hemangiomas?". ( Blei, F, 2015) |
| "This study suggests that propranolol become the first-line treatment of choice for all haemangiomas." | 3.81 | Shouldn't Propranolol Be Used to Treat All Haemangiomas? ( Adams, KG; Adams, S; Hudson, DA; Moodley, ST, 2015) |
| "Our aim was to compare in a prospective study the clinical effects and safety of propranolol given orally, timolol maleate applied locally, and the combination of the two, in the management of superficial infantile haemangiomas." | 3.81 | Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. ( Cheng, C; Gong, H; Li, G; Li, YX; Wang, XK; Xu, DP, 2015) |
| "To explore the effect and safety of topical propranolol hydrochloride gel for treatment of infantile hemangioma." | 3.81 | [Effects of topical propranolol hydrochloride gel for treatment of infantile hemangioma in nude mice]. ( Chen, L; Chengjin, L; Lie, W; Qingjin, H; Shaoquan, C; Shuming, C; Yin, X; Zaizhong, Z, 2015) |
| "To summarize the subsequent therapy experiences for infantile hemangiomas after discontinuation of oral propranolol treatment, and explore the relationships between clinical interventions and types of infantile hemangioma." | 3.81 | [Subsequent therapy for infantile hemangiomas after discontinuation of oral propranolol]. ( Chen, T; Ge, CX; Li, KL; Liu, XJ; Qin, ZP; Tai, MZ, 2015) |
| "Propranolol is emerging as the treatment of choice for high-risk infantile haemangiomas." | 3.80 | Propranolol therapy for cutaneous infantile haemangiomas initiated safely as a day-case procedure. ( McSwiney, E; Murphy, M; Murray, D, 2014) |
| "Propranolol is an effective, safe treatment for complicated infantile haemangiomas (IH)." | 3.80 | Propranolol for the treatment of infantile haemangiomas: our experience with 44 patients. ( Lenane, P; Lynch, M; O'Donnell, BF, 2014) |
| "This study proved high efficiency of propranolol in treatment of infantile hemangioma, as assessed with the objective measures for the first time." | 3.80 | Treatment of infantile hemangiomas with propranolol: clinical guidelines. ( Anderson, W; Stewart, K; Szychta, P, 2014) |
| "Oral propranolol (PRN) has recently been shown to be highly effective for infantile hemangiomas (IHs), and is currently recommended as the first-line treatment of complicated IHs." | 3.80 | Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell. ( Li, KL; Mai, HM; Qin, ZP; Wang, YA; Zhang, L; Zheng, J; Zheng, JW, 2014) |
| "Propranolol seemed to be effective for treatment of hemangiomas in children and adolescents, and not just in the proliferative stage, with responses in almost all the patients." | 3.80 | Treatment of children and adolescents with hemangioma using propranolol: preliminary results from a retrospective study. ( Albuquerque, JC; Bastos, MV; Felix, FH; Félix, JA; Fontenele, JB; Magalhães, RA; Trompieri, NM, 2014) |
| "Propranolol is highly effective in the treatment of infantile hemangioma (IH), but important clinical and pharmacological data are lacking." | 3.80 | Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases. ( Ben Amitai, D; Lapidoth, M; Sagi, L; Zvulunov, A, 2014) |
| "To highlight the importance of Magnetic Resonance Imaging (MRI) and the use of propranolol as both a final diagnostic tool and adequate treatment for orbital Infantile Haemangiomas (IHs)." | 3.80 | Propranolol as first-line treatment in orbital infantile haemangiomas: a case series. ( Coumou, AD; Freling, NJ; Groeneveld, L; Levitt, M; Saeed, P; van der Horst, CM, 2014) |
| "Propranolol, a β-adrenergic receptor (AR) antagonist, is an effective treatment for endangering infantile haemangioma (IH)." | 3.80 | Propranolol targets the contractility of infantile haemangioma-derived pericytes. ( Bischoff, J; Boscolo, E; Durham, JT; Herman, IM; Lee, D; Mulliken, JB, 2014) |
| "A small percentage of complicated infantile haemangiomas need early, safe and effective treatment, and the option of off-label systemic propranolol treatment has been in existence since 2008." | 3.80 | A retrospective analysis of systemic propranolol for the treatment of complicated infantile haemangiomas. ( Cremer, HJ; Ruef, P; Schneider, M, 2014) |
| " Sixteen patients had recrudescence of IH off-treatment, with propranolol discontinued at a median age of 14 months (interquartile range 10-15 months)." | 3.80 | Retrospective analysis of beta-blocker instituted for treatment of hemangiomas (RABBIT study). ( Castelo-Soccio, L; Chu, DH; Gelfand, JM; Perman, MJ; Shaddy, RE; Shah, KN; Treat, JR; Wan, J; Yan, AC, 2014) |
| "Propranolol has been widely used in treating infantile hemangiomas (IHs)." | 3.80 | Propranolol enhanced adipogenesis instead of induction of apoptosis of hemangiomas stem cells. ( Chang, M; Ma, X; Ma, Y; Ouyang, T; Xin, S; Zhao, T, 2014) |
| "To assess the safety and efficacy of systemic propranolol for the treatment of complicated infantile haemangiomas." | 3.80 | Propranolol for infantile haemangiomas: single centre experience of 250 cases and proposed therapeutic protocol. ( Glover, M; Gnarra, M; Harper, JI; Murabit, A; Solman, L; Syed, SB, 2014) |
| "Propranolol is increasingly used to treat problematic infantile haemangioma (IH), although its molecular mechanisms remain unclear." | 3.80 | Increased apoptosis and secretion of tryptase by mast cells in infantile haemangioma treated with propranolol. ( Day, D; Steel, R, 2014) |
| "This study was aimed at assessing the efficacy of propranolol treatment in infantile hemangiomas (IHs) by ultrasound." | 3.80 | Ultrasound in assessing the efficacy of propranolol therapy for infantile hemangiomas. ( Shang, Y; Shi, H; Song, H; Wang, J; Xia, L; Yang, J; Zhou, H, 2014) |
| "Although propranolol is widely used in the treatment of infantile hemangiomas, the standard 40 mg tablet needs to be fractioned to obtain 10 mg parts, with even lower doses (i." | 3.80 | Is propranolol compounding from tablet safe for pediatric use? Results from an experimental test. ( Berti, I; Cardosi, L; Casiraghi, A; Franceschini, I; Minghetti, P; Musazzi, UM; Paragò, V, 2014) |
| "To develop a tool for assessing amblyopic risk and monitoring the treatment effect of propranolol in periocular haemangioma management." | 3.80 | Monitoring propranolol treatment in periocular infantile haemangioma. ( Burne, R; Taylor, R, 2014) |
| "Clinical observation of conservative treatment of the left hemi-liver haemangioma by propranolol in the full-term newborn with initial symptoms of cardiac failure is presented." | 3.80 | [Clinical case of treatment of hepatic haemangioma by propranolol in the newborn]. ( Getman, AN; Ivleva, SA; Kucherov, IuI; Rekhviashvili, MG; Zhirkova, IuV, 2014) |
| "The β-blocker propranolol was discovered to be highly effective for the treatment of infantile hemangiomas (IHs), since 2008." | 3.80 | Adverse effects of propranolol treatment for infantile hemangiomas in China. ( Babajee, K; Chen, X; Hu, X; Jian, D; Li, J; Su, J; Xie, H, 2014) |
| "This study provides multi-institutional practice guidelines for the initiation of propranolol hydrochloride treatment of routine infantile hemangiomas." | 3.79 | Propranolol use for infantile hemangiomas: American Society of Pediatric Otolaryngology Vascular Anomalies Task Force practice patterns. ( Darrow, DH; Grimmer, JF; Manning, SC; Parikh, SR; Perkins, JA; Richter, GT, 2013) |
| "Infantile hemangioma (IH) clearance may be slow or incomplete in response to pulsed dye laser (PDL) or propranolol alone." | 3.79 | Retrospective study of the treatment of infantile hemangiomas using a combination of propranolol and pulsed dye laser. ( Anolik, R; Bernstein, L; Blei, F; Brauer, JA; Brightman, L; Geronemus, RG; Hale, E; Karen, J; Reddy, KK; Waner, M; Weiss, E, 2013) |
| "Propranolol has been used successfully in a limited number of children with infantile hemangiomas (IHs)." | 3.79 | Use of propranolol for the treatment infantile hemangiomas in the maxillofacial region. ( Kasimova, KR; Metellmann, HR; Podmelle, F; Sadykov, RA; Sadykov, RR, 2013) |
| "Propranolol is now widely used to treat severe infantile haemangiomas (IHs)." | 3.79 | Propranolol-resistant infantile haemangiomas. ( Aubert, H; Barbarot, S; Boccara, O; Bursztejn, AC; Caussé, S; Chiaverini, C; Dreyfus, I; Eschard, C; Hadj-Rabia, S; Mahé, E; Maruani, A; Mazereeuw-Hautier, J; Miquel, J; Puzenat, E; Saint-Jean, M; Stalder, JF, 2013) |
| "Although propranolol has become the first-line therapy for infantile haemangiomas (IHs), no study has yet investigated factors associated with the risk of relapse in children with IH treated with propranolol after cessation of treatment." | 3.79 | Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol. ( Ahogo, CK; Boralevi, F; Colona, V; Diallo, A; Ezzedine, K; Léauté-Labrèze, C; Prey, S; Taïeb, A, 2013) |
| " The treatment of atopic dermatitis, exciting advances in the use of propranolol and other beta-blockers for the use of infantile hemangiomas, the use of rapamycin for vascular anomalies, the use of biologics in children, the central nervous system risks of general anesthesia in young children, side effects in the use of isotretinoin, the treatment of tinea capitis, treatment of herpes simplex infections, and the use of technologies such as texting and social media in medicine will be discussed." | 3.79 | What's new in pediatric dermatology?: part II. Treatment. ( Pride, HB; Silverman, R; Tollefson, M, 2013) |
| "Although propranolol can be an effective primary medical therapy for infantile hemangiomas of the head and neck, the duration of treatment and time to discontinue propranolol is unclear." | 3.79 | Successful discontinuation of propranolol for infantile hemangiomas of the head and neck at 12 months of age. ( Chiu, ES; Hong, P; Kluka, EA; Poole, JC; Simon, LM; Tammareddi, N; Walvekar, R, 2013) |
| "To evaluate the efficacy and safety of 1% propranolol ointment in the treatment of superficial infantile hemangiomas (IHs)." | 3.79 | [Treatment of superficial infantile hemangiomas with topical propranolol]. ( Huo, R; Lü, RR; Niu, JN; Xu, GQ, 2013) |
| "This case of a four and a half-month-old girl describes periocular infantile haemangioma which was treated successfully with propranolol." | 3.79 | Periocular infantile haemangioma and the role of propranolol. ( Ahmad, K; Chaudhry, TA; Kamal, M, 2013) |
| "Propranolol, a lipophilic non-selective beta-blocker, has proven to be effective in the treatment of infantile haemangioma (IH)." | 3.79 | Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group. ( Breugem, CC; Breur, JM; Bruijnzeel-Koomen, CA; de Graaf, M; Knol, MJ; Kon, M; Pasmans, SG; Raphael, MF, 2013) |
| "Oral propranolol hydrochloride treatment has been proven effective for infantile hemangiomas." | 3.79 | Effects of oral propranolol on circumscribed choroidal hemangioma: a pilot study. ( Hirose, H; Kitano, T; Sahashi, K; Saito, AM; Tanabe, H; Tomita, Y, 2013) |
| "We sought to determine the effect of propranolol on cardiovascular and blood glucose parameters in infants with symptomatic infantile hemangiomas who were hospitalized for initiation of treatment, and to analyze adverse effects of propranolol throughout the course of inpatient and outpatient treatment." | 3.79 | Cardiovascular and blood glucose parameters in infants during propranolol initiation for treatment of symptomatic infantile hemangiomas. ( Bauman, NM; Boss, EF; Cohen, BA; Puttgen, KB; Schneider, J; Summerer, B, 2013) |
| "Propranolol had a rapid stabilizing effect leading to early regression of hemangiomas when administered orally at a dose of 3 mg/kg/day with good quality safety profile." | 3.79 | Propranolol for hemangiomas. ( Hasan, M; Hoque, S; Khondker, L; Rahman, M; Zahid Hossain, AK, 2013) |
| "We investigated the clinical efficacy of propranolol in treating proliferating infantile haemangiomas, and the serological changes in vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS) during treatment." | 3.79 | Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patients. ( Jin, ZL; Liu, ZY; Wang, XK; Wei, JJ; Xue, L; Yuan, WL, 2013) |
| "We aimed to assess the efficacy and safety of low-dose propranolol for treatment of infantile hemangiomas (IHs) in China." | 3.79 | Preliminary experience on treatment of infantile hemangioma with low-dose propranolol in China. ( Chen, H; Huang, Y; Lin, J; Liu, J; Ma, X; Ouyang, T; Xiao, Y; Yu, J; Zhao, T, 2013) |
| "Treatment options for large subglottic haemangioma include steroids, laser ablation, open excision, tracheostomy and, more recently, propranolol." | 3.79 | Great Ormond Street Hospital treatment guidelines for use of propranolol in infantile isolated subglottic haemangioma. ( Albert, DM; Bajaj, Y; Harper, JI; Hartley, BE; Ifeacho, S; Jephson, CG; Kapoor, K, 2013) |
| "To evaluate the response of nasal tip hemangiomas to systemic propranolol." | 3.78 | Hemangiomas of the nasal tip treated with propranolol. ( Ben-Amitai, D; Halachmi, S; Kalish, E; Lapidoth, M; Raveh, E; Zvulunov, A, 2012) |
| "Propranolol was recently discovered to be an effective treatment for infantile haemangiomas, and varying doses and monitoring regimens have been proposed." | 3.78 | Propranolol for infantile haemangiomas: initiating treatment on an outpatient basis. ( Dyme, JL; Han, EJ; Kotb, ME; Nyirenda, TL; Shin, HT; Thampan, A, 2012) |
| " The beta-blocker propranolol, known for its effectiveness on cutaneous hemangiomas, is also proving useful for the treatment of subglottic or visceral hemangiomas." | 3.78 | [Pediatrics]. ( Chevallay, M; de Buys Roessingh, A; El Ezzi, O; Fischer, CJ; Gehri, M; Giannoni, E; Hauschild, M; Hohlfeld, J; Pauchard, JY; Seneggen, E; Tolsa, JF; Truttmann, AC, 2012) |
| "Thirty-seven infants with propranolol-treated problematic head and neck hemangiomas were included and all patients had a good response." | 3.78 | Propranolol for problematic head and neck hemangiomas: an analysis of 37 consecutive patients. ( Fan, XD; Lv, MM; Su, LX, 2012) |
| "To investigate the mechanism of propranolol on regression of infantile hemangiomas." | 3.78 | Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A. ( Armijo, BS; Chim, H; Gliniak, C; Gosain, AK; Miller, E; Serret, MA, 2012) |
| "Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP)." | 3.78 | Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. ( Blei, F; Carcao, M; Chiu, YE; Drolet, BA; Fangusaro, J; Kelly, ME; Krol, A; Lofgren, S; Mancini, AJ; Metry, DW; Pope, E; Recht, M; Silverman, RA; Tom, WL, 2012) |
| "To evaluate changes in infantile hemangioma tissue before and after propranolol therapy, using gray-scale and color Doppler ultrasound imaging." | 3.78 | Propranolol reduces infantile hemangioma volume and vessel density. ( Bingham, MM; Perkins, JA; Saltzman, B; Vo, NJ, 2012) |
| " To evaluate the effectiveness, safety and tolerability of propranolol as single-agent treatment in patients with problematic, proliferative-phase, infantile hemangiomas (IHs)." | 3.78 | Propranolol treatment for severe infantile hemangiomas: a single-centre 3-year experience. ( Georgountzou, A; Kakourou, T; Karavitakis, E; Klimentopoulou, A; Xaidara, A, 2012) |
| "Propranolol has recently emerged as an effective drug treatment for infantile haemangiomas." | 3.78 | Use of propranolol for treatment of infantile haemangiomas in an outpatient setting. ( Bekhor, PS; Crock, CM; Penington, AJ; Phillips, RJ, 2012) |
| "Discuss effect and dynamics of propranolol (PR) treatment in infantile haemangioma (IH) of head and neck in children during follow-up." | 3.78 | Propranolol for infantile haemangioma: striking effect in the first weeks. ( Csákányi, Z; Gács, E; Gerlinger, I; Katona, G; Ráth, G; Szalai, Z, 2012) |
| "To observe the efficacy of oral Propranolol in the treatment of infantile subglottic hemangioma." | 3.78 | [Treatment of infantile subglottic hemangioma with oral propranolol]. ( Tang, LX; Wang, GX; Zhang, YM, 2012) |
| "Propranolol, a non-selective beta-blocker, has recently been introduced as a novel treatment modality for proliferating hemangiomas." | 3.78 | Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells. ( Chen, S; Ji, Y; Li, K; Xiao, X; Xu, T; Zheng, S, 2012) |
| "In 2008, propranolol was serendipitously observed to cause accelerated involution of infantile haemangioma." | 3.77 | Low-dose propranolol for infantile haemangioma. ( Itinteang, T; Leadbitter, P; Tan, ST, 2011) |
| "We report here the case of an infant with multiple hepatic and cutaneous infantile hemangiomas (IHs) associated with deranged liver function who was treated successfully with low-dose propranolol." | 3.77 | Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function. ( Itinteang, T; Leadbitter, P; Tan, ST, 2011) |
| "To outline a safe, standardized protocol for outpatient initiation of propranolol therapy for infantile hemangiomas." | 3.77 | Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas. ( Boucek, RJ; Cushing, SL; Manning, SC; Perkins, JA; Sidbury, R, 2011) |
| "Recent reports have described the successful use of propranolol to treat severe hemangiomas of infancy." | 3.77 | [Propranolol for the treatment of severe hemangiomas of infancy: results from a series of 28 patients]. ( Bernabeu-Wittel, J; Conejo-Mir, J; de Agustín, JC; Fernández-Pineda, I; Mantrana-Bermejo, ME; Pereyra-Rodríguez, JJ, 2011) |
| "Propranolol has become first-line therapy for the treatment of infantile hemangiomas in many centers." | 3.77 | β-blockers for infantile hemangiomas: a single-institution experience. ( Blatt, J; Buck, S; Burkhart, CN; Gold, S; Morrell, DS; Powell, C; Stavas, J; Zdanski, C, 2011) |
| "To report the efficacy of propranolol as first-line treatment of head and neck hemangiomas in children and to present an optimized protocol for treating hemangiomas." | 3.77 | Propranolol as first-line treatment of head and neck hemangiomas. ( Ayari-Khalfallah, S; Froehlich, P; Fuchsmann, C; Giguere, C; Guibaud, L; McCone, C; Powell, J; Quintal, MC, 2011) |
| "A brief comment on efficacy and safety of propranolol in the treatment of parotid hemangioma is presented, with illustration of a typical case." | 3.77 | Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma. ( Zheng, JW, 2011) |
| "To observe the efficacy and safety of oral propranolol in the treatment of periorbital proliferating phase infantile hemangioma." | 3.77 | [Oral propranolol in the management of periorbital proliferating phase infantile hemangioma]. ( Fu, HB; Guo, X; Huo, R; Lin, LL; Lü, RR; Wui, JC; Xu, GQ; Zhang, J; Zhao, ZF, 2011) |
| "To determine whether propranolol therapy is safe and effective and superior to oral corticosteroids for treating infantile hemangiomas (IHs)." | 3.77 | Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. ( Baum, B; Connelly, EA; Duarte, AM; Lattouf, C; McLeod, M; Price, CJ; Schachner, LA, 2011) |
| "Four children with haemangiomas of the head and neck were treated with propranolol at a tertiary referral centre." | 3.77 | Failure of propranolol in the treatment of childhood haemangiomas of the head and neck. ( Bruce, IA; Goswamy, J; Rothera, MP, 2011) |
| "There has been a dramatic evolution in the treatment of laryngotracheal hemangiomas during the past decade and recent accounts and case reports of propranolol treatment have been encouraging." | 3.77 | Evolving treatments in the management of laryngotracheal hemangiomas: will propranolol supplant steroids and surgery? ( Jacobs, IN; Javia, LR; Zur, KB, 2011) |
| "Four patients with ulcerated hemangioma aged 2, 4, 5 months and 5 weeks were treated with 2 mg/kg KG propranolol." | 3.76 | Successful treatment of ulcerated haemangioma with propranolol. ( Bross, F; Lorette, G; Maruani, A; Naouri, M; Rossler, J; Schill, T, 2010) |
| "To report our experience of using propranolol to treat an infantile airway haemangioma." | 3.76 | Use of propranolol to treat multicentric airway haemangioma. ( Mistry, N; Tzifa, K, 2010) |
| "We report the rapid and dramatic efficacy of propranolol in 8 infants with infantile hepatic hemangiomas." | 3.76 | Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. ( Ammour, A; Benlahrech, S; Bodemer, C; Broue, P; Hoeger, PH; Labenne, M; Léauté-Labrèze, C; Mazereeuw-Hautier, J; Ohanessian, G; Rössler, J; Vabres, P; Vial, J, 2010) |
| "Propranolol is a novel therapeutic agent in the treatment of cutaneous infantile haemangiomas." | 3.76 | Successful treatment of infantile haemangiomas of the orbit with propranolol. ( Li, YC; Martin, FJ; Martin, PA; McCahon, E; Rowe, NA; Wilcsek, GA, 2010) |
| " Oral propranolol is currently the first choice in the treatment of alarming infantile hemangiomas." | 3.76 | Innovative therapeutics in pediatric dermatology. ( Frasin, A; Gelmetti, C; Restano, L, 2010) |
| " Our main outcome measures were colour and size of infantile haemangioma before and after treatment, the change in astigmatism of our patients and the incidence of complications from propranolol." | 3.76 | Propranolol in the management of periorbital infantile haemangioma. ( Cheng, JF; Gole, GA; Sullivan, TJ, 2010) |
| "The successful management of subglottic hemangioma with propranolol has been reported." | 3.76 | Management of infantile subglottic hemangioma: acebutolol or propranolol? ( Amedro, P; Bigorre, M; Blanchet, C; Mondain, M; Nicollas, R, 2010) |
| "Propranolol has recently been reported to be useful in the treatment of infantile hemangiomas." | 3.76 | Outpatient treatment of periocular infantile hemangiomas with oral propranolol. ( Eikenberry, J; Haggstrom, A; Haider, KM; Neely, DE; Plager, DA, 2010) |
| "Propranolol hydrochloride has been prescribed for decades in the pediatric population for a variety of disorders, but its effectiveness in the treatment of infantile hemangiomas (IHs) was only recently discovered." | 3.76 | Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. ( Drolet, BA; Frieden, IJ; Frommelt, PC; Holland, KE; Mancini, AJ; Wyatt, D, 2010) |
| " She was given propranolol after her tracheotomy and had a significant reduction in her subglottic airway obstruction." | 3.76 | Propranolol in the management of airway infantile hemangiomas. ( Frieden, IJ; Maguiness, SM; Meyer, AK; Rosbe, KW; Suh, KY, 2010) |
| "To evaluate the short-term results and safety of propranolol for the treatment of infantile parotid hemangioma." | 3.76 | [Treatment of infantile parotid hemangioma with propranolol]. ( Ge, CX; Li, KL; Liu, XJ; Qin, ZP; Tai, MZ, 2010) |
| "Seven patients presenting with airway obstruction were treated with propranolol." | 3.76 | Propranolol for the treatment of airway hemangiomas: a case series and treatment algorithm. ( Chang, KW; Messner, AH; Perkins, JA; Truong, MT, 2010) |
| " Mean percentage of airway obstruction was 68% (15-90) before propranolol introduction." | 3.76 | Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience. ( Ayari, S; Carrabin, L; Couloigner, V; Cox, A; Denoyelle, F; Fayoux, P; Froehlich, P; Garabédian, EN; Leboulanger, N; Lescanne, E; Marianowski, R; Marie, JP; Mom, T; Mondain, M; Nicollas, R; Roger, G; Teissier, N; Triglia, JM; Van Den Abbeele, T, 2010) |
| "To describe the use of propranolol as first-line treatment or as single therapy to control the proliferating phase of infantile haemangioma in Chinese children." | 3.76 | Use of propranolol in infantile haemangioma among Chinese children. ( Chan, HB; Chik, KK; Luk, CK; Tan, HY, 2010) |
| "Propranolol treatment was recently reported to be successful for the management of severe infantile hemangioma." | 3.76 | Hyperkalemia complicating propranolol treatment of an infantile hemangioma. ( Kietz, S; Lakomek, M; Lauerer, P; Pavlakovic, H; Zutt, M, 2010) |
| "A case of a 4-month-old girl with a subglottic haemangioma successfully treated with propranolol is reported." | 3.76 | A clue on the face... ( Spinks, J, 2010) |
| "There are recent reports of effective treatment of cutaneous hemangiomas with Propranolol." | 3.75 | Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. ( Denoyelle, F; Enjolras, O; Garabedian, EN; Harris, R; Leboulanger, N; Roger, G, 2009) |
| " Our study suggested that oral propranolol combined with topical timolol treatment is very effective and well-tolerated for compound IHs, which can be used as a first line treatment." | 2.82 | Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study. ( Ge, J; Yuan, W; Zhang, L; Zhao, H; Zheng, J, 2016) |
| "Propranolol treatment decreases urinary excretion of MMP-9 in patients with IH." | 2.78 | Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. ( Bauman, N; Brown, KJ; Movius, E; Preciado, D; Saieg, A; Thaivalappil, S, 2013) |
| "Infantile haemangioma is the commonest childhood tumour and approximately 10% requires treatment." | 2.76 | Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. ( Gorst, C; Holmes, WJ; Liew, SH; Mishra, A, 2011) |
| "Infantile hemangioma is one of the most common benign tumors of infancy." | 2.72 | Propranolol treatment of infantile subglottic hemangioma: a report of two cases and a literature review. ( Ganeva, K; Nikiforova, L; Sapundzhiev, N; Shivachev, P, 2021) |
| " We review the indications, dosing regimens, duration of treatment, efficacy and adverse effects of propranolol, and therapeutic alternatives including oral atenolol, acebutolol, nadolol, intralesional propranolol injections, topical propranolol and timolol, and oral captopril." | 2.66 | β-blocker therapy for infantile hemangioma. ( Koh, SP; Leadbitter, P; Smithers, F; Tan, ST, 2020) |
| "Cutaneous hemangiomas are the most frequent benign tumors in children." | 2.61 | Role of Magnetic Resonance Image in Children with Lumbosacral and Perineal Hemangiomas: Case Reports and Review of the Literature. ( Barreda-Solana, M; Correa-González, N; García-Rabasco, A; Ortiz-Salvador, JM; Subiabre-Ferrer, D, 2019) |
| "Infantile hemangiomas are common; but they are extremely heterogeneous and cause a range of complications depending on their morphology, size, or location." | 2.58 | Infantile Hemangiomas in the Head and Neck Region. ( Adams, DM; Ricci, KW, 2018) |
| "Infantile haemangiomas are the most common tumour of infancy." | 2.58 | Topical propranolol for infantile haemangiomas: a systematic review. ( Birchall, JC; Elhassan, HA; Mcleod, RWJ; Price, A; Rai, S, 2018) |
| "Infantile haemangioma is a benign vascular tumour seen in 4-5% of infants." | 2.55 | [Medical treatment of children with infantile haemangiomas]. ( Bygum, A; Hartling, UB; Schuster, A; Velure, HK, 2017) |
| " The dosage was increased up to a maximum of 2 mg/kg/d and was maintained until the lesion had involuted or showed good result." | 2.53 | Treatment of rapidly proliferating haemangiomas in newborns with propranolol and review of the literature. ( Debek, W; Dzienis-Koronkiewicz, E; Hermanowicz, A; Matuszczak, E; Oksiuta, M, 2016) |
| "While options for treatment strategies for infantile hemangiomas (IH) are numerous, evidence-based information about agents, optimal dosage, adverse effects, treatment modality, pretreatment and treatment strategies remain limited." | 2.53 | Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events - a review of the literature. ( Breugem, CC; Breur, JM; Elbert, NJ; Kon, M; Liem, YT; Pasmans, SG; Raphael, MF; Vlasveld, FA, 2016) |
| "Consumptive hypothyroidism is a rare condition usually described in association with diffuse infantile hemangioma of the liver, over-expressing type 3 iodothyronine-deiodinase." | 2.52 | Consumptive hypothyroidism associated with parotid infantile hemangioma. ( Crivellaro, C; De Corti, F; Luzzatto, C; Zanon, GF, 2015) |
| "Infantile hemangioma is the most common vascular tumor of childhood." | 2.49 | [What's new about infantile hemangiomas?]. ( Dreyfus, I; Maza, A; Mazereeuw-Hautier, J, 2013) |
| "Haemangioma is a vascular tumour of infancy that is well known for its rapid growth during the first weeks to months of a child's life, followed by a spontaneous but slow involution." | 2.49 | Pathogenesis of infantile haemangioma. ( Bischoff, J; Greenberger, S, 2013) |
| "Propranolol has been suggested as the new standard of care for treatment of IH." | 2.49 | Infantile hemangioma: treatment with surgery or steroids. ( Mawn, LA, 2013) |
| "Infantile hepatic hemangioma is the most common benign liver tumor during infancy." | 2.48 | Multifocal infantile hepatic hemangiomas--imaging strategy and response to treatment after propranolol and steroids including review of the literature. ( Bosemani, T; Huisman, TA; Puttgen, KB; Tekes, A, 2012) |
| "Propranolol has become an effective first-line treatment, and protocols for its use as well as its potential risks are outlined." | 2.48 | Current management of infantile hemangiomas and their common associated conditions. ( Buckmiller, LM; Hartzell, LD, 2012) |
| "Propranolol has established itself as the first-line treatment." | 2.48 | [Treatment of hemangiomas]. ( Kalajoki-Helmiö, T; Lindahl, P; Overmark, M; Pitkäranta, A; Salminen, P; Vuola, P, 2012) |
| "Infantile haemangiomas are the most common benign tumour of infancy." | 2.47 | Propranolol for infantile haemangiomas: a review. ( Shahidullah, H; Starkey, E, 2011) |
| "Hemangiomas are benign neoplasms of the vasculature frequently encountered in children." | 2.47 | Hemangiomas - current therapeutic strategies. ( Mabeta, P; Pepper, MS, 2011) |
| " Data from the literature and from our own patient cohort (n = 132) confirm the remarkable efficacy of propranolol in complicated IH, without significant adverse effects." | 2.47 | [Treatment of haemangiomas of infancy with propranolol; good results, few side effects]. ( Hermans, DJ; Ottenhof, MJ; van Beynum, IM; van der Horst, CM; van der Vleuten, CJ; Wijnen, MH, 2011) |
| "Infantile hemangioma is the most common tumor in children, but its pathophysiology is still not well understood." | 2.46 | [Infantile hemangioma]. ( Léauté-Labrèze, C; Sans-Martin, V, 2010) |
| "Oral propranolol is a very recent therapeutic option for complicated IH with impressive efficacy and generally good tolerance." | 2.46 | Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. ( Hoeger, PH; Storch, CH, 2010) |
| "Infantile hemangiomas are benign vascular tumors that affect 8-12 % of infants." | 2.46 | [Propanolol used in treatment of infantile hemangioma]. ( Guldbakke, KK; Hanssen, HK; Huldt-Nystrøm, T; Høivik, F; Rørdam, OM, 2010) |
| "Propranolol was started in 30." | 1.91 | Management of infantile hemangiomas-experience of a tertiary hospital. ( Álvares, S; Banquart Leitão, J; Barbosa-Sequeira, J; Correia, MR; Fernandes, A; Fraga, C; Gomes, R; Paiva Coelho, M; Salazar, L, 2023) |
| "Propranolol treatment mostly leads to regression of hemangiomas with satisfactory aesthetic results, but unfortunately not in all cases." | 1.91 | Nd:YAG 1064-nm laser for residual infantile hemangioma after propranolol treatment. ( Avitan-Hersh, E; Khamaysi, Z; Pam, N; Zaaroura, H, 2023) |
| " To evaluate the correlation of clinical features between cutaneous IH and IHH, as well as efficacy of systemic propranolol in the treatment of cutaneous IH combined with IHH." | 1.91 | Clinical features of cutaneous infantile hemangioma combined with asymptomatic infantile hepatic hemangioma and efficacy of propranolol treatment. ( Han, X; Li, L; Ma, L; Sun, Y; Wei, L; Xu, Z; Yu, L; Zhang, B, 2023) |
| "Oral propranolol has not been shown to impact physical development, such as weight and height." | 1.91 | The impact of propranolol on the growth and development of children with proliferative infantile hemangioma during treatment. ( Chen, S; Chen, X; Deng, L; Gao, J; Huang, L; Lin, X; Liu, C; Wang, Q; Wang, T, 2023) |
| "Propranolol was successfully tapered over 3 weeks by reducing the dose by 50% weekly until it reached the therapeutic dose." | 1.91 | Excessively High Chronic Propranolol Overdose in Infantile Hemangioma: A Case Report. ( Alessa, A; Alghanem, A; Alhammad, AM; Alshammari, H; Elsharawy, Y, 2023) |
| "Propranolol (PROP) is a nonselective β-adrenergic receptor antagonist used to treat hypertension and cardiac arrhythmias." | 1.72 | Cyclosporin-A reduced the cytotoxicity of propranolol in HUVECs via p38 MAPK signaling. ( Chen, B; Cui, H; Lv, Z; Shao, C; Xie, G; Yao, Z; Yuan, W, 2022) |
| " Adverse event and drug-related adverse event rates were 87." | 1.72 | Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study. ( Hakamata, A; Hayano, S; Inui, N; Iwashima, S; Kashiwagura, Y; Nagata, E; Nishida, M; Odagiri, K; Okada, E; Sano, S; Tanaka, S; Uchida, S; Umemura, K; Watanabe, H, 2022) |
| "Infantile hemangiomas are the most common benign vascular tumours in infants." | 1.72 | Evaluation of cases with infantile hemangioma requiring treatment. ( Acipayam, C; Dalgiç, EF; Dinçer, S; Güllü, UU; Karaküçük, SN; Maraşli, H; Yurttutan, S, 2022) |
| "Propranolol is a safe, effective and well-tolerated treatment in Australian children with IH." | 1.72 | Immediate possible adverse event rates in infants treated with oral propranolol for infantile haemangiomas at an Australian urban tertiary hospital between 2016 and 2019. ( Adams, L; Ryan, E, 2022) |
| "Severe hypoglycemia was common in infants aged >1 year, when PPL was used for ≥6 months." | 1.72 | Severe hypoglycemia in propranolol treatment for infantile hemangiomas. ( Baba, N; Kaneko, T; Kuwano, Y; Morimoto, A; Ozeki, M; Sasaki, S, 2022) |
| "Propranolol therapy was interrupted for several months while patient was maintained on a diuretic regimen and treated with vincristine and high-dose corticosteroids." | 1.72 | Mediastinal infantile hemangioma with spinal canal extension and extensive gastrointestinal involvement complicated by respiratory failure. ( Anselmo, DM; Cohen-Cutler, S; Detterich, JA; Luu, M; Mascarenhas, L; Miller, JM, 2022) |
| "Hepatic hemangioma is the most common benign liver tumor." | 1.62 | [Propranolol treatment in Kasabach-Merritt Syndrome secondary to congenital hepatic hemangioma. Clinical case]. ( Malla, I; Selzer Soria, EM, 2021) |
| "Although infantile hemangiomas are occasional benign vascular tumors that appear predominantly on the skin, 1-2% of patients may have airway lesions that can sometimes cause potentially life-threatening respiratory condi-tions." | 1.62 | [Cranio-facial-cervical and subglottic hemangioma with respiratory symptoms. A therapeutic emergency]. ( Arredondo Montero, J; Bardají Pascual, C; Molina Caballero, AY; Moreno Alfonso, JC; Pérez Martínez, A; Zubicaray Ugarteche, J, 2021) |
| "Oral propranolol has been well established as the first-line treatment of complicated hemangiomas; however, variability in the administration protocol remains." | 1.62 | Is prolonged monitoring necessary? An updated approach to infantile hemangioma treatment with oral propranolol. ( Johansen, ML; Lawley, LP; Mahendran, G, 2021) |
| "Persistent cutaneous dysesthesias were present in seven patients, in most cases many years after completion of involution." | 1.62 | Persistent dysesthesias in involuted infantile hemangiomas: An uncommon complication in a common condition. ( Antaya, RJ; Braun, M; Frieden, IJ; Kohn, LL; Mancini, AJ; Metry, D, 2021) |
| "Placental chorioangioma (CA) is a benign placental tumor." | 1.56 | Giant placental chorioangioma followed by circulatory failure of the newborn and infantile hemangioma: Case report. ( Araki, S; Aramaki, S; Kusuhara, K; Shibata, E; Suga, S, 2020) |
| "Infantile hemangiomas are the most common benign vascular tumors in childhood." | 1.56 | Propranolol-resistant infantile hemangioma successfully treated with sirolimus. ( Baselga, E; Dávila-Osorio, VL; Iznardo, H; Puig, L; Roé, E, 2020) |
| "Consumptive hypothyroidism is a rare paraneoplastic syndrome characterized by excessive inactivation of the thyroid hormones due to increased type 3 iodothyronine deiodinase activity of tumors." | 1.56 | A Case of Consumptive Hypothyroidism in a 1-Month-Old Boy with Diffuse Infantile Hepatic Hemangiomas. ( Hong, KT; Kim, GB; Kim, YH; Ko, JS; Lee, YA; Lee, YJ; Shin, CH, 2020) |
| "Propranolol was interrupted after complete or almost complete resolution of infantile haemangiomas." | 1.56 | Cutaneous Infantile Haemangiomas with Intracranial and Intraspinal Involvement: A European Multicentre Experience and Review. ( Carnevale, C; Diociaiuti, A; El Hachem, M; Figà-Talamanca, L; Léauté-Labrèze, C; Neri, I; Rotunno, R; Torres, EB, 2020) |
| " Although oral propranolol is currently first-line therapy, optimal dosing for treatment of IH remains debated." | 1.56 | Retrospective case series of increased oral propranolol dosage for infantile hemangiomas. ( Aggarwal, P; Cohen, BA; Huang, AH; Mahon, M; Mannschreck, D, 2020) |
| "Infantile hemangiomas are the most common vascular tumors in childhood." | 1.56 | Evaluation of Clinical Properties and Treatment Responses of Infantile Hemangioma. ( Azizoglu, M; Corapcioglu, F; Demirsoy, U; Yildirimcakar, D, 2020) |
| "Propranolol was started at the age of 3 months and 7 days old with an initial dosage of 1." | 1.51 | Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report. ( Liu, HC; Tsai, MC; Yeung, CY, 2019) |
| "Propranolol is a well-documented medical therapy for cutaneous lesions, but surgical treatment dominates the literature on bladder haemangiomas." | 1.51 | Propranolol as an effective therapy for infantile haemangioma of the urinary bladder. ( Anwar, T; Malm-Buatsi, E, 2019) |
| "Propranolol is the treatment of choice for complicated IH." | 1.51 | [Infantile haemangioma: an update]. ( Ott, H; Reimer, A, 2019) |
| "Propranolol is an effective, non-invasive treatment for life threatening infantile hemangiomas compressing the airway, should be used as a firstline treatment for subglottic hemangiomas when intervention is required." | 1.51 | A Life Threatening Subglottic and Mediastinal Hemangioma in an Infant. ( Gergin, O; Karabulut, B; Onder, SS, 2019) |
| "Treatment with propranolol, with or without dexamethasone, may result in a favorable prognosis." | 1.48 | Huge fetal hepatic Hemangioma: prenatal diagnosis on ultrasound and prognosis. ( Bo-Yang, Y; Jiao-Ling, L; Kun-Shan, C; Qian, F; Qiu-Ming, H; Xiao-Fen, L; Xiu-Ping, G, 2018) |
| "Hemangiomas are the most common tumors of childhood with an average incidence of 10%." | 1.48 | Cleft Palate Repair Using Single Flap Palatoplasty in Patient With Associated Palatal Hemangioma. ( Akyuz, C; Calis, M; Kara, M; Ozgur, F, 2018) |
| "Infantile hemangiomas are the most common tumor of childhood and undergo rapid growth during early infancy followed by gradual involution." | 1.48 | Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment. ( Kagami, S; Kaneko, M; Katori, T; Kishi, A, 2018) |
| "The propranolol treatment for the patient with suspected of bronchial asthma was suspended for 4 months." | 1.48 | Oral propranolol for infantile hemangiomas beyond the proliferative phase. ( Kagami, S; Katori, T, 2018) |
| "Subglottic hemangiomas are a rare presentation of infantile hemangiomas but with significant morbidity." | 1.48 | Subglottic hemangioma: Understanding the association with facial segmental hemangioma in a beard distribution. ( Azbell, C; Grunwaldt, L; Jabbour, N; McCormick, AA; Tarchichi, T, 2018) |
| "Tufted angioma is a benign vascular proliferation which presents most commonly in infants and children and could occasionally be complicated by Kasabach-Merritt syndrome." | 1.48 | Tufted angioma arising at the site of hepatitis B vaccination: A case report. ( Hajizadeh, J; Jowkar, F; Sari-Aslani, F; Sepaskhah, M, 2018) |
| "Hepatic hemangioma is the third most common pediatric tumor, and it is rare in the neonatal period." | 1.48 | Neonatal giant hepatic hemangioma: A case report. ( Cai, P; Chen, J; Gu, Z; Huang, S; Wang, J; Wu, B; Zhu, J; Zhu, Z, 2018) |
| "Propranolol has been demonstrated to be effective for IHs; however, the factors affecting its therapeutic effect remain unknown." | 1.46 | Analysis of factors affecting the therapeutic effect of propranolol for infantile haemangioma of the head and neck. ( Dong, JY; Huang, YY; Li, K; Li, RH; Liu, C; Liu, SH; Ning, JX; Wang, XX; Yue, LL, 2017) |
| " The dosage of propranolol was increased from 0." | 1.46 | Successful Treatment of Infantile Hemangiomas With Propranolol in Low-Birth-Weight Infants. ( Hayashi, A; Kado, M; Matsumura, T; Mizuno, H; Mochizuki, M; Shimizu, A, 2017) |
| "Diffuse hepatic hemangiomas are a challenging disease that can be life threatening." | 1.46 | Diffuse Hepatic Hemangiomas Successfully Treated Using Sirolimus and High-Dose Propranolol. ( Diaz, L; Levy, M; Warren, D, 2017) |
| "Hemangioma is a frequent disease which has a proliferative and involution phase." | 1.46 | Clinical features and treatment results in children with hemangioma. ( Artık, HA; Ataş, E; Koç, O, 2017) |
| "Infantile hemangiomas are the most common tumors affecting children." | 1.46 | Promotion of Propranolol Delivery to Hemangiomas by Using Anti-VEGFR Antibody-Conjugated Poly(lactic-co-glycolic acid) Nanoparticles. ( Dong, C; Gong, Y; Guo, X; Liu, D; Sun, J; Zhu, X, 2017) |
| "Hemangiomas are common skin lesion, affecting 10-12% of children <1year of age." | 1.43 | The treatment of problematic hemangiomas in children with propranolol and 940nm diode laser. ( Dementieva, N; Jones, S, 2016) |
| "Hemangiomas are the most common benign tumors of the liver." | 1.43 | Hepatic Hemangioma with Kasabach-Merritt Syndrome in an Adult Patient. ( Cho, EA; Cho, SB; Choi, SK; Joo, YE; Jun, CH; Kim, HS; Lee, DH; Oak, CY; Park, CH; Rew, JS, 2016) |
| "Oral treatment with propranolol (3 mg/kg/day) resulted in complete involution of the skin and hepatic haemangiomas over the period of treatment, which lasted until the child was aged 15 months." | 1.43 | Multifocal infantile haemangioma: a diagnostic challenge. ( Leaute-Labreze, C; Rosa, J; Soares-de-Almeida, L; Torres, E, 2016) |
| "Oral propranolol was successful in 95." | 1.43 | Propranolol treatment for infantile hemangioma: a case series of sixty-two patients. ( Barbato, G; Boccaletti, V; Carano, N; Cerasoli, G; Gritti, A; Lombardi, AA; Marchesi, M; Stringari, G; Tchana, B; Zanzucchi, M, 2016) |
| "Propranolol is the only treatment that the U." | 1.43 | Use of Propranolol for Treating Hemangiomas in Infants with Previously Diagnosed Hypoglycemic Conditions. ( De Léon, DD; McMahon, P; Treat, JR; Yang, TB, 2016) |
| " However, the appropriate drug dosage, dosing regimen, time for initiation, optimal duration, monitoring for side effects remains controversial." | 1.43 | [Chinese experts consensus on the use of oral propranolol for treatment of infantile hemangiomas]. ( Fan, XD; Huo, R; Li, K; Liu, SH; Qin, ZP; Wang, XK; Wang, XY; Yang, YW; Zhao, JH; Zheng, JW; Zhou, DK, 2016) |
| "Infantile hemangiomas are well known for their rapid growth during the first 6 to 9 months of life, followed by a spontaneous but slow involution." | 1.42 | Diode laser for the treatment of telangiectasias following hemangioma involution. ( Cerrati, EW; Chung, H; O, TM; Waner, M, 2015) |
| "Prior to propranolol the systemic treatment for haemangiomas was prednisolone and then the concern was the opposite, namely hypertension." | 1.42 | Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome. ( Batul Syed, S; Gnarra, M; Harper, J; Solman, L, 2015) |
| "Infantile hemangiomas are the most common vascular tumors in childhood." | 1.42 | Delayed-onset of multiple cutaneous infantile hemangiomas due to propranolol: a case report. ( del Boz González, J; Navarro Morón, J; Porcel Chacón, R, 2015) |
| " The dosage of Propranolol was increased over the course of treatment, which initiated three days." | 1.42 | Large Doses of Propranolol for the Treatment of Infantile Cephalic and Facial Hemangiomas: A Clinical Report of 38 Cases. ( Jianguo, K; Mingkun, Z; Qiaoling, C; Wenjin, L; Xichun, W, 2015) |
| "Haemangiomas are benign vascular tumours that generally arise in the skin during the first days of life." | 1.42 | Propranolol (Hemangiol) and severe infantile haemangiomas. The drug of first choice. ( , 2015) |
| "Cardiac hemangiomas are benign tumors with an unpredictable natural history." | 1.42 | Conservative Management of Cardiac Hemangioma for 11 Years. ( Boughzela, E; Gribaa, R; Neffati, E; Slim, M, 2015) |
| "Pulmonary hemangioma is a rare benign tumor of the lungs." | 1.40 | Successful treatment of pulmonary hemangioma with propranolol. ( Akyüz, C; Emiralioğlu, N; Ersöz, DD; Kiper, N; Oğuz, B; Özçelik, U; Yalçın, B; Yalçın, E, 2014) |
| "Propranolol, has been quickly adopted as the first line medical treatment for complicated infantile hemangioma; and it is the only treatment to have a marketing authorization in this indication." | 1.40 | [Infantile hemangiomas: the revolution of beta-blockers]. ( Leaute-Labreze, C, 2014) |
| " The most important adverse effects were hypotension (3·4%), wheezing (9·2%), nocturnal restlessness (22·4%) and cold extremities (36·2%)." | 1.39 | Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions. ( Bauland, CG; Hermans, DJ; van Beynum, IM; van der Vleuten, CJ; Zweegers, J, 2013) |
| "Infantile hemangioma is a common benign pediatric tumor which shares many features with epulis, such as rich vascularity, high incidence of female patients, high hormone level and similar treatments." | 1.38 | New treatment strategy for granulomatous epulis: intralesional injection of propranolol. ( Fan, ZN; Li, KL; Liu, C; Liu, SH; Qin, ZP; Wang, YM; Wei, FC; Zhao, WJ, 2012) |
| "Consumptive hypothyroidism is a rare condition related to massive infantile hemangiomas producing an excess of the thyroid-hormone-inactivating enzyme type 3 iodothyronine deiodinase." | 1.38 | Difficult treatment of consumptive hypothyroidism in a child with massive parotid hemangioma. ( Chiumello, G; Cortinovis, F; Di Frenna, M; Gelmetti, C; Passoni, A; Persani, L; Rabbiosi, S; Vigone, MC; Weber, G, 2012) |
| "Adult hemangiomas are usually benign vascular tumors presenting as painless progressive proptosis, sometimes accompanied by serious visual loss due to compression of the optic nerve." | 1.38 | Management of adult onset orbital hemangioma by oral propranalol: a case report. ( Goswami, M; Murthy, GJ, 2012) |
| "Propranolol has been recently discovered to shrink these lesions effectively." | 1.37 | Propranolol, infantile haemangiomas, and serendipity: new use for an old drug. ( Grech, V; Scerri, C, 2011) |
| "Infantile haemangioma is a benign tumour of the microvasculature characterised by excessive proliferation of immature endothelial cells." | 1.37 | Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. ( Brasch, HD; Day, DJ; Itinteang, T; Tan, ST, 2011) |
| "Propranolol was given to 20 patients with IH, who suffered from ulceration at the start of treatment (mean age at onset of treatment, 3." | 1.37 | Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. ( Hermans, DJ; Schultze Kool, LJ; van Beynum, IM; van de Kerkhof, PC; van der Vleuten, CJ; Wijnen, MH, 2011) |
| "Propranolol appears to be an effective and well-tolerated treatment for ulcerated IH." | 1.37 | Propranolol for treatment of ulcerated infantile hemangiomas. ( Barbarot, S; Bodak, N; Hadj-Rabia, S; Hamel-Teillac, D; Kupfer-Bessaguet, I; Lacour, JP; Léauté-Labrèze, C; Mazereeuw-Hautier, J; Naouri, M; Nguyen, JM; Saint-Jean, M; Stalder, JF; Vabres, P, 2011) |
| "Propranolol appears to be an effective treatment option for IH even in the nonproliferative phase and after the first year of life." | 1.37 | Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. ( Breugem, CC; Breur, JMPJ; de Graaf, M; Pasmans, SGMA; Raphaël, MF; Vos, M, 2011) |
| "PHACE syndrome is a neurocutaneous disorder with large facial segmental hemangionas associated with anomalies of the brain, eye, heart and aorta." | 1.37 | Use of propranolol for treatment of hemangiomas in PHACE syndrome. ( Deming, D; Hopper, A; Merritt, TA; Ninnis, J; Solomon, T, 2011) |
| "Oral propranolol was given for a period of 6 months with monthly follow up." | 1.37 | Initial experiences with propranolol treatment of infantile hemangiomas: report of three cases. ( Halilbasic, A; Halilbasic, M; Hotic, N; Husaric, E; Husaric, S; Rahmanovic, E, 2011) |
| "Hemangiomas are the most common vascular tumors in children." | 1.36 | Successful treatment of a large hemangioma with propranolol. ( Haas, E; Kues, K; Lauerer, P; Mousa, W; Pavlakovic, H; Schön, MP; Zutt, M, 2010) |
| "Haemangiomas are the most common soft tissue tumours in infancy, occurring in approximately 5-10% of 1-year-old children." | 1.36 | Propranolol as a novel treatment for congenital visceral haemangioma. ( Cornette, L; Decaluwe, W; Van Geet, C; Vandelanotte, M; Vanlander, A, 2010) |
| "Subglottic hemangioma is a rare, potentially life threatening tumor of infancy which poses serious treatment challenges." | 1.36 | Case report: Treatment failure using propanolol for treatment of focal subglottic hemangioma. ( Baum, ED; Canadas, KT; Lee, S; Ostrower, ST, 2010) |
| "Propranolol was given to 32 children (21 girls; mean age at onset of treatment: 4." | 1.35 | Propranolol for severe infantile hemangiomas: follow-up report. ( Berge, J; Boralevi, F; de la Roque, ED; Dupuis, E; Ezzedine, K; Grenier, N; Léauté-Labrèze, C; Lipsker, D; Mazereeuw-Hautier, J; Sans, V; Taïeb, A; Vergnes, P, 2009) |
| "Subglottic haemangioma is a rare but potentially life threatening condition which requires intervention." | 1.35 | Successful treatment of isolated subglottic haemangioma with propranolol alone. ( Harper, J; Hartley, BE; Jephson, CG; Manunza, F; Mills, NA; Syed, S, 2009) |
| "Hemangioma is the most common tumor of infancy." | 1.35 | [Response to oral propranolol therapy for ulcerated hemangiomas in infancy]. ( Michel, JL; Patural, H, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.15) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (1.78) | 29.6817 |
| 2010's | 519 (76.89) | 24.3611 |
| 2020's | 143 (21.19) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, Q | 1 |
| Hai, Y | 1 |
| Chen, S | 13 |
| Feng, N | 1 |
| Mo, Z | 1 |
| Wei, Y | 1 |
| Luo, Q | 1 |
| Huang, X | 1 |
| Fan, L | 1 |
| Chen, J | 6 |
| Xiang, W | 1 |
| Pandey, V | 5 |
| Tiwari, P | 5 |
| Imran, M | 1 |
| Mishra, A | 7 |
| Kumar, D | 1 |
| Sharma, SP | 4 |
| Cotter, C | 1 |
| Solman, L | 5 |
| Flohr, C | 3 |
| Makkeyah, SM | 1 |
| Elseedawy, ME | 1 |
| Abdel-Kader, HM | 1 |
| Mokhtar, GM | 1 |
| Ragab, IA | 2 |
| Yüksel, H | 1 |
| Yaşar, A | 1 |
| Gürbüz, N | 1 |
| Bizbirlik, ZI | 1 |
| Yilmaz, Ö | 1 |
| Liu, C | 6 |
| Zhao, Z | 3 |
| Guo, S | 1 |
| Zhang, L | 7 |
| Fan, X | 2 |
| Zheng, J | 7 |
| Ye, Y | 1 |
| Zhong, H | 1 |
| Dou, L | 1 |
| Song, W | 3 |
| Dong, C | 7 |
| Lu, W | 3 |
| Dong, K | 2 |
| Li, K | 8 |
| Li, J | 7 |
| He, L | 1 |
| Gao, W | 4 |
| Xia, C | 1 |
| Wang, L | 12 |
| Colmant, C | 1 |
| Powell, J | 6 |
| Zhang, T | 1 |
| Qian, Y | 1 |
| Yuan, C | 1 |
| Wu, Y | 2 |
| Qian, H | 1 |
| Lu, H | 1 |
| Hu, C | 1 |
| Li, W | 4 |
| Schmid, F | 1 |
| Hoeger, PH | 8 |
| Nikfarjam, U | 1 |
| Wegner, J | 1 |
| Grabbe, S | 1 |
| Schepler, H | 1 |
| Juchems, E | 1 |
| Seebauer, CT | 1 |
| Graus, MS | 1 |
| Huang, L | 4 |
| McCann, A | 1 |
| Wylie-Sears, J | 2 |
| Fontaine, F | 2 |
| Karnezis, T | 1 |
| Zurakowski, D | 1 |
| Staffa, SJ | 1 |
| Meunier, F | 1 |
| Mulliken, JB | 3 |
| Bischoff, J | 6 |
| Francois, M | 2 |
| Yu, L | 2 |
| Wei, L | 3 |
| Xu, Z | 3 |
| Zhang, B | 2 |
| Han, X | 2 |
| Sun, Y | 2 |
| Liu, Y | 2 |
| Wang, C | 3 |
| Qiu, L | 2 |
| Xiu, B | 1 |
| He, R | 1 |
| Li, L | 6 |
| Ma, L | 5 |
| Pahl, KS | 1 |
| McLean, TW | 3 |
| Letertre, O | 1 |
| Boccara, O | 7 |
| Prey, S | 7 |
| Pedespan, JM | 1 |
| Boralevi, F | 4 |
| Léauté-Labrèze, C | 23 |
| Lv, Z | 1 |
| Xie, G | 1 |
| Cui, H | 1 |
| Yao, Z | 2 |
| Shao, C | 1 |
| Yuan, W | 4 |
| Chen, B | 1 |
| Schrenk, S | 1 |
| Boscolo, E | 2 |
| Baselga, E | 12 |
| El Hachem, M | 4 |
| Diociaiuti, A | 3 |
| Carnevale, C | 3 |
| Downey, C | 2 |
| Roe, E | 5 |
| Mascaro, P | 1 |
| Neri, I | 5 |
| Leuzzi, M | 1 |
| Bernabeu-Wittel, J | 3 |
| Monserrat-García, MT | 1 |
| Ortiz-Prieto, A | 1 |
| Torrelo, A | 6 |
| Knopfel, N | 3 |
| Vercellino, N | 3 |
| Manunza, F | 2 |
| Oranges, T | 3 |
| Bassi, A | 2 |
| Gonzalez-Enseñat, MA | 2 |
| Vicente, A | 1 |
| Gich, I | 1 |
| Puig, L | 2 |
| Meyer-Mueller, C | 1 |
| Nicholson, C | 1 |
| Polcari, I | 1 |
| Boull, C | 1 |
| Maguiness, S | 1 |
| Twist, J | 1 |
| Chen, A | 1 |
| Poffenberger, P | 1 |
| Zinn, Z | 2 |
| Bera, RN | 2 |
| Tiwary, N | 1 |
| Der Sarkissian, S | 1 |
| Ge, L | 1 |
| Sun, HY | 1 |
| Chen, MKY | 1 |
| Sebaratnam, DF | 1 |
| Gatts, JE | 1 |
| Rush, MC | 1 |
| Check, JF | 1 |
| Samelak, DM | 1 |
| D'Ambrosio, PD | 1 |
| Cardoso, PFG | 1 |
| Silva, PLD | 1 |
| Fernandes, PMP | 1 |
| Minamoto, H | 1 |
| Bleve, C | 1 |
| Conighi, ML | 1 |
| Valerio, E | 1 |
| Cutrone, M | 3 |
| Iannucci, G | 1 |
| Segna, A | 1 |
| Chiarenza, SF | 1 |
| Kashiwagura, Y | 2 |
| Hakamata, A | 2 |
| Shirai, M | 1 |
| Endoh, A | 1 |
| Tanaka, S | 2 |
| Inui, N | 2 |
| Watanabe, H | 2 |
| Namiki, N | 1 |
| Uchida, S | 2 |
| Chen, T | 3 |
| Gudipudi, R | 1 |
| Nguyen, SA | 1 |
| Carroll, W | 1 |
| Clemmens, C | 1 |
| Chang, SJ | 5 |
| Chang, HF | 2 |
| Qiu, Y | 11 |
| Chang, L | 10 |
| Jin, Y | 7 |
| Lin, X | 12 |
| Colmenero, M | 1 |
| Del Boz, J | 1 |
| Bernabeu Wittel, J | 1 |
| Feito-Rodríguez, M | 1 |
| Vicente-Villa, MA | 1 |
| Martín-Santiago, A | 1 |
| Palencia Pérez, SI | 1 |
| Azon, A | 1 |
| Valdivielso-Ramos, M | 1 |
| Sánchez Moya, AI | 1 |
| Campos-Domínguez, M | 1 |
| Garnacho-Saucedo, G | 1 |
| Azaña Defez, JM | 1 |
| Vera Casaño, Á | 1 |
| Tercedor-Sánchez, J | 1 |
| Alcalá, R | 1 |
| González-Enseyat, MA | 1 |
| Giacaman, A | 1 |
| Hernández-Martin, Á | 2 |
| Monserrat García, MT | 1 |
| Bauzá, A | 1 |
| Domínguez-Cruz, J | 1 |
| García-Doval, I | 2 |
| Grau-Pérez, M | 1 |
| Hermans, MM | 3 |
| Breugem, CC | 8 |
| Schappin, R | 3 |
| Jonge Poerink, E | 1 |
| Mendels, EJ | 3 |
| Ragamin, A | 1 |
| Breur, JMPJ | 5 |
| Langeveld, HR | 3 |
| Raphael, MF | 8 |
| De Laat, PCJ | 3 |
| De Wildt, SN | 3 |
| Rietman, AB | 3 |
| Pasmans, SGMA | 5 |
| De Graaf, M | 7 |
| Nagata, E | 1 |
| Okada, E | 1 |
| Sano, S | 1 |
| Nishida, M | 1 |
| Hayano, S | 1 |
| Iwashima, S | 1 |
| Odagiri, K | 1 |
| Umemura, K | 1 |
| Odaman Al, I | 1 |
| Demirağ, B | 1 |
| Erdem, M | 1 |
| Genç, S | 1 |
| Karapinar, TH | 1 |
| Kaulanjan-Checkmodine, P | 1 |
| Oucherif, S | 1 |
| Gontier, E | 1 |
| Lacomme, S | 1 |
| Loot, M | 1 |
| Miljkovic-Licina, M | 1 |
| Cario, M | 1 |
| Taieb, A | 4 |
| Moisan, F | 1 |
| Rezvani, HR | 1 |
| Ishikawa, T | 1 |
| Seki, K | 1 |
| Uchiyama, H | 1 |
| Song, D | 3 |
| Guo, L | 3 |
| Hung, YT | 1 |
| Chung, WH | 1 |
| Chen, CB | 1 |
| Ganeva, K | 1 |
| Shivachev, P | 1 |
| Sapundzhiev, N | 1 |
| Nikiforova, L | 1 |
| Maraşli, H | 1 |
| Acipayam, C | 1 |
| Güllü, UU | 1 |
| Dinçer, S | 1 |
| Dalgiç, EF | 1 |
| Karaküçük, SN | 1 |
| Yurttutan, S | 1 |
| Morais, CG | 1 |
| Alves, I | 1 |
| Coelho, J | 1 |
| Vilares, AT | 1 |
| Do Bom-Sucesso, M | 1 |
| Ling, J | 1 |
| Yang, K | 4 |
| Huo, R | 10 |
| Zhang, D | 3 |
| Adams, L | 1 |
| Ryan, E | 1 |
| Morimoto, A | 1 |
| Ozeki, M | 4 |
| Sasaki, S | 1 |
| Baba, N | 1 |
| Kuwano, Y | 2 |
| Kaneko, T | 2 |
| Cohen-Cutler, S | 1 |
| Detterich, JA | 1 |
| Miller, JM | 1 |
| Anselmo, DM | 1 |
| Luu, M | 2 |
| Mascarenhas, L | 1 |
| Lorusso, B | 1 |
| Cerasoli, G | 2 |
| Falco, A | 1 |
| Frati, C | 1 |
| Graiani, G | 1 |
| Madeddu, D | 1 |
| Nogara, A | 1 |
| Corradini, E | 1 |
| Roti, G | 1 |
| Cerretani, E | 1 |
| Gherli, A | 1 |
| Caputi, M | 1 |
| Gnetti, L | 1 |
| Pilato, FP | 1 |
| Quaini, F | 1 |
| Lagrasta, C | 1 |
| Chen, H | 7 |
| Li, Y | 4 |
| Kleinman, EP | 1 |
| Blei, F | 6 |
| Adams, D | 4 |
| Greenberger, S | 3 |
| Tirelli, LL | 1 |
| Luna, PC | 1 |
| Panizzardi, AA | 1 |
| Larralde, M | 1 |
| Huang, H | 3 |
| Chen, X | 6 |
| Cai, B | 1 |
| Yu, J | 2 |
| Wang, B | 1 |
| Chen, Q | 3 |
| Ying, H | 4 |
| Yu, Z | 5 |
| Chen, Z | 2 |
| Hasbani, DJ | 1 |
| Hamie, L | 1 |
| Zamil, DH | 1 |
| Fernandez, JK | 1 |
| Brown, DN | 1 |
| Kralik, SF | 1 |
| Herd, TJ | 1 |
| Yang, E | 1 |
| Wang, X | 4 |
| Huang, S | 4 |
| Li, M | 5 |
| Geng, Y | 1 |
| Liu, X | 6 |
| Wu, H | 3 |
| Frieden, I | 3 |
| Delarue, A | 9 |
| Benetton, C | 2 |
| Pace, MD | 2 |
| De Corti, F | 3 |
| Cimador, M | 2 |
| Gamba, P | 2 |
| Midrio, P | 2 |
| Pandey, A | 1 |
| Srivastava, A | 1 |
| Pant, N | 1 |
| Singh, S | 1 |
| Rawat, J | 1 |
| Gomes, R | 1 |
| Salazar, L | 1 |
| Fraga, C | 1 |
| Correia, MR | 1 |
| Barbosa-Sequeira, J | 1 |
| Fernandes, A | 1 |
| Álvares, S | 1 |
| Banquart Leitão, J | 1 |
| Paiva Coelho, M | 1 |
| Yuan, WL | 2 |
| Wang, XK | 10 |
| Zhou, L | 1 |
| Li, H | 1 |
| Yamada-Kanazawa, S | 1 |
| Shimada, S | 1 |
| Nakayama, W | 1 |
| Sawamura, S | 1 |
| Nishimura, Y | 1 |
| Kajihara, I | 1 |
| Makino, K | 1 |
| Aoi, J | 1 |
| Masuguchi, S | 1 |
| Amano, F | 1 |
| Fukushima, S | 1 |
| Beqo, BP | 1 |
| Gasparella, P | 1 |
| Flucher, C | 1 |
| Spendel, S | 1 |
| Quehenberger, F | 1 |
| Haxhija, EQ | 1 |
| Mahmoud, I | 1 |
| Kotirkova, D | 1 |
| Gospodinova, K | 1 |
| Darlenski, R | 1 |
| Kazandjieva, J | 1 |
| Fu, R | 1 |
| Zou, Y | 1 |
| Wu, Z | 2 |
| Jin, P | 1 |
| Cheng, J | 2 |
| Bai, H | 1 |
| Huang, M | 2 |
| Huan, X | 1 |
| Yuan, H | 1 |
| Höger, PH | 2 |
| Hamm, H | 1 |
| Zhao, P | 1 |
| Dai, T | 1 |
| Arredondo Montero, J | 2 |
| Molina Caballero, AY | 2 |
| Moreno, JC | 1 |
| Antona, G | 1 |
| Gonzalez Martinez, OG | 1 |
| Langer, PD | 1 |
| Milman, T | 1 |
| Khamaysi, Z | 3 |
| Pam, N | 3 |
| Zaaroura, H | 1 |
| Avitan-Hersh, E | 1 |
| Panda, SK | 1 |
| Nikhila, GP | 1 |
| Kavya, PS | 1 |
| Eroglu, N | 1 |
| Sen, HS | 2 |
| Kar, YD | 1 |
| Pektas, A | 1 |
| Eker, I | 1 |
| Wang, T | 2 |
| Deng, L | 1 |
| Wang, Q | 4 |
| Gao, J | 2 |
| Hali, F | 2 |
| Moubine, I | 1 |
| Berrami, H | 1 |
| Serhier, Z | 1 |
| Othmani, MB | 1 |
| Chiheb, S | 2 |
| Zhao, X | 1 |
| Huang, J | 4 |
| Lin, N | 1 |
| Xu, Q | 2 |
| Lin, C | 1 |
| Zhang, Z | 1 |
| Borst, AJ | 1 |
| Hammill, AM | 2 |
| Iacobas, I | 1 |
| Atkinson, A | 1 |
| Shah, T | 1 |
| Margolin, JF | 1 |
| Bayliff, SL | 1 |
| Blatt, J | 2 |
| Shang, Y | 2 |
| Li, X | 6 |
| Qiu, T | 2 |
| Zhou, J | 2 |
| Gong, X | 1 |
| Lan, Y | 1 |
| Ji, Y | 11 |
| Alshammari, H | 1 |
| Alessa, A | 1 |
| Elsharawy, Y | 1 |
| Alghanem, A | 1 |
| Alhammad, AM | 1 |
| Pino, G | 1 |
| Zambrano, MJ | 1 |
| Kramer, D | 1 |
| Cervilla, K | 1 |
| González, S | 1 |
| Singh, P | 1 |
| Chamlin, S | 2 |
| Hignett, E | 1 |
| Silverberg, JI | 1 |
| Lekwuttikarn, R | 1 |
| Josephs, S | 1 |
| Teng, JM | 1 |
| Qiao, C | 2 |
| Ma, G | 7 |
| Janmohamed, SR | 5 |
| Harris, J | 1 |
| Phillips, JD | 2 |
| de Wild, SR | 1 |
| Moyakine, AV | 3 |
| van der Vleuten, CJM | 3 |
| Li, HH | 2 |
| Lou, Y | 2 |
| Zhang, RR | 1 |
| Xie, J | 3 |
| Cao, DS | 2 |
| Xu, P | 1 |
| Yu, Q | 1 |
| Zhang, W | 2 |
| Lim, TH | 1 |
| Yap, E | 1 |
| Norhatizah, BS | 1 |
| Bessar, H | 1 |
| Kandil, AH | 1 |
| Nasr, NM | 1 |
| Khattab, F | 1 |
| Kotlukova, NP | 1 |
| Osmanov, IM | 1 |
| Konstantinova, NK | 1 |
| Trunina, II | 1 |
| Lavrova, TR | 1 |
| Karelina, EV | 1 |
| Grishkin, AN | 1 |
| Mosin, IM | 1 |
| Tripathy, D | 1 |
| Olsen, GM | 1 |
| Hansen, LM | 1 |
| Stefanko, NS | 1 |
| Mathes, E | 2 |
| Puttgen, KB | 8 |
| Tollefson, MM | 3 |
| Lauren, C | 2 |
| Mancini, AJ | 8 |
| McCuaig, CC | 1 |
| Frieden, IJ | 13 |
| Gupta, D | 1 |
| Frommelt, P | 1 |
| Garzon, MC | 5 |
| Horii, K | 2 |
| Klajn, J | 1 |
| Maheshwari, M | 1 |
| Newell, B | 2 |
| Nguyen, HL | 1 |
| Nopper, A | 2 |
| Siegel, DH | 3 |
| Drolet, BA | 8 |
| Sun, B | 2 |
| Lei, H | 2 |
| Gong, Y | 4 |
| Zhang, Y | 5 |
| Zhang, H | 5 |
| Sun, L | 2 |
| Tan, JMC | 1 |
| Lim, HW | 1 |
| Koh, MJ | 1 |
| Xerfan, EMS | 1 |
| Andersen, ML | 1 |
| Facina, AS | 1 |
| Tufik, S | 1 |
| Tomimori, J | 1 |
| Oesch, V | 1 |
| Theiler, M | 3 |
| Szello, P | 1 |
| Weibel, L | 4 |
| Aizman, L | 1 |
| Van Den Anker, J | 1 |
| Tender, J | 1 |
| Krishnan, A | 1 |
| Kirkorian, AY | 1 |
| Liang, H | 1 |
| Duell, K | 1 |
| McNab, S | 1 |
| Betlloch-Mas, I | 1 |
| Martínez-Miravete, MT | 1 |
| Berbegal-DeGracia, L | 1 |
| Sánchez-Vázquez, L | 1 |
| Sánchez-Payá, J | 1 |
| Kridin, K | 2 |
| Bergman, R | 1 |
| Zheng, K | 1 |
| Wang, Y | 2 |
| Robert, J | 1 |
| Tavernier, E | 1 |
| Mashiah, J | 1 |
| Mazereeuw-Hautier, J | 9 |
| Maruani, A | 5 |
| Suga, S | 1 |
| Araki, S | 1 |
| Aramaki, S | 1 |
| Shibata, E | 1 |
| Kusuhara, K | 1 |
| Joshi, K | 1 |
| Bolia, R | 1 |
| Poddar, U | 1 |
| Dabadgao, P | 1 |
| Park, M | 1 |
| Jung, HL | 2 |
| Shim, YJ | 1 |
| Kim, HS | 3 |
| Yoon, HS | 1 |
| Park, SK | 1 |
| Cheuh, HW | 1 |
| Lee, MJ | 1 |
| Lee, JM | 1 |
| Park, ES | 1 |
| Lee, JH | 1 |
| Lim, YJ | 1 |
| Choi, YB | 1 |
| Dávila-Osorio, VL | 1 |
| Iznardo, H | 1 |
| Tani, S | 1 |
| Kunimoto, K | 1 |
| Inaba, Y | 1 |
| Mikita, N | 1 |
| Kaminaka, C | 1 |
| Kanazawa, N | 1 |
| Yamamoto, Y | 2 |
| Kakimoto, N | 1 |
| Suenaga, T | 1 |
| Takeuchi, T | 1 |
| Suzuki, H | 1 |
| Jinnin, M | 1 |
| Goto, K | 1 |
| Yasue, S | 1 |
| Endo, S | 1 |
| Fukao, T | 2 |
| Kim, YH | 1 |
| Lee, YA | 1 |
| Shin, CH | 1 |
| Hong, KT | 1 |
| Kim, GB | 1 |
| Ko, JS | 1 |
| Lee, YJ | 1 |
| Yang, J | 2 |
| Azzarelli, A | 1 |
| Vaccaro, A | 1 |
| Mazzatenta, C | 1 |
| Koh, SP | 1 |
| Leadbitter, P | 4 |
| Smithers, F | 1 |
| Tan, ST | 5 |
| Chen, YQ | 1 |
| Zhong, LL | 1 |
| Ding, XF | 1 |
| Bonafede, L | 1 |
| Go, M | 1 |
| Belcastro, AA | 1 |
| Bellet, JS | 1 |
| Gabr, H | 1 |
| Freedman, SF | 1 |
| Velez, FG | 1 |
| Hanson, T | 1 |
| Hanson, J | 1 |
| Torres, EB | 1 |
| Rotunno, R | 1 |
| Figà-Talamanca, L | 1 |
| Wei, T | 2 |
| Johnson, A | 1 |
| Sun, R | 1 |
| Richter, G | 1 |
| Strub, GM | 1 |
| Hartmann, F | 2 |
| Lockmann, A | 2 |
| Himpel, O | 1 |
| Kühnle, I | 2 |
| Hensen, J | 1 |
| Schön, MP | 3 |
| Thoms, KM | 2 |
| Huang, AH | 2 |
| Mannschreck, D | 1 |
| Aggarwal, P | 1 |
| Mahon, M | 1 |
| Cohen, BA | 2 |
| Tognetti, L | 1 |
| Pianigiani, E | 1 |
| Ierardi, F | 1 |
| Cartocci, A | 1 |
| Fiorani, D | 1 |
| de Quattro, M | 1 |
| Caini, M | 1 |
| Cinotti, E | 1 |
| Cevenini, G | 1 |
| Rubegni, P | 1 |
| Macdonald, A | 1 |
| Durkin, N | 1 |
| Deganello, A | 1 |
| Sellars, ME | 1 |
| Makin, E | 1 |
| Davenport, M | 1 |
| Czechowicz, JA | 1 |
| Benjamin, T | 1 |
| Bly, RA | 1 |
| Ganti, SN | 1 |
| Balkin, DM | 1 |
| Perkins, JA | 7 |
| Rosbe, KW | 4 |
| Galdeano, F | 1 |
| Herón, A | 1 |
| Moreno, S | 1 |
| Aprea, G | 1 |
| Meneses, M | 1 |
| Liao, S | 1 |
| Wu, J | 1 |
| Li, Z | 2 |
| Cheng, G | 1 |
| Lu, B | 1 |
| Liu, G | 1 |
| Frongia, G | 1 |
| Byeon, JO | 1 |
| Mehrabi, A | 1 |
| Günther, P | 1 |
| Wu, C | 2 |
| Sun, J | 3 |
| Yildirimcakar, D | 1 |
| Demirsoy, U | 1 |
| Azizoglu, M | 1 |
| Corapcioglu, F | 1 |
| Frost, S | 1 |
| Saddi, V | 1 |
| Teng, A | 1 |
| Mallitt, KA | 1 |
| Adams, S | 5 |
| Williamson, B | 1 |
| Wargon, O | 6 |
| Yalçın, B | 2 |
| Canpınar, H | 1 |
| Ocak, S | 1 |
| Akyüz, C | 3 |
| Zhao, ZL | 1 |
| Wang, QZ | 1 |
| Zhang, WB | 1 |
| Shao, L | 1 |
| Wu, HW | 2 |
| Zheng, JW | 10 |
| Selzer Soria, EM | 1 |
| Malla, I | 1 |
| Li, S | 3 |
| Gao, Q | 1 |
| Lv, R | 3 |
| Xu, G | 3 |
| Bi, J | 2 |
| Park, HJ | 1 |
| Lee, SY | 1 |
| Rho, MH | 1 |
| Aydin Köker, S | 1 |
| Kömüroğlu, AU | 1 |
| Köksoy, AY | 1 |
| Şiraz, ÜG | 1 |
| Tekin, E | 1 |
| Köker, A | 1 |
| Yang, W | 1 |
| Wolter, NE | 1 |
| Cushing, SL | 2 |
| Pope, E | 7 |
| Wolter, JK | 1 |
| Propst, EJ | 1 |
| Sun, X | 1 |
| Fang, Y | 1 |
| Ma, Y | 2 |
| Moreno Alfonso, JC | 1 |
| Pérez Martínez, A | 1 |
| Zubicaray Ugarteche, J | 1 |
| Bardají Pascual, C | 1 |
| Zhang, X | 2 |
| Xiang, B | 6 |
| Jiang, X | 2 |
| Xu, X | 2 |
| Dai, S | 1 |
| Kong, F | 1 |
| Lu, G | 2 |
| Qiu, Q | 1 |
| Nagoba, B | 1 |
| Davane, M | 1 |
| Warad, B | 1 |
| Jamadar, N | 1 |
| Gavkare, AM | 1 |
| Konstantinidou, S | 1 |
| Butler, CR | 1 |
| Hartley, B | 1 |
| Frauenfelder, C | 1 |
| Miyazaki, T | 1 |
| Sasai, H | 1 |
| Ohnishi, H | 1 |
| Johansen, ML | 1 |
| Mahendran, G | 1 |
| Lawley, LP | 2 |
| von der Heydt, S | 1 |
| Schwieger-Briel, A | 1 |
| Luchsinger, I | 1 |
| Smith, A | 1 |
| Kernland-Lang, K | 1 |
| Waelchli, R | 1 |
| Neuhaus, K | 2 |
| Kohler, M | 1 |
| Gnannt, R | 1 |
| Schoch, SF | 1 |
| Kurth, S | 1 |
| Kardasevic, M | 1 |
| Dinarevic, SM | 1 |
| Farshchian, M | 1 |
| Potts, GA | 1 |
| Braun, M | 1 |
| Metry, D | 3 |
| Antaya, RJ | 2 |
| Kohn, LL | 1 |
| McMichael, J | 1 |
| Dong, JY | 1 |
| Ning, JX | 1 |
| Wang, XX | 1 |
| Li, RH | 1 |
| Yue, LL | 1 |
| Huang, YY | 1 |
| Liu, SH | 4 |
| Velure, HK | 1 |
| Hartling, UB | 1 |
| Schuster, A | 1 |
| Bygum, A | 1 |
| Higuchi, S | 1 |
| Takagi, M | 1 |
| Hasegawa, Y | 1 |
| Kim, KH | 2 |
| Choi, TH | 1 |
| Choi, Y | 1 |
| Park, YW | 2 |
| Hong, KY | 1 |
| Kim, DY | 2 |
| Choe, YS | 1 |
| Lee, H | 1 |
| Cheon, JE | 1 |
| Park, JB | 1 |
| Park, KD | 1 |
| Kang, HJ | 1 |
| Shin, HY | 1 |
| Jeong, JH | 1 |
| Gesualdo, F | 1 |
| Berti, I | 2 |
| Boccaletti, V | 2 |
| Porcedda, G | 1 |
| Greco, A | 1 |
| Dalmonte, P | 2 |
| Kado, M | 1 |
| Shimizu, A | 1 |
| Matsumura, T | 1 |
| Mochizuki, M | 1 |
| Mizuno, H | 1 |
| Hayashi, A | 1 |
| Yang, Y | 2 |
| Charny, JW | 1 |
| Moon, AT | 1 |
| Treat, JR | 3 |
| Oberlin, KE | 1 |
| Keller, RG | 2 |
| Stevens, S | 1 |
| Hochman, M | 2 |
| Goldberg, V | 1 |
| Martinez, B | 1 |
| Cnop, K | 1 |
| Rohloff, P | 1 |
| Bayart, CB | 1 |
| Tamburro, JE | 1 |
| Vidimos, AT | 1 |
| Golden, AB | 1 |
| Taran, K | 3 |
| Wnęk, A | 3 |
| Kobos, J | 3 |
| Andrzejewska, E | 3 |
| Przewratil, P | 5 |
| Mahamadou, G | 2 |
| Saka, B | 2 |
| Mouhari-Toure, A | 2 |
| Tchaou, M | 1 |
| Pessinaba, S | 1 |
| Gnassingbé, W | 1 |
| Kombaté, K | 2 |
| Pitché, P | 2 |
| Yazici, N | 2 |
| Sarialioglu, F | 3 |
| Erbay, A | 2 |
| Paul, SP | 1 |
| Boyd, GM | 1 |
| Warren, D | 1 |
| Diaz, L | 1 |
| Levy, M | 1 |
| González-Llorente, N | 1 |
| Del Olmo-Benito, I | 1 |
| Muñoz-Ollero, N | 1 |
| Descalzo, MA | 1 |
| Shilpakar, R | 1 |
| Lemperle, G | 1 |
| Mentzel, T | 1 |
| Shakya, J | 1 |
| Bhandari, SB | 1 |
| Herwegen, B | 1 |
| Schwartz, T | 1 |
| Faria, J | 1 |
| Pawar, S | 1 |
| Siegel, D | 2 |
| Chun, RH | 3 |
| Chong, JH | 1 |
| Mya, HT | 1 |
| Labreze, C | 2 |
| Csoma, ZR | 1 |
| Dalmády, S | 1 |
| Ábrahám, R | 1 |
| Rózsa, T | 1 |
| Rácz, K | 1 |
| Kemény, L | 1 |
| Guo, X | 5 |
| Zhu, X | 4 |
| Liu, D | 3 |
| Jin, X | 1 |
| Chen, YZ | 1 |
| Bai, N | 1 |
| Bi, JH | 1 |
| Liu, XW | 1 |
| Xu, GQ | 4 |
| Zhang, LF | 1 |
| Li, XQ | 1 |
| Lv, D | 2 |
| Gu, Y | 3 |
| Abdellaoui, T | 1 |
| Laaribi, N | 1 |
| Zerrouk, R | 1 |
| Elasri, F | 1 |
| Reda, K | 1 |
| Oubaaz, A | 1 |
| Tosoni, A | 1 |
| Dalle Carbonare, M | 1 |
| Pettenazzo, A | 1 |
| Perilongo, G | 1 |
| Sartori, S | 1 |
| Rotter, A | 2 |
| de Oliveira, ZNP | 1 |
| Darrow, DH | 4 |
| Adams, DM | 2 |
| Ricci, KW | 1 |
| Espinel, AG | 1 |
| Bauman, NM | 6 |
| Bangiyev, JN | 1 |
| Gurgel, R | 1 |
| Vanderhooft, SL | 1 |
| Grimmer, JF | 3 |
| Roncone, K | 1 |
| Kindley, KJ | 1 |
| Zlotoff, B | 1 |
| Espahbodi, M | 1 |
| Yan, K | 1 |
| McCormick, ME | 1 |
| Jiao-Ling, L | 1 |
| Xiu-Ping, G | 1 |
| Kun-Shan, C | 1 |
| Qiu-Ming, H | 1 |
| Xiao-Fen, L | 1 |
| Bo-Yang, Y | 1 |
| Qian, F | 1 |
| Mahon, C | 1 |
| Heron, G | 1 |
| Perkins, D | 1 |
| Drage, A | 1 |
| Zheng, L | 1 |
| Ataş, E | 1 |
| Koç, O | 1 |
| Artık, HA | 1 |
| Price, A | 1 |
| Rai, S | 1 |
| Mcleod, RWJ | 1 |
| Birchall, JC | 1 |
| Elhassan, HA | 1 |
| Wrobel, LJ | 1 |
| Boehncke, WH | 1 |
| Le Gal, FA | 1 |
| Kagami, S | 4 |
| Kaneko, M | 2 |
| Katori, T | 4 |
| Kara, M | 1 |
| Calis, M | 1 |
| Ozgur, F | 1 |
| Zhu, L | 1 |
| Liu, Z | 2 |
| Huang, Z | 1 |
| Yin, H | 1 |
| Qi, W | 1 |
| Yang, Z | 1 |
| Zhou, T | 1 |
| Gao, G | 1 |
| Zhang, J | 3 |
| Yang, X | 3 |
| Kumar, R | 1 |
| Singh, OP | 1 |
| Xiong, F | 1 |
| Lund, EB | 1 |
| Chamlin, SL | 2 |
| Mong, EF | 1 |
| Akat, KM | 1 |
| Canfield, J | 1 |
| Lockhart, J | 1 |
| VanWye, J | 1 |
| Matar, A | 1 |
| Tsibris, JCM | 1 |
| Wu, JK | 4 |
| Tuschl, T | 1 |
| Totary-Jain, H | 1 |
| Del Frari, L | 1 |
| Guibaud, L | 3 |
| Barbarot, S | 4 |
| Lacour, JP | 2 |
| Chaumont, C | 1 |
| Voisard, JJ | 7 |
| Brunner, V | 1 |
| Takechi, T | 1 |
| Kumokawa, T | 1 |
| Kato, R | 1 |
| Higuchi, T | 1 |
| Ieiri, I | 1 |
| Lopez, T | 1 |
| Miraglia, E | 2 |
| Schiavetti, A | 3 |
| Varrasso, G | 3 |
| Calvieri, S | 2 |
| Giustini, S | 2 |
| Yao, TH | 1 |
| Pataer, P | 1 |
| Regmi, KP | 1 |
| Gu, XW | 1 |
| Li, QY | 1 |
| Du, JT | 1 |
| Ge, SM | 1 |
| Tu, JB | 1 |
| Glover, M | 3 |
| Beattie, PE | 2 |
| Buckley, H | 1 |
| Clark, S | 1 |
| Gach, JE | 1 |
| Giardini, A | 1 |
| Helbling, I | 1 |
| Hewitt, RJ | 1 |
| Laguda, B | 2 |
| Langan, SM | 1 |
| Martinez, AE | 1 |
| Murphy, R | 1 |
| Proudfoot, L | 1 |
| Ravenscroft, J | 1 |
| Shahidullah, H | 3 |
| Shaw, L | 2 |
| Syed, SB | 2 |
| Wells, L | 1 |
| Babiak-Choroszczak, L | 2 |
| Giżewska-Kacprzak, K | 2 |
| Gawrych, E | 2 |
| Fischer, K | 1 |
| Walecka, A | 1 |
| Puchalska-Niedbał, L | 1 |
| Rajewska-Majchrzak, J | 1 |
| Bagłaj, M | 2 |
| Droitcourt, C | 1 |
| Kerbrat, S | 1 |
| Rault, C | 1 |
| Botrel, MA | 1 |
| Happe, A | 1 |
| Garlantezec, R | 1 |
| Guillot, B | 1 |
| Schleich, JM | 1 |
| Oger, E | 1 |
| Dupuy, A | 2 |
| Hagen, R | 1 |
| Ghareeb, E | 1 |
| Jalali, O | 1 |
| Sancho, KFCB | 1 |
| Zett, C | 1 |
| Gonçalves Júnior, I | 1 |
| Morales, MC | 1 |
| Maia, M | 1 |
| Mattos Neto, RB | 1 |
| Samorano, LP | 1 |
| Rivitti-Machado, MC | 1 |
| Oliveira, ZNP | 1 |
| Gontijo, B | 1 |
| Polites, SF | 2 |
| Rodrigue, BB | 1 |
| Chute, C | 2 |
| Hammill, A | 1 |
| Dasgupta, R | 2 |
| Kishi, A | 1 |
| Tian, Y | 2 |
| Guo, XS | 1 |
| Nan, J | 1 |
| Wang, XL | 1 |
| Shen, G | 1 |
| Gültekin, ND | 1 |
| Yilmaz, FH | 1 |
| Altunhan, H | 1 |
| Findik, S | 1 |
| Tokgöz, H | 1 |
| Çalişkan, Ü | 1 |
| Chaturvedi, K | 1 |
| Steinberg, JS | 1 |
| Snyder, CS | 1 |
| Dembowska-Baginska, B | 1 |
| Wyrzykowski, D | 3 |
| López Gutiérrez, JC | 3 |
| Rychłowska-Pruszyńska, M | 1 |
| de Lucas-Laguna, R | 1 |
| Esteve-Martinez, A | 1 |
| Zaim, M | 1 |
| Menon, Y | 1 |
| Gautier, S | 2 |
| Lebbé, G | 3 |
| Bouroubi, A | 1 |
| Xu, W | 1 |
| Yu, F | 1 |
| An, W | 1 |
| Wang, W | 2 |
| Sun, C | 2 |
| McCormick, AA | 1 |
| Tarchichi, T | 1 |
| Azbell, C | 1 |
| Grunwaldt, L | 1 |
| Jabbour, N | 1 |
| Tangtatco, JA | 1 |
| Freedman, C | 1 |
| Phillips, J | 1 |
| Lin, Z | 1 |
| Huang, G | 1 |
| Lin, H | 1 |
| Watanabe, M | 1 |
| Crafton, T | 1 |
| Jenkins, TM | 1 |
| Alvarez-Allende, CR | 1 |
| Martin, JM | 1 |
| Sanchez, S | 1 |
| González, V | 1 |
| Cordero, P | 1 |
| Ramon, D | 1 |
| Sepaskhah, M | 1 |
| Hajizadeh, J | 1 |
| Sari-Aslani, F | 1 |
| Jowkar, F | 1 |
| Zhu, Z | 1 |
| Cai, P | 1 |
| Zhu, J | 1 |
| Wu, B | 1 |
| Gu, Z | 1 |
| Wang, J | 3 |
| Lahrichi, A | 1 |
| Baline, K | 1 |
| Fatoiki, FZE | 1 |
| Khadir, K | 1 |
| Álvarez-Neri, H | 1 |
| Penchyna-Grub, J | 1 |
| Teyssier-Morales, G | 1 |
| Morera-Serna, E | 1 |
| Torre, C | 1 |
| Villamor, P | 1 |
| Novoa, M | 1 |
| Beltran, S | 1 |
| Giraldo, L | 1 |
| Shahbaz, A | 1 |
| Pardo-Hernandez, H | 1 |
| Arevalo-Rodriguez, I | 1 |
| López-Gutiérrez, JC | 1 |
| Subiabre-Ferrer, D | 1 |
| García-Rabasco, A | 1 |
| Correa-González, N | 1 |
| Ortiz-Salvador, JM | 1 |
| Barreda-Solana, M | 1 |
| Lee, SM | 1 |
| Khwarg, SI | 1 |
| Ahn, JH | 1 |
| Campanelli, R | 1 |
| Codazzi, AC | 1 |
| Poletto, V | 1 |
| Abbà, C | 1 |
| Catarsi, P | 1 |
| Fois, G | 1 |
| Avanzini, MA | 1 |
| Brazzelli, V | 2 |
| Tzialla, C | 2 |
| De Silvestri, A | 1 |
| Tinelli, C | 1 |
| Licari, A | 1 |
| Berra-Romani, R | 1 |
| Zuccolo, E | 1 |
| Moccia, F | 1 |
| Mannarino, S | 2 |
| Rosti, V | 1 |
| Massa, M | 1 |
| Xu, ZG | 1 |
| Dawid, G | 1 |
| Tsai, MC | 1 |
| Liu, HC | 1 |
| Yeung, CY | 1 |
| Anwar, T | 1 |
| Malm-Buatsi, E | 1 |
| Ji, Z | 1 |
| Jiang, Y | 1 |
| Welfringer-Morin, A | 1 |
| Fraitag, S | 1 |
| Balguerie, X | 1 |
| Laaengh-Massoni, C | 1 |
| Leclerc-Mercier, S | 1 |
| Hadj-Rabia, S | 3 |
| Bodemer, C | 2 |
| Mellerio, JE | 1 |
| Feng, L | 1 |
| Yuan, WE | 2 |
| Ramtohul, P | 1 |
| Beylerian, M | 1 |
| Dambricourt, L | 1 |
| Matonti, F | 1 |
| Denis, D | 1 |
| Düzenli Kar, Y | 1 |
| Özdemir, ZC | 1 |
| Acu, B | 1 |
| Bör, Ö | 1 |
| Cai, R | 1 |
| Moro, R | 1 |
| Fabiano, A | 1 |
| Mangeri, F | 1 |
| Di Buduo, A | 1 |
| Manerba, A | 1 |
| Rossini, M | 1 |
| Calzavara-Pinton, PG | 1 |
| Gualdi, G | 1 |
| Celli, M | 1 |
| Akakpo, AS | 1 |
| Téclessou, JN | 1 |
| Djalogue, L | 1 |
| Gottara, WS | 1 |
| Tchangai-Walla, K | 1 |
| O'Bryhim, BE | 1 |
| Li, AS | 1 |
| Bayliss, SJ | 1 |
| Tychsen, L | 1 |
| Lueder, GT | 1 |
| Rajagopal, R | 1 |
| Liu, Q | 1 |
| Zuo, S | 1 |
| Mannschreck, DB | 1 |
| Lie, E | 2 |
| Psoter, K | 1 |
| Puttgen, K | 2 |
| Jiang, D | 1 |
| Zhao, S | 1 |
| Wang, A | 1 |
| Rokugo, Y | 1 |
| Ota, C | 1 |
| Kimura, M | 1 |
| Sasahara, Y | 1 |
| Yeo, YH | 1 |
| Jackson, C | 1 |
| Trimble, K | 1 |
| Anger, J | 1 |
| Oliveira, EM | 1 |
| Gabel, J | 1 |
| Reimer, A | 2 |
| Ott, H | 1 |
| Wu, W | 1 |
| Wang, H | 2 |
| Hao, J | 1 |
| Gao, Z | 1 |
| Li, F | 1 |
| Chen, Y | 1 |
| Bakalli, I | 1 |
| Kola, E | 1 |
| Lluka, R | 1 |
| Celaj, E | 1 |
| Sala, D | 1 |
| Gjeta, I | 1 |
| Sallabanda, S | 1 |
| Klironomi, D | 1 |
| Chai, Y | 1 |
| Zhou, Z | 1 |
| Song, J | 1 |
| Onder, SS | 1 |
| Gergin, O | 1 |
| Karabulut, B | 1 |
| Prasad, A | 2 |
| Sinha, AK | 1 |
| Kumar, B | 1 |
| Kumari, M | 1 |
| Overman, J | 1 |
| Moustaqil, M | 1 |
| Meurer, M | 1 |
| Chiang, IK | 1 |
| Lesieur, E | 1 |
| Patel, J | 1 |
| Zuegg, J | 1 |
| Pasquier, E | 1 |
| Sierecki, E | 1 |
| Gambin, Y | 1 |
| Hamdan, M | 1 |
| Khosrotehrani, K | 1 |
| Andelfinger, G | 1 |
| Fernández Ibieta, M | 1 |
| Méndez Aguirre, NA | 1 |
| Girón Vallejo, O | 1 |
| Ruiz Jiménez, JI | 1 |
| Ben-Amitai, D | 1 |
| Halachmi, S | 1 |
| Zvulunov, A | 5 |
| Raveh, E | 1 |
| Kalish, E | 1 |
| Lapidoth, M | 3 |
| Parikh, SR | 2 |
| Manning, SC | 3 |
| Richter, GT | 7 |
| Craiglow, BG | 1 |
| Reddy, KK | 1 |
| Brauer, JA | 1 |
| Waner, M | 4 |
| Anolik, R | 1 |
| Bernstein, L | 1 |
| Brightman, L | 1 |
| Hale, E | 1 |
| Karen, J | 1 |
| Weiss, E | 1 |
| Geronemus, RG | 2 |
| Sadykov, RR | 1 |
| Podmelle, F | 1 |
| Sadykov, RA | 1 |
| Kasimova, KR | 1 |
| Metellmann, HR | 1 |
| McGee, P | 1 |
| Miller, S | 1 |
| Black, C | 1 |
| Hoey, S | 2 |
| Dreyfus, I | 2 |
| Maza, A | 1 |
| Caussé, S | 1 |
| Aubert, H | 1 |
| Saint-Jean, M | 2 |
| Puzenat, E | 1 |
| Bursztejn, AC | 1 |
| Eschard, C | 1 |
| Mahé, E | 1 |
| Miquel, J | 2 |
| Chiaverini, C | 1 |
| Stalder, JF | 2 |
| Ahogo, CK | 1 |
| Ezzedine, K | 4 |
| Colona, V | 1 |
| Diallo, A | 1 |
| Mendiratta, V | 1 |
| Varghese, B | 1 |
| Chander, R | 1 |
| Parakh, A | 1 |
| Solanki, RS | 1 |
| Pride, HB | 1 |
| Tollefson, M | 1 |
| Silverman, R | 1 |
| Hong, P | 1 |
| Tammareddi, N | 1 |
| Walvekar, R | 1 |
| Chiu, ES | 1 |
| Poole, JC | 1 |
| Kluka, EA | 1 |
| Simon, LM | 1 |
| Block, SL | 1 |
| Blackmon, L | 1 |
| Wang, HW | 1 |
| Zhang, N | 1 |
| Zhang, JL | 2 |
| Fette, A | 1 |
| Chandran, S | 1 |
| Ari, D | 1 |
| Jose, J | 1 |
| Niu, JN | 1 |
| Lü, RR | 3 |
| Tlougan, BE | 1 |
| Lee, MT | 1 |
| Shibata, S | 1 |
| Uwajima, Y | 1 |
| Yamada, D | 1 |
| Miyamoto, A | 1 |
| Miyagawa, T | 1 |
| Araki, M | 1 |
| Takahashi, K | 1 |
| Isomura, S | 1 |
| Aozasa, N | 1 |
| Masui, Y | 1 |
| Yamamoto, M | 1 |
| Inuzuka, R | 1 |
| Sato, S | 1 |
| Romanini, MV | 1 |
| Pelegrini, M | 1 |
| Rimini, A | 1 |
| Occella, C | 1 |
| Ferrandiz, L | 1 |
| Toledo-Pastrana, T | 1 |
| Moreno-Ramirez, D | 1 |
| Bardallo-Cruzado, L | 1 |
| Perez-Bertolez, S | 1 |
| Luna-Lagares, S | 1 |
| Rios-Martin, JJ | 1 |
| Engberg Damsgaard, T | 1 |
| Vandborg Bjerre, J | 1 |
| Huoh, KC | 2 |
| Frost, G | 1 |
| Relic, J | 1 |
| Sondhi, V | 1 |
| Patnaik, SK | 1 |
| Chaudhry, TA | 1 |
| Kamal, M | 1 |
| Ahmad, K | 1 |
| McSwiney, E | 1 |
| Murray, D | 1 |
| Murphy, M | 1 |
| Cavalli, R | 2 |
| Novotna, V | 1 |
| Buffon, RB | 1 |
| Gelmetti, C | 3 |
| Knol, MJ | 1 |
| Bruijnzeel-Koomen, CA | 1 |
| Kon, M | 2 |
| Breur, JM | 3 |
| Pasmans, SG | 3 |
| Xiao, X | 4 |
| Xu, T | 2 |
| Zheng, S | 4 |
| Peng, WJ | 1 |
| Cao, Y | 1 |
| Thaivalappil, S | 1 |
| Bauman, N | 1 |
| Saieg, A | 1 |
| Movius, E | 1 |
| Brown, KJ | 1 |
| Preciado, D | 1 |
| Ng, SY | 1 |
| Kader Ibrahim, SB | 1 |
| Tanabe, H | 1 |
| Sahashi, K | 1 |
| Kitano, T | 1 |
| Tomita, Y | 1 |
| Saito, AM | 1 |
| Hirose, H | 1 |
| Theunissen, CI | 1 |
| van der Horst, CM | 3 |
| Summerer, B | 1 |
| Schneider, J | 1 |
| Boss, EF | 1 |
| Biesbroeck, L | 1 |
| Brandling-Bennett, HA | 1 |
| Haider, KM | 2 |
| Neely, DE | 2 |
| Plager, DA | 2 |
| Mawn, LA | 1 |
| Puligadda, RK | 1 |
| Vijayalakshmi, B | 1 |
| Lynch, M | 1 |
| Lenane, P | 1 |
| O'Donnell, BF | 2 |
| Kum, JJ | 1 |
| Khan, ZA | 1 |
| Malik, MA | 1 |
| Menon, P | 1 |
| Rao, KL | 1 |
| Samujh, R | 1 |
| Gu, MZ | 1 |
| Wu, JL | 1 |
| Zhao, LM | 1 |
| Ni, K | 1 |
| Chen, SM | 1 |
| Chen, JR | 2 |
| Chen, F | 1 |
| Li, XY | 2 |
| Szychta, P | 1 |
| Stewart, K | 1 |
| Anderson, W | 1 |
| Chim, H | 2 |
| Mai, HM | 1 |
| Wang, YA | 1 |
| Qin, ZP | 7 |
| Li, KL | 5 |
| Rössler, J | 4 |
| Braunschweiger, F | 1 |
| Schill, T | 4 |
| Albuquerque, JC | 1 |
| Magalhães, RA | 1 |
| Félix, JA | 1 |
| Bastos, MV | 1 |
| Fontenele, JB | 1 |
| Trompieri, NM | 1 |
| Felix, FH | 1 |
| Wang, Z | 1 |
| Andersen, IG | 1 |
| Rechnitzer, C | 1 |
| Charabi, B | 1 |
| McCarter, RJ | 1 |
| Guzzetta, PC | 1 |
| Shin, JJ | 2 |
| Oh, AK | 1 |
| Preciado, DA | 1 |
| He, J | 1 |
| Greene, EA | 2 |
| Sagi, L | 1 |
| Ben Amitai, D | 1 |
| Chen, BS | 1 |
| Saltzman, B | 2 |
| Levitt, M | 1 |
| Coumou, AD | 1 |
| Groeneveld, L | 1 |
| Freling, NJ | 1 |
| Saeed, P | 1 |
| Chang, TC | 1 |
| Estes, R | 1 |
| Emiralioğlu, N | 1 |
| Oğuz, B | 1 |
| Kiper, N | 1 |
| Ersöz, DD | 1 |
| Yalçın, E | 1 |
| Özçelik, U | 1 |
| Soldatskiĭ, IuL | 1 |
| Timofeeva, MIu | 1 |
| Koltukova, NP | 1 |
| Strygina, IuV | 1 |
| Gasparian, SF | 1 |
| Kislenko, OA | 1 |
| Bruneau, B | 1 |
| Lee, D | 1 |
| Durham, JT | 1 |
| Herman, IM | 1 |
| Schneider, M | 2 |
| Cremer, HJ | 2 |
| Ruef, P | 2 |
| Chu, DH | 1 |
| Castelo-Soccio, L | 1 |
| Wan, J | 1 |
| Gelfand, JM | 1 |
| Shaddy, RE | 1 |
| Shah, KN | 1 |
| Perman, MJ | 1 |
| Yan, AC | 1 |
| Laranjo, S | 1 |
| Costa, G | 1 |
| Paramés, F | 1 |
| Freitas, I | 1 |
| Martins, JD | 1 |
| Trigo, C | 1 |
| Pinto, FF | 1 |
| Zhou, H | 3 |
| Li, QF | 1 |
| Cao, GL | 1 |
| Ling, HZ | 1 |
| Dai, HR | 1 |
| Chen, XH | 1 |
| Monneret, C | 1 |
| Song, H | 2 |
| Shi, H | 2 |
| Yu, Y | 1 |
| Chen, W | 1 |
| England, RW | 2 |
| Hardy, KL | 2 |
| Kitajewski, AM | 2 |
| Wong, A | 2 |
| Kitajewski, JK | 3 |
| Shawber, CJ | 3 |
| Ma, X | 2 |
| Zhao, T | 2 |
| Ouyang, T | 2 |
| Xin, S | 1 |
| Chang, M | 1 |
| Murabit, A | 1 |
| Gnarra, M | 2 |
| Harper, JI | 4 |
| Jacobson, D | 1 |
| Nayan, S | 1 |
| Macnay, R | 1 |
| Maclean, J | 1 |
| Qi, M | 1 |
| Xie, HF | 1 |
| Ding, JS | 1 |
| Jian, D | 3 |
| Zhou, W | 1 |
| He, S | 1 |
| Ding, J | 1 |
| Crivellaro, C | 1 |
| Zanon, GF | 1 |
| Luzzatto, C | 1 |
| Tai, M | 1 |
| Qin, Z | 1 |
| Ge, C | 1 |
| Steel, R | 1 |
| Day, D | 1 |
| Nakayama, H | 1 |
| Klagsbrun, M | 1 |
| Xu, C | 1 |
| Kaushik, S | 1 |
| Kaur, S | 1 |
| Pandav, SS | 1 |
| Gupta, A | 1 |
| Xia, L | 1 |
| Bonifazi, E | 1 |
| Milano, A | 1 |
| Foti, C | 1 |
| Casiraghi, A | 2 |
| Musazzi, UM | 2 |
| Franceschini, I | 1 |
| Paragò, V | 1 |
| Cardosi, L | 1 |
| Minghetti, P | 2 |
| Lind, H | 1 |
| Zaharov, T | 1 |
| Godballe, C | 1 |
| Ehsani, AH | 1 |
| Noormohammadpoor, P | 1 |
| Abdolreza, M | 1 |
| Balighi, K | 1 |
| Arianian, Z | 1 |
| Daklan, S | 1 |
| Burne, R | 1 |
| Taylor, R | 2 |
| Sterker, I | 1 |
| Tegetmeyer, H | 1 |
| Sorge, I | 1 |
| Weißer, M | 1 |
| Böhm, R | 1 |
| Goelz, R | 1 |
| Poets, CF | 1 |
| Oksiuta, M | 1 |
| Matuszczak, E | 1 |
| Debek, W | 1 |
| Dzienis-Koronkiewicz, E | 1 |
| Hermanowicz, A | 1 |
| Kounami, S | 1 |
| Okuhira, H | 1 |
| Nakamura, Y | 1 |
| Furukawa, F | 1 |
| Hoff, SR | 1 |
| Rastatter, JC | 1 |
| Cerrati, EW | 1 |
| O, TM | 1 |
| Chung, H | 1 |
| Benvenisti, H | 1 |
| Ben-Sira, L | 1 |
| Constantini, S | 1 |
| Roth, J | 1 |
| Bin, L | 1 |
| Manli, C | 1 |
| Jie, L | 1 |
| Xiaopeng, Y | 1 |
| Zhaoquan, L | 1 |
| Zhongcheng, G | 1 |
| Korownyk, C | 1 |
| Ross, D | 1 |
| Fiorillo, L | 1 |
| Villalba-Moreno, AM | 1 |
| Cotrina-Luque, J | 1 |
| Del Vayo-Benito, CA | 1 |
| Flores-Moreno, S | 1 |
| Bautista-Paloma, FJ | 1 |
| Su, L | 1 |
| Wang, D | 1 |
| Cremer, H | 3 |
| Tinghui, Z | 1 |
| Xiaorong, M | 1 |
| Yingying, H | 1 |
| Huiping, C | 1 |
| Yan, X | 1 |
| Tianxiang, O | 1 |
| Filippi, L | 1 |
| Dal Monte, M | 1 |
| Casini, G | 1 |
| Daniotti, M | 1 |
| Sereni, F | 1 |
| Bagnoli, P | 1 |
| Kovačević, M | 1 |
| Lukinović Škudar, V | 1 |
| Maričić, G | 1 |
| Krnjević-Pezić, G | 1 |
| Stanimirović, A | 1 |
| Xu, DP | 6 |
| Cao, RY | 1 |
| Xue, L | 4 |
| Sun, NN | 2 |
| Tong, S | 3 |
| Kucherov, IuI | 1 |
| Zhirkova, IuV | 1 |
| Getman, AN | 1 |
| Ivleva, SA | 1 |
| Rekhviashvili, MG | 1 |
| Vlasveld, FA | 2 |
| Slieker, MG | 1 |
| Harper, J | 2 |
| Batul Syed, S | 1 |
| Yuan, SM | 1 |
| Zhang, M | 1 |
| Guo, Y | 1 |
| Cui, L | 1 |
| Hong, ZJ | 1 |
| Jiang, HQ | 1 |
| Giorgini, C | 1 |
| Barruscotti, S | 1 |
| Codazzi, CA | 1 |
| Stronati, M | 1 |
| Marseglia, GL | 1 |
| Borroni, G | 1 |
| Li, G | 3 |
| Sun, HL | 1 |
| Cheng, C | 2 |
| Liu, ZM | 3 |
| Xi, SL | 2 |
| Hoeger, P | 1 |
| Posiunas, G | 1 |
| Phillips, RJ | 4 |
| Caceres, H | 1 |
| Ballona, R | 1 |
| Friedlander, SF | 2 |
| Perek, D | 1 |
| Metz, B | 1 |
| Szalai, ZZ | 1 |
| Krol, A | 2 |
| Foelster-Holst, R | 2 |
| Febrer Bosch, MI | 1 |
| Su, J | 2 |
| Buckova, H | 1 |
| Cambazard, F | 1 |
| Grantzow, R | 1 |
| Roessler, J | 1 |
| Valencia, AM | 1 |
| Glick, S | 1 |
| Birchall, N | 1 |
| Benjamin, L | 1 |
| Vabres, P | 3 |
| Souteyrand, P | 1 |
| Berul, CI | 1 |
| Mehta, CR | 1 |
| Morgan, CC | 1 |
| Heritier, S | 1 |
| Pan, WK | 1 |
| Li, P | 3 |
| Guo, ZT | 1 |
| Huang, Q | 1 |
| Gao, Y | 2 |
| Porcel Chacón, R | 1 |
| del Boz González, J | 1 |
| Navarro Morón, J | 1 |
| Chen, ZG | 1 |
| Yuan, ML | 1 |
| Okuno, T | 1 |
| Tokuriki, S | 1 |
| Yoshino, T | 1 |
| Tanaka, N | 1 |
| Ohshima, Y | 1 |
| Guo, Z | 2 |
| Pan, W | 2 |
| You, HS | 1 |
| Kim, BS | 1 |
| Kim, MB | 1 |
| Ko, HC | 1 |
| Horev, A | 2 |
| Haim, A | 2 |
| Aly, MM | 1 |
| Hamza, AF | 1 |
| Abdel Kader, HM | 1 |
| Saafan, HA | 1 |
| Ghazy, MS | 1 |
| Rodríguez-Ruiz, M | 1 |
| Tellado, MG | 1 |
| del Pozo Losada, J | 1 |
| Bonnet, D | 1 |
| Boon, LM | 2 |
| Ciofi Degli Atti, M | 1 |
| Oranje, AP | 4 |
| Rubin, AT | 1 |
| Siegel, B | 1 |
| Mehta, D | 2 |
| Lockman, JL | 1 |
| Schwartz, AJ | 1 |
| Ames, JA | 1 |
| Sykes, JM | 1 |
| Baena-Gómez, MA | 1 |
| Priego Ruiz, MP | 1 |
| Mateos González, E | 1 |
| Peña Rosa, MJ | 1 |
| Muñoz Sánchez, R | 1 |
| Elluru, RG | 1 |
| Friess, MR | 1 |
| Moore, N | 3 |
| Padys, P | 1 |
| Fouque, L | 1 |
| Le Duff, M | 1 |
| D'Hervé, D | 1 |
| Poulain, P | 1 |
| Dave, T | 1 |
| Dave, VP | 1 |
| Shah, G | 1 |
| Pappuru, RR | 1 |
| Tozzi, A | 1 |
| Jianguo, K | 1 |
| Xichun, W | 1 |
| Mingkun, Z | 1 |
| Qiaoling, C | 1 |
| Wenjin, L | 1 |
| Patel, KG | 1 |
| El Rassi, E | 1 |
| MacArthur, CJ | 2 |
| Zhu, JY | 1 |
| Ren, JG | 1 |
| Chen, G | 1 |
| Zhao, YF | 1 |
| Reinhardt, D | 1 |
| Qu, X | 1 |
| Moodley, ST | 1 |
| Hudson, DA | 1 |
| Adams, KG | 1 |
| Tran, C | 1 |
| Tamburro, J | 2 |
| Rhee, A | 1 |
| Golden, A | 2 |
| Gong, H | 2 |
| Li, YX | 1 |
| Vergine, G | 2 |
| Sorci, M | 1 |
| Rosafio, C | 1 |
| Bigucci, B | 1 |
| Filippini, B | 1 |
| Ancora, G | 1 |
| Yang, B | 1 |
| Zhang, LX | 1 |
| Sun, YJ | 1 |
| Wedgeworth, E | 1 |
| Irvine, AD | 1 |
| Clayton, TH | 1 |
| Bjerre, JV | 1 |
| Burrows, NP | 1 |
| Hedelund, L | 1 |
| Audrain, H | 1 |
| Bhate, K | 1 |
| Brown, SJ | 1 |
| Baryschpolec, S | 1 |
| Darne, S | 1 |
| Durack, A | 1 |
| Dvorakova, V | 1 |
| Gach, J | 1 |
| Goldstraw, N | 1 |
| Goodyear, H | 1 |
| Grabczynska, S | 1 |
| Greenblatt, D | 1 |
| Halpern, J | 1 |
| Hearn, RM | 1 |
| Hughes, B | 1 |
| Jayaraj, R | 1 |
| Johansson, EK | 1 |
| Lam, M | 1 |
| Leech, S | 1 |
| O'Regan, GM | 1 |
| Morrison, D | 1 |
| Porter, W | 1 |
| Ramesh, R | 1 |
| Taylor, AE | 1 |
| Thomson, J | 1 |
| Tiffin, P | 1 |
| Tsakok, M | 1 |
| McPherson, T | 1 |
| Patrizi, A | 2 |
| Ravenscroft, JC | 1 |
| Svensson, A | 1 |
| Wahlgren, CF | 1 |
| Méchineaud, M | 1 |
| Nicaise, D | 1 |
| Martin, L | 1 |
| Gangopadhyay, AN | 1 |
| Gupta, DK | 1 |
| Gribaa, R | 1 |
| Slim, M | 1 |
| Neffati, E | 1 |
| Boughzela, E | 1 |
| Munabi, NC | 1 |
| Edwards, AK | 1 |
| Kitajewski, AA | 1 |
| Tan, QK | 1 |
| Weinstein, A | 1 |
| Kung, JE | 1 |
| Wilcox, M | 1 |
| Elbert, NJ | 1 |
| Liem, YT | 1 |
| Yujuan, T | 1 |
| Shaoquan, C | 2 |
| Zaizhong, Z | 2 |
| Shuming, C | 2 |
| Guoliang, H | 1 |
| Lie, W | 2 |
| MacIsaac, ZM | 1 |
| Nayar, HS | 1 |
| Gehris, R | 1 |
| Geisler, S | 1 |
| Grunwaldt, LJ | 1 |
| Yu, W | 1 |
| Zaher, H | 1 |
| Rasheed, H | 1 |
| El-Komy, MM | 1 |
| Hegazy, RA | 2 |
| Gawdat, HI | 1 |
| Abdel Halim, DM | 1 |
| Abdel Hay, RM | 1 |
| Mohy, AM | 1 |
| Chinnadurai, S | 1 |
| Fonnesbeck, C | 1 |
| Snyder, KM | 1 |
| Sathe, NA | 1 |
| Morad, A | 1 |
| Likis, FE | 1 |
| McPheeters, ML | 1 |
| Krstulovic, C | 1 |
| Ibañez-Alcañiz, I | 1 |
| Alamar-Velázquez, A | 1 |
| López-Andreu, J | 1 |
| Evoli-Buselli, M | 1 |
| Neckman, JP | 1 |
| Ge, J | 1 |
| Zhao, H | 1 |
| Seidmann, L | 1 |
| Anspach, L | 1 |
| Roth, W | 1 |
| Techasatian, L | 1 |
| Komwilaisak, P | 1 |
| Panombualert, S | 1 |
| Uppala, R | 1 |
| Jetsrisuparb, C | 1 |
| Laken, PA | 1 |
| Hu, L | 1 |
| Zhou, B | 1 |
| Shah, SD | 1 |
| McCuaig, C | 2 |
| Coulie, J | 1 |
| Haggstrom, AN | 1 |
| Newell, BD | 1 |
| García-Romero, MT | 1 |
| Grimes, B | 1 |
| Shao, RZ | 1 |
| Zhao, DH | 1 |
| Dementieva, N | 1 |
| Jones, S | 1 |
| Nozawa, A | 1 |
| Hori, T | 1 |
| Kanda, K | 1 |
| Kimura, T | 1 |
| Kawamoto, N | 1 |
| Chengjin, L | 1 |
| Yin, X | 1 |
| Chen, L | 1 |
| Qingjin, H | 1 |
| Tai, MZ | 2 |
| Liu, XJ | 3 |
| Ge, CX | 2 |
| Kang, E | 1 |
| Friedman, N | 1 |
| Mamoun, I | 1 |
| Yi, LF | 1 |
| Wen, HX | 1 |
| Qiu, M | 1 |
| Zhang, JY | 1 |
| Cao, XX | 1 |
| Oak, CY | 1 |
| Jun, CH | 1 |
| Cho, EA | 1 |
| Lee, DH | 1 |
| Cho, SB | 1 |
| Park, CH | 1 |
| Joo, YE | 1 |
| Rew, JS | 1 |
| Choi, SK | 1 |
| Szemraj, J | 1 |
| Chrzanowska, B | 1 |
| Robertson, SA | 1 |
| Kimble, RM | 1 |
| Storey, KJ | 1 |
| Gee Kee, EL | 1 |
| Stockton, KA | 1 |
| Jin, L | 1 |
| Torres, E | 1 |
| Rosa, J | 1 |
| Soares-de-Almeida, L | 1 |
| Danchin, M | 1 |
| Boyce, SL | 1 |
| Phuong, L | 1 |
| Cooper, E | 1 |
| Vidmar, S | 1 |
| Stringari, G | 1 |
| Barbato, G | 1 |
| Zanzucchi, M | 1 |
| Marchesi, M | 1 |
| Tchana, B | 1 |
| Gritti, A | 1 |
| Lombardi, AA | 1 |
| Carano, N | 1 |
| Streicher, JL | 1 |
| Riley, EB | 1 |
| Castelo-Soccio, LA | 1 |
| Sirachainan, N | 1 |
| Lekanan, W | 1 |
| Thammagasorn, Y | 1 |
| Wanitkun, S | 1 |
| Kadegasem, P | 1 |
| Chunharas, A | 1 |
| Castaneda, S | 1 |
| Melendez-Lopez, S | 1 |
| Garcia, E | 1 |
| De la Cruz, H | 1 |
| Sanchez-Palacio, J | 1 |
| Furuta, S | 1 |
| Sato, H | 1 |
| Tsuji, S | 1 |
| Murakami, F | 1 |
| Kitagawa, H | 1 |
| Lucky, A | 1 |
| Feigenbaum, D | 1 |
| Savva, Y | 1 |
| Holland, K | 1 |
| Drolet, B | 1 |
| Morel, KD | 1 |
| Yang, L | 1 |
| Rocco, P | 1 |
| Franzè, S | 1 |
| Yang, TB | 1 |
| McMahon, P | 1 |
| De Léon, DD | 1 |
| Yarbrough, KB | 1 |
| Krol, AL | 1 |
| Leitenberger, SL | 1 |
| Mann, JA | 1 |
| Cheng, CE | 1 |
| Fan, XD | 3 |
| Yang, YW | 2 |
| Zhao, JH | 2 |
| Wang, XY | 2 |
| Zhou, DK | 2 |
| Erdoğan, İ | 1 |
| Degrugillier-Chopinet, C | 1 |
| Ortis, V | 1 |
| Lafon, M | 1 |
| Montagne, A | 1 |
| Slaughter, KA | 1 |
| Williams, E | 1 |
| Hardison, S | 1 |
| Wan, W | 1 |
| Dodson, KM | 1 |
| Salice, P | 1 |
| Giovanni Bianchetti, M | 1 |
| Giavarini, A | 1 |
| Gondoni, E | 1 |
| Maria Colli, A | 1 |
| Lombardi, F | 1 |
| Grönemeyer, LL | 1 |
| Haenssle, HA | 1 |
| Zutt, M | 3 |
| von Fintel, H | 1 |
| Petrovic, J | 1 |
| Trifunovic, B | 1 |
| Vukomanovic, G | 1 |
| Topalovic, M | 1 |
| Trajkovic, G | 1 |
| Parezanović, V | 1 |
| Lanciotti, S | 1 |
| Sapio, M | 1 |
| Ferrara, E | 1 |
| De Grazia, A | 1 |
| Clerico, A | 1 |
| He, A | 1 |
| Khanna, R | 1 |
| Kwatra, SG | 1 |
| Li, D | 1 |
| Grech, V | 1 |
| Scerri, C | 1 |
| Spillekom-van Koulil, S | 1 |
| Yu, X | 1 |
| Liu, M | 1 |
| Chen, R | 1 |
| Crock, CM | 2 |
| Penington, AJ | 2 |
| Bekhor, PS | 2 |
| Piccolo, V | 2 |
| Moscarella, E | 1 |
| Ametrano, O | 1 |
| Picciocchi, R | 1 |
| Russo, T | 2 |
| Mei-Zahav, M | 1 |
| Blau, H | 1 |
| Hoshen, M | 1 |
| Mussaffi, H | 1 |
| Prais, D | 1 |
| Stafler, P | 1 |
| Steuer, G | 1 |
| Amitai, DB | 1 |
| Jiang, CH | 2 |
| Lei, SR | 1 |
| Matsuura, T | 1 |
| Kadono, T | 1 |
| Koizumi, H | 1 |
| Kawakami, T | 1 |
| Soma, Y | 1 |
| Boyvat, F | 1 |
| Demir, Ş | 1 |
| Özçay, F | 1 |
| Uslu, N | 1 |
| Fraser, K | 1 |
| Theletsane, T | 1 |
| Redfern, A | 1 |
| Raynham, O | 1 |
| Harris, T | 1 |
| Prose, NS | 1 |
| Khumalo, NP | 1 |
| Denoyelle, F | 4 |
| Leboulanger, N | 3 |
| Enjolras, O | 1 |
| Harris, R | 1 |
| Roger, G | 2 |
| Garabedian, EN | 4 |
| Pérez, RS | 1 |
| Mora, PC | 1 |
| Rodríguez, JD | 1 |
| Sánchez, FR | 1 |
| de Torres, Jde L | 1 |
| Buckmiller, L | 2 |
| Dyamenahalli, U | 2 |
| Sans, V | 1 |
| de la Roque, ED | 1 |
| Berge, J | 1 |
| Grenier, N | 2 |
| Lipsker, D | 1 |
| Dupuis, E | 1 |
| Vergnes, P | 1 |
| Eivazi, B | 3 |
| Teymoortash, A | 2 |
| Stiller, S | 1 |
| Werner, JA | 3 |
| Mousa, W | 1 |
| Kues, K | 1 |
| Haas, E | 1 |
| Lauerer, P | 2 |
| Pavlakovic, H | 2 |
| Jephson, CG | 2 |
| Syed, S | 1 |
| Mills, NA | 1 |
| Hartley, BE | 2 |
| Buckmiller, LM | 3 |
| Löffler, H | 1 |
| Kosel, C | 1 |
| Kachel, W | 1 |
| Michel, JL | 1 |
| Patural, H | 1 |
| Holmes, WJM | 3 |
| Gorst, C | 5 |
| Liew, SH | 4 |
| Naouri, M | 3 |
| Lorette, G | 2 |
| Maturo, S | 1 |
| Hartnick, C | 1 |
| Truong, MT | 2 |
| Chang, KW | 2 |
| Berk, DR | 1 |
| Heerema-McKenney, A | 1 |
| Bruckner, AL | 1 |
| Munson, PD | 1 |
| Dai, Y | 2 |
| Zimmermann, AP | 1 |
| Wiegand, S | 2 |
| Fay, A | 1 |
| Nguyen, J | 1 |
| Jakobiec, FA | 1 |
| Meyer-Junghaenel, L | 1 |
| Zhou, Q | 1 |
| Yang, XJ | 1 |
| Sans-Martin, V | 1 |
| Akhavan, A | 1 |
| Zippin, JH | 1 |
| Baetz, J | 1 |
| Eigelshoven, S | 1 |
| Marquard, J | 1 |
| Bruch-Gerharz, D | 1 |
| Homey, B | 1 |
| Meissner, T | 1 |
| Bross, F | 1 |
| Mistry, N | 1 |
| Tzifa, K | 1 |
| Vanlander, A | 1 |
| Decaluwe, W | 1 |
| Vandelanotte, M | 1 |
| Van Geet, C | 1 |
| Cornette, L | 1 |
| Fölster-Holst, R | 1 |
| Storch, CH | 1 |
| Benlahrech, S | 1 |
| Ammour, A | 1 |
| Broue, P | 1 |
| Vial, J | 1 |
| Ohanessian, G | 1 |
| Labenne, M | 1 |
| Li, YC | 1 |
| McCahon, E | 1 |
| Rowe, NA | 1 |
| Martin, PA | 1 |
| Wilcsek, GA | 1 |
| Martin, FJ | 1 |
| Frasin, A | 1 |
| Restano, L | 1 |
| Cheng, JF | 1 |
| Gole, GA | 1 |
| Sullivan, TJ | 1 |
| Blanchet, C | 1 |
| Nicollas, R | 2 |
| Bigorre, M | 1 |
| Amedro, P | 1 |
| Mondain, M | 2 |
| Schwartz, RA | 1 |
| Sidor, MI | 1 |
| Musumeci, ML | 1 |
| Lin, RL | 1 |
| Micali, G | 1 |
| Eikenberry, J | 1 |
| Haggstrom, A | 2 |
| Itinteang, T | 4 |
| Meyer, L | 1 |
| Graffstaedt, H | 1 |
| Giest, H | 1 |
| Truebenbach, J | 1 |
| Holland, KE | 2 |
| Frommelt, PC | 2 |
| Wyatt, D | 1 |
| Suh, KY | 1 |
| Meyer, AK | 2 |
| Maguiness, SM | 1 |
| Messner, AH | 1 |
| Fusilli, G | 1 |
| Merico, G | 1 |
| Gurrado, R | 1 |
| Rosa, T | 1 |
| Acquafredda, A | 1 |
| Cavallo, L | 1 |
| Holmes, WJ | 1 |
| Fayoux, P | 1 |
| Teissier, N | 1 |
| Cox, A | 2 |
| Van Den Abbeele, T | 1 |
| Carrabin, L | 1 |
| Couloigner, V | 1 |
| Triglia, JM | 1 |
| Ayari, S | 1 |
| Froehlich, P | 2 |
| Lescanne, E | 1 |
| Marianowski, R | 1 |
| Mom, T | 1 |
| Marie, JP | 1 |
| Arneja, JS | 1 |
| Pappas, PN | 1 |
| Shwayder, TA | 1 |
| Cullen, ML | 1 |
| Becker, CJ | 1 |
| Hamzavi, FH | 1 |
| Roarty, JD | 1 |
| Madgy, DN | 1 |
| Baker, JD | 1 |
| Canadas, KT | 1 |
| Baum, ED | 1 |
| Lee, S | 1 |
| Ostrower, ST | 1 |
| Brasch, HD | 1 |
| Day, DJ | 1 |
| Fretheim, A | 1 |
| Guldbakke, KK | 1 |
| Rørdam, OM | 1 |
| Huldt-Nystrøm, T | 1 |
| Hanssen, HK | 1 |
| Høivik, F | 1 |
| Ho, KM | 1 |
| Chik, KK | 1 |
| Luk, CK | 1 |
| Chan, HB | 1 |
| Tan, HY | 1 |
| Schiestl, C | 1 |
| Zoller, S | 1 |
| Subotic, U | 1 |
| Forster-Kuebler, I | 1 |
| Michels, R | 1 |
| Balmer, C | 1 |
| Krause, H | 1 |
| Haß, HJ | 1 |
| Kroker, S | 1 |
| Meyer, F | 1 |
| Halloul, Z | 1 |
| Wagemann, W | 1 |
| O'Loughlin, A | 1 |
| Watson, R | 1 |
| Kietz, S | 1 |
| Lakomek, M | 1 |
| Muthamilselvan, S | 1 |
| Vinoth, PN | 1 |
| Vilvanathan, V | 1 |
| Ninan, B | 1 |
| Amboiram, P | 1 |
| Sai, V | 1 |
| Anand, V | 1 |
| Scott, JX | 1 |
| Mangold, C | 1 |
| Guye, E | 1 |
| Chollet-Rivier, M | 1 |
| Schröder, D | 1 |
| Sandu, K | 1 |
| Hohlfeld, J | 2 |
| de Buys Roessingh, A | 2 |
| Cuccaro, P | 1 |
| Rapacciuolo, A | 1 |
| Vitiello, R | 1 |
| di Pietro, E | 1 |
| Montaldo, P | 1 |
| Esposito, F | 1 |
| Maresca, G | 1 |
| Correra, A | 1 |
| Bonanno, C | 1 |
| Paccanaro, M | 1 |
| Fontanellilea, A | 1 |
| Freshwater, MF | 1 |
| Peridis, S | 1 |
| Pilgrim, G | 1 |
| Athanasopoulos, I | 1 |
| Parpounas, K | 1 |
| Morais, P | 1 |
| Magina, S | 1 |
| Mateus, M | 1 |
| Trindade, E | 1 |
| Jesus, JM | 1 |
| Azevedo, F | 1 |
| Hermans, DJ | 3 |
| van Beynum, IM | 3 |
| Schultze Kool, LJ | 1 |
| van de Kerkhof, PC | 1 |
| Wijnen, MH | 2 |
| van der Vleuten, CJ | 4 |
| Bodak, N | 1 |
| Hamel-Teillac, D | 1 |
| Kupfer-Bessaguet, I | 1 |
| Nguyen, JM | 1 |
| Shayan, YR | 1 |
| Prendiville, JS | 1 |
| Goldman, RD | 1 |
| Holmes, W | 1 |
| Liew, S | 2 |
| Martínez-Escanamé, M | 1 |
| Castillo-Martínez, C | 1 |
| Torres-Álvarez, B | 1 |
| González, FJ | 1 |
| Oros-Valle, C | 1 |
| Moncada, B | 1 |
| Boucek, RJ | 2 |
| Sidbury, R | 2 |
| Kim, LHC | 1 |
| Hogeling, M | 2 |
| Jiwane, A | 1 |
| Pereyra-Rodríguez, JJ | 1 |
| Mantrana-Bermejo, ME | 1 |
| Fernández-Pineda, I | 1 |
| de Agustín, JC | 1 |
| Conejo-Mir, J | 1 |
| Morrell, DS | 1 |
| Buck, S | 1 |
| Zdanski, C | 1 |
| Gold, S | 1 |
| Stavas, J | 1 |
| Powell, C | 1 |
| Burkhart, CN | 1 |
| Schöni, MH | 1 |
| Kernland Lang, K | 1 |
| Fuchsmann, C | 1 |
| Quintal, MC | 1 |
| Giguere, C | 1 |
| Ayari-Khalfallah, S | 1 |
| McCone, C | 1 |
| Sierpina, DI | 1 |
| Chaudhary, HM | 1 |
| Walner, DL | 1 |
| Aljadeff, G | 1 |
| Dubrow, IW | 1 |
| Ghosh, PS | 1 |
| Ghosh, D | 1 |
| Vos, M | 1 |
| Restrepo, R | 1 |
| Palani, R | 1 |
| Cervantes, LF | 1 |
| Duarte, AM | 2 |
| Amjad, I | 1 |
| Altman, NR | 1 |
| Starkey, E | 1 |
| Azzopardi, S | 1 |
| Wright, TC | 1 |
| Chun, YH | 1 |
| Moon, CJ | 1 |
| Yoon, JS | 1 |
| Kim, HH | 1 |
| Kim, JT | 1 |
| Lee, JS | 1 |
| Zide, BM | 1 |
| Levine, SM | 1 |
| Greenhill, NB | 1 |
| Deacon, GB | 1 |
| Zhan, MK | 1 |
| Xie, YD | 1 |
| Guo, ZH | 1 |
| Huang, BR | 1 |
| Zhou, YK | 1 |
| Chen, XS | 1 |
| Yang, YC | 1 |
| Jin, YB | 1 |
| Lin, XX | 1 |
| Ye, XX | 1 |
| Da, C | 1 |
| Chen, XD | 1 |
| Hu, XJ | 1 |
| Zhao, ZF | 2 |
| Fu, HB | 2 |
| Wui, JC | 1 |
| Lin, LL | 1 |
| Price, CJ | 1 |
| Lattouf, C | 1 |
| Baum, B | 1 |
| McLeod, M | 1 |
| Schachner, LA | 1 |
| Connelly, EA | 1 |
| Goswamy, J | 1 |
| Rothera, MP | 1 |
| Bruce, IA | 1 |
| Mabeta, P | 1 |
| Pepper, MS | 1 |
| Javia, LR | 1 |
| Zur, KB | 1 |
| Jacobs, IN | 1 |
| Raol, N | 1 |
| Edmonds, J | 1 |
| Chandy, B | 1 |
| Sulek, M | 1 |
| Larrier, D | 1 |
| Arevalo, JF | 1 |
| Arias, JD | 1 |
| Serrano, MA | 1 |
| Ottenhof, MJ | 1 |
| Bähr, A | 1 |
| Truckenmüller, W | 1 |
| Noellke, P | 1 |
| Niemeyer, CM | 1 |
| Solomon, T | 1 |
| Ninnis, J | 1 |
| Deming, D | 1 |
| Merritt, TA | 1 |
| Hopper, A | 1 |
| Menezes, MD | 1 |
| McCarter, R | 1 |
| El-Shabrawi, M | 1 |
| Hassanin, F | 1 |
| Fan, ZN | 1 |
| Zhao, WJ | 1 |
| Wang, YM | 1 |
| Wei, FC | 1 |
| Dyme, JL | 1 |
| Thampan, A | 1 |
| Han, EJ | 1 |
| Nyirenda, TL | 1 |
| Kotb, ME | 1 |
| Shin, HT | 1 |
| Lu, J | 1 |
| Qin, G | 1 |
| Zhao, J | 1 |
| Xiang, Y | 1 |
| Zuo, C | 1 |
| Yang, S | 1 |
| Tna, L | 1 |
| Shepherd, D | 1 |
| Jaffe, A | 1 |
| Nunn, A | 1 |
| Shah, U | 1 |
| Ford, J | 1 |
| Madern, GC | 2 |
| Nieuwenhuis, K | 1 |
| de Laat, PC | 2 |
| Kleber, CJ | 1 |
| Spiess, A | 1 |
| Kleber, JB | 1 |
| Hinz, U | 1 |
| Holland-Cunz, S | 1 |
| Weiss, J | 1 |
| Bosemani, T | 1 |
| Huisman, TA | 1 |
| Tekes, A | 1 |
| Constantinides, J | 1 |
| Prowse, P | 1 |
| Didi, MA | 1 |
| Mahadevan, M | 1 |
| Cheng, A | 1 |
| Barber, C | 1 |
| Halilbasic, A | 1 |
| Hotic, N | 1 |
| Husaric, E | 1 |
| Rahmanovic, E | 1 |
| Halilbasic, M | 1 |
| Husaric, S | 1 |
| Fischer, CJ | 1 |
| Giannoni, E | 1 |
| Truttmann, AC | 1 |
| Tolsa, JF | 1 |
| Chevallay, M | 1 |
| El Ezzi, O | 1 |
| Seneggen, E | 1 |
| Pauchard, JY | 1 |
| Gehri, M | 1 |
| Hauschild, M | 1 |
| Küpeli, S | 1 |
| Lv, MM | 1 |
| Su, LX | 1 |
| Hou, F | 1 |
| Fan, CY | 1 |
| Saad, A | 1 |
| Suen, J | 1 |
| Thayal, PK | 1 |
| Bhandari, PS | 1 |
| Sarin, YK | 1 |
| Talaat, AA | 1 |
| Elbasiouny, MS | 1 |
| Elgendy, DS | 1 |
| Elwakil, TF | 1 |
| Hsu, TC | 1 |
| Wang, JD | 1 |
| Chen, CH | 1 |
| Chang, TK | 1 |
| Wang, TM | 1 |
| Chou, CM | 1 |
| Lin, HK | 1 |
| Prashanth, GP | 1 |
| Vigone, MC | 1 |
| Cortinovis, F | 1 |
| Rabbiosi, S | 1 |
| Di Frenna, M | 1 |
| Passoni, A | 1 |
| Persani, L | 1 |
| Chiumello, G | 1 |
| Weber, G | 1 |
| Armijo, BS | 1 |
| Miller, E | 1 |
| Gliniak, C | 1 |
| Serret, MA | 1 |
| Gosain, AK | 1 |
| Hartzell, LD | 1 |
| Chiu, YE | 2 |
| Carcao, M | 1 |
| Fangusaro, J | 1 |
| Kelly, ME | 1 |
| Lofgren, S | 1 |
| Metry, DW | 1 |
| Recht, M | 1 |
| Silverman, RA | 1 |
| Tom, WL | 1 |
| Bingham, MM | 1 |
| Vo, NJ | 1 |
| Spinks, J | 1 |
| Chakkittakandiyil, A | 1 |
| Lara-Corrales, I | 1 |
| Maki, E | 1 |
| Weinstein, M | 1 |
| Celik, A | 1 |
| Tiryaki, S | 1 |
| Musayev, A | 1 |
| Kismali, E | 1 |
| Levent, E | 1 |
| Ergun, O | 1 |
| Dorresteijn, EM | 1 |
| Jan Danser, AH | 1 |
| Georgountzou, A | 1 |
| Karavitakis, E | 1 |
| Klimentopoulou, A | 1 |
| Xaidara, A | 1 |
| Kakourou, T | 1 |
| Zweegers, J | 2 |
| Durr, ML | 1 |
| Tan, M | 1 |
| Duan, B | 1 |
| Zhou, CM | 1 |
| Murthy, GJ | 1 |
| Goswami, M | 1 |
| Marsciani, A | 1 |
| Pedini, A | 1 |
| Brocchi, S | 1 |
| Marsciani, M | 1 |
| Desiderio, E | 1 |
| Bertelli, S | 1 |
| Vecchi, V | 1 |
| Katona, G | 1 |
| Csákányi, Z | 1 |
| Gács, E | 1 |
| Szalai, Z | 1 |
| Ráth, G | 1 |
| Gerlinger, I | 1 |
| Salminen, P | 1 |
| Vuola, P | 1 |
| Overmark, M | 1 |
| Lindahl, P | 1 |
| Kalajoki-Helmiö, T | 1 |
| Pitkäranta, A | 1 |
| Loizzi, M | 1 |
| De Palma, A | 1 |
| Pagliarulo, V | 1 |
| Quaranta, N | 1 |
| Tang, LX | 1 |
| Zhang, YM | 1 |
| Wang, GX | 1 |
| Izadpanah, A | 2 |
| Kanevsky, J | 1 |
| Belzile, E | 1 |
| Schwarz, K | 1 |
| Baranowski, S | 1 |
| Winkler, A | 1 |
| Kunzi-Rapp, K | 1 |
| Schaal, M | 1 |
| Hempel, S | 1 |
| Debatin, KM | 1 |
| Posovszky, C | 1 |
| Babajee, K | 1 |
| Hu, X | 1 |
| Xie, H | 1 |
| Hasan, M | 1 |
| Rahman, M | 1 |
| Hoque, S | 1 |
| Zahid Hossain, AK | 1 |
| Khondker, L | 1 |
| Liberman, L | 1 |
| MacLellan-Tobert, S | 1 |
| Seefeldt, M | 2 |
| Ward, KM | 1 |
| Cassidy, L | 1 |
| Joachim, S | 1 |
| Kwon, EK | 2 |
| Martin, K | 1 |
| Perkins, J | 1 |
| Xia, Y | 1 |
| Zhai, Y | 1 |
| Li, C | 1 |
| Yeom, KB | 1 |
| Choi, JW | 1 |
| Shin, H | 1 |
| Bauland, CG | 1 |
| Jin, ZL | 1 |
| Wei, JJ | 1 |
| Liu, ZY | 1 |
| Dumas de la Roque, E | 1 |
| Nacka, F | 1 |
| Abouelfath, A | 1 |
| Rebola, M | 1 |
| Uzunaslan, D | 1 |
| Saygin, C | 1 |
| Gungor, S | 1 |
| Hasiloglu, Z | 1 |
| Ozdemir, N | 1 |
| Celkan, T | 1 |
| Xiao, Y | 1 |
| Huang, Y | 1 |
| Liu, J | 1 |
| Lin, J | 1 |
| Bajaj, Y | 1 |
| Kapoor, K | 1 |
| Ifeacho, S | 1 |
| Albert, DM | 1 |
| Liu, L | 1 |
| Wang, G | 1 |
| Gao, T | 1 |
| Bianchi, A | 1 |
| Daniel, RH | 1 |
| Hubler, WR | 1 |
| Wolf, JE | 1 |
| Holder, WR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma[NCT01908972] | Phase 4 | 34 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Sirolimus in the Treatment for Propranolol-resistant Infantile Hepatic Hemangioendothelioma[NCT04406870] | Phase 4 | 36 participants (Anticipated) | Interventional | 2020-07-31 | Not yet recruiting | ||
| Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma[NCT02342275] | Phase 3 | 377 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Propranolol vs Prednisolone for Infant Hemangiomas-A Clinical and Molecular Study[NCT00967226] | Phase 2 | 19 participants (Actual) | Interventional | 2009-07-31 | Terminated (stopped due to Serious adverse events with prednisolone, primarily temporary growth retardation, <5th percentile.) | ||
| Natural Berry Extract Treatment of Hemangiomas[NCT04020419] | Early Phase 1 | 12 participants (Actual) | Interventional | 2020-12-01 | Terminated (stopped due to Study ending early due to program transferring to another site.) | ||
| A Randomised, Controlled, Multidose, Multicentre, Adaptive Phase II/III Study in Infants With Proliferating Infantile Hemangiomas (IHs) Requiring Systemic Therapy to Compare 4 Regimens of Propranolol (1 or 3 mg/kg/Day for 3 or 6 Months) to Placebo (Double[NCT01056341] | Phase 2/Phase 3 | 512 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Influence of Systemic Propranolol Treatment on the Physical Development of Paediatric Patients With Infantile Hemangiomas[NCT04651049] | 128 participants (Actual) | Observational | 2010-07-15 | Completed | |||
| "'' Efficacy of Propranolol in the Treatment of Infantile Hemangioma"[NCT04684667] | Phase 2 | 100 participants (Anticipated) | Interventional | 2021-01-01 | Not yet recruiting | ||
| A Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Proliferative and Involuting Cutaneous Infantile Hemangioma[NCT01072045] | Phase 2 | 50 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations[NCT02335242] | Phase 2 | 22 participants (Actual) | Interventional | 2015-05-23 | Completed | ||
| The Efficacy of Timolol 0.5% Gel Forming Solution for the Treatment of Ulcerated Hemangiomas[NCT01408056] | Phase 2 | 0 participants (Actual) | Interventional | 2011-02-28 | Withdrawn (stopped due to Difficulty with recruitment) | ||
| Propanolol Effect on Red Cell Adhesion in Non-Asthmatic Children With Sickle Cell Disease: A Dose Finding Study[NCT02012777] | Phase 1 | 9 participants (Actual) | Interventional | 2010-06-30 | Terminated (stopped due to Inability to recruit patients into the study.) | ||
| Open-label, Uncontrolled Study of the Off Label Use of Propranolol for Infancy Hemangiomas to Identify Side Effects[NCT01211080] | 72 participants (Actual) | Observational | 2008-08-31 | Completed | |||
| A Phase II, Randomized, Double-Blind Comparison of Corticosteroid and Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)[NCT01074437] | Phase 2 | 9 participants (Actual) | Interventional | 2010-02-28 | Terminated (stopped due to Insufficient enrollment) | ||
| Role of Propranolol as Compared to Bleomycin in Management of Hemangioma[NCT05327309] | 90 participants (Actual) | Interventional | 2015-05-08 | Completed | |||
| Propanolol for Primary Prophylaxis for Variceal Bleed in Biliary Atresia - An Open Label Randomized Controlled Study[NCT04494763] | 92 participants (Anticipated) | Interventional | 2020-08-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of Participants in Which, facial edema occurs, Anytime During the 16 Weeks.. (NCT01908972)
Timeframe: up to 16weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 5 |
| Propranolol | 0 |
Number of Participants in Which, Glucose levels fall (to <50mg/dl), Anytime During the 16 Weeks.. (NCT01908972)
Timeframe: up to 16weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 0 |
| Propranolol | 0 |
Number of Participants in which, the Heart rate fell to <70% of acceptable age related minimum post-dose with child awake, anytime during the 16 weeks Count of patients whose Heart rate fall to <70% of acceptable age related minimum post-dose with child awake (NCT01908972)
Timeframe: up to 16weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 1 |
| Propranolol | 5 |
Number of Participants in Which, the Systolic blood pressure fall of >25% of baseline postdose with child awake, Anytime During the 16 Weeks.. (NCT01908972)
Timeframe: up to 16weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 1 |
| Propranolol | 5 |
All symptoms associated adverse drug reaction will be checked (NCT01908972)
Timeframe: up to 16weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 15 |
| Propranolol | 16 |
The primary efficacy variable was the clinical response at 16 weeks, classified as follows: when the volume did not increase or decreased by less than 25% after treatment began, we defined it as stop of progression; when the volume decreased by 25% or more compared with the original size, we defined it as regression. Both stop of progression and regressionwere defined as reaction. If the volume at the primary efficacy evaluation point was greater than the size measured when treatment started,we called it an increase. Increase was defined as a nonreaction. (NCT01908972)
Timeframe: After 16weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 14 |
| Propranolol | 16 |
We checked Number of participants with Drug compliance within 16 weeks (NCT01908972)
Timeframe: After 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 15 |
| Propranolol | 17 |
Number of Participants With Gastroesophageal reflux within 16 weeks.. (NCT01908972)
Timeframe: up to 16weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 0 |
| Propranolol | 0 |
Number of Participants with Growth Retardation within 16 weeks.. (NCT01908972)
Timeframe: up to 16weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 2 |
| Propranolol | 0 |
Number of participants with Reepithelialzation in 16weeks.. (NCT01908972)
Timeframe: After 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 4 |
| Propranolol | 8 |
Number of participants whose hemangioma showed regression in 16 weeks. (NCT01908972)
Timeframe: Within 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 9 |
| Propranolol | 13 |
size was measure the horizontal and vertical size (2-dimension) of ulceration (from baseline to 16 weeks after medication) (NCT01908972)
Timeframe: After 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 2 |
| Propranolol | 1 |
Number of participants whose hemangioma stop proliferating in 16weeks (NCT01908972)
Timeframe: After 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisolone | 15 |
| Propranolol | 17 |
Percent Reduction in Hemangioma Volume from Baseline (measured by MRI or Sono (from basline to 16 weeks)) (NCT01908972)
Timeframe: After 16 weeks
| Intervention | % from baseline (Mean) |
|---|---|
| Prednisolone | 46.52 |
| Propranolol | 55.87 |
Participants were observed for any change in color. The possible change in colors included change to Red/Purple/Blue/Gray/Apricot. Reported are the number of participants who experienced a change in color by the type of color (NCT01908972)
Timeframe: After 16 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Red | Purple | |
| Prednisolone | 13 | 0 |
| Propranolol | 14 | 0 |
The complete healing time of the ulceration was defined as the time from the first dosage of propranolol or atenolol until complete healing of the hemangioma ulceration (assessed up to 6 months). Ulceration is defined as a break in the integrity of the hemangioma surface epithelium (or skin) with or without infection. The information included the extent of ulceration, complications of ulceration, prior duration of ulceration (before treatment), concurrent treatments, and complete healing time. Prior duration of ulceration was defined as the time from the first sign of ulceration until before β-blocker treatment. The complete healing time of the ulceration was defined as the time from the first dosage of propranolol or atenolol until complete healing of the hemangioma ulceration. Concurrent treatments, including oral pain medication, oral antibiotics, topical ointment antibiotics and/or wound dressings, were permitted to treat ulcerated IH and were recorded. (NCT02342275)
Timeframe: from the first dosage of propranolol or atenolol until complete healing ofthe hemangioma ulceration.
| Intervention | weeks (Mean) |
|---|---|
| Propranolol | 4.94 |
| Atenolol | 4.82 |
A complete/nearly complete response at week 96 was considered median-term efficacy. (NCT02342275)
Timeframe: 96 week
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 156 |
| Atenolol | 149 |
Regrowth of more than 20% in hemangioma appearance (including changes in color and/or volume) after stopping the medication was considered significant rebound. The inclusion criteria for rebound analysis were as follows: (1) patients who completed 6 months of treatment and (2) patients who discontinued therapy or were tapering treatment after achieving an any response. The exclusion criteria were as follows: (1) patients who were noncompliant with treatment and (2) patients who did not respond to treatment. Whether a patient had hemangioma rebound was based on the site investigators' assessments after the week 24 treatment. In patients with significant rebound, reinitiation of systemic therapy (either propranolol or atenolol) was recommended. Minor rebound, which was defined as those patients in whose rebound was noted but no reinitiation of systemic therapy or further treatment was necessary, was not included in the analysis. (NCT02342275)
Timeframe: between weeks 24 and 96
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 19 |
| Atenolol | 12 |
"A successful initial response was defined as a HAS score decrease at 1 week after treatment.~A successful initial response was assessed by using HAS in the intention-to-treat population. Previous studies demonstrated that HAS decreases over time after β-blocker treatment, with a dramatic drop occurring in the first week, indicating an immediate therapeutic response. HAS can reflect the rapid effect of β-blocker (either propranolol or atenolol) therapy shortly after initiation." (NCT02342275)
Timeframe: 1 week after treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 171 |
| Atenolol | 163 |
"Changes in IH size and color were classified as a complete response, nearly complete response, partial response or no response. The primary outcome measure was any response at 6 months in the intention-to-treat population of all patients who underwent randomization. The any response included compete, nearly complete and partial responses.~A complete response was defined as no redundant tissue or telangiectasia was identified.~A nearly complete response was defined as a minimal degree of telangiectasis, erythema and skin thickening.~A partial response was defined as a size reduction or change in color that did not meet the nearly complete resolution criteria." (NCT02342275)
Timeframe: 6 month
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 178 |
| Atenolol | 173 |
"HAS was measured at baseline and at 1, 4, 12, and 24 weeks, including the degree of deep swelling, the color of the hemangioma, and the ulceration assessment:~Assessment of the degree of swelling. It was scored as follows:~6 points if the swelling was tense;~4 points if the swelling was'neutral;~2 points when the swelling was reduced by 50% or more at follow-up; or~0 point when there was no more visible swelling at a follow-up.~Assessment of the color of the IH.~5 points if the hemangioma lesion was bright red all over;~3 points if the hemangioma lesion was matte red or reddish-purple;~1 point if the hemangioma lesion was totally or partially gray;~0 points if the hemangioma lesion was totally or partially skin-colored after involution.~(2) Assessment of the ulceration. -0.5 point for an ulcer ≤1.0 cm2;~One point for an ulcer >1.0 cm2 but <25 cm2;~Two points for an ulcer ≥25 cm2. The HAS score= (Swelling score + color score)/2 +Ulceration score." (NCT02342275)
Timeframe: Baseline and at 1, 4, 12, and 24 weeks
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 1 | Week 4 | Week 12 | Week 24 | |
| Atenolol | 4.54 | 3.47 | 2.33 | 1.54 | 0.82 |
| Propranolol | 4.61 | 3.31 | 2.42 | 1.54 | 0.82 |
Number of allergy/immunology AE per study arm (NCT00967226)
Timeframe: enrollment through study closeout or study withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Allergy/Immunology Events Propranolol | 1 |
| Allergy/Immunology Events Prednisolone | 1 |
Number of constitutional AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study close out or withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Constitutional AEs Propranolol | 2 |
| Constitutional AEs Prednisolone | 3 |
A priori primary outcome was proportional change in the total surface area as measured by lesion's outer margin length x width at baseline minus the same measure at 4 months with surrogate data used at 5 months if 4 months not available. (NCT00967226)
Timeframe: 4-5 months after initiating therapy
| Intervention | mm squared (Mean) |
|---|---|
| Propranolol | 0.57 |
| Prednisolone | 0.63 |
Number of Dermatologic Adverse Events in each study arm. (NCT00967226)
Timeframe: enrollment to study close out or withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Dermatologic AEs Propranolol | 2 |
| Dermatologic AEs Prednisolone | 1 |
Number of Endocrinologic AEs (of which adrenal crisis does not overlap). (NCT00967226)
Timeframe: enrollment to close out or study withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Endocrine AEs Propranolol | 0 |
| Endocrinologic AEs Prednisolone | 7 |
Number of Gastrointestinal AEs in each arm (NCT00967226)
Timeframe: enrollment to study withdrawal or study close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Gastrointestinal AEs Propranolol | 6 |
| Gastrointestinal AEs Prednisolone | 6 |
Number of Growth and Development AEs in each study arm (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Growth/Developoment AEs Propranolol | 0 |
| Growth/Development AEs Prednisolone | 1 |
Number of infectious AEs in each study arm (i.e. conjunctivitis, thrush, fever) (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Infectious AEs Propranolol | 5 |
| Infectious AEs Prednisolone | 3 |
Number of Metabolic or Laboratory AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Metabolic/Laboratory AEs Propranolol | 1 |
| Metabolic/Laboratory AEs Prednisolone | 0 |
Number of serious adverse events experienced by the participants in each treatment arm within the categories adrenal crisis, growth/development, constitutional. Serious adverse events are defined as events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity, or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered Serious Adverse Events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned. (NCT00967226)
Timeframe: enrollment until study close out or withdrawal up to 9 months
| Intervention | Serious Adverse Events (Number) |
|---|---|
| Number of Serious Adverse Events in Propranolol | 1 |
| Number of Serious Adverse Events in Prednisolone | 11 |
Number of pulmonary/respiratory adverse events (CTCAE 22) in each study arm (NCT00967226)
Timeframe: enrollment through study close out or withdrawal, up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Pulmonary/Respiratory AEs Propranolol | 14 |
| Pulmonary/Respiratory AEs Prednisolone | 4 |
Number of Vascular AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Vascular AEs Propranolol | 3 |
| Vascular AEs Prednisolone | 4 |
All adverse events relating to medication tolerability including: adrenal crisis, growth/development, constitutional (dehydration), allergy/immunology, dermatologic, endocrine, GI, infection, metabolism/labs, pulmonary, vascular. (NCT00967226)
Timeframe: enrollment until study close out or withdrawal up to 9 months
| Intervention | Events (Number) | |
|---|---|---|
| Adverse Events | Serious Adverse Events | |
| Overall Number of Adverse Events in Prednisolone | 30 | 11 |
| Overall Number of Adverse Events in Propranolol | 34 | 1 |
(NCT01056341)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 8.0 |
| Propranolol 1mg/kg/d 3 Months | 9.8 |
| Propranolol 1 mg/kg/d 6 Months | 37.5 |
| Propranolol 3 mg/kg/d 3 Months | 7.7 |
| Propranolol 3 mg/kg/d 6 Months | 62.8 |
(NCT01056341)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 3.6 |
| Propranolol 3mg/kg/d 6 Months | 60.4 |
Participants will be followed for the duration of the study, an expected average of 20 weeks. (NCT02335242)
Timeframe: Baseline, week 20
| Intervention | percentage of volume (Mean) |
|---|---|
| Double-Blind Placebo | 5.89 |
| Open-Label Sildenafil | -8.54 |
| Double-blind Sildenafil | -0.642 |
"Subject's evaluation of the overall change in lymphatic malformation. Participants will be followed from baseline to 20 weeks.~Patients rated change as no improvement, minimal improvement (1-25% change), fair improvement (25-50% change), good improvement (50-75% change), and excellent improvement (75-100% change)." (NCT02335242)
Timeframe: Baseline, week 20
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| No improvement | Minimal improvement | Fair improvement | Good improvement | Excellent improvement | |
| Double-Blind Placebo | 1 | 2 | 0 | 2 | 0 |
| Double-Blind Sildenafil | 2 | 4 | 1 | 1 | 0 |
101 reviews available for propranolol and Angioma
| Article | Year |
|---|---|
Mediastinal and subglottic hemangioma in an infant: a case report and literature review.
Topics: Hemangioma; Humans; Infant; Laryngeal Neoplasms; Male; Mediastinum; Propranolol; Retrospective Studi | 2021 |
Medical Management of Infantile Hemangiomas: An Update.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin | 2022 |
Infantile Hemangioma: A Current Review.
Topics: Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Timolol | 2022 |
Should Propranolol Remain the Gold Standard for Treatment of Infantile Hemangioma? A Systematic Review and Meta-Analysis of Propranolol Versus Atenolol.
Topics: Adrenergic beta-Antagonists; Atenolol; Drug-Related Side Effects and Adverse Reactions; Hemangioma; | 2023 |
Propranolol treatment of infantile subglottic hemangioma: a report of two cases and a literature review.
Topics: Child; Hemangioma; Hemangioma, Capillary; Humans; Infant; Laryngeal Neoplasms; Laryngoscopy; Propran | 2021 |
Sirolimus for diffuse intestinal infantile hemangioma with PHACE features: systematic review.
Topics: Aortic Coarctation; Eye Abnormalities; Female; Hemangioma; Hemangioma, Capillary; Humans; Infant; Pr | 2023 |
Comparison of the efficacy and safety of lasers, topical timolol, and combination therapy for the treatment of infantile hemangioma: A meta-analysis of 10 studies.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Combined Modality Therapy; Hemangioma; Humans; | 2022 |
Infantile Hemangiomas.
Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outcome | 2022 |
[Infantile hemangioma : Clinical manifestation, treatment, and differential diagnoses].
Topics: Child; Diagnosis, Differential; Hemangioma; Hemangioma, Capillary; Humans; Neoplasms, Vascular Tissu | 2023 |
Sleep disturbances as an adverse effect of propranolol use in children with infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Sleep Wake Disorders | 2020 |
β-blocker therapy for infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Hemangioma; Humans; | 2020 |
[Medical treatment of children with infantile haemangiomas].
Topics: Adrenergic beta-Antagonists; Algorithms; Diagnosis, Differential; Hemangioma; Humans; Infant; Propra | 2017 |
Efficacy and rebound rates in propranolol-treated subglottic hemangioma: A literature review.
Topics: Hemangioma; Humans; Propranolol; Tracheal Diseases; Treatment Outcome; Vasodilator Agents | 2017 |
Cardiac arrest in a toddler treated with propranolol for infantile Hemangioma: a case report.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow | 2017 |
Infantile hemangioma: pathogenesis and mechanisms of action of propranolol.
Topics: Angiogenesis Inducing Agents; Cell Proliferation; Female; Hemangioma; Humans; Infant, Newborn; Matri | 2017 |
Management of Infantile Hemangiomas of the Airway.
Topics: Airway Obstruction; Hemangioma; Humans; Infant; Laser Therapy; Propranolol; Respiratory Tract Neopla | 2018 |
Infantile Hemangiomas in the Head and Neck Region.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Head and Neck Neoplasms; Hemangioma; Humans; Infa | 2018 |
Psychosocial Impact of Vascular Anomalies on Children and Their Families.
Topics: Adaptation, Psychological; Adult; Arteriovenous Malformations; Child; Head and Neck Neoplasms; Heman | 2018 |
Effect of topical timolol on response rate and adverse events in infantile hemangioma: a meta-analysis.
Topics: Administration, Topical; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; | 2018 |
Topical propranolol for infantile haemangiomas: a systematic review.
Topics: Administration, Cutaneous; Antineoplastic Agents; Gels; Hemangioma; Humans; Ointments; Propranolol; | 2018 |
Infantile hemangiomas: what have we learned from propranolol?
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outc | 2018 |
PHACE syndrome: clinical manifestations, diagnostic criteria, and management.
Topics: Aortic Coarctation; Brain; Eye Abnormalities; Face; Facial Neoplasms; Hemangioma; Humans; Infant; Ma | 2018 |
[Tiempo de respuesta terapéutica al propranolol sistémico en el manejo de hemangiomas subglóticos pediátricos: serie de casos y revisión de la literatura].
Topics: Administration, Oral; Antineoplastic Agents; Female; Hemangioma; Humans; Infant; Laryngeal Neoplasms | 2018 |
Interventions for infantile haemangiomas of the skin: abridged Cochrane systematic review and GRADE assessments.
Topics: Administration, Cutaneous; Administration, Oral; Adrenergic beta-Antagonists; Bradycardia; GRADE App | 2019 |
Clinical and economic impact of surgery for treating infantile hemangiomas in the era of propranolol: overview of single-center experience from La Paz Hospital, Madrid.
Topics: Adrenergic beta-Antagonists; Child; Female; Glucocorticoids; Health Care Costs; Hemangioma; Humans; | 2019 |
Role of Magnetic Resonance Image in Children with Lumbosacral and Perineal Hemangiomas: Case Reports and Review of the Literature.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Lipoma; Lumbosacral Region; Male; P | 2019 |
Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: A systematic review.
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Atenolol; | 2019 |
[What's new in pediatric dermatology?]
Topics: Arteriovenous Malformations; Dermatology; Hemangioma; Humans; Pediatrics; Propranolol; Risk Factors; | 2018 |
Deep coma in a child treated with propranolol for infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Coma; Glucose; Hemangioma; Humans; Hypoglycemia; | 2019 |
Management of infantile hemangiomas : current and potential pharmacotherapeutic approaches.
Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Aminoquinolines; Hemangioma; | 2013 |
[Infantile hemangioma: update and treatment].
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Early Medical Intervention; Esthetics; Follow- | 2013 |
[What's new about infantile hemangiomas?].
Topics: Hemangioma; Humans; Infant, Newborn; Propranolol; Skin Neoplasms; Skin Ulcer; Vasodilator Agents | 2013 |
Pathogenesis of infantile haemangioma.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Angiopoietins; Embryonic Stem Cells; Endotheli | 2013 |
Haemangioma: clinical course, complications and management.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Cicatrix; Congenita | 2013 |
Propranolol in use for treatment of complex infant hemangiomas: literature review regarding current guidelines for preassessment and standards of care before initiation of therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Child; Evidence-Based Medicine; Guideline Adherence; | 2013 |
Use of propanolol for treatment of large infantile haemangiomas-a report of two cases and review of the literature.
Topics: Antineoplastic Agents; Child, Preschool; Facial Neoplasms; Female; Follow-Up Studies; Forearm; Hand; | 2013 |
Infantile hemangiomas of the head and neck.
Topics: Diagnostic Imaging; Head and Neck Neoplasms; Hemangioma; Humans; Infant; Propranolol; Vasodilator Ag | 2013 |
Multiple cutaneous and hepatic infantile hemangiomas having a successful response to propranolol as monotherapy at neonatal period.
Topics: Adrenergic beta-Antagonists; Disease Management; Female; Hemangioma; Humans; Infant, Newborn; Liver | 2013 |
The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies.
Topics: Antineoplastic Agents; Hemangioma; Humans; Infant; Propranolol | 2014 |
Hemangiomas treated with propranolol: do the rewards outweigh the risks?
Topics: Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Orbital Neoplasms; Propranolol; Treatment Ou | 2013 |
Infantile hemangioma: treatment with surgery or steroids.
Topics: Adrenergic beta-Antagonists; Glucocorticoids; Hemangioma; Humans; Infant; Ophthalmologic Surgical Pr | 2013 |
Diagnosis and management of infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Diagnosis, Differential; Hemangioma; Humans; Infant; Propranolol; Skin | 2014 |
[Two news drugs (ivacaftor & bedaquiline), one biomarker (florbetapir) and a re-positioned drug (propranolol) on the market].
Topics: Adrenergic beta-Antagonists; Adult; Alzheimer Disease; Aminophenols; Aniline Compounds; Antitubercul | 2014 |
Intra-thyroidal hemangioma--a rare congenital anomaly: case presentation and literature review.
Topics: Adrenergic beta-Antagonists; Bronchoscopy; Dexamethasone; Female; Glucocorticoids; Hemangioma; Human | 2014 |
Consumptive hypothyroidism associated with parotid infantile hemangioma.
Topics: Administration, Oral; Hemangioma; Humans; Hypothyroidism; Infant; Male; Parotid Neoplasms; Propranol | 2015 |
The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action.
Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Apoptosis; Catecholamines; Hemangioma; Humans; | 2015 |
[Propranolol therapy for periocular and orbital infantile haemangiomas].
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant, Newborn; Male; Orbital Neoplasms; P | 2014 |
Incidence and treatment of infantile haemangioma in preterm infants.
Topics: Adrenergic beta-Antagonists; Cryotherapy; Hemangioma; Humans; Incidence; Infant, Premature; Infant, | 2015 |
Treatment of rapidly proliferating haemangiomas in newborns with propranolol and review of the literature.
Topics: Adrenergic beta-Antagonists; Facial Neoplasms; Female; Hemangioma; Humans; Infant, Newborn; Male; Pr | 2016 |
Head and neck vascular lesions.
Topics: Arteriovenous Malformations; Biopsy, Needle; Child; Child, Preschool; Female; Follow-Up Studies; Hea | 2015 |
Novel treatment for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Infant, Newborn; Propranolol; Timolol | 2014 |
Infantile hemangiomas, retinopathy of prematurity and cancer: a common pathogenetic role of the β-adrenergic system.
Topics: Adrenergic beta-Antagonists; Animals; Cell Line, Tumor; Child, Preschool; Hemangioma; Humans; Hypoxi | 2015 |
Topical propranolol cream in treatment of superficial infantile hemangiomas: a literature review and 4 years of clinical experience.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Propranolol; Skin Cream; Trea | 2014 |
Propranolol induced hypoglycemia.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Hypoglycemia; Infant; Practice Guidelines as Topic; | 2015 |
Treatment of infantile haemangiomas: recommendations of a European expert group.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Aortic Coarctation; Cryotherapy; Diagnosis, Di | 2015 |
Current trends in medical management of infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Dermatologic Agents; Early Medical Intervention; Esthetics; Glucocortic | 2015 |
Evidence-Based Medicine in the Treatment of Infantile Hemangiomas.
Topics: Evidence-Based Medicine; Hemangioma; Humans; Infant; Laser Therapy; Propranolol; Steroids | 2015 |
Effectiveness and Safety of Oral Propranolol versus Other Treatments for Infantile Hemangiomas: A Meta-Analysis.
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents; Hemangioma; Humans; Infant; Propranolol; Safety | 2015 |
"Cyrano nose" associated with hepatic hemangiomas successfully treated with propranolol.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Liver Neoplasms; | 2015 |
Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events - a review of the literature.
Topics: Adrenergic beta-Antagonists; Drug-Related Side Effects and Adverse Reactions; Hemangioma; Humans; In | 2016 |
Pharmacologic Interventions for Infantile Hemangioma: A Meta-analysis.
Topics: Administration, Oral; Administration, Topical; Adrenergic beta-Antagonists; Glucocorticoids; Hemangi | 2016 |
Infantile Hemangiomas: Pathogenesis and Review of Propranolol Use.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Infant, Newborn; Propranolol | 2016 |
Beta Blockade as Treatment for Intracranial Infantile Hemangioma: Case Report and Literature Review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Antineoplastic Agents; Brain Neoplasms; Hemangiom | 2016 |
Infantile hemangiomas, complications and treatments.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Airway Obstruction; Drug Therapy, Combination; | 2016 |
Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol; Tr | 2016 |
Vascular Lesions.
Topics: Adrenergic beta-Antagonists; Combined Modality Therapy; Hemangioma; Humans; Plastic Surgery Procedur | 2016 |
The use of propranolol in the treatment of subglottic hemangiomas: A literature review and meta-analysis.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Airway Obstruction; Endoscopy; Hemangioma; Hum | 2016 |
Infantile haemangioma.
Topics: Adrenergic beta-Antagonists; Heart Failure; Hemangioma; Humans; Infant; Propranolol; Respiratory Dis | 2017 |
LUMBAR syndrome: A case manifesting as cutaneous infantile hemangiomas of the lower extremity, perineum and gluteal region, and a review of published work.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Biopsy; Buttocks; Female; Hemangioma; Humans; | 2017 |
Propranolol treatment for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Head and Neck Neoplasms; Hemangioma; Humans; Infant; Propranolol | 2009 |
Initial experience using propranolol as the sole treatment for infantile airway hemangiomas.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Magnetic Reson | 2010 |
Propranolol therapy for infantile haemangiomas: review of the literature.
Topics: Adrenergic beta-Antagonists; Apoptosis; Down-Regulation; Endothelial Cells; Fibroblast Growth Factor | 2010 |
[Infantile hemangioma].
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Antineoplastic Agents, Phytogenic; Child; Chil | 2010 |
Current treatments for infantile hemangiomas.
Topics: Adrenal Cortex Hormones; Aminoquinolines; Hemangioma; Humans; Imiquimod; Infant; Infant, Newborn; In | 2010 |
Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action.
Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Apoptosis; Female; Fibroblast Growth Factors; | 2010 |
Infantile haemangiomas: a challenge in paediatric dermatology.
Topics: Adrenergic beta-Antagonists; Cell Proliferation; Hemangioma; Humans; Infant, Newborn; Neovasculariza | 2010 |
[Propanolol used in treatment of infantile hemangioma].
Topics: Adrenergic beta-Antagonists; Eye Neoplasms; Female; Hemangioma; Humans; Infant; Neoplasms, Multiple | 2010 |
[Therapeutic options for haemangiomas of infancy].
Topics: Adrenergic beta-Antagonists; Cryotherapy; Hemangioma; Humans; Infant; Infant, Newborn; Laser Therapy | 2012 |
A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemangioma; Humans; Infant; | 2011 |
Infantile haemangioma and β-blockers in otolaryngology.
Topics: Acebutolol; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Hemangioma; Humans; Infan | 2011 |
An infantile bronchial hemangioma unresponsive to propranolol therapy: case report and literature review.
Topics: Adrenergic beta-Antagonists; Beclomethasone; Bronchial Neoplasms; Bronchoscopy; Child, Preschool; Di | 2011 |
Hemangiomas revisited: the useful, the unusual and the new. Part 2: endangering hemangiomas and treatment.
Topics: Child; Child, Preschool; Contrast Media; Diagnostic Imaging; Hemangioma; Humans; Infant; Infant, New | 2011 |
Propranolol for infantile haemangiomas: a review.
Topics: Adrenergic beta-Antagonists; Child, Preschool; Drug Administration Schedule; Hemangioma; Humans; Inf | 2011 |
Novel strategies for managing infantile hemangiomas: a review.
Topics: Adrenergic beta-Antagonists; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Bleomyc | 2012 |
Hemangioma update: pearls from 30 years of treatment.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Age Factors; Antibiotics, Antineoplastic; Bleo | 2012 |
Hemangiomas - current therapeutic strategies.
Topics: Angiogenesis Inhibitors; Bleomycin; Child; Cyclophosphamide; Hemangioma; Humans; Interferons; Neovas | 2011 |
[Treatment of haemangiomas of infancy with propranolol; good results, few side effects].
Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Disease Progression; Hemangioma; Humans; Infan | 2011 |
Propranolol for proliferating infantile haemangioma is superior to corticosteroid therapy--a retrospective, single centre study.
Topics: Adrenal Cortex Hormones; Female; Hemangioma; Humans; Infant; Male; Propranolol; Retrospective Studie | 2012 |
Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial.
Topics: Age Factors; Child; Child, Preschool; Hemangioma; Humans; Prednisolone; Propranolol; Recurrence; Tre | 2011 |
Propranolol safety profile in children.
Topics: Adrenergic beta-Antagonists; Age Factors; Angina Pectoris; Central Nervous System Diseases; Child; D | 2011 |
Infantile hemangioma-mechanism(s) of drug action on a vascular tumor.
Topics: Adrenergic beta-Antagonists; Biomarkers; Cell Differentiation; Cell Proliferation; Glucocorticoids; | 2011 |
Multifocal infantile hepatic hemangiomas--imaging strategy and response to treatment after propranolol and steroids including review of the literature.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Female; Glucocorticoids; Heart Failure; Hema | 2012 |
Current management of infantile hemangiomas and their common associated conditions.
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents, Phytogenic; Antiviral Agents; Bronchoscopy; Cong | 2012 |
The psychosocial impact of an infantile haemangioma on children and their parents.
Topics: Adrenergic beta-Antagonists; Child; Child Behavior; Child, Preschool; Hemangioma; Humans; Infant; In | 2012 |
[Treatment of hemangiomas].
Topics: Adrenal Cortex Hormones; Angiography; Embolization, Therapeutic; Hemangioma; Humans; Infant; Infant, | 2012 |
Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis.
Topics: Adrenal Cortex Hormones; Hemangioma; Humans; Infant; Propranolol | 2013 |
Medical management of vascular anomalies.
Topics: Adrenergic beta-Antagonists; Hemangioendothelioma; Hemangioma; Humans; Kasabach-Merritt Syndrome; Pr | 2012 |
Management of vascular tumors.
Topics: Adrenergic beta-Antagonists; Child; Granuloma, Pyogenic; Hemangioendothelioma; Hemangioma; Humans; K | 2012 |
Initiation and use of propranolol for infantile hemangioma: report of a consensus conference.
Topics: Consensus Development Conferences as Topic; Hemangioma; Humans; Infant; Propranolol; Research Report | 2013 |
Novel use of propranolol for management of pain in children with vertebral hemangioma: report of two cases.
Topics: Adolescent; Adrenergic beta-Antagonists; Back Pain; Child; Female; Follow-Up Studies; Hemangioma; Hu | 2013 |
Infantile hemangiomas: an update.
Topics: Adrenal Cortex Hormones; Biopsy, Needle; Combined Modality Therapy; Dermatologic Surgical Procedures | 2013 |
38 trials available for propranolol and Angioma
| Article | Year |
|---|---|
Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2023 |
Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2023 |
Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2023 |
Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2023 |
Itraconazole versus propranolol: therapeutic and pharmacologic effect on serum angiopoietin-2 in patients with infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angiopoietin-2; Antifungal Agents; Child; Hemangi | 2022 |
Change of serum cytokine profiles by propranolol treatment in patients with infantile hemangioma.
Topics: Cytokines; Female; Hemangioma; Humans; Infant; Male; Propranolol | 2020 |
Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial.
Topics: Female; Glucocorticoids; Hemangioma; Humans; Infant; Infant, Newborn; Magnetic Resonance Imaging; Ma | 2017 |
Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study.
Topics: Administration, Oral; Blood Glucose; Blood Pressure; Female; Heart Rate; Hemangioma; Humans; Infant, | 2017 |
Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study.
Topics: Adrenergic beta-Antagonists; Atenolol; Case-Control Studies; Female; Hemangioma; Humans; Infant; Inf | 2017 |
Thirty-two Japanese cases of infantile hemangiomas treated with oral propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Body Image; Female; Follow-Up Studies; Hemangioma | 2018 |
Role of intralesional bleomycin and intralesional triamcinolone therapy in residual haemangioma following propranolol.
Topics: Antibiotics, Antineoplastic; Bleomycin; Child, Preschool; Female; Glucocorticoids; Hemangioma; Human | 2018 |
Efficacy of Propranolol Between 6 and 12 Months of Age in High-Risk Infantile Hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Administration Schedule; Female; Hemangioma; | 2018 |
Propranolol is more effective than pulsed dye laser and cryosurgery for infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Cryosurgery; Drug Administration Schedule; Female | 2013 |
The use of propranolol for complicated infantile hemangiomas.
Topics: Administration, Oral; Child, Preschool; Facial Dermatoses; Female; Follow-Up Studies; Hemangioma; Hu | 2013 |
Propranolol for infantile hemangioma (PINCH): an open-label trial to assess the efficacy of propranolol for treating infantile hemangiomas and for determining the decline in heart rate to predict response to propranolol.
Topics: Child; Child, Preschool; Female; Heart Rate; Hemangioma; Humans; Infant; Infant, Newborn; Male; Prog | 2013 |
Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas.
Topics: Adrenergic beta-Antagonists; Age Factors; Antineoplastic Agents, Hormonal; Cohort Studies; Female; H | 2013 |
Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Drug Administration Sch | 2013 |
Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Female; Hemangioma; Humans; Infant; Infant, N | 2014 |
Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Female; Hemangioma; Humans; Infant; Infant, N | 2014 |
Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Female; Hemangioma; Humans; Infant; Infant, N | 2014 |
Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Female; Hemangioma; Humans; Infant; Infant, N | 2014 |
Propranolol therapy for reducing the number of nasal infantile hemangioma invasive procedures.
Topics: Adolescent; Adrenergic beta-Antagonists; Child; Child, Preschool; Female; Hemangioma; Humans; Laser | 2014 |
Formulation, characterization and clinical evaluation of propranolol hydrochloride gel for transdermal treatment of superficial infantile hemangioma.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Animals; Chemistry, Pharmaceutical; Child, P | 2015 |
Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial.
Topics: Administration, Topical; Combined Modality Therapy; Female; Hemangioma; Humans; Infant; Lasers, Dye; | 2014 |
A randomized, controlled trial of oral propranolol in infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Double-Blind Me | 2015 |
A randomized, controlled trial of oral propranolol in infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Double-Blind Me | 2015 |
A randomized, controlled trial of oral propranolol in infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Double-Blind Me | 2015 |
A randomized, controlled trial of oral propranolol in infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Double-Blind Me | 2015 |
Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Therapy, Combination; Female; Follow-Up Stud | 2015 |
Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study.
Topics: Acetaminophen; Administration, Oral; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Hem | 2016 |
Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Female; Hemangioma; Humans; Infant; Male; Pepti | 2016 |
Oral Propranolol With Topical Timolol Maleate Therapy for Mixed Infantile Hemangiomas in Oral and Maxillofacial Regions.
Topics: Administration, Oral; Administration, Topical; Antineoplastic Agents; Drug Therapy, Combination; Fac | 2016 |
Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study.
Topics: Administration, Oral; Administration, Topical; Aftercare; Female; Hemangioma; Humans; Infant; Infant | 2016 |
Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Body Height; Body Weight; Child; C | 2016 |
Clinical features and management of multifocal hepatic hemangiomas in children: a retrospective study.
Topics: Administration, Oral; Child, Preschool; Female; Hemangioma; Humans; Infant; Liver Neoplasms; Male; P | 2016 |
Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Arkansas; Child, Preschool; Dose-Response Relatio | 2010 |
Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Facial Neoplasms; Female; Hemangioma; Humans; Inf | 2011 |
A randomized controlled trial of propranolol for infantile hemangiomas.
Topics: Bronchiolitis; Child, Preschool; Double-Blind Method; Female; Gastroenteritis; Hemangioma; Humans; I | 2011 |
[Preliminary clinical study on the treatment of severe infantile hemangioma with high-dose propranolol in China].
Topics: China; Female; Hemangioma; Humans; Infant; Male; Propranolol; Treatment Outcome | 2011 |
[A prospective study of propranolol as first-line treatment for problematic infantile hemangioma in China].
Topics: Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolol; Prospective Studies; Treat | 2011 |
Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial.
Topics: Age Factors; Child; Child, Preschool; Hemangioma; Humans; Prednisolone; Propranolol; Recurrence; Tre | 2011 |
[Propranolol in the treatment of problematic infantile hemangiomas].
Topics: Female; Hemangioma; Humans; Infant; Male; Propranolol; Prospective Studies; Skin Neoplasms; Subcutan | 2011 |
Evaluation of intra-lesional corticosteroids in the treatment of peri-ocular haemangioma of infancy: still an alternative besides propranolol.
Topics: Adrenal Cortex Hormones; Eyelid Neoplasms; Female; Hemangioma; Humans; Infant, Newborn; Injections, | 2012 |
Urinary matrix metalloproteinases-2/9 in healthy infants and haemangioma patients prior to and during propranolol therapy.
Topics: Adrenergic beta-Antagonists; Age Factors; Biomarkers; Case-Control Studies; Drug Administration Sche | 2012 |
Propranolol treatment of infantile hemangioma: clinical and radiologic evaluations.
Topics: Adrenergic beta-Antagonists; Drug Administration Schedule; Female; Follow-Up Studies; Hemangioma; Hu | 2012 |
[The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface].
Topics: Angiogenesis Inhibitors; Combined Modality Therapy; Hemangioma; Humans; Lasers, Solid-State; Propran | 2012 |
Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants < 4 months of age.
Topics: Antineoplastic Agents; Cicatrix; Double-Blind Method; Female; Head and Neck Neoplasms; Hemangioma; H | 2013 |
537 other studies available for propranolol and Angioma
| Article | Year |
|---|---|
Adverse Drug Reactions Following Propranolol in Infantile Hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Child, Preschool; Drug-Related Side Effect | 2021 |
A national audit of oral propranolol for the treatment of infantile haemangiomas.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outc | 2022 |
Vascular endothelial growth factor response with propranolol therapy in patients with infantile hemangioma.
Topics: Hemangioma; Humans; Infant; Propranolol; Prospective Studies; Vascular Endothelial Growth Factor A | 2022 |
Infantile Glottic Hemangioma: Bronchoscopic Evaluation and Propranolol Treatment.
Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Treatment Outcome | 2021 |
Exosomal miR-27a-3p derived from tumor-associated macrophage suppresses propranolol sensitivity in infantile hemangioma.
Topics: Animals; Drug Resistance, Neoplasm; Exosomes; Gene Expression Regulation, Neoplastic; Hemangioma; He | 2021 |
Propranolol inhibits the angiogenic capacity of hemangioma endothelia via blocking β-adrenoceptor in mast cell.
Topics: Cell Proliferation; Cytokines; Endothelial Cells; Hemangioma; Hemangioma, Capillary; Humans; Mast Ce | 2022 |
Propranolol Suppresses Proliferation and Migration of HUVECs through Regulation of the miR-206/VEGFA Axis.
Topics: Apoptosis; Cell Proliferation; Cell Survival; Cells, Cultured; Hemangioma; Human Umbilical Vein Endo | 2021 |
Propranolol response in patients with segmental versus focal facial hemangiomas: A retrospective case-control study.
Topics: Adrenergic beta-Antagonists; Case-Control Studies; Facial Neoplasms; Hemangioma; Humans; Infant; Pro | 2022 |
Significance of the pulsed dye laser in treatment of acral infantile hemangioma.
Topics: Hemangioma; Humans; Infant; Laser Therapy; Lasers, Dye; Propranolol; Skin Neoplasms | 2022 |
Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma.
Topics: Animals; Atenolol; Hemangioma; Humans; Mice; Neoplastic Stem Cells; Neovascularization, Pathologic; | 2022 |
Safety assessment of propranolol for infantile hemangioma: a study in an Asian population.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Retrospe | 2022 |
Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Face; Hemangioma; Humans; Infant; Infant, | 2022 |
Cyclosporin-A reduced the cytotoxicity of propranolol in HUVECs via p38 MAPK signaling.
Topics: Antioxidants; Apoptosis; Cell Proliferation; Cyclosporine; Hemangioma; Human Umbilical Vein Endothel | 2022 |
A transcription factor is the target of propranolol treatment in infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Animals; Child; Hemangioma; Humans; Mice; Propranolol; SOXF Transcripti | 2022 |
Sequelae following infantile haemangiomas treated with propranolol.
Topics: Administration, Oral; Antineoplastic Agents; Female; Hemangioma; Humans; Infant; Male; Propranolol; | 2021 |
Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2022 |
Propranolol therapy for hemangiomas in infants with neonatal abstinence syndrome may produce intolerable side effects.
Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Iatrogenic Disease; Infant; | 2022 |
Sandwich therapy in the management of propranolol resistant infantile hemangioma of the lip.
Topics: Bleomycin; Hemangioma; Humans; Lip; Propranolol | 2022 |
Atenolol as treatment for hepatic hemangiomas in a premature infant.
Topics: Atenolol; Hemangioma; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Disease | 2022 |
Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma; Hemangioma, | 2022 |
Management of infantile subglottic hemangioma with T-tube placement and propranolol.
Topics: Hemangioma; Humans; Infant; Laryngeal Neoplasms; Propranolol; Treatment Outcome | 2022 |
Surgical management of large scalp infantile hemangioma in 30-month-old infant.
Topics: Child, Preschool; Female; Hemangioma; Hemorrhage; Humans; Infant; Infant, Newborn; Propranolol; Scal | 2022 |
Topical Formulations of Propranolol for Infantile Hemangiomas: Characteristics of Formulations and Three Cases of Infants Administered Topical Propranolol Cream.
Topics: Child; Hemangioma; Humans; Hypromellose Derivatives; Infant; Propranolol; Skin; Skin Neoplasms | 2022 |
Does Oral Propranolol Improve the Final Outcome of All Involuted Infantile Hemangiomas? A Matched Retrospective Comparative Study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Disease Progression; Hemangioma; Hemangioma, Capi | 2022 |
Inter- and intra-observer variability in the selection of therapy for infantile hemangiomas among pediatric dermatologists in Spain.
Topics: Child; Cross-Sectional Studies; Dermatologists; Hemangioma; Hemangioma, Capillary; Humans; Observer | 2022 |
Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma.
Topics: Adrenergic beta-Antagonists; Atenolol; Cross-Sectional Studies; Esthetics; Hemangioma; Hemangioma, C | 2022 |
Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2022 |
A Retrospective Analysis of Clinical Characteristics, Treatment Modalities and Outcome of the Patients With Infantile Hepatic Hemangiomas: Single-center Experience From Turkey.
Topics: Adrenal Cortex Hormones; Hemangioma; Humans; Infant; Infant, Newborn; Liver Neoplasms; Propranolol; | 2023 |
Is Infantile Hemangioma a Neuroendocrine Tumor?
Topics: Adrenergic beta-Antagonists; Endothelial Cells; Hemangioma; Humans; Infant; Infant, Newborn; Neuroen | 2022 |
Efficacy of intravenous propranolol for life-threatening diffuse neonatal hemangiomatosis.
Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Infant, Newborn; Liver Neoplasms; Propranolol; Tr | 2022 |
Clinical evaluation of transcatheter arterial embolization combined with propranolol orally treatment of infantile hepatic hemangioma.
Topics: Child; Embolization, Therapeutic; Female; Heart Failure; Hemangioma; Hemangioma, Capillary; Humans; | 2022 |
A premonitory mark of segmental infantile hemangioma.
Topics: Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms | 2022 |
Evaluation of cases with infantile hemangioma requiring treatment.
Topics: Administration, Oral; Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Skin Neoplasms | 2022 |
Multifocal Infantile Hepatic Hemangiomas Complicated by Consumptive Hypothyroidism: The Benefits of Early Diagnosis and Treatment.
Topics: Child; Early Diagnosis; Hemangioma; Humans; Hypothyroidism; Infant; Liver Neoplasms; Propranolol | 2023 |
A Retrospective Study of Lip Hemangiomas: Curative Effect of Oral Propranolol Combined with Topical Sclerotherapy.
Topics: Hemangioma; Humans; Lip; Propranolol; Retrospective Studies; Sclerotherapy | 2022 |
Immediate possible adverse event rates in infants treated with oral propranolol for infantile haemangiomas at an Australian urban tertiary hospital between 2016 and 2019.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Australia; Hemangioma; Hemangioma, Capillary; Hos | 2022 |
Severe hypoglycemia in propranolol treatment for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Child; Female; Hemangioma; Hemangioma, Capillary; Humans; Hypoglycemia; | 2022 |
Mediastinal infantile hemangioma with spinal canal extension and extensive gastrointestinal involvement complicated by respiratory failure.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Diuretics; Hemangioma; Hemangioma, Capillary; | 2022 |
Β-blockers activate autophagy on infantile hemangioma-derived endothelial cells in vitro.
Topics: Adrenergic beta-Antagonists; Amines; Atenolol; Autophagy; Cell Proliferation; Child; Endothelial Cel | 2022 |
Circular RNA hsa_circ_0000915 promotes propranolol resistance of hemangioma stem cells in infantile haemangiomas.
Topics: Biotin; Caspase 3; Cell Movement; Gene Expression Regulation, Neoplastic; Hemangioma; Humans; Interl | 2022 |
[Management of ulcers on a segmental hemangioma: A combination of systemic and topical therapies in two pediatric cases].
Topics: Administration, Oral; Child; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Skin Ulcer; Tr | 2022 |
Apelin Receptor Can Act as a Specific Marker and Promising Therapeutic Target for Infantile Hemangioma.
Topics: Animals; Apelin Receptors; Cell Proliferation; Endothelial Cells; Hemangioma; Humans; Mice; Proprano | 2023 |
Bleomycin-triamcinolone sclerotherapy in the management of propranolol resistant infantile hemangioma of the maxillofacial region: A single arm prospective evaluation of clinical outcome and Doppler ultrasound parameters.
Topics: Bleomycin; Hemangioma; Humans; Neoplasm Recurrence, Local; Propranolol; Sclerotherapy; Treatment Out | 2023 |
Intracranial hemangioma-associated cranial nerve VII palsy treated with propranolol in an infant with possible PHACE syndrome.
Topics: Brain Neoplasms; Facial Nerve; Facial Paralysis; Female; Hemangioma; Humans; Infant; Propranolol; Sy | 2022 |
Shikonin reverses pyruvate kinase isoform M2-mediated propranolol resistance in infantile hemangioma through reactive oxygen species-induced autophagic dysfunction.
Topics: Adrenergic beta-Antagonists; Animals; Endothelial Cells; Hemangioma; Propranolol; Pyruvate Kinase; R | 2023 |
Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Atenolol; Child; Cross-Sectional Studies; Female; Hemangioma; Hemangiom | 2023 |
Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Atenolol; Child; Cross-Sectional Studies; Female; Hemangioma; Hemangiom | 2023 |
Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Atenolol; Child; Cross-Sectional Studies; Female; Hemangioma; Hemangiom | 2023 |
Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Atenolol; Child; Cross-Sectional Studies; Female; Hemangioma; Hemangiom | 2023 |
Propranolol and infantile hemangiomas: Outcome from a tricentric study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neo | 2023 |
Propranolol and infantile hemangiomas: Outcome from a tricentric study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neo | 2023 |
Propranolol and infantile hemangiomas: Outcome from a tricentric study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neo | 2023 |
Propranolol and infantile hemangiomas: Outcome from a tricentric study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neo | 2023 |
Intralesional steroid in the era of propranolol for infantile hemangioma-Do we need it?
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Prospective Studies; Skin Neop | 2023 |
Management of infantile hemangiomas-experience of a tertiary hospital.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Female; Hemangioma; Humans; Infant; Male; | 2023 |
[Effects of oral propranolol on urine bFGF, MMP-2, MMP-9 expression in children with proliferative infantile hemangioma].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Endothelial Cells; Hemangioma; Humans; Infant; Ma | 2022 |
Distribution of problematic localized facial infantile haemangiomas and their response to propranolol: a retrospective cohort study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2023 |
A study of 95 infantile hemangiomas treated with propranolol: A potentially efficacious combination with laser therapy.
Topics: Administration, Oral; Erythema; Hemangioma; Humans; Infant; Laser Therapy; Propranolol; Skin Neoplas | 2023 |
Indications for surgical resection of complicated infantile hemangiomas in the β-blocker's era: a single-institution experience from a retrospective cohort study.
Topics: Adrenergic beta-Antagonists; Child; Health Facilities; Hemangioma; Humans; Infant; Propranolol; Retr | 2023 |
Allergic contact dermatitis caused by topical propranolol therapy for infantile haemangioma.
Topics: Adrenergic beta-Antagonists; Dermatitis, Allergic Contact; Hemangioma; Humans; Infant; Propranolol | 2023 |
Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2023 |
Our experience with propranolol for infantile hemangioma.
Topics: Administration, Oral; Child; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outc | 2023 |
Intratracheal infantile haemangioma: an infrequent cause of lower airway obstruction in early infancy.
Topics: Hemangioma; Humans; Propranolol | 2023 |
Propranolol-induced Involution of Infantile Hemangioma.
Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Skin Ne | 2023 |
Nd:YAG 1064-nm laser for residual infantile hemangioma after propranolol treatment.
Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Lasers, Solid-State; Propranolol; Prospective Stu | 2023 |
Propranolol in Congenital Hepatic Arteriovenous Malformation.
Topics: Arteriovenous Malformations; Hemangioma; Humans; Liver Diseases; Propranolol | 2023 |
Can Propranolol Affect Platelet Indices in Infantile Hemangioma?
Topics: Blood Platelets; Hemangioma; Humans; Mean Platelet Volume; Propranolol; Vascular Endothelial Growth | 2023 |
Clinical features of cutaneous infantile hemangioma combined with asymptomatic infantile hepatic hemangioma and efficacy of propranolol treatment.
Topics: Child, Preschool; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol; Retrospective Studies; S | 2023 |
The impact of propranolol on the growth and development of children with proliferative infantile hemangioma during treatment.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Growth and Development; Hemangioma; Hemang | 2023 |
Predictors of poor response to oral propranolol in infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Female; Hemangioma; Humans; Infant; Male; | 2023 |
The effects of propranolol on the biology and Notch signaling pathway of human umbilical vein endothelial cells.
Topics: Biology; Cell Proliferation; Hemangioma; Human Umbilical Vein Endothelial Cells; Humans; Propranolol | 2023 |
Practice Variations in Managing Infantile Hemangiomas.
Topics: Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Treatme | 2023 |
Intralesional betamethasone versus oral propranolol for localized infantile hemangiomas of the lip.
Topics: Adrenergic beta-Antagonists; Betamethasone; Child; Hemangioma; Humans; Infant; Lip; Propranolol; Pro | 2023 |
Effects of propranolol on glucose metabolism in hemangioma-derived endothelial cells.
Topics: Cell Proliferation; Child; Endothelial Cells; Glucose; Hemangioma; Humans; Phosphates; Propranolol; | 2023 |
Excessively High Chronic Propranolol Overdose in Infantile Hemangioma: A Case Report.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Drug Overdose; Female; Hemangioma; Hemangi | 2023 |
Symplastic hemangioma developing over an infantile hemangioma during propranolol treatment.
Topics: Female; Hemangioma; Humans; Infant; Neoplasms, Second Primary; Propranolol; Skin Neoplasms; Vasodila | 2019 |
Trends in healthcare utilization for infantile haemangioma in the U.S.A.
Topics: Hemangioma; Humans; Infant; Patient Acceptance of Health Care; Propranolol | 2020 |
Successful Medical Management of Life-threatening Hepatic Hemangioma in Neonates.
Topics: Drug Therapy, Combination; Embolization, Therapeutic; Female; Glucocorticoids; Hemangioma; Hepatic A | 2019 |
A 7-year follow-up study on untreated deep or mixed facial infantile hemangioma in East-Asian patients: When propranolol was not yet an option.
Topics: Asian People; Cardiovascular Agents; Child; Child, Preschool; Conservative Treatment; Disease Progre | 2019 |
Comment on "Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas".
Topics: Hemangioma; Hemangioma, Capillary; Humans; Propranolol; Timolol | 2019 |
Evaluating the Clinical Outcomes of Parotid Hemangiomas in the Pediatric Patient Population.
Topics: Adrenal Cortex Hormones; Drug Administration Schedule; Female; Hemangioma; Hemangioma, Capillary; Hu | 2021 |
Does treatment with propranolol affect quality of life in infantile hemangioma patients and their parents?
Topics: Child, Preschool; Cohort Studies; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Paren | 2019 |
Propranolol Accelerats Hemangioma Stem Cell Transformation Into Adipocyte.
Topics: Adipocytes; Cell Differentiation; Cells, Cultured; Child; Hemangioma; Humans; Neoplastic Stem Cells; | 2019 |
Lip Infantile Hemangiomas Involving the Vermillion Border Have Worse Outcomes and Prognosis to Oral Propranolol Than Lesions Confined to One Side of the Vermillion.
Topics: Hemangioma; Humans; Infant; Lip; Prognosis; Propranolol; Retrospective Studies; Treatment Outcome | 2020 |
Facial segmental haemangioma with PHACE Syndrome successfully treated with oral propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aortic Coarctation; Disease Progression; Eye Abno | 2019 |
[Modern Approach and Successful Experience of Conservative Treatment of Infantile Hemangiomas with Non-Selective Beta-Blocker Propranolol].
Topics: Adrenergic beta-Antagonists; Algorithms; Conservative Treatment; Hemangioma; Humans; Infant; Propran | 2019 |
Commentary: Propranolol for infantile hemangiomas - The intralesional route.
Topics: Eyelid Neoplasms; Hemangioma; Hemangioma, Capillary; Humans; Propranolol | 2019 |
Evaluating the Safety of Oral Propranolol Therapy in Patients With PHACE Syndrome.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aortic Coarctation; Cohort Studies; Eye Abnormali | 2020 |
Propranolol inhibits proliferation and induces apoptosis of hemangioma-derived endothelial cells via Akt pathway by down-regulating Ang-2 expression.
Topics: Angiopoietin-2; Apoptosis; Cell Line; Cell Proliferation; Down-Regulation; Endothelial Cells; Hemang | 2020 |
Oral propranolol for the treatment of infantile haemangiomas in Singapore.
Topics: Adrenergic beta-Antagonists; Child; Female; Hemangioma; Humans; Infant; Infant, Newborn; Infant, Pre | 2021 |
Rebound of Involuted Infantile Hemangioma After Administration of Salbutamol.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Bronchitis; Child, Preschool; Female; Hemangioma; Hu | 2020 |
Special management considerations for propranolol use in breastfed infants of mothers taking antihypertensives.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Breast Feeding; Female; Hemangioma; Humans; In | 2020 |
Enhanced efficacy of propranolol therapy for infantile hemangiomas based on a mesoporous silica nanoplatform through mediating autophagy dysfunction.
Topics: Animals; Antineoplastic Agents; Autophagy; Drug Carriers; Endoplasmic Reticulum Stress; Hemangioma; | 2020 |
Propranolol and topical timolol for infantile haemangiomas of the skin.
Topics: Hemangioma; Hemangioma, Capillary; Humans; Propranolol; Skin; Timolol | 2020 |
Teledermatology in paediatrics: Health-care impact on the early treatment of infantile haemangiomas.
Topics: Child; Female; Hemangioma; Humans; Infant; Male; Pediatrics; Propranolol; Referral and Consultation; | 2021 |
Oral propranolol administration is effective for infantile hemangioma in late infancy: A retrospective cohort study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Infant; Propranolol; R | 2020 |
Influence of Cytochrome P450 2D6 Polymorphisms on the Efficacy of Oral Propranolol in Treating Infantile Hemangioma.
Topics: Administration, Oral; Cytochrome P-450 CYP2D6; Female; Genotype; Hemangioma; Humans; Infant; Male; P | 2020 |
Modalities of use of oral propranolol in proliferative infantile haemangiomas: an international survey among practitioners.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms | 2020 |
Giant placental chorioangioma followed by circulatory failure of the newborn and infantile hemangioma: Case report.
Topics: Adrenergic beta-Antagonists; Anemia, Hemolytic; Disseminated Intravascular Coagulation; Edema; Eryth | 2020 |
Consumptive Hypothyroidism Due to Diffuse Hepatic Hemangiomas Treated With Propranolol Therapy.
Topics: Hemangioma; Humans; Hypothyroidism; Infant; Liver Neoplasms; Propranolol; Thyroid Hormones; Treatmen | 2020 |
Serum cytokine profiles in infants with infantile hemangiomas on oral propranolol treatment: VEGF and bFGF, potential biomarkers predicting clinical outcomes.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Chemoki | 2020 |
Propranolol-resistant infantile hemangioma successfully treated with sirolimus.
Topics: Adrenergic beta-Antagonists; Child; Hemangioma; Hemangioma, Capillary; Humans; Infant; Prednisolone; | 2020 |
A retrospective study of 2 or 3 mg/kg/day propranolol for infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Propran | 2020 |
A Case of Consumptive Hypothyroidism in a 1-Month-Old Boy with Diffuse Infantile Hepatic Hemangiomas.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Cholestasis; Drug Therapy, Combination; Heart | 2020 |
Successful treatment of infantile hemangioma with high risk of severe sequelae by microneedle radiofrequency.
Topics: Disease Progression; Hemangioma; Humans; Infant; Propranolol | 2020 |
At-home dose escalation of propranolol for infantile hemangiomas during the COVID-19 pandemic.
Topics: COVID-19; Hemangioma; Humans; Infant; Propranolol; SARS-CoV-2 | 2020 |
[Clinical effect of propranolol in the treatment of respiratory hemangioma in infants and young children].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Child, Preschool; Hemangioma; Humans; Infa | 2020 |
Periocular infantile hemangioma masquerading as dacryocele.
Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Lacrimal Duct Obstruction; Male; Nasolacrimal Duc | 2020 |
Strawberry mark: our daughter's journey with an infantile hemangioma.
Topics: Adaptation, Psychological; Adrenergic beta-Antagonists; Antineoplastic Agents; Female; Health Knowle | 2020 |
Cutaneous Infantile Haemangiomas with Intracranial and Intraspinal Involvement: A European Multicentre Experience and Review.
Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Retrosp | 2020 |
NOTCH pathway activation in infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Cell Proliferation; Child, Preschool; DNA-Bind | 2021 |
Combination therapy of oral propranolol and combined Nd:YAG/pulsed dye laser therapy in infantile hemangiomas: a retrospective analysis of 48 treated hemangiomas in 30 children.
Topics: Administration, Oral; Hemangioma; Humans; Infant; Laser Therapy; Lasers, Dye; Propranolol; Retrospec | 2020 |
Retrospective case series of increased oral propranolol dosage for infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Infant; Propranolol; R | 2020 |
A new clinical and dermoscopic monitoring of infantile hemangiomas treated with oral propranolol.
Topics: Hemangioma; Humans; Infant; Infant, Newborn; Neoplasm Recurrence, Local; Propranolol; Skin Neoplasms | 2020 |
Historical and Contemporary Management of Infantile Hepatic Hemangioma: A 30-year Single-center Experience.
Topics: Adolescent; Adrenergic beta-Antagonists; Child; Child, Preschool; Embolization, Therapeutic; Female; | 2022 |
Airway Hemangiomas in PHACE Syndrome: A Multicenter Experience.
Topics: Aortic Coarctation; Eye Abnormalities; Female; Hemangioma; Humans; Infant; Infant, Newborn; Male; Ne | 2021 |
Multiple pulmonary infantile hemangiomas responsive to oral propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2021 |
Study on the Mechanism of Targeted Poly(lactic-coglycolic acid) Nano-Delivery Carriers in the Treatment of Hemangiomas.
Topics: Apoptosis; Cell Proliferation; Child; Child, Preschool; Drug Carriers; Hemangioma; Humans; Infant; N | 2021 |
Recurrence rate of infantile hemangioma after oral propranolol therapy.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Neoplasm Recurrence, | 2021 |
Transcatheter Arterial Sclerosing Embolization for the Treatment of Giant Propranolol-Resistant Infantile Hemangiomas in the Parotid Region.
Topics: Antineoplastic Agents; Bleomycin; Drug Resistance, Neoplasm; Embolization, Therapeutic; Ethiodized O | 2021 |
Evaluation of Clinical Properties and Treatment Responses of Infantile Hemangioma.
Topics: Age Factors; Esthetics; Facial Neoplasms; Female; Glucocorticoids; Hemangioma; Hemorrhage; Humans; I | 2020 |
Propranolol's effects on the sleep of infants with hemangiomas: A prospective pilot study.
Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Hemangioma; Humans; Infant; Infant, Newborn; P | 2021 |
Serum levels of VEGF and bFGF in infantile hemangiomas treated with propranolol.
Topics: Fibroblast Growth Factor 2; Hemangioma; Humans; Infant; Propranolol; Prospective Studies; Vascular E | 2020 |
A survey on the application of oral propranolol and atenolol for the management of infantile hemangiomas in mainland China: Survey on propranolol atenolol hemangiomas.
Topics: Administration, Oral; Antihypertensive Agents; Atenolol; China; Female; Hemangioma; Humans; Infant; | 2021 |
[Propranolol treatment in Kasabach-Merritt Syndrome secondary to congenital hepatic hemangioma. Clinical case].
Topics: Hemangioma; Humans; Infant, Newborn; Kasabach-Merritt Syndrome; Liver Neoplasms; Propranolol | 2021 |
Oral propranolol therapy in parotid hemangiomas: A retrospective comparison with other infantile hemangiomas.
Topics: Administration, Oral; Hemangioma; Humans; Infant; Neoplasm Recurrence, Local; Propranolol; Retrospec | 2021 |
Propranolol Participates in the Treatment of Infantile Hemangioma by Inhibiting HUVECs Proliferation, Migration, Invasion, and Tube Formation.
Topics: Cell Adhesion; Cell Movement; Cell Proliferation; Cells, Cultured; Hemangioma; Human Umbilical Vein | 2021 |
Ultrasound and MRI findings as predictors of propranolol therapy response in patients with infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Magnetic Resonan | 2021 |
Propranolol for infantile hemangioma: Evaluating efficacy and predictors of response and rebound growth.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Cohort Studies; Hemangioma; Humans; Infant; Infan | 2021 |
Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma.
Topics: Angiopoietin-2; Biomarkers; Child; Child, Preschool; Cross-Sectional Studies; Enzyme-Linked Immunoso | 2021 |
Propranolol versus nadolol for treatment of pediatric subglottic hemangioma.
Topics: Adrenergic beta-Antagonists; Child; Female; Hemangioma; Humans; Infant; Male; Nadolol; Propranolol; | 2021 |
[Applied value of color Doppler flow imaging in diagnosis of congenital subglottic haemangioma in infant].
Topics: Child; Glottis; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Propranolol; Retrospective Studies; | 2021 |
[Cranio-facial-cervical and subglottic hemangioma with respiratory symptoms. A therapeutic emergency].
Topics: Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Propranolol; Tr | 2021 |
Propranolol for the treatment of ulcerated infantile hemangiomas: A prospective study.
Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Prospec | 2022 |
Using Topical Citric Acid to Treat an Infected Ulcerated Hemangioma in an Infant: A Case Study.
Topics: Child; Citric Acid; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outcome; Ulce | 2021 |
Subglottic ectopic thymus mimicking airway haemangioma.
Topics: Hemangioma; Humans; Infant; Infant, Newborn; Laryngeal Neoplasms; Lymphatic Diseases; Propranolol; R | 2021 |
Propranolol for infantile hemangiomas with hyperinsulinemic hypoglycemia.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Hypogl | 2021 |
Is prolonged monitoring necessary? An updated approach to infantile hemangioma treatment with oral propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Retrospe | 2021 |
Sleep behavior of infants with infantile hemangioma treated with propranolol-a cohort study.
Topics: Adrenergic beta-Antagonists; Cohort Studies; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms | 2021 |
Infantile Sacral Region Hemangioma and Combination Treatment with Propranolol and Topical Timolol: Case Review and Reference Review.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Bosnia and Herzegovina; Female; Hemangioma; Hu | 2021 |
Transient hypertriglyceridaemia associated with propranolol for treatment of infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Hypertriglyceridemia; Infant; Propranolol; | 2021 |
Persistent dysesthesias in involuted infantile hemangiomas: An uncommon complication in a common condition.
Topics: Administration, Cutaneous; Adolescent; Adult; Child; Child, Preschool; Hemangioma; Hemangioma, Capil | 2021 |
Propranolol for infantile hemangiomas in developing countries.
Topics: Afghanistan; Developing Countries; Facial Neoplasms; Female; Hemangioma; Humans; Infant; Male; Propr | 2017 |
Analysis of factors affecting the therapeutic effect of propranolol for infantile haemangioma of the head and neck.
Topics: Administration, Oral; Antineoplastic Agents; Female; Head and Neck Neoplasms; Hemangioma; Humans; In | 2017 |
Use of liothyronine without levothyroxine in the treatment of mild consumptive hypothyroidism caused by hepatic hemangiomas.
Topics: Hemangioma; Hormone Replacement Therapy; Humans; Hypothyroidism; Infant; Liver; Liver Neoplasms; Mal | 2017 |
Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experience.
Topics: Administration, Oral; Age Factors; Cohort Studies; Dose-Response Relationship, Drug; Drug Administra | 2017 |
Successful Treatment of Infantile Hemangiomas With Propranolol in Low-Birth-Weight Infants.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant, Low Birth Weight; Infant, Newborn; | 2017 |
Scalp Infantile Hemangioma Complicated by Life-Threatening Bleeding.
Topics: Adrenergic beta-Antagonists; Female; Glucocorticoids; Hemangioma; Hemorrhage; Humans; Infant; Predni | 2017 |
Expanding uses of propranolol in dermatology.
Topics: Administration, Cutaneous; Administration, Oral; Dermatology; Hemangioma; Humans; Practice Patterns, | 2017 |
Modern Management of Nasal Hemangiomas.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Algorithms; Child; Child, Preschool; Combined Modality T | 2017 |
Propranolol therapy for infantile hemangioma: our experience.
Topics: Administration, Oral; Hemangioma; Humans; Propranolol; Retrospective Studies | 2017 |
Use of propranolol in a remote region of rural Guatemala to treat a large facial infantile haemangioma.
Topics: Aortic Coarctation; Diagnosis, Differential; Eye Abnormalities; Face; Female; Guatemala; Hemangioma; | 2017 |
Tissue and serum mRNA profile of MMPs-2/9 as a potential novel biomarker for the most individual approach in infantile hemangiomas and cancer disease.
Topics: Biomarkers, Tumor; Child, Preschool; Female; Hemangioma; Humans; Immunohistochemistry; Infant; Infan | 2017 |
[Benign neonatal hemangiomatosis: An observation in a child in Togo].
Topics: Female; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Togo; Vasodilator Agents | 2017 |
Use of proporanolol compounding from tablet in infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Chemistry, Pharmaceutical; Drug Compounding; Hemangioma; Humans; Infant | 2017 |
Efficacy and Safety of 2% Topical Propranolol Cream for the Treatment of Proliferating Infantile Strawberry Hemangiomas: Correspondence.
Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Cavernous; Humans; Infant; Propranolol; Skin Ne | 2017 |
Diffuse Hepatic Hemangiomas Successfully Treated Using Sirolimus and High-Dose Propranolol.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Immunosuppressive Agents; Infant, Newborn; Liver; L | 2017 |
Study of Cognitive Function in Children Treated with Propranolol for Infantile Hemangioma.
Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Cognition; Female; Hemangioma; Humans; Infant; | 2017 |
Unexpected Effect of Propranolol and Prednisolone on Infantile Facial Rhabdomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Diagnosis, Differential; Facial Neoplasms; F | 2017 |
Use of the Hemangioma Severity Scale to facilitate treatment decisions for infantile hemangiomas.
Topics: Clinical Decision-Making; Cohort Studies; Databases, Factual; Female; Follow-Up Studies; Hemangioma; | 2017 |
Can the extent of heart rate reduction predict the clinical response of infantile haemangiomas to propranolol?
Topics: Anti-Arrhythmia Agents; Bradycardia; Drug Administration Schedule; Female; Heart Rate; Hemangioma; H | 2018 |
[Infantile haemangioma: clinical and demographic characteristics, experiences in the treatment].
Topics: Adrenergic beta-Antagonists; Child, Preschool; Follow-Up Studies; Hemangioma; Humans; Hungary; Infan | 2017 |
PLGA nanoparticles with CD133 aptamers for targeted delivery and sustained release of propranolol to hemangioma.
Topics: AC133 Antigen; Animals; Aptamers, Nucleotide; Cell Proliferation; Cell Survival; Delayed-Action Prep | 2017 |
Propranolol inhibits the proliferation, migration and tube formation of hemangioma cells through HIF-1α dependent mechanisms.
Topics: Apoptosis; Cell Movement; Cell Proliferation; Hemangioma; Humans; Hypoxia-Inducible Factor 1, alpha | 2017 |
Infantile hemangioma: factors causing recurrence after propranolol treatment.
Topics: Biomarkers; Female; Hemangioma; Hemodynamics; Humans; Infant; Infant, Newborn; Male; MicroRNAs; Prop | 2018 |
[Giant infantile hemangioma of the eyelid].
Topics: Abdominal Neoplasms; Eyelid Neoplasms; Eyelids; Female; Hemangioma; Humans; Infant; Propranolol; Tum | 2017 |
Significant inhibition of infantile hemangioma growth by sustained delivery of urea from liposomes-in-microspheres.
Topics: Administration, Oral; Animals; Cell Proliferation; Cells, Cultured; Delayed-Action Preparations; Dis | 2018 |
Reversible profound sensorineural hearing loss due to propranolol sensitive hemangioma in an infant with PHACE syndrome.
Topics: Adrenergic beta-Antagonists; Aortic Coarctation; Eye Abnormalities; Hearing Loss, Sensorineural; Hem | 2017 |
Eczematous dermatitis in an infantile hemangioma with minimal or arrested growth.
Topics: Adrenergic beta-Antagonists; Eczema; Glucocorticoids; Hemangioma; Humans; Hydrocortisone; Infant; Ma | 2018 |
Management trends of infantile hemangioma: A national perspective.
Topics: Biopsy; Child; Child, Preschool; Databases, Factual; Endoscopy; Female; Hemangioma; Hospital Charges | 2018 |
Huge fetal hepatic Hemangioma: prenatal diagnosis on ultrasound and prognosis.
Topics: Adult; Contrast Media; Dexamethasone; Female; Glucocorticoids; Hemangioma; Humans; Infant, Newborn; | 2018 |
Oral propranolol for infantile haemangioma may be associated with transient gross motor delay.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma; Humans; Inf | 2018 |
Clinical features and treatment results in children with hemangioma.
Topics: Adolescent; Adrenergic beta-Antagonists; Child; Child, Preschool; Female; Glucocorticoids; Hemangiom | 2017 |
Promotion of Propranolol Delivery to Hemangiomas by Using Anti-VEGFR Antibody-Conjugated Poly(lactic-co-glycolic acid) Nanoparticles.
Topics: Drug Delivery Systems; Hemangioma; Humans; Infant; Lactic Acid; Nanoparticles; Polyglycolic Acid; Po | 2017 |
[Benign aggressive vascular anomalies in children].
Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Arteriovenous Malformations; Child; Child, Pres | 2018 |
[Repurposing of betablockers in dermatology].
Topics: Adrenergic beta-Antagonists; Cell Proliferation; Dermatology; Hemangioma; Humans; Infant; Propranolo | 2018 |
Cleft Palate Repair Using Single Flap Palatoplasty in Patient With Associated Palatal Hemangioma.
Topics: Cleft Palate; Comorbidity; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Palatal Neoplasms; | 2018 |
Pigment epithelium-derived factor/vascular endothelial growth factor ratio plays a crucial role in the spontaneous regression of infant hemangioma and in the therapeutic effect of propranolol.
Topics: Apoptosis; Cell Movement; Cell Proliferation; Cells, Cultured; Endothelial Cells; Eye Proteins; Hema | 2018 |
Effects of Propranolol on Neurodevelopmental Outcomes in Patients with Infantile Hemangioma: A Case-Control Study.
Topics: Administration, Oral; Case-Control Studies; Central Nervous System; Female; Hemangioma; Humans; Infa | 2018 |
Utility of routine electrocardiographic screening before initiation of propranolol for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Electrocardiography; Female; Hemangioma; Humans; Infant; Male; Mass Scr | 2018 |
Modulation of LIN28B/Let-7 Signaling by Propranolol Contributes to Infantile Hemangioma Involution.
Topics: Antineoplastic Agents; Case-Control Studies; Cell Proliferation; Cellular Senescence; Epithelial-Mes | 2018 |
Propranolol pharmacokinetics in infants treated for Infantile Hemangiomas requiring systemic therapy: Modeling and dosing regimen recommendations.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Body Weight; Drug Administration Schedule; Drug D | 2018 |
Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Area Under Curve; Computer Simulation; Dose-Respo | 2018 |
Effectiveness of oral propranolol for infantile hemangiomas started after 5 months of age.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Propranolol; | 2020 |
Propranolol induces hemangioma endothelial cell apoptosis via a p53‑BAX mediated pathway.
Topics: Apoptosis; bcl-2-Associated X Protein; Endothelial Cells; Female; Hemangioma; Humans; Male; Mitochon | 2018 |
Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines.
Topics: Administration, Oral; Aortic Coarctation; Clinical Decision-Making; Consensus; Delphi Technique; Der | 2018 |
Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas?
Topics: Child; Fibroblast Growth Factor 2; Hemangioma; Humans; Infant; Neovascularization, Pathologic; Propr | 2018 |
Safety of Oral Propranolol for Infantile Hemangioma.
Topics: Administration, Oral; Bradycardia; Bronchitis; Child, Preschool; Cohort Studies; Databases, Factual; | 2018 |
Effects of oral propranolol for circumscribed choroidal hemangioma.
Topics: Adult; Choroid Neoplasms; Hemangioma; Humans; Longitudinal Studies; Middle Aged; Propranolol; Prospe | 2018 |
Propranolol versus steroids for the treatment of ulcerated infantile hemangiomas.
Topics: Adrenal Cortex Hormones; Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Propranolol; Re | 2018 |
Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Lasers, Dye; | 2018 |
[Effect of treatment of infant parotid hemangioma with no response to oral propranolol].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Embolization, Therapeutic; Hemangioma; Humans; In | 2018 |
Coexistence of Kasabach-Merritt Syndrome and placental chorioangioma in a premature infant.
Topics: Anti-Inflammatory Agents; Comorbidity; Fatal Outcome; Female; Hemangioma; Humans; Infant, Newborn; K | 2018 |
Cost-effectiveness of treating infantile haemangioma with propranolol in an outpatient setting.
Topics: Adrenergic beta-Antagonists; Cost of Illness; Cost-Benefit Analysis; Female; Hemangioma; Humans; Inf | 2018 |
Oral propranolol for infantile hemangiomas beyond the proliferative phase.
Topics: Administration, Oral; Asthma; Exanthema Subitum; Female; Hemangioma; Humans; Infant; Male; Photograp | 2018 |
Propranolol inhibits proliferation and invasion of hemangioma-derived endothelial cells by suppressing the DLL4/Notch1/Akt pathway.
Topics: Adaptor Proteins, Signal Transducing; Calcium-Binding Proteins; Cell Movement; Cell Proliferation; C | 2018 |
Role of Thrombospondin-1 and Nuclear Factor-κB Signaling Pathways in Antiangiogenesis of Infantile Hemangioma.
Topics: Adrenergic beta-Antagonists; Animals; Cell Proliferation; Endothelial Cells; Female; Hemangioma; Hum | 2018 |
Subglottic hemangioma: Understanding the association with facial segmental hemangioma in a beard distribution.
Topics: Antineoplastic Agents; Combined Modality Therapy; Facial Neoplasms; Female; Hemangioma; Humans; Infa | 2018 |
Surgical treatment outcomes of infantile hemangioma in children: Does prior medical treatment matter.
Topics: Adrenergic beta-Antagonists; Canada; Child; Child, Preschool; Cohort Studies; Female; Glucocorticoid | 2018 |
Minimizing differences in treatment: expert- and evidence-based guidelines for propranolol treatment of infantile haemangiomas in the U.K. and beyond.
Topics: Adrenergic beta-Antagonists; Child; Consensus; Dermatology; Hemangioma; Humans; Propranolol | 2018 |
Propranolol inhibits the activity of PI3K, AKT, and HIF-1α in infantile hemangiomas.
Topics: Animals; Disease Models, Animal; Hemangioma; Hypoxia-Inducible Factor 1, alpha Subunit; Mice, Nude; | 2018 |
Surgical resection of infantile hemangiomas following medical treatment with propranolol versus corticosteroids.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Female; Glucocorticoids; Hemang | 2019 |
Infantile hemangiomas with minimal or arrested growth: A retrospective case series.
Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Disease Progression; Female; Hemangioma; Human | 2019 |
Tufted angioma arising at the site of hepatitis B vaccination: A case report.
Topics: Adrenergic beta-Antagonists; Female; Glucocorticoids; Hemangioma; Hepatitis B Vaccines; Humans; Infa | 2018 |
Neonatal giant hepatic hemangioma: A case report.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant, Newborn; Liver; Liver Neoplasms; Ma | 2018 |
Effects of propranolol therapy in Moroccan children with infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Morocco | 2018 |
Epithelioid hemangioma of the orbit treated with oral propranolol in adult.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Hemangioma; Hum | 2018 |
Kinetic and Angiogenic Activity of Circulating Endothelial Colony Forming Cells in Patients with Infantile Haemangioma Receiving Propranolol.
Topics: Adrenergic beta-Antagonists; Antigens, CD34; Calcium; Calcium Signaling; Cell Movement; Chemokine CX | 2019 |
No Increased Risks Associated with Propranolol Treatment for Infantile Hemangioma in Preterm Infants were Identified at 3 Years of Age.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma; Humans; Inf | 2019 |
Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Pressure; Child; Heart Rate; Hemangioma; Hu | 2019 |
Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol | 2019 |
Propranolol as an effective therapy for infantile haemangioma of the urinary bladder.
Topics: Female; Hemangioma; Humans; Infant, Newborn; Propranolol; Treatment Outcome; Urinary Bladder Neoplas | 2019 |
MiR-187-3p Enhances Propranolol Sensitivity of Hemangioma Stem Cells.
Topics: Base Sequence; Cell Cycle Proteins; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; | 2019 |
Late ulceration of residual abortive infantile haemangioma: a rare complication.
Topics: Adolescent; Bandages; Biopsy; Female; Hemangioma; Humans; Leg Ulcer; Propranolol; Skin; Time Factors | 2019 |
Associations between short-term efficacy and clinical characteristics of infantile hemangioma treated by propranolol.
Topics: Adrenergic beta-Antagonists; Age Factors; Drug Administration Schedule; Female; Hemangioma; Humans; | 2019 |
Beta blockers for infantile haemangiomas: where should we go from here?
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Propranolol; Skin | 2019 |
Progressive infantile hepatic hemangioma not responding to propranolol.
Topics: Adrenergic beta-Antagonists; Age of Onset; Child, Preschool; Disease Progression; Fatal Outcome; Fem | 2019 |
Propranolol-Loaded Mesoporous Silica Nanoparticles for Treatment of Infantile Hemangiomas.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Hema | 2019 |
Secondary Congenital Glaucoma Associated With Retro-orbital Infantile Hemangioma: A Masquerade Syndrome.
Topics: Diagnosis, Differential; Female; Glaucoma; Hemangioma; Humans; Hydrophthalmos; Infant; Intraocular P | 2019 |
Infantile hemangioma: Efficacy of low-dose propranolol and of intralesional bleomycin injection for propranolol non-response.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Bleomycin; Female; Hemangioma; Humans; Infant; In | 2019 |
Clinical and radiological outcomes of infantile hemangioma treated with oral propranolol: A long-term follow-up study.
Topics: Administration, Oral; Child, Preschool; Disease Progression; Erythema; Female; Follow-Up Studies; He | 2019 |
Objective evaluation of the response of infantile haemangiomas to propranolol treatment using a three-dimensional imaging system.
Topics: Administration, Oral; Feasibility Studies; Female; Follow-Up Studies; Hemangioma; Humans; Imaging, T | 2019 |
Effectiveness of oral propranolol in a patient with neurofibromatosis type 1 and infantile hemangiomas.
Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Neurofibromatosis 1; Propranolol | 2021 |
[Vascular Cutaneous Abnormalities in Togo: a 120-Case Study].
Topics: Adrenal Cortex Hormones; Child, Preschool; Cohort Studies; Female; Hemangioma; Humans; Infant; Klipp | 2018 |
Successful treatment of an exudative choroidal hemangioma with oral propranolol in a 10-year-old boy.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Choroid; Choroid Neoplasms; Dose-Response | 2019 |
The sustained and targeted treatment of hemangiomas by propranolol-loaded CD133 aptamers conjugated liposomes-in-microspheres.
Topics: AC133 Antigen; Animals; Aptamers, Nucleotide; Cell Proliferation; Cells, Cultured; Delayed-Action Pr | 2019 |
Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas.
Topics: Administration, Oral; Administration, Topical; Adrenergic beta-Antagonists; Combined Modality Therap | 2019 |
Propranolol suppresses infantile hemangioma cell proliferation and promotes apoptosis by upregulating miR-125b expression.
Topics: Adrenergic beta-Antagonists; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Gene Expression Regul | 2019 |
Preoperative administration of propranolol reduced the surgical risks of PHACES syndrome in a 14-month-old girl.
Topics: Abnormalities, Multiple; Administration, Oral; Adrenergic beta-Antagonists; Airway Obstruction; Aort | 2019 |
Treatment failure with propranolol for subglottic haemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Laryngeal Neoplasms; | 2019 |
EFFECTIVENESS OF FIXED DOSES OF PROPRANOLOL IN THE TREATMENT OF HEMANGIOMAS REGARDLESS OF CHILD'S WEIGHT GAIN: A CASE REPORT.
Topics: Adrenergic beta-Antagonists; Child; Dose-Response Relationship, Drug; Female; Hemangioma; Humans; Pr | 2019 |
[Infantile haemangioma: an update].
Topics: Child; Face; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outcome | 2019 |
Therapeutic efficacy of propranolol for infantile hemangiomas.
Topics: Administration, Oral; Hemangioma; Humans; Infant; Logistic Models; Propranolol; Retrospective Studie | 2019 |
Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Body Height; Body Weight; Child Development; Dose-Response Relationship | 2019 |
A Life Threatening Subglottic and Mediastinal Hemangioma in an Infant.
Topics: Female; Hemangioma; Hemangioma, Capillary; Humans; Infant; Laryngeal Neoplasms; Mediastinal Neoplasm | 2019 |
Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Dose-Response Relationship, Dru | 2019 |
R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma.
Topics: Adrenergic beta-Antagonists; Animals; Disease Models, Animal; Enzyme Inhibitors; Hemangioma; Humans; | 2019 |
[Rapid response of a multifocal liver hemangioma to propranolol treatment].
Topics: Female; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol; Remission Induction; Time Factors | 2013 |
Hemangiomas of the nasal tip treated with propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Israel; Male; | 2012 |
Propranolol use for infantile hemangiomas: American Society of Pediatric Otolaryngology Vascular Anomalies Task Force practice patterns.
Topics: Adrenergic beta-Antagonists; Blood Glucose; Blood Pressure; Dose-Response Relationship, Drug; Drug A | 2013 |
Retrospective study of the treatment of infantile hemangiomas using a combination of propranolol and pulsed dye laser.
Topics: Combined Modality Therapy; Hemangioma; Humans; Infant; Infant, Newborn; Lasers, Dye; Propranolol; Re | 2013 |
Use of propranolol for the treatment infantile hemangiomas in the maxillofacial region.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Face; Female; Hemangioma; Human | 2013 |
Propranolol for infantile haemangioma: a review of current dosing regime in a regional paediatric hospital.
Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemangioma | 2013 |
Propranolol-resistant infantile haemangiomas.
Topics: Age of Onset; Antineoplastic Agents; Child, Preschool; Drug Resistance, Neoplasm; Facial Neoplasms; | 2013 |
Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol.
Topics: Administration, Oral; Antineoplastic Agents; Child; Child, Preschool; Female; Head and Neck Neoplasm | 2013 |
Propranolol for infantile haemangiomas: initiating treatment on an outpatient basis.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol; Skin Neoplasms | 2013 |
Successful management of airway hemangioma with propranolol.
Topics: Adrenergic beta-Antagonists; Airway Obstruction; Epiglottis; Female; Head and Neck Neoplasms; Hemang | 2013 |
What's new in pediatric dermatology?: part II. Treatment.
Topics: Acyclovir; Antiviral Agents; Dermatitis, Atopic; Dermatology; Hemangioma; Humans; Internet; Proprano | 2013 |
Successful discontinuation of propranolol for infantile hemangiomas of the head and neck at 12 months of age.
Topics: Adrenergic beta-Antagonists; Age Factors; Female; Follow-Up Studies; Head and Neck Neoplasms; Hemang | 2013 |
Treating infantile hemangiomatosis: a case study.
Topics: Antineoplastic Agents; Female; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms | 2013 |
[A case of congenital subglottic hemangiomas].
Topics: Administration, Oral; Bronchoscopy; Female; Glottis; Hemangioma; Humans; Infant, Newborn; Laryngeal | 2013 |
[Treatment of superficial infantile hemangiomas with topical propranolol].
Topics: Female; Hemangioma; Humans; Infant; Male; Ointments; Propranolol; Skin Neoplasms; Treatment Outcome | 2013 |
Medical management of tumors associated with Kasabach-Merritt phenomenon: an expert survey.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Data Collection; Hemangioendothelioma; Hemangioma; H | 2013 |
An update on infantile haemangiomas.
Topics: Antineoplastic Agents; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms | 2013 |
Diffuse neonatal hemangiomatosis with partial response to propranolol.
Topics: Female; Hemangioma; Humans; Infant, Newborn; Liver Neoplasms; Propranolol; Skin Neoplasms; Vasodilat | 2014 |
Haemangioma and propranolol.
Topics: Adrenergic beta-Antagonists; Cardiovascular Agents; Combined Modality Therapy; Facial Neoplasms; Fem | 2014 |
Dangers of propranolol in preterm infants.
Topics: Apnea; Bradycardia; Hemangioma; Humans; Infant; Infant, Premature; Mouth Neoplasms; Propranolol; Ski | 2013 |
Periocular infantile haemangioma and the role of propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Eyelid Neoplasms; Female; Hemangioma; Humans; Inf | 2013 |
Propranolol therapy for cutaneous infantile haemangiomas initiated safely as a day-case procedure.
Topics: Adrenergic beta-Antagonists; Day Care, Medical; Female; Hemangioma; Humans; Infant; Male; Propranolo | 2014 |
Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Atenolol; Facial Neoplasms; Fem | 2013 |
Upregulated autocrine vascular endothelial growth factor (VEGF)/VEGF receptor-2 loop prevents apoptosis in haemangioma-derived endothelial cells.
Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Apoptosis; Cell Survival; Culture Media, Serum | 2014 |
A Case of PHACES Syndrome with Successful Treatment of Facial Haemangioma With Propranolol.
Topics: Hemangioma; Humans; Infant; Propranolol; Syndrome | 2013 |
Effects of oral propranolol on circumscribed choroidal hemangioma: a pilot study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Choroid Neoplasms; Coloring Agents; Female | 2013 |
Propranolol as diagnostic tool for infantile hemangiomas.
Topics: Diagnosis, Differential; Facial Neoplasms; Hemangioma; Humans; Infant; Male; Myofibroma; Propranolol | 2013 |
Cardiovascular and blood glucose parameters in infants during propranolol initiation for treatment of symptomatic infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Blood Glucose; Blood Pressure; Cardiovascular System; Dose-Response Rel | 2013 |
Propranolol for infantile haemangiomas: review of report of a consensus conference.
Topics: Congresses as Topic; Hemangioma; Humans; Infant; Patient Selection; Propranolol; Vasodilator Agents | 2014 |
Large orbital hemangioma: managed with systemic propranolol.
Topics: Administration, Oral; Hemangioma; Humans; Infant; Male; Orbital Neoplasms; Propranolol | 2014 |
Propranolol for the treatment of infantile haemangiomas: our experience with 44 patients.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Infant, Newborn; Male; Propranolol | 2014 |
Propranolol inhibits growth of hemangioma-initiating cells but does not induce apoptosis.
Topics: Adrenergic beta-Antagonists; Apoptosis; Caspase 3; Cell Count; Cell Proliferation; Cyclin D1; Hemang | 2014 |
[Controlling therapy with propranolol for infants with parotid gland hemangiomas].
Topics: Hemangioma; Humans; Infant; Parotid Gland; Parotid Neoplasms; Propranolol | 2013 |
Treatment of infantile hemangiomas with propranolol: clinical guidelines.
Topics: Adrenergic beta-Antagonists; Child, Preschool; Clinical Protocols; Facial Neoplasms; Female; Hemangi | 2014 |
Propranolol: a novel antihemangioma agent with multiple potential mechanisms of action.
Topics: Adrenergic beta-Antagonists; Endothelial Cells; Hemangioma; Humans; Hypoxia-Inducible Factor 1, alph | 2015 |
Reply to letter: "propranolol: a novel antihemangioma agent with multiple potential mechanisms of action".
Topics: Adrenergic beta-Antagonists; Endothelial Cells; Hemangioma; Humans; Hypoxia-Inducible Factor 1, alph | 2015 |
Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Cell Proliferation; Cells, Cultured; | 2014 |
[Medication-based therapy of infantile hemangioma and lymphatic malformations].
Topics: Antibiotics, Antineoplastic; Female; Head and Neck Neoplasms; Hemangioma; Humans; Infant; Infant, Ne | 2014 |
Treatment of children and adolescents with hemangioma using propranolol: preliminary results from a retrospective study.
Topics: Adolescent; Adrenergic beta-Antagonists; Age Factors; Chi-Square Distribution; Child; Child, Prescho | 2014 |
Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Topics: Adrenergic beta-Antagonists; Female; Hemangioendothelioma; Hemangioma; Humans; Kasabach-Merritt Synd | 2014 |
Effectiveness of propanolol for treatment of infantile haemangioma.
Topics: Adrenergic beta-Antagonists; Drug Administration Schedule; Female; Hemangioma; Humans; Infant; Infan | 2014 |
Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases.
Topics: Administration, Oral; Dermatologic Agents; Female; Follow-Up Studies; Hemangioma; Hospitals, Univers | 2014 |
Propranolol as first-line treatment in orbital infantile haemangiomas: a case series.
Topics: Administration, Oral; Contrast Media; Female; Hemangioma; Humans; Infant; Magnetic Resonance Imaging | 2014 |
Beta blocker treatment of infantile conjunctival hemangiomas--observations from 2 cases.
Topics: Adrenergic beta-Antagonists; Conjunctival Neoplasms; Female; Hemangioma; Humans; Infant; Propranolol | 2014 |
Successful treatment of pulmonary hemangioma with propranolol.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Lung Neoplasms; Propranolol; Radiog | 2014 |
[The effectiveness of propranolol therapy of subfold hemangioma in the children during the first year of life].
Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Female; Glottis; Hemangioma; Humans; | 2014 |
Successful treatment of multifocal intracerebral and spinal hemangiomas with propranolol.
Topics: Brain Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; | 2014 |
Propranolol targets the contractility of infantile haemangioma-derived pericytes.
Topics: Adrenergic beta-Antagonists; Animals; Blood Volume; Cell Proliferation; Endothelial Cells; Epinephri | 2014 |
A retrospective analysis of systemic propranolol for the treatment of complicated infantile haemangiomas.
Topics: Female; Hemangioma; Humans; Infant; Male; Propranolol; Retrospective Studies; Skin Neoplasms; Treatm | 2014 |
Retrospective analysis of beta-blocker instituted for treatment of hemangiomas (RABBIT study).
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; In | 2014 |
The role of propranolol in the treatment of infantile hemangioma.
Topics: Child; Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Propranolol; Prospective Studies; | 2014 |
Successful treatment of diffuse neonatal hemangiomatosis with propranolol: a case report.
Topics: Administration, Oral; Hemangioma; Humans; Infant, Newborn; Joint Instability; Male; Phimosis; Propra | 2014 |
Safety profile of a divided dose of propranolol for heart rate in children with infantile haemangioma during 16 weeks of treatment.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Case-Control Studies; Child; Dose-Response Rela | 2015 |
Oral propranolol (Hemangeol) for infantile hemangioma.
Topics: Administration, Oral; Antineoplastic Agents; Hemangioma; Humans; Infant; Propranolol | 2014 |
Propranolol promotes accelerated and dysregulated adipogenesis in hemangioma stem cells.
Topics: Adipogenesis; Hemangioma; Humans; Neoplastic Stem Cells; Propranolol; Time Factors; Tumor Cells, Cul | 2014 |
Propranolol enhanced adipogenesis instead of induction of apoptosis of hemangiomas stem cells.
Topics: Adipogenesis; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Differentiation; Cells, Cult | 2014 |
Propranolol for infantile haemangiomas: single centre experience of 250 cases and proposed therapeutic protocol.
Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Prop | 2014 |
[Effectiveness of external propranolol gel for treatment of superficial infantile hemangioma].
Topics: Child, Preschool; Female; Gels; Hemangioma; Humans; Infant; Male; Propranolol | 2014 |
[Clinical analysis for treatment of 1 080 cases of infantile hemangiomas with oral propranolol].
Topics: Administration, Oral; Female; Hemangioma; Humans; Male; Propranolol; Retrospective Studies; Treatmen | 2014 |
Increased apoptosis and secretion of tryptase by mast cells in infantile haemangioma treated with propranolol.
Topics: Apoptosis; Biopsy; Case-Control Studies; Cell Degranulation; Endothelial Cells; Extracellular Matrix | 2014 |
Glucose transporter 1-positive endothelial cells in infantile hemangioma exhibit features of facultative stem cells.
Topics: Cell Differentiation; Cell Proliferation; Child; Child, Preschool; Endothelial Cells; Female; Glucos | 2015 |
Intractable choroidal effusion with exudative retinal detachment in Sturge-Weber syndrome.
Topics: Administration, Oral; Antihypertensive Agents; Child, Preschool; Choroid Neoplasms; Exudates and Tra | 2014 |
Ultrasound in assessing the efficacy of propranolol therapy for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Child, Preschool; Female; Follow-Up Studies; Hemangioma; Humans; Infant | 2014 |
Allergic contact dermatitis caused by topical propranolol in a 5-month-old baby.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Dermatitis, Allergic Contact; Female; Hand; | 2014 |
Is propranolol compounding from tablet safe for pediatric use? Results from an experimental test.
Topics: Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Dermatologic Agents; Drug Compoundi | 2014 |
[Subglottic haemangioma].
Topics: Female; Glottis; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Laryngoscopy; Propranolol; Rare Di | 2014 |
Monitoring propranolol treatment in periocular infantile haemangioma.
Topics: Administration, Oral; Adolescent; Adrenergic beta-Antagonists; Amblyopia; Child; Child, Preschool; D | 2014 |
Successful treatment of tufted angioma with propranolol.
Topics: Hemangioma; Humans; Infant; Male; Propranolol; Skin; Skin Neoplasms; Vasodilator Agents | 2014 |
Diode laser for the treatment of telangiectasias following hemangioma involution.
Topics: Child; Child, Preschool; Female; Hemangioma; Humans; Infant; Lasers, Semiconductor; Male; Propranolo | 2015 |
Giant cranial and cerebellar hemangioma treated with propranolol.
Topics: Adrenergic beta-Antagonists; Cerebellar Neoplasms; Female; Hemangioma; Humans; Infant, Newborn; Prop | 2015 |
[Expression of serum and urinary vascular endothelial growth factor-A and epidermal growth factor-like domain 7 in proliferating hemangioma treated with propranolol].
Topics: EGF Family of Proteins; Enzyme-Linked Immunosorbent Assay; Hemangioma; Humans; Infant; Propranolol; | 2014 |
Nadolol for the treatment of infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Child, Preschool; Female; Heart Rate; Hemangioma; Human | 2015 |
Comprehensive therapy for hemangioma presenting with Kasabach-Merritt syndrome in the maxillofacial region.
Topics: Blood Coagulation Tests; Combined Modality Therapy; Embolization, Therapeutic; Female; Follow-Up Stu | 2015 |
Topical treatment with propranolol gel as a supplement to the existing treatment of hemangiomas.
Topics: Administration, Topical; Female; Gels; Hemangioma; Humans; Infant; Male; Propranolol; Retrospective | 2014 |
[Effects of propranolol on proliferation of hemangioma-derived mesenchymal stem cells ].
Topics: Adipogenesis; Antigens; Cell Differentiation; Cell Proliferation; Cells, Cultured; Endothelium, Vasc | 2014 |
Treatment of severe infantile hemangiomas with propranolol: an evaluation of the efficacy and effects of cardiovascular parameters in 25 consecutive patients.
Topics: Administration, Oral; Blood Glucose; Blood Pressure; Echocardiography; Electrocardiography; Facial N | 2015 |
[Clinical case of treatment of hepatic haemangioma by propranolol in the newborn].
Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemangioma; | 2014 |
Propranolol for infantile haemangiomas: certain chances, potential risks.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Propranolol; Skin Neoplasms | 2015 |
Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas?: A cohort study.
Topics: Adrenergic beta-Antagonists; Cardiovascular Diseases; Child, Preschool; Cohort Studies; Drug Monitor | 2015 |
Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Antineoplastic Agents, Hormonal; Blepharoptosi | 2015 |
Intralesional injection of diprospan is effective for infantile hemangioma.
Topics: Betamethasone; Drug Combinations; Female; Follow-Up Studies; Glucocorticoids; Head and Neck Neoplasm | 2015 |
Evidence and nuances of propranolol safety.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Female; Heart Rate; Hemangioma; Humans; Male; P | 2015 |
[Infantile hemangiomas: the revolution of beta-blockers].
Topics: Adrenergic beta-Antagonists; Dermatologic Agents; Early Medical Intervention; Esthetics; Follow-Up S | 2014 |
Efficacy of propranolol for cutaneous hemangiomas in premature children.
Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemangioma | 2016 |
Oral propranolol for parotid infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Color; Female; Follow-Up Studies; Hemangioma; Hum | 2015 |
Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway.
Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Cell Cycle Checkpoints; Cell Proliferation; Ce | 2015 |
[Propranolol in infantile hemangiomas].
Topics: Adrenergic beta-Antagonists; Child, Preschool; Facial Neoplasms; Hemangioma; Humans; Propranolol; Sk | 2015 |
Delayed-onset of multiple cutaneous infantile hemangiomas due to propranolol: a case report.
Topics: Dose-Response Relationship, Drug; Heart Defects, Congenital; Hemangioma; Humans; Infant; Infant, New | 2015 |
A novel topical nano-propranolol for treatment of infantile hemangiomas.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Hydrogels; Infant; | 2015 |
Diffuse neonatal hemangiomatosis in a very low-birthweight infant treated with erythropoietin.
Topics: Adrenergic beta-Antagonists; Anemia, Neonatal; Erythropoietin; Gestational Age; Hemangioma; Humans; | 2015 |
Propranolol represses infantile hemangioma cell growth through the β2-adrenergic receptor in a HIF-1α-dependent manner.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; He | 2015 |
Propranolol to treat infantile hemangioma (IH) in patients with congenital heart disease.
Topics: Female; Heart Defects, Congenital; Hemangioma; Humans; Infant; Male; Propranolol; Prospective Studie | 2015 |
[Combination of pulsed dye laser and propranolol in the treatment of ulcerated infantile haemangioma].
Topics: Hemangioma; Humans; Infant; Lasers, Dye; Propranolol; Retrospective Studies; Skin Neoplasms; Treatme | 2016 |
Open airway surgery for subglottic hemangioma in the era of propranolol: Is it still indicated?
Topics: Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma; Humans; Laryngeal Neoplasms; Lary | 2015 |
Infantile Hemangioma in the Airway.
Topics: Airway Obstruction; Biopsy; Hemangioma; Humans; Infant; Laryngoscopy; Propranolol; Respiratory Sound | 2015 |
Propanolol effectively treats significant infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol | 2015 |
[Hepatic hemangiomas: Spectacular response to treatment with propranolol].
Topics: Abdominal Neoplasms; Hemangioma; Humans; Infant; Propranolol; Treatment Outcome | 2015 |
Multicenter Evaluation of the Effectiveness of Systemic Propranolol in the Treatment of Airway Hemangiomas.
Topics: Airway Obstruction; Endoscopy; Female; Hemangioma; Humans; Infant; Infant, Newborn; Laryngeal Neopla | 2015 |
Risk of neurodevelopmental abnormalities in children treated with propranolol.
Topics: Adrenergic beta-Antagonists; Animals; Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Ne | 2015 |
Propranolol during pregnancy for large chorioangioma.
Topics: Adult; Female; Hemangioma; Humans; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome | 2015 |
DIFFUSE CHOROIDAL HEMANGIOMA MASQUERADING AS CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH ORAL PROPRANOLOL.
Topics: Adolescent; Adrenergic beta-Antagonists; Central Serous Chorioretinopathy; Choroid Neoplasms; Diagno | 2016 |
Use of propranolol on a nasal hemangioma in an extremely low birthweight premature infant.
Topics: Child, Preschool; Hemangioma; Humans; Infant; Infant, Extremely Low Birth Weight; Infant, Extremely | 2015 |
Oral Propranolol for Infantile Hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol | 2015 |
Oral Propranolol for Infantile Hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol | 2015 |
Large Doses of Propranolol for the Treatment of Infantile Cephalic and Facial Hemangiomas: A Clinical Report of 38 Cases.
Topics: Antineoplastic Agents; Blood Glucose; Blood Pressure; Drug Administration Schedule; Facial Neoplasms | 2015 |
Propranolol (Hemangiol) and severe infantile haemangiomas. The drug of first choice.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Hemangioma; Humans; Prednisolone; Propranolol | 2015 |
Propranolol-responsive cranial nerve palsies in a patient with PHACES syndrome.
Topics: Aortic Coarctation; Bell Palsy; Eye Abnormalities; Hemangioma; Humans; Infant; Neurocutaneous Syndro | 2015 |
Commentary on Moodley S et al. "Shouldn't Propranolol be Used to Treat All Hemangiomas?".
Topics: Animals; Cadaver; Evidence-Based Medicine; Hemangioma; Humans; Propranolol | 2015 |
[Making hemangiomas disappear with cardiac agents: pediatric surgeons greet the new study results].
Topics: Child; Child, Preschool; Controlled Clinical Trials as Topic; Drug Approval; Germany; Hemangioma; Hu | 2015 |
Characterization of Endothelial Microparticles Induced by Different Therapeutic Drugs for Infantile Hemangioma.
Topics: Cells, Cultured; Dexamethasone; Endothelium, Vascular; Flow Cytometry; Hemangioma; Human Umbilical V | 2015 |
[Oral propranolol effective for hemangioma].
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol | 2015 |
Shouldn't Propranolol Be Used to Treat All Haemangiomas?
Topics: Female; Hemangioma; Humans; Infant; Male; Propranolol; Retrospective Studies; Skin Neoplasms | 2015 |
Propranolol for Treatment of Genital Infantile Hemangioma.
Topics: Adolescent; Child; Child, Preschool; Female; Genital Neoplasms, Female; Genital Neoplasms, Male; Hem | 2016 |
Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas.
Topics: Adrenergic beta-Antagonists; Drug Combinations; Hemangioma; Humans; Propranolol; Prospective Studies | 2015 |
Clinical Characteristics and Treatment Options of Infantile Vascular Anomalies.
Topics: Adrenal Cortex Hormones; Age Factors; China; Combined Modality Therapy; Female; Hemangioma; Humans; | 2015 |
Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey.
Topics: Administration, Oral; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Hemangioma; H | 2016 |
Haemangioma in an infant whose mother was receiving long-term propranolol treatment during pregnancy.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Propranolol; Skin Neoplasms | 2016 |
Conservative Management of Cardiac Hemangioma for 11 Years.
Topics: Adrenergic beta-Antagonists; Adult; Coronary Angiography; Drug Therapy, Combination; Echocardiograph | 2015 |
Reply of the authors.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Hypoglycemia; Propranolol | 2015 |
Response to "Propranolol Induced Hypoglycemia" by Amir Horev, MD, Alon Haim, MD, Alex Zvulunov, MD.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Hypoglycemia; Propranolol | 2015 |
Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation.
Topics: Animals; Apoptosis; Cell Proliferation; Cyclic AMP; Dose-Response Relationship, Drug; Hemangioma; Hu | 2016 |
[Effect of propranolol gel on plasma VEGF, bFGF and MMP-9 in proliferating infantile hemangiomas of superficial type].
Topics: Administration, Topical; Case-Control Studies; Child; Enzyme-Linked Immunosorbent Assay; Fibroblast | 2015 |
Treatment for Infantile Hemangiomas: Selection Criteria, Safety, and Outcomes Using Oral Propranolol During the Early Phase of Propranolol Use for Hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Antineoplastic Agents; Body Weight; Cohort Studie | 2016 |
Use of propranolol for parotid hemangioma.
Topics: Administration, Oral; Female; Hemangioma; Humans; Infant; Infant, Newborn; Male; Neoplasm Recurrence | 2016 |
[Fast response of subglottic haemangiomas to propranolol].
Topics: Child, Preschool; Female; Glottis; Hemangioma; Humans; Infant; Infant, Newborn; Laryngeal Neoplasms; | 2016 |
Safety of Propranolol Therapy for Severe Infantile Hemangioma.
Topics: Administration, Oral; Antineoplastic Agents; Causality; Child; Child, Preschool; Compassionate Use T | 2016 |
Commentary on Moodley S et al. "Shouldn't Propranolol be Used to Treat All Hemangiomas?" and Dr. Blei's Invited Commentary.
Topics: Hemangioma; Humans; Propranolol | 2016 |
The embryo-placental CD15-positive "vasculogenic zones" as a source of propranolol-sensitive pediatric vascular tumors.
Topics: Age of Onset; Cell Lineage; Child; Drug Resistance, Neoplasm; Embryo, Mammalian; Endothelial Cells; | 2016 |
Propranolol was effective in treating cutaneous infantile haemangiomas in Thai children.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Female; Hemangioma; Humans; Infant, Newborn; | 2016 |
Rebound Growth of Infantile Hemangiomas After Propranolol Therapy.
Topics: Adrenergic beta-Antagonists; Cohort Studies; Drug Administration Schedule; Female; Hemangioma; Human | 2016 |
Hemangiomas and β-Blockers: On the Rebound.
Topics: Adrenergic beta-Antagonists; Hemangioma; Infant; Propranolol | 2016 |
Treatment of infantile hemangioma by intralesional injection of propranolol combined with compound betamethasone.
Topics: Betamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Inj | 2016 |
The treatment of problematic hemangiomas in children with propranolol and 940nm diode laser.
Topics: Administration, Oral; Antineoplastic Agents; Child, Preschool; Combined Modality Therapy; Female; He | 2016 |
Propranolol for infantile hemangioma: Effect on plasma vascular endothelial growth factor.
Topics: Administration, Oral; Adolescent; Adrenergic beta-Antagonists; Child; Child, Preschool; Dose-Respons | 2016 |
Oral Propranolol for the Treatment of Infantile Hemangiomas in the Post-Proliferative Phase: A-Single Center Retrospective Study of 31 Cases.
Topics: Administration, Oral; Child, Preschool; Female; Head and Neck Neoplasms; Hemangioma; Humans; Infant; | 2016 |
[Effects of topical propranolol hydrochloride gel for treatment of infantile hemangioma in nude mice].
Topics: Animals; Gels; Hemangioma; Humans; Immunohistochemistry; Mice; Mice, Nude; Propranolol; Skin Neoplas | 2015 |
[Subsequent therapy for infantile hemangiomas after discontinuation of oral propranolol].
Topics: Administration, Oral; Bleomycin; Child, Preschool; Face; Female; Hemangioma; Humans; Hyperplasia; Hy | 2015 |
[Changes in ambulatory electrocardiographic findings after oral administration of low-dose propranolol in infants with hemangioma].
Topics: Administration, Oral; Electrocardiography; Female; Heart Rate; Hemangioma; Humans; Infant; Male; Pro | 2016 |
Hepatic Hemangioma with Kasabach-Merritt Syndrome in an Adult Patient.
Topics: Abdomen; Ecchymosis; Female; Gastrointestinal Hemorrhage; Hemangioma; Humans; Kasabach-Merritt Syndr | 2016 |
Serum and tissue profile of VEGF and its receptors VGFR1/R2 in children with infantile hemangiomas on systemic propranolol treatment.
Topics: Angiogenesis Inhibitors; Female; Gene Expression Profiling; Hemangioma; Humans; Immunohistochemistry | 2016 |
3D photography is a reliable method of measuring infantile haemangioma volume over time.
Topics: Adrenergic beta-Antagonists; Aftercare; Female; Follow-Up Studies; Hemangioma; Humans; Imaging, Thre | 2016 |
Clinical Outcomes of Infants With Periorbital Hemangiomas Treated With Oral Propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Administration Schedule; Eye; Female; Follow | 2016 |
Role of oral propranolol in the treatment of infantile subglottic hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Glottis; Hemangioma; Humans; Infant; Infa | 2016 |
Multifocal infantile haemangioma: a diagnostic challenge.
Topics: Adrenergic beta-Antagonists; Anemia; Diagnosis, Differential; Hemangioma; Humans; Infant; Infant, Ne | 2016 |
Low Dose Propanolol for Infantile Haemangioma.
Topics: Dose-Response Relationship, Drug; Hemangioma; Humans; Infant; Propranolol | 2016 |
Propranolol treatment for infantile hemangioma: a case series of sixty-two patients.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma; Humans; Inf | 2016 |
Reevaluating the Need for Electrocardiograms Prior to Initiation of Treatment With Propranolol for Infantile Hemangiomas.
Topics: Contraindications, Drug; Electrocardiography; Fee-for-Service Plans; Heart Diseases; Hemangioma; Hum | 2016 |
Response to propranolol in infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Biopsy; Dose-Response Relationship, Drug; Female; Hemangioma; Humans; I | 2016 |
The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol.
Topics: Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Hemangioma; H | 2016 |
Effective treatment for infantile hemangioma with long-pulsed dye laser with oral propranolol medication: a preliminary report.
Topics: Administration, Oral; Combined Modality Therapy; Female; Hemangioma; Humans; Infant; Lasers, Dye; Ma | 2016 |
Corticosteroids as an adjunct to propranolol for infantile haemangiomas complicated by recalcitrant ulceration.
Topics: Administration, Oral; Chronic Disease; Drug Therapy, Combination; Glucocorticoids; Hemangioma; Human | 2017 |
Topical Timolol Maleate Treatment of Infantile Hemangiomas.
Topics: Administration, Oral; Administration, Topical; Adrenergic beta-Antagonists; Cohort Studies; Female; | 2016 |
Topical Treatment of Infantile Haemangiomas: A Comparative Study on the Selection of a Semi-Solid Vehicle.
Topics: Administration, Cutaneous; Drug Carriers; Drug Delivery Systems; Hemangioma; Humans; Organ Culture T | 2016 |
Use of Propranolol for Treating Hemangiomas in Infants with Previously Diagnosed Hypoglycemic Conditions.
Topics: Administration, Oral; Female; Hemangioma; Humans; Hypoglycemia; Infant, Newborn; Infant, Premature, | 2016 |
Is Routine Electrocardiography Necessary Before Initiation of Propranolol for Treatment of Infantile Hemangiomas?
Topics: Adrenergic beta-Antagonists; Electrocardiography; Hemangioma; Hemangioma, Capillary; Humans; Infant; | 2016 |
[Chinese experts consensus on the use of oral propranolol for treatment of infantile hemangiomas].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Consensus; Female; Hemangioma; Humans; Infant; La | 2016 |
Cardiac evaluation in children with hemangiomas.
Topics: Contraindications; Echocardiography; Female; Heart Diseases; Heart Ventricles; Hemangioma; Humans; I | 2016 |
Expression of β-Adrenergic Receptor Subtypes in Proliferative, Involuted, and Propranolol-Responsive Infantile Hemangiomas.
Topics: Blotting, Western; Case-Control Studies; Facial Neoplasms; Female; Hemangioma; Humans; Infant; Male; | 2017 |
Cardiovascular Profile of Propranolol after Multiple Dosing in Infantile Hemangioma.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Dose-Response Relationship, Drug; Drug Monitoring; Fema | 2017 |
Nd:YAG and pulsed dye laser therapy in infantile haemangiomas: a retrospective analysis of 271 treated haemangiomas in 149 children.
Topics: Adrenergic beta-Antagonists; Child; Combined Modality Therapy; Female; Hemangioma; Humans; Infant; L | 2017 |
Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment.
Topics: Administration, Oral; Blood Pressure; Drug Dosage Calculations; Electrocardiography, Ambulatory; Fem | 2017 |
Propranolol as first-line treatment for life-threatening diffuse infantile hepatic hemangioma: A case report.
Topics: Female; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol; Remission Induction; Severity of I | 2017 |
Cytochrome P450 isoform genotyping in poor propranolol responders for hemangioma treatment.
Topics: Cytochrome P-450 Enzyme System; Genotype; Hemangioma; Humans; Infant; Propranolol; Protein Isoforms; | 2017 |
Downregulation of miR-382 by propranolol inhibits the progression of infantile hemangioma via the PTEN-mediated AKT/mTOR pathway.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplast | 2017 |
Propranolol, infantile haemangiomas, and serendipity: new use for an old drug.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol | 2011 |
Propranolol treatment of infantile hemangioma is not associated with psychological problems at 7 years of age.
Topics: Child; Female; Hemangioma; Humans; Male; Mental Disorders; Propranolol; Prospective Studies; Psychol | 2017 |
Prolonged tumour growth after treatment of infantile haemangioma with propranolol.
Topics: Child; Child, Preschool; Disease Progression; Female; Hemangioma; Humans; Infant; Infant, Newborn; M | 2017 |
When to stop propranolol for infantile hemangioma.
Topics: Administration, Oral; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Female | 2017 |
Image Gallery: PELVIS syndrome.
Topics: Antineoplastic Agents; Female; Hemangioma; Humans; Infant; Magnetic Resonance Imaging; Meningomyeloc | 2017 |
Propranolol treatment for infantile hemangioma does not increase risk of childhood wheezing.
Topics: Adrenergic beta-Antagonists; Asthma; Case-Control Studies; Child, Preschool; Female; Hemangioma; Hos | 2017 |
[Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas].
Topics: Administration, Topical; Adrenergic beta-Antagonists; Asian People; Consensus; Expert Testimony; Hem | 2016 |
Molecular and immunohistochemical expression of apoptotic proteins Bax, Bcl-2 and Caspase 3 in infantile hemangioma tissues as an effect of propranolol treatment.
Topics: Angiogenesis Inhibitors; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cells, Cultured; Female; | 2017 |
Successful propranolol treatment for diffuse neonatal hemangiomatosis.
Topics: Administration, Oral; Female; Hemangioma; Humans; Infant, Newborn; Liver Neoplasms; Magnetic Resonan | 2017 |
A New Perspective for Infantile Hepatic Hemangioma in the Age of Propranolol: Experience at Baskent University.
Topics: Age of Onset; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Critical Pathways; Female; | 2017 |
67th annual meeting of the American Academy of Dermatology: San Francisco, California, USA, 6-10 March 2009.
Topics: Acne Vulgaris; Dermatology; Hemangioma; Humans; Keratosis, Actinic; Melanoma; Methicillin-Resistant | 2009 |
Life-threatening infantile haemangioma: a dramatic response to propranolol.
Topics: Female; Hemangioma; Humans; Infant, Newborn; Propranolol | 2009 |
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal | 2009 |
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal | 2009 |
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal | 2009 |
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal | 2009 |
[Treatment of infantile hemangioma with propranolol].
Topics: Antihypertensive Agents; Hemangioma; Humans; Infant; Male; Propranolol | 2010 |
[Treatment of infantile hemangioma with propranolol].
Topics: Antihypertensive Agents; Hemangioma; Humans; Infant; Male; Propranolol | 2010 |
[Treatment of infantile hemangioma with propranolol].
Topics: Antihypertensive Agents; Hemangioma; Humans; Infant; Male; Propranolol | 2010 |
[Treatment of infantile hemangioma with propranolol].
Topics: Antihypertensive Agents; Hemangioma; Humans; Infant; Male; Propranolol | 2010 |
Propranolol for airway hemangiomas: case report of novel treatment.
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents, Phytogenic; Bronchoscopy; Disease Progression; F | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
[Use of beta blockers--a new perspective in therapy of infantile hemangiomas of the head and neck area].
Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2010 |
Successful treatment of a large hemangioma with propranolol.
Topics: Female; Hemangioma; Humans; Infant, Newborn; Infant, Premature; Propranolol; Thoracic Neoplasms; Tre | 2010 |
Successful treatment of isolated subglottic haemangioma with propranolol alone.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glottis; | 2009 |
[Propranolol and haemangiomas].
Topics: Child; Hemangioma; Humans; Propranolol | 2009 |
[Propranolol therapy to treat problematic hemangiomas : a new standard therapy makes its debut].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Pressure; Facial Neoplasms; Female; Follow- | 2009 |
[Response to oral propranolol therapy for ulcerated hemangiomas in infancy].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Forearm; Hemangioma; Humans; Infant; Prop | 2009 |
Propranolol as first-line treatment for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Propranolol | 2010 |
[Angiomas].
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Lasers, Dye; Propranolol; Skin Neoplasms | 2009 |
Propranolol for the treatment of a life-threatening subglottic and mediastinal infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Airway Obstruction; Antineoplastic Agents, Hormon | 2010 |
Propranolol for isolated orbital infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Biomarkers, Tumor; Female; Hemangioma; Humans; In | 2010 |
Propranolol may become first-line treatment in obstructive subglottic infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Laryngeal Neoplasms; Propranolol | 2010 |
[Treatment of infantile hemangiomas with low-dose propranolol: evaluation of short-term efficacy and safety].
Topics: Dose-Response Relationship, Drug; Female; Hemangioma; Humans; Infant; Male; Propranolol; Prospective | 2009 |
[Infantile hemangioma. Successful treatment with propranolol].
Topics: Female; Hemangioma; Humans; Infant, Newborn; Propranolol; Skin Neoplasms; Treatment Outcome; Vaginal | 2010 |
Successful treatment of ulcerated haemangioma with propranolol.
Topics: Female; Hemangioma; Humans; Infant; Infant, Newborn; Male; Propranolol; Ulcer | 2010 |
Use of propranolol to treat multicentric airway haemangioma.
Topics: Adrenergic beta-Antagonists; Airway Obstruction; Anti-Inflammatory Agents; Dexamethasone; Endoscopy; | 2010 |
Propranolol as a novel treatment for congenital visceral haemangioma.
Topics: Abdominal Neoplasms; Hemangioma; Humans; Infant, Newborn; Male; Propranolol; Umbilical Cord; Vascula | 2010 |
[Propranolol in the therapy of infantile hemangioma--fascinating, but not with risk].
Topics: Child; Hemangioma; Humans; Propranolol; Vasodilator Agents | 2010 |
Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis.
Topics: Adrenal Cortex Hormones; Female; Heart Failure; Hemangioma; Humans; Infant; Liver Neoplasms; Male; P | 2010 |
Successful treatment of infantile haemangiomas of the orbit with propranolol.
Topics: Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma; Humans; Infant; Magnetic Resonanc | 2010 |
Innovative therapeutics in pediatric dermatology.
Topics: Adolescent; Adrenal Cortex Hormones; Alopecia Areata; Autoimmune Diseases; Child; Child, Preschool; | 2010 |
Propranolol in the management of periorbital infantile haemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Astigmatism; Eyelid Neoplasms; Female; Hemangioma | 2010 |
Management of infantile subglottic hemangioma: acebutolol or propranolol?
Topics: Acebutolol; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Drug Administration Sched | 2010 |
Outpatient treatment of periocular infantile hemangiomas with oral propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Infant, Newborn; Orbi | 2010 |
Low-dose propranolol for infantile haemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Breast Neoplasms; Ear Neoplasms; Female; Follow-U | 2011 |
Effectiveness of propranolol in a newborn with liver hemangiomatosis.
Topics: Cardiovascular Agents; Female; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol | 2010 |
Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Dose-Response Relationship, Drug; | 2010 |
Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Dose-Response Relationship, Drug; | 2010 |
Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Dose-Response Relationship, Drug; | 2010 |
Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Dose-Response Relationship, Drug; | 2010 |
Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Dose-Response Relationship, Drug; | 2010 |
Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Dose-Response Relationship, Drug; | 2010 |
Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Dose-Response Relationship, Drug; | 2010 |
Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Dose-Response Relationship, Drug; | 2010 |
Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Dose-Response Relationship, Drug; | 2010 |
Propranolol in the management of airway infantile hemangiomas.
Topics: Adrenal Cortex Hormones; Airway Obstruction; Combined Modality Therapy; Drug Therapy, Combination; F | 2010 |
[Treatment of infantile parotid hemangioma with propranolol].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; In | 2010 |
Propranolol for the treatment of airway hemangiomas: a case series and treatment algorithm.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Airway Obstruction; Female; Hemangioma; Humans; I | 2010 |
Role of propranolol in the management of periocular hemangiomas.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Eye; Facial Neoplasms; Female; Follo | 2010 |
Propranolol for infantile haemangiomas and neuroglycopenic seizures.
Topics: Adrenergic beta-Antagonists; Blood Glucose; Hemangioma; Humans; Hyperphagia; Hypoglycemia; Infant; L | 2010 |
Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience.
Topics: Adrenergic beta-Antagonists; Airway Obstruction; Drug Resistance; Hemangioma; Humans; Infant; Infant | 2010 |
Management of complicated facial hemangiomas with beta-blocker (propranolol) therapy.
Topics: Adrenergic beta-Antagonists; Facial Neoplasms; Female; Hemangioma; Humans; Infant; Propranolol | 2010 |
Case report: Treatment failure using propanolol for treatment of focal subglottic hemangioma.
Topics: Female; Follow-Up Studies; Glottis; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Laryngoscopy; L | 2010 |
Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution.
Topics: Adrenergic beta-Antagonists; Angiotensins; Biomarkers, Tumor; Cell Proliferation; Disease Progressio | 2011 |
[Documented good enough?].
Topics: Adrenergic beta-Antagonists; Documentation; Evidence-Based Medicine; Hemangioma; Humans; Propranolol | 2010 |
Research in infantile haemangioma: local perspectives.
Topics: Adrenergic beta-Antagonists; Hemangioma; Hong Kong; Humans; Infant; Propranolol; Radiography; Resear | 2010 |
Use of propranolol in infantile haemangioma among Chinese children.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Dose-Response Relationship, Dru | 2010 |
Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Drug Administration Schedule; Female; Heart Rate; Heman | 2011 |
Invited commentary.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Infant, Newborn; Prop | 2011 |
Mature infantile haemangiomas role for propranolol.
Topics: Hemangioma; Humans; Infant; Propranolol; Treatment Outcome | 2011 |
Hyperkalemia complicating propranolol treatment of an infantile hemangioma.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Antagonists; Albuterol; Female; Fluid Therapy; | 2010 |
Hepatic haemangioma of infancy: role of propranolol.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant, Low Birth Weight; Infant, Newborn; | 2010 |
Hemangiomas of the nasal tip: an approach to a therapeutic challenge.
Topics: Adrenergic beta-Antagonists; Child, Preschool; Cicatrix; Cryotherapy; Esthetics; Female; Follow-Up S | 2011 |
Propranolol treatment for subglottic haemangioma.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Laryngoscopy; Laryngos | 2011 |
Propranolol for severe hemangioma of infancy.
Topics: Facial Neoplasms; Female; Hemangioma; Humans; Infant; Propranolol; Vasoconstrictor Agents | 2011 |
Propranolol for severe hemangioma of infancy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diuretics; Facial Neoplasms; Female; Hemangioma; Humans; I | 2011 |
Treatment of vascular anomalies of the upper extremity.
Topics: Child; Child, Preschool; Female; Hemangioma; Humans; Male; Propranolol; Radiography; Risk Assessment | 2011 |
Efficacy and safety of propranolol in the treatment of parotid hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Hemangioendothelioma; Hemangioma; Humans; Infant; Liver Neoplas | 2011 |
Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls.
Topics: Adrenergic beta-Antagonists; Female; Head and Neck Neoplasms; Hemangioma; Humans; Infant; Male; Prop | 2011 |
Propranolol for treatment of ulcerated infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Female; Head and Neck Neoplasms; Hemangioma; H | 2011 |
Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function.
Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Follow-Up Studies; Hemangioma; Humans | 2011 |
Use of propranolol in treating hemangiomas.
Topics: Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Propranolol | 2011 |
Management of complicated facial hemangiomas with Beta-blocker (propranolol) therapy.
Topics: Adrenergic beta-Antagonists; Facial Neoplasms; Hemangioma; Humans; Infant; Propranolol | 2011 |
Diffuse neonatal hemangiomatosis: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Gastrointestinal Neop | 2012 |
Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Cardiovascular System; Child, Preschool; Dose-Response | 2011 |
Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Cardiovascular System; Child, Preschool; Dose-Response | 2011 |
Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Cardiovascular System; Child, Preschool; Dose-Response | 2011 |
Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Cardiovascular System; Child, Preschool; Dose-Response | 2011 |
Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2011 |
[Propranolol for the treatment of severe hemangiomas of infancy: results from a series of 28 patients].
Topics: Administration, Oral; Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Propranolol; Sever | 2011 |
β-blockers for infantile hemangiomas: a single-institution experience.
Topics: Administration, Oral; Administration, Topical; Adrenergic beta-Antagonists; Drug Monitoring; Female; | 2011 |
[Hemangiomas in childhood].
Topics: Adrenergic beta-Antagonists; Disease Progression; Female; Hemangioma; Hemangioma, Cavernous; Humans; | 2011 |
Propranolol as first-line treatment of head and neck hemangiomas.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Child, Preschool; Female; Head and Neck Neopla | 2011 |
Infantile intraspinal and extensive cutaneous hemangiomas: excellent response to propranolol.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Female; Hemangioma; Hemangioma, Cavernous, Cen | 2011 |
Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants.
Topics: Adrenergic beta-Antagonists; Biopsy, Needle; Bronchial Hyperreactivity; Cohort Studies; Dose-Respons | 2011 |
Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Hemangioendothelioma; Hemangioma; Humans; Liver Neoplasms; Neop | 2011 |
[Past, present, and future of propranolol for hemangiomas of infancy].
Topics: Forecasting; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms | 2011 |
The Cyrano nose: different treatment approaches to management of hemangiomas of the nasal tip.
Topics: Hemangioma; Humans; Infant; Nose Neoplasms; Propranolol; Rhinoplasty | 2011 |
Successful treatment of infantile subglottic hemangioma with oral propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal Neo | 2012 |
Atenolol: a promising alternative to propranolol for the treatment of hemangiomas.
Topics: Atenolol; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; | 2011 |
Giving propranolol tablets to infants with hemangiomas - solubility in water.
Topics: Adrenergic beta-Antagonists; Dosage Forms; Hemangioma; Humans; Infant; Propranolol; Solubility | 2011 |
[Oral propranolol in the management of periorbital proliferating phase infantile hemangioma].
Topics: Child; Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Orbital Neoplasms; Propranolol; R | 2011 |
Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Cost-Benefit Analysis; Female; Glucocorticoids; H | 2011 |
Failure of propranolol in the treatment of childhood haemangiomas of the head and neck.
Topics: Adrenal Cortex Hormones; Airway Obstruction; Anti-Inflammatory Agents; Combined Modality Therapy; Co | 2011 |
Evolving treatments in the management of laryngotracheal hemangiomas: will propranolol supplant steroids and surgery?
Topics: Cohort Studies; Female; Follow-Up Studies; Hemangioma; Hospitals, Pediatric; Humans; Immunohistochem | 2011 |
Propranolol for the treatment of subglottic hemangiomas.
Topics: Administration, Oral; Female; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Male; Propranolol; Re | 2011 |
Oral propranolol for exudative retinal detachment in diffuse choroidal hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Choroid Neoplasms; Exudates and Transudates; Fema | 2011 |
In brief: oral propranolol infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Hemangioma; Humans; Infant; Pro | 2011 |
Use of propranolol for treatment of hemangiomas in PHACE syndrome.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Facial Neoplasms; Female; Hemangioma; Humans; | 2011 |
New treatment strategy for granulomatous epulis: intralesional injection of propranolol.
Topics: Adrenergic beta-Antagonists; Female; Gingiva; Gingival Diseases; Granuloma; Hemangioma; Humans; Infa | 2012 |
Propranolol for infantile haemangiomas: initiating treatment on an outpatient basis.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Outpatients; Propranolol; Ret | 2012 |
Childhood wheeze while taking propranolol for treatment of infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Androstadienes; Antineoplastic Agents; Dermatologic Agents; Face; Fluti | 2012 |
Giving propranolol tablets to infants with hemangiomas.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Propranolol | 2011 |
[The change of serum vascular endothelial growth factor and matrix metalloproteinases-9 in proliferative hemangioma treated with propranolol].
Topics: Female; Hemangioma; Humans; Infant; Male; Matrix Metalloproteinase 9; Propranolol; Serum; Vascular E | 2011 |
Reply to the letter to the Editor on "Low-dose propranolol for infantile haemangioma".
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Propranolol | 2012 |
Adrenal suppression following steroid treatment of infantile hemangiomas: expediting the move toward propranolol?
Topics: Adrenal Insufficiency; Glucocorticoids; Hemangioma; Humans; Infant; Prednisolone; Propranolol; Prosp | 2012 |
Treatment of subglottic hemangiomas with propranolol: initial experience in 10 infants.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Glottis; Hemangioma; Humans; Infant; Larynge | 2011 |
Initial experiences with propranolol treatment of infantile hemangiomas: report of three cases.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Propranolol; Skin Neoplasms; | 2011 |
[Pediatrics].
Topics: Adrenergic beta-Agonists; Bacterial Infections; Breast Feeding; Enterocolitis, Necrotizing; Fever; G | 2012 |
Use of propranolol for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Bronchial Spasm; Hemangioma; Humans; Infant; Infant, Newborn; Propranol | 2012 |
Propranolol for problematic head and neck hemangiomas: an analysis of 37 consecutive patients.
Topics: Age Factors; Cohort Studies; Drug Administration Schedule; Female; Head and Neck Neoplasms; Hemangio | 2012 |
[Hemangioma. New aspects of pathogenesis, differential diagnosis and therapy].
Topics: Child; Child, Preschool; Cryotherapy; Female; Hemangioma; Humans; Infant, Newborn; Male; Propranolol | 2012 |
Decreased eNOS protein expression in involuting and propranolol-treated hemangiomas.
Topics: Adolescent; Blotting, Western; Child; Child, Preschool; Cross-Sectional Studies; Female; Hemangioma; | 2012 |
Comparison of efficacy of intralesional bleomycin and oral propanolol in management of hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Antibiotics, Antineoplastic; Bleomycin; Child, Pr | 2012 |
Treatment with propranolol for infantile hemangioma in 13 Taiwanese newborns and young infants.
Topics: Female; Hemangioma; Humans; Infant; Infant, Newborn; Male; Propranolol; Taiwan | 2012 |
How "unsafe" is propranolol when used in the treatment of infantile hemangioma?
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol; Skin Neoplasms | 2012 |
Topical propranolol for treatment of superficial infantile hemangiomas.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Oint | 2012 |
Difficult treatment of consumptive hypothyroidism in a child with massive parotid hemangioma.
Topics: Adrenal Cortex Hormones; Congenital Hypothyroidism; Female; Hemangioma; Humans; Hypothyroidism; Infa | 2012 |
Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A.
Topics: Adrenergic beta-Antagonists; Cell Migration Assays; Cell Survival; Dose-Response Relationship, Drug; | 2012 |
Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Topics: Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioendothelioma; Hemangioma; Humans; Inf | 2012 |
Propranolol reduces infantile hemangioma volume and vessel density.
Topics: Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Propranolol; Skin Neoplasms | 2012 |
A clue on the face...
Topics: Bronchoscopy; Diagnosis, Differential; Female; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Lary | 2010 |
Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Administration Schedule; Feasibility Studies | 2013 |
Propranolol as the first-line therapy for infantile hemangiomas: preliminary results of two centers.
Topics: Adrenergic beta-Antagonists; Child, Preschool; Feasibility Studies; Female; Follow-Up Studies; Heman | 2012 |
Treating hemangioma of infancy with beta-blockers: is there really a risk of hypotension?
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol; Skin Neoplasms | 2012 |
Propranolol treatment for severe infantile hemangiomas: a single-centre 3-year experience.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Photogr | 2012 |
Early growth of infantile hemangiomas: what parents' photographs tell us.
Topics: Adrenal Cortex Hormones; Age Factors; Diseases in Twins; Facial Neoplasms; Female; Hemangioma; Human | 2012 |
Airway hemangiomas in PHACE syndrome.
Topics: Aortic Coarctation; Bronchoscopy; Disease-Free Survival; Eye Abnormalities; Female; Follow-Up Studie | 2012 |
Management of adult onset orbital hemangioma by oral propranalol: a case report.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Diagnosis, Differential; Female; Hemangioma; Huma | 2012 |
Use of propranolol for treatment of infantile haemangiomas in an outpatient setting.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Child; Child, Preschool; Drug Administ | 2012 |
Efficacy of propranolol treatment in thyroid dysfunction associated with severe infantile hepatic hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol; Sever | 2012 |
Propranolol for infantile haemangioma: striking effect in the first weeks.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Cohort Studies; Dose-Response Relationship, Drug; | 2012 |
Propranolol as first-line treatment of a severe subglottic haemangioma.
Topics: Bronchoscopy; Constriction, Pathologic; Female; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Pro | 2013 |
Propranolol accelerates adipogenesis in hemangioma stem cells and causes apoptosis of hemangioma endothelial cells.
Topics: Adipogenesis; Adrenergic beta-Antagonists; Annexin A5; Apoptosis; Cell Proliferation; Dose-Response | 2012 |
[Treatment of infantile subglottic hemangioma with oral propranolol].
Topics: Female; Glottis; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Male; Propranolol; Treatment Outco | 2012 |
[Infantile hepatic hemangiomas: first-line propranolol monotherapy as new treatment strategy?].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Beckwith-Wiedemann Syndrome; Female; Follow-Up St | 2012 |
Adverse effects of propranolol treatment for infantile hemangiomas in China.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Bronchial Hyperreactivity; China; Female; Hemangi | 2014 |
Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells.
Topics: Analysis of Variance; Apoptosis; Blotting, Western; Caspases; Cell Proliferation; Down-Regulation; E | 2012 |
Propranolol for hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Child, Preschool; Dose-Response Relationsh | 2013 |
Topical propranolol hydrochloride gel for superficial infantile hemangiomas.
Topics: Female; Gels; Hemangioma; Humans; Infant; Infant, Newborn; Male; Propranolol | 2012 |
Effect of propranolol on the treatment of infantile hemangiomas: a single tertiary center 3-year experience.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Photogr | 2014 |
Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Administration Schedule; Female; Hemangioma; | 2013 |
Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patients.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Analysis of Variance; Endothelium, Vascular; Enzy | 2013 |
Preliminary experience on treatment of infantile hemangioma with low-dose propranolol in China.
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin II; China; Female; Hemangioma; Humans; Infant; | 2013 |
Great Ormond Street Hospital treatment guidelines for use of propranolol in infantile isolated subglottic haemangioma.
Topics: Constriction, Pathologic; Glottis; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Practice Guideli | 2013 |
Congenital disseminated tufted angioma.
Topics: Capillaries; Drug Substitution; Female; Glucocorticoids; Hemangioma; Humans; Infant; Prednisone; Pro | 2013 |
Congenital primarily ulcerated hemangioma mimicking cleft lip.
Topics: Cleft Lip; Diagnosis, Differential; Hemangioma; Humans; Infant; Infant, Newborn; Propranolol; Treatm | 2013 |
Nevus anemicus. Donor-dominant defect.
Topics: Hemangioma; Humans; Male; Middle Aged; Phentolamine; Propranolol; Skin Neoplasms; Skin Transplantati | 1977 |